0001326190-22-000013.txt : 20221110 0001326190-22-000013.hdr.sgml : 20221110 20221110161301 ACCESSION NUMBER: 0001326190-22-000013 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 66 CONFORMED PERIOD OF REPORT: 20220930 FILED AS OF DATE: 20221110 DATE AS OF CHANGE: 20221110 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Altimmune, Inc. CENTRAL INDEX KEY: 0001326190 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 202726770 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-32587 FILM NUMBER: 221377311 BUSINESS ADDRESS: STREET 1: 910 CLOPPER ROAD STREET 2: SUITE 201S CITY: GAITHERSBURG STATE: MD ZIP: 20878 BUSINESS PHONE: 2406541450 MAIL ADDRESS: STREET 1: 910 CLOPPER ROAD STREET 2: SUITE 201S CITY: GAITHERSBURG STATE: MD ZIP: 20878 FORMER COMPANY: FORMER CONFORMED NAME: PHARMATHENE, INC DATE OF NAME CHANGE: 20071016 FORMER COMPANY: FORMER CONFORMED NAME: HEALTHCARE ACQUISITION CORP DATE OF NAME CHANGE: 20050505 10-Q 1 alt-20220930x10q.htm 10-Q
492865354137076845881547408439050001326190--12-312022Q349161637409937680.480.811.371.79P20DP20Dfalse0001326190us-gaap:CommonStockMemberus-gaap:IPOMember2020-07-162020-07-160001326190us-gaap:RetainedEarningsMember2022-09-300001326190us-gaap:AdditionalPaidInCapitalMember2022-09-300001326190us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-09-300001326190us-gaap:RetainedEarningsMember2022-06-300001326190us-gaap:AdditionalPaidInCapitalMember2022-06-300001326190us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-06-3000013261902022-06-300001326190us-gaap:RetainedEarningsMember2022-03-310001326190us-gaap:AdditionalPaidInCapitalMember2022-03-310001326190us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-03-3100013261902022-03-310001326190us-gaap:RetainedEarningsMember2021-12-310001326190us-gaap:AdditionalPaidInCapitalMember2021-12-310001326190us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-12-310001326190us-gaap:RetainedEarningsMember2021-09-300001326190us-gaap:AdditionalPaidInCapitalMember2021-09-300001326190us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-09-300001326190us-gaap:RetainedEarningsMember2021-06-300001326190us-gaap:AdditionalPaidInCapitalMember2021-06-300001326190us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-06-3000013261902021-06-300001326190us-gaap:RetainedEarningsMember2021-03-310001326190us-gaap:AdditionalPaidInCapitalMember2021-03-310001326190us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-03-3100013261902021-03-310001326190us-gaap:RetainedEarningsMember2020-12-310001326190us-gaap:AdditionalPaidInCapitalMember2020-12-310001326190us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-12-310001326190us-gaap:CommonStockMember2022-09-300001326190us-gaap:CommonStockMember2022-06-300001326190us-gaap:CommonStockMember2022-03-310001326190us-gaap:CommonStockMember2021-12-310001326190us-gaap:CommonStockMember2021-09-300001326190us-gaap:CommonStockMember2021-06-300001326190us-gaap:CommonStockMember2021-03-310001326190us-gaap:CommonStockMember2020-12-310001326190us-gaap:CommonStockMemberus-gaap:IPOMember2020-07-160001326190alt:TwoThousandAndNineteenEmployeeStockPurchasePlanMember2022-07-012022-09-300001326190alt:TwoThousandAndNineteenEmployeeStockPurchasePlanMember2022-01-012022-09-300001326190alt:TwoThousandAndNineteenEmployeeStockPurchasePlanMember2021-07-012021-09-300001326190alt:TwoThousandAndNineteenEmployeeStockPurchasePlanMember2021-01-012021-09-300001326190us-gaap:GrantMemberalt:MedicalTechnologyEnterpriseConsortiumCollaborativeArrangementMember2022-07-012022-09-300001326190us-gaap:GrantMemberalt:MedicalTechnologyEnterpriseConsortiumCollaborativeArrangementMember2022-01-012022-09-300001326190alt:BARDAContractMemberus-gaap:GrantMember2021-07-012021-09-300001326190us-gaap:GrantMemberalt:MedicalTechnologyEnterpriseConsortiumCollaborativeArrangementMember2021-01-012021-09-300001326190alt:BARDAContractMemberus-gaap:GrantMember2021-01-012021-09-300001326190alt:MedicalTechnologyEnterpriseConsortiumCollaborativeArrangementMember2020-06-012020-06-300001326190alt:BARDAContractMemberus-gaap:InvestmentPerformanceMember2016-07-012016-07-310001326190us-gaap:CommonStockMember2022-07-012022-09-300001326190us-gaap:CommonStockMember2022-04-012022-06-300001326190us-gaap:CommonStockMember2021-07-012021-09-300001326190us-gaap:CommonStockMember2021-04-012021-06-300001326190alt:BARDAContractMember2016-07-310001326190alt:LonzaManufacturingAgreementMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsNonrecurringMemberus-gaap:ConstructionInProgressMember2021-09-300001326190alt:LonzaManufacturingAgreementMemberus-gaap:ConstructionInProgressMember2021-01-012021-09-300001326190us-gaap:IPOMember2020-07-162020-07-160001326190us-gaap:CommonStockMemberus-gaap:OverAllotmentOptionMember2020-07-162020-07-160001326190alt:AtTheMarketOfferingMember2022-01-012022-09-300001326190alt:PiperSandlerCompanyAndEvercoreGroupLimitedLiabilityCompanyAndBRileySecuritiesIncMemberalt:AtTheMarketOfferingMemberalt:EquityDistributionAgreementMember2021-02-252022-09-300001326190us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-07-012022-09-300001326190us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-04-012022-06-300001326190us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-07-012021-09-300001326190us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-04-012021-06-300001326190us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-01-012021-03-310001326190us-gaap:RetainedEarningsMember2022-07-012022-09-300001326190us-gaap:RetainedEarningsMember2022-04-012022-06-300001326190us-gaap:RetainedEarningsMember2022-01-012022-03-310001326190us-gaap:RetainedEarningsMember2021-07-012021-09-300001326190us-gaap:RetainedEarningsMember2021-04-012021-06-300001326190alt:ExchangingStockholdersMemberalt:ExchangeWarrantsMember2021-02-250001326190us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2022-09-300001326190us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2022-09-300001326190us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001326190us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001326190alt:LonzaManufacturingAgreementMemberus-gaap:ConstructionInProgressMember2021-10-012021-12-310001326190alt:LonzaManufacturingAgreementMember2021-01-012021-09-300001326190alt:BARDAContractMembersrt:MinimumMember2021-01-010001326190alt:BARDAContractMembersrt:MaximumMember2021-01-010001326190us-gaap:EmployeeStockOptionMember2022-09-300001326190us-gaap:RestrictedStockUnitsRSUMember2022-09-300001326190us-gaap:RestrictedStockMember2022-09-300001326190us-gaap:RestrictedStockUnitsRSUMember2022-01-012022-09-300001326190us-gaap:RestrictedStockMember2022-01-012022-09-300001326190us-gaap:EmployeeStockOptionMember2022-01-012022-09-300001326190alt:PiperSandlerCompanyAndEvercoreGroupLimitedLiabilityCompanyAndBRileySecuritiesIncMemberalt:AtTheMarketOfferingMemberalt:EquityDistributionAgreementMember2021-02-250001326190alt:ExchangeWarrantsMember2022-01-240001326190alt:PreFundedWarrantsMember2022-09-300001326190alt:ExchangeWarrantsMember2021-02-250001326190alt:PreFundedWarrantsMemberus-gaap:IPOMember2020-07-160001326190alt:SpitfirePharmaIncMemberalt:PhaseTwoMilestoneMember2022-09-300001326190us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-3100013261902021-09-3000013261902020-12-310001326190srt:MaximumMemberalt:SpitfirePharmaIncMemberus-gaap:CommonStockMember2019-07-120001326190alt:SpitfirePharmaIncMemberalt:SalesMilestoneMember2019-07-120001326190alt:SpitfirePharmaIncMemberalt:PhaseTwoMilestoneMember2022-04-012022-06-100001326190alt:RegulatoryMilestoneMemberalt:ClinicalTrialNotificationMember2020-09-302020-11-190001326190alt:SpitfirePharmaIncMemberalt:PhaseTwoMilestoneMember2022-06-100001326190alt:SpitfirePharmaIncMemberalt:ClinicalTrialNotificationMember2020-11-190001326190alt:SpitfirePharmaIncMemberalt:InvestigationalNewDrugApplicationMilestoneMember2019-07-120001326190alt:SpitfirePharmaIncMemberalt:InvestigationalNewDrugApplicationAndRegulatoryMilestonesMember2019-07-120001326190alt:SpitfirePharmaIncMember2019-07-122019-07-120001326190us-gaap:USTreasurySecuritiesMember2022-09-300001326190us-gaap:AssetBackedSecuritiesMember2022-09-300001326190alt:CommercialPaperAndCorporateDebtSecuritiesMember2022-09-300001326190us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2022-09-300001326190us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2022-09-300001326190us-gaap:FairValueMeasurementsRecurringMember2022-09-300001326190us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001326190us-gaap:FairValueMeasurementsRecurringMember2021-12-310001326190us-gaap:WarrantMember2022-07-012022-09-300001326190us-gaap:RestrictedStockUnitsRSUMember2022-07-012022-09-300001326190us-gaap:RestrictedStockMember2022-07-012022-09-300001326190us-gaap:EmployeeStockOptionMember2022-07-012022-09-300001326190us-gaap:WarrantMember2022-01-012022-09-300001326190us-gaap:RestrictedStockUnitsRSUMember2022-01-012022-09-300001326190us-gaap:RestrictedStockMember2022-01-012022-09-300001326190us-gaap:EmployeeStockOptionMember2022-01-012022-09-300001326190us-gaap:WarrantMember2021-07-012021-09-300001326190us-gaap:RestrictedStockUnitsRSUMember2021-07-012021-09-300001326190us-gaap:RestrictedStockMember2021-07-012021-09-300001326190us-gaap:EmployeeStockOptionMember2021-07-012021-09-300001326190us-gaap:WarrantMember2021-01-012021-09-300001326190us-gaap:RestrictedStockUnitsRSUMember2021-01-012021-09-300001326190us-gaap:RestrictedStockMember2021-01-012021-09-300001326190us-gaap:EmployeeStockOptionMember2021-01-012021-09-300001326190us-gaap:ResearchAndDevelopmentExpenseMember2022-07-012022-09-300001326190us-gaap:GeneralAndAdministrativeExpenseMember2022-07-012022-09-300001326190us-gaap:ResearchAndDevelopmentExpenseMember2022-01-012022-09-300001326190us-gaap:GeneralAndAdministrativeExpenseMember2022-01-012022-09-300001326190us-gaap:ResearchAndDevelopmentExpenseMember2021-07-012021-09-300001326190us-gaap:GeneralAndAdministrativeExpenseMember2021-07-012021-09-300001326190us-gaap:ResearchAndDevelopmentExpenseMember2021-01-012021-09-300001326190us-gaap:GeneralAndAdministrativeExpenseMember2021-01-012021-09-300001326190us-gaap:AdditionalPaidInCapitalMember2022-07-012022-09-3000013261902022-07-012022-09-300001326190us-gaap:AdditionalPaidInCapitalMember2022-04-012022-06-3000013261902022-04-012022-06-300001326190us-gaap:AdditionalPaidInCapitalMember2022-01-012022-03-3100013261902022-01-012022-03-310001326190us-gaap:AdditionalPaidInCapitalMember2021-07-012021-09-3000013261902021-07-012021-09-300001326190us-gaap:AdditionalPaidInCapitalMember2021-04-012021-06-3000013261902021-04-012021-06-3000013261902022-11-040001326190us-gaap:CommonStockMember2022-01-012022-03-310001326190alt:ExchangeWarrantsMember2021-02-252021-02-250001326190us-gaap:CommonStockMember2021-01-012021-03-310001326190us-gaap:RetainedEarningsMember2021-01-012021-03-310001326190alt:ExchangeWarrantsMember2022-01-242022-01-240001326190us-gaap:AdditionalPaidInCapitalMember2021-01-012021-03-3100013261902021-01-012021-03-310001326190alt:BARDAContractMember2021-01-012021-01-010001326190alt:BARDAContractMember2016-07-012016-07-310001326190alt:AtTheMarketOfferingMemberalt:EquityDistributionAgreementMember2022-09-300001326190alt:SpitfirePharmaIncMemberalt:RegulatoryMilestoneMember2019-07-122019-07-120001326190alt:SpitfirePharmaIncMemberalt:PhaseTwoMilestoneMember2022-06-102022-06-1000013261902022-01-012022-09-300001326190alt:ClinicalTrialNotificationMember2020-11-192020-11-190001326190alt:LonzaManufacturingAgreementMember2021-03-012021-03-310001326190alt:PreFundedWarrantsMemberus-gaap:IPOMember2020-07-162020-07-160001326190alt:SpitfirePharmaIncMemberalt:InvestigationalNewDrugApplicationMilestoneMember2019-07-122019-07-120001326190alt:SpitfirePharmaIncMemberalt:InvestigationalNewDrugApplicationAndRegulatoryMilestonesMember2019-07-122019-07-120001326190alt:SpitfirePharmaIncMemberalt:SalesMilestoneMember2019-07-122019-07-120001326190alt:PiperSandlerCompanyAndEvercoreGroupLimitedLiabilityCompanyAndBRileySecuritiesIncMemberalt:AtTheMarketOfferingMemberalt:EquityDistributionAgreementMember2021-02-252021-02-2500013261902021-01-012021-09-3000013261902022-09-3000013261902021-12-31iso4217:USDiso4217:USDxbrli:sharesxbrli:purexbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2022

or

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from                  to                 

Commission file number 001-32587

Graphic

ALTIMMUNE, INC.

(Exact Name of Registrant as Specified in its Charter)

    

Delaware

    

20-2726770

(State or Other Jurisdiction of

Incorporation or Organization)

 

(I.R.S. Employer

Identification No.)

910 Clopper Road Suite 201S, Gaithersburg, Maryland

    

20878

(Address of Principal Executive Offices)

 

(Zip Code)

(240) 654-1450

(Registrant’s Telephone Number, Including Area Code)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common stock, par value $0.0001 per share

ALT

The NASDAQ Global Market

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.   Yes      No

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).   Yes      No 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer

Accelerated filer

Non-accelerated filer

Smaller reporting company

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act).   Yes      No  

As of November 4, 2022, there were 49,159,056 shares of the registrant’s common stock, par value $0.0001 per share, outstanding.

ALTIMMUNE, INC.

TABLE OF CONTENTS

Page

PART I. FINANCIAL INFORMATION

Item 1.

Financial Statements

1

Consolidated Balance Sheets as of September 30, 2022 (unaudited) and December 31, 2021

1

Consolidated Statements of Operations and Comprehensive Loss for the three and nine months ended September 30, 2022 and 2021 (unaudited)

2

Consolidated Statements of Changes in Stockholders’ Equity for the three and nine months ended September 30, 2022 and 2021 (unaudited)

3

Consolidated Statements of Cash Flows for the nine months ended September 30, 2022 and 2021 (unaudited)

5

Notes to Consolidated Financial Statements (unaudited)

6

Item 2.

Management’s Discussion and Analysis of Financial Condition and Results of Operations

16

Item 3.

Quantitative and Qualitative Disclosures about Market Risk

23

Item 4.

Controls and Procedures

23

PART II. OTHER INFORMATION

Item 1.

Legal Proceedings

23

Item 1A.

Risk Factors

24

Item 2.

Unregistered Sales of Equity Securities and Use of Proceeds

24

Item 3.

Defaults Upon Senior Securities

24

Item 4.

Mine Safety Disclosures

24

Item 5.

Other Information

24

Item 6.

Exhibits

25

Signatures

26

PART I. FINANCIAL INFORMATION

Item 1. Financial Statements

ALTIMMUNE, INC.

CONSOLIDATED BALANCE SHEETS

(In thousands, except share and per share data)

    

September 30, 

December 31, 

2022

2021

(Unaudited)

ASSETS

 

 

  

Current assets:

 

  

 

  

Cash and cash equivalents

$

127,465

$

190,301

Restricted cash

 

34

 

34

Total cash, cash equivalents and restricted cash

 

127,499

 

190,335

Short-term investments

 

74,362

 

Accounts receivable

 

633

 

429

Income tax and R&D incentive receivables

 

3,720

 

5,410

Prepaid expenses and other current assets

 

4,790

 

7,952

Total current assets

 

211,004

 

204,126

Property and equipment, net

 

1,172

 

1,448

Intangible assets, net

 

12,419

 

12,419

Other assets

 

682

 

872

Total assets

$

225,277

$

218,865

LIABILITIES AND STOCKHOLDERS’ EQUITY

 

  

 

  

Current liabilities:

 

  

 

  

Accounts payable

$

1,419

$

2,034

Contingent consideration

6,090

Accrued expenses and other current liabilities

 

14,323

 

10,152

Total current liabilities

 

15,742

 

18,276

Other long-term liabilities

 

4,506

 

1,454

Total liabilities

 

20,248

 

19,730

Commitments and contingencies (Note 14)

 

  

 

  

Stockholders’ equity:

 

  

 

  

Common stock, $0.0001 par value; 200,000,000 shares authorized; 49,161,637 and 40,993,768 shares issued and outstanding as of September 30, 2022 and December 31, 2021, respectively

5

4

Additional paid-in capital

 

566,551

 

497,342

Accumulated deficit

 

(356,224)

 

(293,171)

Accumulated other comprehensive loss, net

 

(5,303)

 

(5,040)

Total stockholders’ equity

 

205,029

 

199,135

Total liabilities and stockholders’ equity

$

225,277

$

218,865

The accompanying notes are an integral part of the unaudited consolidated financial statements.

1

ALTIMMUNE, INC.

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

(Unaudited)

(In thousands, except share and per share data)

Three Months Ended

Nine Months Ended

September 30, 

September 30, 

2022

    

2021

    

2022

    

2021

Revenues

$

2

$

158

$

42

$

1,133

Operating expenses:

 

  

 

  

 

  

 

  

Research and development

 

20,262

 

29,206

 

51,359

 

54,356

General and administrative

 

4,492

 

4,156

 

13,329

 

11,636

Impairment loss on construction-in-progress

 

 

 

 

8,070

Total operating expenses

 

24,754

 

33,362

 

64,688

 

74,062

Loss from operations

 

(24,752)

 

(33,204)

 

(64,646)

 

(72,929)

Other income (expense):

 

  

 

  

 

  

 

  

Interest expense

 

(64)

 

(33)

 

(191)

 

(67)

Interest income

 

1,053

 

13

 

1,402

 

88

Other income (expense), net

 

50

 

(286)

 

185

 

(293)

Total other income (expense), net

 

1,039

 

(306)

 

1,396

 

(272)

Net loss before income taxes

 

(23,713)

 

(33,510)

 

(63,250)

 

(73,201)

Income tax benefit

 

197

 

 

197

 

Net loss

 

(23,516)

 

(33,510)

 

(63,053)

 

(73,201)

Other comprehensive income — unrealized (loss) gain on short-term investments

 

(143)

 

(2)

 

(263)

 

4

Comprehensive loss

$

(23,659)

$

(33,512)

$

(63,316)

$

(73,197)

Net loss per share, basic and diluted

$

(0.48)

$

(0.81)

$

(1.37)

$

(1.79)

Weighted-average common shares outstanding, basic and diluted

 

49,286,535

 

41,370,768

 

45,881,547

 

40,843,905

The accompanying notes are an integral part of the unaudited consolidated financial statements.

2

ALTIMMUNE, INC.

CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY

(Unaudited)

(In thousands, except share amounts)

Accumulated

Additional

Other

Total

    

Common Stock

    

Paid-In

    

Accumulated

    

Comprehensive

    

Stockholders’

Shares

Amount

Capital

Deficit

Loss

Equity

Balance at December 31, 2021

40,993,768

$

4

$

497,342

$

(293,171)

$

(5,040)

$

199,135

Stock-based compensation

 

 

 

2,033

 

 

 

2,033

Exercise of stock options

 

95,771

 

 

197

 

 

 

197

Vesting of restricted stock awards including withholding, net

17,568

(170)

(170)

Issuance of common stock from Employee Stock Purchase Plan

 

16,450

 

 

113

 

 

 

113

Issuance of common stock in at-the-market offerings, net

 

335,485

 

 

2,990

 

2,990

Issuance of common stock upon exercise of warrants

1,760,854

Net loss

(19,430)

(19,430)

Balance at March 31, 2022

 

43,219,896

 

$

4

 

$

502,505

 

$

(312,601)

 

$

(5,040)

 

$

184,868

Stock-based compensation

 

 

$

 

$

2,048

 

$

 

$

 

$

2,048

Exercise of stock options

152,913

 

 

403

 

 

 

403

Vesting of restricted stock awards including withholding, net

 

(5,865)

 

 

(80)

 

 

 

(80)

Issuance of common stock in at-the-market offerings, net

2,157,717

1

21,346

21,347

Issuance of common stock related to contingent consideration liability

847,444

6,176

6,176

Unrealized (loss) gain on short-term investments

 

 

 

 

 

(120)

 

(120)

Net loss

 

 

 

 

(20,107)

 

 

(20,107)

Balance at June 30, 2022

 

46,372,105

 

$

5

 

$

532,398

 

$

(332,708)

 

$

(5,160)

 

$

194,535

Stock-based compensation

 

 

$

 

$

2,128

 

$

 

$

 

$

2,128

Exercise of stock options

76,161

 

 

268

 

 

 

268

Vesting of restricted stock awards including withholding, net

 

(7,744)

 

 

(140)

 

 

 

(140)

Issuance of common stock in at-the-market offerings, net

2,711,013

 

 

31,829

 

 

31,829

Issuance of common stock from Employee Stock Purchase Plan

9,945

 

 

68

 

 

68

Other increase

157

 

 

 

 

Unrealized loss on short-term investments

 

 

 

 

 

(143)

 

(143)

Net loss

 

 

 

 

(23,516)

 

 

(23,516)

Balance at September 30, 2022

 

49,161,637

 

$

5

 

$

566,551

 

$

(356,224)

 

$

(5,303)

 

$

205,029

The accompanying notes are an integral part of the unaudited consolidated financial statements.

3

ALTIMMUNE, INC.

CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY

(Unaudited)

(In thousands, except share amounts)

Accumulated

Additional

Other

Total

    

Common Stock

    

Paid-In

    

Accumulated

    

Comprehensive

    

Stockholders’

Shares

Amount

Capital

Deficit

Loss

Equity

Balance at December 31, 2020

37,142,946

$

4

$

417,337

$

(186,421)

$

(5,044)

$

225,876

Stock-based compensation

 

 

 

1,218

 

1,218

Vesting of restricted stock awards including withholding, net

 

(6,349)

 

 

(92)

 

(92)

Issuance of common stock from Employee Stock Purchase Plan

 

8,733

 

 

106

 

106

Retirement of common stock in exchange for common stock warrant

 

(1,000,000)

 

 

(7,540)

(9,660)

 

(17,200)

Issuance of common stock warrant in exchange for retirement of common stock

 

 

 

17,200

 

17,200

Issuance of common stock in at-the-market offerings, net

 

2,110,800

 

 

34,178

 

34,178

Issuance of common stock upon cashless exercise of warrants

1,050

10

10

Unrealized gain on short-term investments

5

5

Net loss

(14,864)

(14,864)

Balance at March 31, 2021

 

38,257,180

 

$

4

 

$

462,417

 

$

(210,945)

 

$

(5,039)

 

$

246,437

Stock-based compensation

 

 

$

 

$

1,485

 

$

 

$

 

$

1,485

Exercise of stock options

38,217

94

94

Vesting of restricted stock awards including withholding, net

 

(7,583)

 

 

(90)

 

 

 

(90)

Issuance of common stock in at-the-market offerings, net

 

1,405,710

 

 

18,178

 

 

 

18,178

Unrealized (loss) gain on short-term investments

 

 

 

 

 

1

 

1

Net loss

 

 

 

 

(24,827)

 

 

(24,827)

Balance at June 30, 2021

 

39,693,524

 

$

4

 

$

482,084

 

$

(235,772)

 

$

(5,038)

 

$

241,278

Stock-based compensation

 

 

$

 

$

1,497

 

$

 

$

 

$

1,497

Exercise of stock options

398

6

6

Vesting of restricted stock awards including withholding, net

 

(6,521)

 

 

(124)

 

 

 

(124)

Issuance of common stock from Employee Stock Purchase Plan

 

15,367

 

 

119

 

 

 

119

Unrealized loss on short-term investments

 

 

 

 

 

(2)

 

(2)

Net loss

(33,510)

(33,510)

Balance at September 30, 2021

 

39,702,768

 

$

4

 

$

483,582

 

$

(269,282)

 

$

(5,040)

 

$

209,264

The accompanying notes are an integral part of the unaudited consolidated financial statements.

4

ALTIMMUNE, INC.

CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

(In thousands)

    

Nine Months Ended September 30, 

2022

2021

CASH FLOWS FROM OPERATING ACTIVITIES:

 

  

 

  

Net loss

$

(63,053)

$

(73,201)

Adjustments to reconcile net loss to net cash used in operating activities:

 

  

 

Change in fair value of contingent consideration liability

 

86

 

1,560

Impairment loss on construction-in-progress

 

 

8,070

Stock-based compensation expense

 

6,209

 

4,200

Depreciation and amortization

 

31

 

434

Unrealized (gains) losses on foreign currency exchange

 

(183)

 

297

Changes in operating assets and liabilities:

 

 

Accounts receivable

 

(204)

 

3,036

Prepaid expenses and other assets

 

3,204

 

(5,263)

Accounts payable

 

(615)

 

(606)

Accrued expenses and other liabilities

 

7,555

 

6,916

Income tax and R&D incentive receivables

 

1,690

 

(1,714)

Net cash used in operating activities

 

(45,280)

 

(56,271)

CASH FLOWS FROM INVESTING ACTIVITIES:

 

  

 

  

Proceeds from sales and maturities of short-term investments

 

 

82,406

Purchases of short-term investments

 

(74,292)

 

(7,592)

Purchases of property and equipment, net

 

(88)

 

(11,970)

Cash paid for internally developed patents

 

 

(190)

Net cash (used in) provided by investing activities

 

(74,380)

 

62,654

CASH FLOWS FROM FINANCING ACTIVITIES:

 

  

 

  

Payments of deferred offering costs

(118)

Proceeds from issuance of common stock in at-the-market offerings, net

 

56,166

 

52,356

Proceeds from issuance of common stock from Employee Stock Purchase Plan

 

181

 

225

Proceeds from exercises of stock options, net

 

477

 

100

Net cash provided by financing activities

 

56,824

 

52,563

Net (decrease) increase in cash and cash equivalents and restricted cash

 

(62,836)

 

58,946

Cash, cash equivalents and restricted cash at beginning of period

 

190,335

 

115,952

Cash, cash equivalents and restricted cash at end of period

$

127,499

$

174,898

SUPPLEMENTAL NON-CASH ACTIVITIES:

 

 

Common stock issued related to contingent consideration liability

$

6,176

$

Operating lease liability and right of use asset addition

$

$

72

The accompanying notes are an integral part of the unaudited consolidated financial statements.

5

ALTIMMUNE, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

1. Nature of Business and Basis of Presentation

Nature of Business

Altimmune, Inc., headquartered in Gaithersburg, Maryland, United States, together with its subsidiaries (collectively, the “Company” or “Altimmune”) is a clinical stage biopharmaceutical company incorporated under the laws of the State of Delaware.

The Company is focused on developing treatments for obesity and liver diseases. The Company’s pipeline includes next generation peptide therapeutics for obesity and non-alcoholic steatohepatitis (“NASH”) (for both, pemvidutide, formerly known as ALT-801), and for chronic hepatitis B (HepTcell). Since its inception, the Company has devoted substantially all of its efforts to business planning, research and development, recruiting management and technical staff and raising capital, and has financed its operations through the issuance of common and preferred stock, long-term debt and proceeds from research grants and government contracts. The Company has not generated any revenues from the sale of any products to date, and there is no assurance of any future revenues from product sales.

Basis of Presentation

The accompanying unaudited consolidated financial statements are prepared pursuant to the rules and regulations of the U.S. Securities and Exchange Commission (“SEC”) regarding interim financial reporting. Accordingly, they do not include all of the information and disclosures required by accounting principles generally accepted in the United States (“U.S. GAAP”) for complete consolidated financial statements and should be read in conjunction with the audited consolidated financial statements for the year ended December 31, 2021 included in the Annual Report on Form 10-K which was filed with the SEC on March 15, 2022. In the opinion of management, the Company has prepared the accompanying unaudited consolidated financial statements on the same basis as the audited consolidated financial statements, and these consolidated financial statements include all adjustments, consisting only of normal recurring adjustments, necessary for a fair presentation of the results of the interim periods presented. The operating results for the interim periods presented are not necessarily indicative of the results expected for the full year 2022 or any future years or periods.

The accompanying unaudited consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation.

The accompanying unaudited consolidated financial statements have been prepared on the basis of continuity of operations, realization of assets, and the satisfaction of liabilities in the ordinary course of business. The financial statements do not include any adjustments relating to the recoverability and classification of recorded assets and liabilities that might be necessary should we be unable to continue as a going concern.

2. Summary of Significant Accounting Policies

During the nine months ended September 30, 2022, there have been no significant changes to the Company’s summary of significant accounting policies contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021 as filed with the SEC.

Use of Estimates

The preparation of these financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. The extent to which the COVID-19 pandemic, including any resurgences or the emergence of new variants, may directly or indirectly impact the Company’s business, financial condition, and results of operations is highly uncertain and subject to change.

6

The Company considered the potential impact of the COVID-19 pandemic on the Company’s estimates and assumptions and determined that there was not a material impact to the Company’s unaudited consolidated financial statements as of and for the three and nine months ended September 30, 2022. However, actual results could differ from those estimates and there may be changes to the Company’s estimates in future periods.

3. Fair Value Measurements

The Company’s assets measured at fair value on a recurring basis as of September 30, 2022 consisted of the following (in thousands):

Fair Value Measurement at September 30, 2022

    

Total

    

Level 1

    

Level 2

    

Level 3

Assets:

Cash equivalents - money market funds

$

123,921

$

123,921

$

$

Short-term investments

 

74,362

 

 

74,362

 

Total

$

198,283

$

123,921

$

74,362

$

The Company’s assets and liabilities measured at fair value on a recurring basis as of December 31, 2021 consisted of the following (in thousands):

Fair Value Measurement at December 31, 2021

    

Total

    

Level 1

    

Level 2

    

Level 3

Assets:

Cash equivalents - money market funds

$

65,634

    

$

65,634

    

$

    

$

Total

$

65,634

$

65,634

$

$

Liabilities:

Contingent consideration liability (see Note 6)

$

6,090

$

$

$

6,090

Total

$

6,090

$

$

$

6,090

As described in Note 6 the remaining milestone payment underlying the contingent consideration liability was fully settled in shares of the Company’s common stock. As of September 30, 2022, the Company had no contingent consideration liability.

Short-term investments have been initially valued at the transaction price and subsequently valued, at the end of each reporting period, utilizing third party pricing services or other market observable data (Level 2). The pricing services utilize industry standard valuation models, including both income and market-based approaches and observable market inputs to determine value.

Short-term investments had quoted prices as of September 30, 2022 as shown below (in thousands):

September 30, 2022

Amortized Cost

Unrealized Loss

Market Value

United States treasury securities

    

$

17,784

    

$

(112)

    

$

17,672

Commercial paper and corporate debt securities

49,931

(124)

49,807

Asset backed securities

 

6,910

 

(27)

 

6,883

Total

$

74,625

$

(263)

$

74,362

Separate disclosure is required for assets and liabilities measured at fair value on a recurring basis from those measured at fair value on a non-recurring basis. Assets recorded at fair value on a non-recurring basis, such as property and equipment and intangible assets are recognized at fair value when they are impaired. During the nine months ended September 30, 2022, the Company had no significant assets or liabilities that were measured at fair value on a non-recurring basis. During the year ended December 31, 2021, the Company recorded non-cash impairment charges to property and equipment, net on a non-recurring basis (see below).

7

Lonza Manufacturing Agreement

In March 2021, the Company expanded its manufacturing collaboration with Lonza Houston, Inc. (“Lonza”) for the manufacture of AdCOVID or other adenovirus-based vaccines. Under the expanded agreement, the Company had committed approximately $23.0 million to Lonza to procure long-lead equipment and construct a dedicated manufacturing suite for clinical and commercial production of adenovirus-based vaccines. In June 2021, the Company announced the discontinuation of further development of AdCOVID following the Company’s review of findings from its Phase 1 clinical trial. Construction continued at Lonza, and the Company assessed its strategic options with respect to the suite. This work was completed during the fourth quarter of 2021. The Company capitalized a total of $11.4 million as construction-in-progress (“CIP”) during the nine months ended September 30, 2021 under this expanded agreement.

In connection with the discontinuation of further development of AdCOVID, the Company recorded a non-cash impairment charge of $8.1 million in the unaudited consolidated statements of operations and comprehensive loss for the nine months ended September 30, 2021 to write-down the CIP associated with the construction of the Lonza facility to its fair value of $3.3 million as of September 30, 2021. As of September 30, 2021, the fair value of the CIP related assets was primarily determined utilizing the cost approach, which reflected the replacement cost of the asset being appraised, adjusted for contractual restrictions on the assets, the probability of satisfying the contractual restrictions, physical deterioration, functional obsolescence and economic obsolescence. The fair value measurement was considered a Level 3 measurement within the valuation hierarchy.

Furthermore, the remaining $3.3 million CIP was fully charged to impairment during the three months ended December 31, 2021 upon termination of the agreement.

4. Operating Leases

The Company rents office and laboratory space in the United States which expires in April 2025. Rent expense under the Company’s operating leases was $0.1 million and $0.4 million during each of the three and nine months ended September 30, 2022 and 2021, respectively. Rent expense includes short-term leases and variable lease costs that are not included in the lease obligation.

Short-term leases are leases having a term of twelve months or less. The Company recognizes short-term leases on a straight-line basis and does not record a related lease asset or liability for such leases.

The office space lease provides for increases in future minimum annual rental payments as defined in the lease agreement. The office space lease also includes an option to renew the lease as of the end of the term. The Company has determined that the lease renewal option is not reasonably certain of being exercised.

The cash paid for operating lease liabilities for each of the nine months ended September 30, 2022 and 2021 was $0.4 million.

Supplemental other information related to the operating leases balance sheet information is as follows (in thousands):

 

September 30, 2022

December 31, 2021

 

Operating lease obligations (see Note 5 and 7)

    

$

1,230

    

$

1,535

Operating lease right-of-use assets (included in "Other assets" in Balance Sheet)

$

649

$

798

Weighted-average remaining lease term (years)

 

2.6

 

3.3

Weighted-average discount rate

 

7.2

%  

 

7.2

%

8

5. Accrued Expenses

Accrued expenses and other current liabilities consist of the following (in thousands):

September 30, 2022

December 31, 2021

Accrued professional services

    

$

624

    

$

396

Accrued payroll and employee benefits

 

2,110

 

2,313

Accrued research and development

 

9,930

 

6,988

Lease obligation, current portion (see Note 4)

 

442

 

411

Income tax payable

1,169

Accrued interest and other

 

48

 

44

Total accrued expenses and other current liabilities

$

14,323

$

10,152

6. Contingent Consideration

The Company entered into an Agreement and Plan of Merger and Reorganization, dated July 8, 2019, by and among the Company, Springfield Merger Sub, Inc., Springfield Merger Sub, LLC, Spitfire Pharma, Inc. and David Collier, as the Stockholder Representative (the “Spitfire Merger Agreement”) to acquire all of the equity interests of Spitfire Pharma, Inc. (“Spitfire”). Spitfire was a privately held, preclinical pharmaceutical company developing a novel GLP-1/glucagon receptor dual agonist for the treatment of NASH.

The transaction closed on July 12, 2019. The Company issued 1,887,250 unregistered shares of its common stock as upfront consideration to certain former securityholders of Spitfire, representing an amount equal to $5.0 million less working capital and transaction expense adjustment amounts as defined in the agreement.

The acquisition of Spitfire was accounted for as an asset acquisition instead of a business combination because substantially all of the fair value of the gross assets acquired was concentrated in a single identifiable asset or group of similar identifiable assets, and therefore, the asset was not considered a business. The Company expensed the acquired intellectual property as of the acquisition date as in-process research and development with no alternative future uses.

The Spitfire Merger Agreement also includes future contingent payments up to $88.0 million in cash and shares of the Company’s common stock as follows:

a one-time payment of $5.0 million (the “IND Milestone Consideration Amount”) within sixty days of the submission of an Investigational New Drug Application (“IND”) to the United States Food and Drug Administration (the “FDA”) or other applicable governmental authority in a foreign jurisdiction, which IND has not been rejected or placed on clinical hold by the FDA or such applicable foreign governmental authority within time specified in the Spitfire Merger Agreement;
a one-time payment of $3.0 million (the “Phase 2 Milestone Consideration Amount” and together with the IND Milestone Consideration Amount, the “Regulatory Milestones”) within sixty days of the initiation (first patient, first dosing) of a Phase 2 clinical trial of a product candidate anywhere in the world (a “Phase 2 Milestone Event”); and
payments of up to $80.0 million upon the achievement of specified worldwide net sales (the “Sales Milestones”) of all products developed using the technology acquired in the Amended and Restated License Agreement, dated July 12, 2019, by and between Mederis Diabetes, LLC and Spitfire, within ten years following the approval of a new drug application filed with the FDA.

The Regulatory Milestones were payable in shares of the Company’s common stock, with the number of shares of the Company’s common stock issued in connection with each milestone amount, if any, dependent on the share price at the time of achievement. The number of shares issued in consideration for the IND Milestone Consideration Amount was determined based on the lower of (A) the average of the closing prices of the Company’s common stock as reported on the Nasdaq Global Market for the twenty (20) consecutive trading days prior to the IND Reference Date or (B) $2.95.

9

The number of shares issued in consideration for the Phase 2 Milestone Consideration Amount was determined based on the lower of (A) the average of the closing trading prices of the Company’s common stock as reported on the Nasdaq Global Market for the twenty (20) consecutive trading days immediately preceding the date of the occurrence of the Phase 2 Milestone Event or (B) $3.54.

The contingent payments related to the Regulatory Milestones were stock-based payments accounted for under FASB Accounting Standards Codification Topic 480, Distinguishing Liabilities From Equity (“ASC 480”). Such stock-based payments are subject to a lock-up whereby 50% of the shares are released at 3 months following issuance and 50% are released at 6 months following issuance. The future contingent payments related to the Sales Milestones are predominately cash-based payments accounted for under FASB Accounting Standards Codification Topic 450, Contingencies. Accordingly, the Company will recognize the Sales Milestones when the contingency is probable and the amount can be reasonably estimated.

On November 3, 2020, the Company received acknowledgement from the Australian Government Department of Health on the Company’s submitted clinical trial notification (“CTN”) which triggered the obligation to settle the IND Milestone payment to the former owners. As a result, on November 19, 2020, the Company issued 1,694,906 shares of its common stock valued at $9.57 per share for the amount value of $13.6 million to the former Spitfire stockholders. Pursuant to the Spitfire Merger Agreement, the Company issued the shares within sixty days of the submission of the CTN, which was October 29, 2020. From September 30, 2020 through November 19, 2020, the date of issuance, the Company recognized a decrease in the fair value of the IND Milestone payment of $5.4 million to research and development expense and reclassified the balance in the contingent consideration liability associated with the fair value of the IND Milestone payment to equity in the Company’s consolidated balance sheet.

On April 26, 2022, the Company dosed the first patient in the Phase 2 MOMENTUM trial of pemvidutide in obesity, which triggered the obligation to pay the Phase 2 Milestone Consideration Amount to the former owners. As a result, on June 10, 2022, the Company issued 847,444 shares of its common stock valued at $8.55 per share for the amount value of $7.2 million to the former Spitfire stockholders. From the last valuation date on March 31, 2022 through June 10, 2022, the date of issuance, the Company recognized an increase in the fair value of the Phase 2 Milestone Consideration Amount of $1.9 million to research and development expense and reclassified the balance in the contingent consideration liability to equity in the Company’s consolidated balance sheet. As of September 30, 2022, the Company had no contingent consideration liability.

Below is a summary of the contingent consideration activity (in thousands):

Nine Months Ended September 30, 

2022

2021

Beginning balance

    

$

6,090

    

$

5,390

Change in fair value

 

86

 

1,560

Fair value of payments settled in common stock (Phase II Milestone)

 

(6,176)

 

Ending balance

$

$

6,950

7. Other Long-Term Liabilities

During the nine months ended September 30, 2022, the Company received a total of $3.4 million in cash for research and development (“R&D”) incentive credit that the Company earned during the fiscal years 2021 and 2020 through the participation in the Australian research and development incentive credit program administered through the Australian Tax Office. The Company recorded the receipt as long-term liability until there is reasonable assurance that the Company will comply with the conditions attached to the incentive credit. See Note 2. Summary of Significant Accounting Policies in the Company’s 2021 Annual Report on Form 10-K for accounting policies related to research and development incentive credits.

10

The Company’s other long-term liabilities are summarized as follows (in thousands):

September 30, 2022

December 31, 2021

Research and development incentive credit

$

3,402

$

Lease obligation, long-term portion (see Note 4)

    

788

    

1,124

Conditional economic incentive grants

 

250

 

250

Other

 

66

 

80

Total other long-term liabilities

$

4,506

$

1,454

8. Common Stock

Public Offering

On July 16, 2020, the Company offered and sold (i) 3,369,564 shares of common stock, at a price to the public of $23.00 per share, and (ii) pre-funded warrants of the Company to purchase 1,630,436 shares of common stock at an exercise price equal to $0.0001 per share (the “Pre-Funded Warrants”), at a price to the public of $22.9999 per share of common stock underlying the Pre-Funded Warrants (equal to the public offering price per share of Common Stock, minus the exercise price of each Pre-Funded Warrant). The Pre-Funded Warrants are exercisable at any time, provided that each Pre-Funded Warrant holder will be prohibited from exercising such Pre-Funded Warrants into shares of the Company’s common stock if, as a result of such exercise, the holder, together with its affiliates, would own more than 4.99% of the total number of shares of the Company’s common stock then issued and outstanding, which percentage may change at the holders’ election to any other number less than or equal to 19.99% upon 61 days’ notice to the Company. The gross proceeds of this offering were approximately $132.2 million, which includes the exercise in full of the underwriters’ option to purchase an additional 750,000 shares of common stock, before deducting underwriting discounts and commissions and offering expenses during the third quarter of 2020. The net proceeds of this offering were approximately $124.0 million, after deducting underwriting discounts and commissions and offering expenses payable by the Company.

The Company has assessed the Pre-Funded Warrants for appropriate equity or liability classification and determined that the Pre-Funded Warrants are freestanding instruments that do not meet the definition of a liability pursuant to ASC 480 and do not meet the definition of a derivative pursuant to FASB Accounting Standards Codification Topic 815, Derivatives and Hedging (“ASC 815”). The Pre-Funded Warrants are indexed to the Company’s common stock and meet all other conditions for equity classification under ASC 480 and ASC 815. Accordingly, the Pre-Funded Warrants are classified as equity and are accounted for as a component of additional paid-in capital at the time of issuance. As of September 30, 2022, 760,870 of the Pre-Funded Warrants were exercised, leaving 869,566 remaining Pre-Funded Warrants unexercised.

At-the-Market Offerings

On February 25, 2021, the Company entered into an Equity Distribution Agreement (the “2021 Agreement”) with Piper Sandler & Co., Evercore Group L.L.C. and B. Riley Securities, Inc., serving as sales agents (the “Sales Agents”) with respect to an at-the-market offerings program under which the Company offered and sold shares of its common stock, par value $0.0001 per share (the “Common Stock”), having an aggregate offering price of up to $125.0 million (the “Shares”) through the Sales Agents (the “2021 Offering”). All the Shares offered and sold in the 2021 Offering were issued pursuant to the Company’s Registration Statement on Form S-3 filed with the Securities and Exchange Commission (the “SEC”) on December 31, 2020, which was declared effective on January 11, 2021 (“2021 Shelf”), the prospectus supplement relating to the 2021 Offering filed with the SEC on February 25, 2021 and any applicable additional prospectus supplements related to the 2021 Offering that form a part of the Registration Statement.

During the nine months ended September 30, 2022, the Company sold 5,204,415 shares of Common Stock under the 2021 Agreement resulting in approximately $56.2 million in proceeds, net of $1.9 million commission and other offering costs. As of September 30, 2022, the Company has sold 10,004,869 shares of Common Stock under the 2021 Agreement resulting in approximately $121.0 million in proceeds, net of $4.0 million commission and other offering costs, As of September 30, 2022, there were no remaining shares available for issuance under the 2021 Agreement. The Company

11

recorded approximately $0.3 million of other offering costs which offset the proceeds received from the shares sold through September 30, 2022.

Exchange Agreement

On February 25, 2021, the Company entered into an exchange agreement (the “Exchange Agreement”) with an investor and its affiliates (the “Exchanging Stockholders”), pursuant to which the Company exchanged an aggregate of 1,000,000 shares of the Company’s common stock, par value $0.0001 per share, owned by the Exchanging Stockholders for pre-funded warrants (the “Exchange Warrants”) to purchase an aggregate of 1,000,000 shares of common stock (subject to adjustment in the event of any stock dividends and splits, reverse stock split, recapitalization, reorganization or similar transaction, as described in the Exchange Warrants), with an exercise price of $0.0001 per share. The Exchange Warrants did not have an expiration date and were exercisable at any time except that the Exchange Warrants could not be exercised by the Exchanging Stockholders if, after giving effect thereto, the Exchanging Stockholders would beneficially own more than 9.99% of the Company’s common stock, subject to certain exceptions. In accordance with FASB Accounting Standards Codification Topic 505, Equity, the Company recorded the retirement of the common stock exchanged as a reduction of common shares outstanding and a corresponding debit to additional paid-in-capital and accumulated deficit at the fair value of the Exchange Warrants on the issuance date. The Exchange Warrants were classified as equity in accordance with ASC 480 and the fair value of the Exchange Warrants was recorded as a credit to additional paid-in-capital and is not subject to remeasurement. The Company determined that the fair value of the Exchange Warrants is substantially similar to the fair value of the retired shares on the issuance date due to the negligible exercise price for the Exchange Warrants. On January 24, 2022, the Exchange Warrants to purchase 1,000,000 shares were net exercised, resulting in the issuance of 999,984 shares of common stock, and no Exchange Warrants remain outstanding.

9. Warrants

A summary of warrant activity during the nine months ended September 30, 2022 is as follows:

Weighted-Average

    

    

Weighted

Remaining

Number of

Average

Contractual Term

Warrants

Exercise Price

(Years)

Warrants outstanding, December 31, 2021

 

2,776,191

 

Expired

(155)

Exercises (see Note 8)

 

(1,760,870)

 

Warrants outstanding, September 30, 2022

 

1,015,166

 

$

0.66

1.2

The warrants outstanding as of September 30, 2022 included 869,566 Pre-Funded Warrants with an exercise price of $0.0001 per-share and no expiration date.

10. Stock-Based Compensation

Stock Options

The Company’s stock option awards generally vest over four years and typically have a contractual life of ten years. As of September 30, 2022, there was $13.7 million of unrecognized compensation cost related to stock options, which is expected to be recognized over a weighted-average period of 2.6 years. During the nine months ended September 30, 2022, the Company granted 1,433,427 stock options with a weighted average exercise price of $8.39 and per share weighted average grant date fair value of $6.97.

12

Information related to stock options outstanding as of September 30, 2022 is as follows (in thousands, except share and per share data):

    

    

    

Weighted-Average

    

Weighted-

Remaining

Number of

Average

Contractual Term

Aggregate Intrinsic

Stock Options

Exercise Price

(Years)

Value

Outstanding

 

3,528,473

$

9.09

 

5.9

$

16,975

Exercisable

 

1,382,587

$

8.75

 

5.8

$

7,824

Unvested

 

2,145,886

$

9.31

 

6.0

$

9,151

Restricted Stock

As of September 30, 2022, the Company had unvested restricted stock of 13,454 shares with total unrecognized compensation expense of $47,000, which the Company expects to recognize over a weighted average period of approximately 0.2 years. During the nine months ended September 30, 2022, the Company issued 34,132 of unrestricted common stock as a result of the vesting of 60,546 restricted stock net of 26,414 shares of common stock withheld to satisfy tax withholding obligations.

Restricted Stock Units (RSUs)

During the nine months ended September 30, 2022, the Company granted 285,000 shares of RSUs with a weighted average grant date fair value of $7.11 which vest over four years. As of September 30, 2022, the Company had unvested RSUs of 470,275 shares with total unrecognized compensation expense of $3.4 million, which the Company expects to recognize over a weighted average period of approximately 3.1 years. During the nine months ended September 30, 2022, the Company issued 30,373 shares of unrestricted common stock as a result of the vesting of 46,653 RSUs net of 16,280 shares of common stock withheld to satisfy tax withholding obligations.

2019 Employee Stock Purchase Plan (ESPP)

Under the ESPP, employees purchased 26,395 shares for $0.2 million during the nine months ended September 30, 2022. During the three and nine months ended September 30, 2022, the Company recognized compensation expense of $0.1 million and $0.2 million respectively. During the three and nine months ended September 30, 2021, the Company recognized compensation expense of $29,000 and $0.3 million, respectively.

Stock-based Compensation Expense

Stock-based compensation expense is classified in the unaudited consolidated statements of operations and comprehensive loss for the three and nine months ended September 30, 2022 and 2021 as follows (in thousands):

    

For the Three Months Ended

    

For the Nine Months Ended

September 30, 

September 30, 

2022

    

2021

2022

    

2021

Research and development

$

743

$

449

$

2,024

$

1,211

General and administrative

 

1,385

 

1,048

 

4,185

 

2,989

Total

$

2,128

$

1,497

$

6,209

$

4,200

11. U.S. Government Contracts and Grants

In June 2020, the Company was awarded $4.7 million from the U.S. Army Medical Research & Development Command (“USAMRDC”) to fund its Phase 1/2 clinical trial of T-COVID. The competitive award was granted by USAMRDC in collaboration with the Medical Technology Enterprise Consortium (“MTEC”), a 501(c)(3) biomedical technology consortium working in partnership with the Department of Defense (“DoD”). Under the contract, MTEC paid the Company a firm fixed fee based upon the achievement of certain milestones for conduct and completion of a Phase 1/2 study and research and development work on the replication-deficient adenovirus 5 (“RD-Ad5”) vector vaccine

13

platform. For the nine months ended September 30, 2021, the Company recognized approximately $0.5 million of grant revenue under the contract, which completed the full recognition of this award. No revenue was recognized for this contract for the three and nine months ended September 30, 2022.

In July 2016, the Company signed a five-year contract with Biomedical Advanced Research and Development Authority (“BARDA”). The contract, as amended, had a total value of up to $136.8 million to be used to fund clinical development of NasoShield. Under the contract, BARDA paid the Company a fixed fee and reimbursed certain costs for the research and development of an Ad5-vectored, protective antigen-based intranasal anthrax vaccine through cGMP manufacture and conduct of a Phase 1 clinical trial dose ranging assessment of safety and immunogenicity. The contract consisted of an initial base performance period providing approximately $30.9 million in funding for the period July 2016 through December 2021. BARDA had seven options to extend the contract to fund certain continued development and manufacturing activities for the anthrax vaccine, including Phase 2 clinical studies. Each option, if exercised by BARDA, would have provided additional funding ranging from approximately $1.1 million to $34.4 million for a three-year period beginning in 2021. For the three and nine months ended September 30, 2021, the Company recognized approximately $0.1 million and $0.4 million, respectively, of grant revenue under the BARDA contract. For the three and nine months ended September 30, 2022, the Company has recognized de minimis grant revenue related to the close-out of the BARDA contract. BARDA did not extend the contract beyond the end of December 2021.

12. Income Taxes

During the three and nine months ended September 30, 2022, the Company recorded a total of $0.2 million income tax benefit related to interest received and receivable on income tax refunds. Other than the tax benefit related to interest, the Company did not record an income tax benefit in the three and nine months ended September 30, 2022 and 2021 due to a full valuation allowance.

13. Net Loss Per Share

Because the Company has reported a net loss attributable to common stockholders for all periods presented, basic and diluted net loss per share attributable to common stockholders are the same for all periods presented.

Basic net loss per share attributable to common stockholders is computed by dividing the net loss attributable to common stockholders by the weighted average numbers of shares of common stock outstanding for the period. Basic shares outstanding includes the weighted average effect of the Company’s outstanding pre-funded warrants, the exercise of which requires little or no consideration for the delivery of shares of common stock.

Diluted net loss per share is calculated by adjusting weighted average shares outstanding for the dilutive effect of common stock equivalents outstanding for the period. As such, all unvested restricted stock, restricted stock units, common stock warrants and stock options have been excluded from the computation of diluted weighted average shares outstanding because such securities would have an anti-dilutive impact for all periods presented.

Potential common shares issuable upon conversion, vesting or exercise of unvested restricted stock, restricted stock units, common stock warrants and stock options that are excluded from the computation of diluted weighted-average shares outstanding, as they are anti-dilutive, are as follows:

For the Three and Nine Months Ended

September 30, 

2022

2021

Common stock warrants

 

145,600

 

145,755

 

Common stock options

 

3,542,534

 

2,626,482

 

Restricted stock units

 

470,275

 

207,529

Restricted stock

 

13,454

 

94,181

 

14

14. Commitments and Contingencies

Spitfire Acquisition

As disclosed in Note 6, the Company is obligated to make payments of up to $80.0 million upon the achievement of specified worldwide net sales of all products developed using the technology acquired from Spitfire Pharma Inc. within ten years following the approval of a new drug application filed with the FDA.

Litigation

In December 2019, a complaint was filed by Dr. De-Chu Christopher Tang (“Plaintiff”) against the Company, which was removed to the United States District Court for the Eastern District of Texas. The Plaintiff amended the complaint in February 2020 to include Vipin K. Garg and David J. Drutz as defendants, in addition to the Company (Dr. Garg, Dr. Drutz, and the Company are collectively referred to as “Defendants”). In March 2020 the Defendants filed a motion to dismiss the complaint. The Court denied the motion without prejudice and allowed Plaintiff an opportunity to file an amended complaint. Plaintiff’s second amended complaint was filed on April 17, 2020, and Defendants filed a motion to dismiss that complaint on May 1, 2020. A hearing on Defendants’ motion to dismiss was held on May 20, 2020. Plaintiff, who is representing himself, alleges five causes of action as follows: (1) Defendants’ alleged retention of Plaintiff’s lab notebooks after the termination of his employment in 2012; (2) alleged plagiarism based on publishing an article without naming Plaintiff as an author; (3) use of the Adhigh System, which Plaintiff alleges he developed; (4) allegations that Defendants manipulated the Company’s stock and caused a decrease in value; and (5) allegations that the Defendants “wast[ed] government grant money and poison[ed] science by leaving data to rot.” On September 30, 2020, Plaintiff filed a motion titled “Motion to Proscribe Defendants’ Allegedly Illegal Use of Plaintiff’s AdHigh System in Altimmune’s Human Clinical Trials,” to which Defendants filed an opposition on October 13, 2020. The court has not yet ruled on that motion, which also remains pending. On November 6, 2020, Defendants filed a motion for summary judgment on the basis of lack of personal jurisdiction, insufficient service of process, and failure to state a claim. The court ruled on that motion on March 25, 2021, which dismissed the case on the basis of lack of personal jurisdiction. On December 1, 2020, the magistrate judge assigned to the case issued a report and recommendation that Defendants’ motion to dismiss of May 1, 2020 be granted and that this action be dismissed for lack of personal jurisdiction. Plaintiff filed objections to the report and recommendation on December 14, 2020, and the resolution of those objections by the district court remains pending.

In December 2021, the Plaintiff refiled the complaint in the United States District Court for the District of Maryland. On February 24, 2022, Defendants filed a memorandum containing a brief description of the planned motion and a concise summary of the factual and legal support for it. On the basis of that memorandum, the Court granted Defendants’ request to file a motion to dismiss and allowed Plaintiff an opportunity to file an amended complaint. Plaintiff’s amended complaint was filed on March 3, 2022, and Defendants filed a motion to dismiss that complaint on April 4, 2022. The Company believes the allegations in the complaint are without merit and intends to vigorously defend the litigation.

The Company is a party in various contracts and subject to disputes, litigation and potential claims arising in the ordinary course of business, none of which are currently reasonably possible or probable of material loss.

15

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

The following discussion and analysis of our financial condition and results of operations should be read together with our consolidated financial statements and related notes appearing elsewhere in this Quarterly Report on Form 10-Q and our consolidated financial statements and related notes for the year ended December 31, 2021 included in our Annual Report on Form 10-K, which was filed with the Securities and Exchange Commission on March 15, 2022.

This Quarterly Report on Form 10-Q contains forward-looking statements that involve substantial risks and uncertainties. The words “expect,” “anticipate,” “intend,” “plan,” “believe,” “estimate,” “may,” “will,” “should,” “could,” “target,” “strategy,” “intend,” “project,” “guidance,” “likely,” “usually,” “potential,” or the negative of these words or variations of such words, similar expressions, or comparable terminology are intended to identify such forward-looking statements, although not all forward-looking statements contain these identifying words. There are a number of important risks and uncertainties that could cause our actual results to differ materially from those indicated by forward-looking statements. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make. A further list and description of risks, uncertainties and other factors that could cause actual results or events to differ materially from the forward-looking statements that we make is included in the cautionary statements herein and in our other filings with the Securities and Exchange Commission, including those set forth under Part I, Item 1A, Risk Factors in our Annual Report on Form 10-K for the year ended December 31, 2021. Our forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures or investments that we may make.

We have based the forward-looking statements included in this Quarterly Report on Form 10-Q on information available to us on the date of this quarterly report, and we assume no obligation to update any such forward-looking statements, other than as required by law. Although we undertake no obligation to revise or update any forward-looking statements, whether as a result of new information, future events or otherwise, you are advised to consult any additional disclosures that we may make directly to you or through reports that we, in the future, may file with the SEC, including Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K.

Overview

Altimmune, Inc. is a clinical stage biopharmaceutical company focused on developing treatments for obesity and liver diseases. Our lead product candidate, pemvidutide (formerly known as ALT-801), is a GLP-1/glucagon receptor dual agonist that is being developed for the treatment of obesity and non-alcoholic steatohepatitis (“NASH”). In addition, we are developing HepTcell, an immunotherapeutic agent designed to achieve a functional cure for chronic hepatitis B.

Impact of COVID-19

We are closely monitoring how the spread of COVID-19, including any resurgences or the emergence of new variants, is affecting our employees, business, preclinical studies and clinical trials. We have reopened our executive office to allow employees to return to the office based on an approach that is intended to comply with federal and state guidelines, with a focus on employee safety and optimal work environment. We are continuing our regular interactions with the FDA and other regulatory agencies and, based on current information, we do not anticipate COVID-19 to materially affect our regulatory timelines for our ongoing clinical trials. Furthermore, as a government contractor, we are subject to the federal government vaccination mandate, which requires federal contractor employees, except in certain limited circumstances, to be vaccinated against COVID-19 by December 8, 2021. While the vaccination mandate remains subject to the interpretation of various government agencies and other entities, and questions remain regarding the specific application of the vaccination mandate, we are continuing to develop and implement health, safety, employment and operational protocols in order to timely comply with the vaccination mandate. As of and for the nine months ended September 30, 2022, the vaccination mandate has not had a material impact on our employees or operations.

Although operations have not been materially affected by the COVID-19 pandemic as of and for the three and nine months ended September 30, 2022, at this time, however, disruptions caused by the COVID-19 pandemic may result in difficulties or delays in initiating, enrolling, conducting or completing our planned and ongoing trials and the incurrence

16

of unforeseen costs as a result of disruptions in clinical supply or preclinical study or clinical trial delays. The impact of COVID-19 on our future results will largely depend on future developments, which are highly uncertain and cannot be predicted with confidence, such as the ultimate geographic spread of the disease, the duration of the pandemic, travel restrictions and social distancing in the United States and other countries, business closures or business disruptions, the ultimate impact on financial markets and the global economy, and the effectiveness of actions taken in the United States and other countries to contain and treat the disease. In addition, a recurrence of COVID-19 cases, or variants thereof, could cause other widespread or more severe impacts depending on where infection rates are highest. We continue to monitor developments as we deal with the disruptions and uncertainties relating to the COVID-19 pandemic. See “Risk Factors” in Part II, Item 1A of this Quarterly Report on Form 10-Q and “Item 1A. Risk Factors” of our Annual Report on Form 10-K for the year ended December 31, 2021.

Recent Global Events

Russia and Ukraine Conflict

The military conflict in Russia and Ukraine that began in February 2022 continues as of the date of this quarterly report. As the conflict continues to evolve, we are closely monitoring the impact on our business. The conflict, and the sanctions and counter-sanctions imposed in response to it, have created increased economic uncertainty and operational complexity globally. While we have no direct exposure to Russia and Ukraine, and do not at the moment believe the situation will have a material impact on our operating results, we are monitoring any broader economic impact from the situation. Should the conflict continue or escalate, it could have a significant negative effect on the global economy or on our operations, including continued inflationary pressures on raw materials, supply chain and logistics disruptions, volatility in foreign exchange rates and interest rates and heightened cybersecurity threats.

U.S. Government Contracts and Grants

In June 2020, we were awarded $4.7 million from the U.S. Army Medical Research & Development Command (“USAMRDC”) to fund our Phase 1/2 clinical trial of T-COVID. The competitive award was granted by USAMRDC in collaboration with the Medical Technology Enterprise Consortium (“MTEC”), a 501(c)(3) biomedical technology consortium working in partnership with the Department of Defense (“DoD”). Under the contract, MTEC paid us a firm fixed fee based upon the achievement of certain milestones for conduct and completion of a Phase 1/2 study and research and development work on the replication-deficient adenovirus 5 (“RD-Ad5”) vector vaccine platform. For the nine months ended September 30, 2021, we recognized approximately $0.5 million of grant revenue under the contract, which completed the full recognition of this award. No revenue was recognized for this contract for the three and nine months ended September 30, 2022.

In July 2016, we signed a five-year contract with Biomedical Advanced Research and Development Authority (“BARDA”). The contract, as amended, had a total value of up to $136.8 million to be used to fund clinical development of NasoShield. Under the contract, BARDA paid us a fixed fee and reimbursed certain costs for the research and development of an Ad5-vectored, protective antigen-based intranasal anthrax vaccine through cGMP manufacture and conduct of a Phase 1 clinical trial dose ranging assessment of safety and immunogenicity. The contract consisted of an initial base performance period providing approximately $30.9 million in funding for the period July 2016 through December 2021. BARDA had seven options to extend the contract to fund certain continued development and manufacturing activities for the anthrax vaccine, including Phase 2 clinical trials. Each option, if exercised by BARDA, would have provided additional funding ranging from approximately $1.1 million to $34.4 million for a three-year period beginning in 2021. For the three and nine months ended September 30, 2021, we recognized approximately $0.1 million and $0.4 million, respectively, of grant revenue under the BARDA contract. For the three and nine months ended September 30, 2022, we have recognized de minimis grant revenue related to the close-out of the BARDA contract. BARDA did not extend the contract beyond the end of December 2021.

Critical Accounting Policies and Significant Judgment and Estimates

Management’s Discussion and Analysis of Financial Condition and Results of Operations is based upon our unaudited consolidated financial statements, which have been prepared in accordance with accounting principles generally

17

accepted in the U.S. and the rules and regulations of the SEC for interim financial reporting. The preparation of these financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues, expenses and the disclosure of contingent liabilities in our consolidated financial statements. We base our estimates and judgments on historical experience, knowledge of current conditions and expectations of what could occur in the future given available information.

There have been no changes in our critical accounting policies and significant judgment and estimates as disclosed in our Annual Report on Form 10-K for the year ended December 31, 2021. For more information regarding our critical accounting policies, we encourage you to read the discussion contained in Item 7 under the heading “Critical Accounting Policies and Significant Judgments and Estimates” and Note 2 “Summary of Significant Accounting Policies” included in the notes to the consolidated financial statements contained in our Annual Report on Form 10-K for the year ended December 31, 2021.

Results of Operations

Comparison of the three months ended September 30, 2022 and 2021:

For the Three Months Ended

September 30, 

(in thousands)

    

2022

    

2021

    

Increase (Decrease)

 

Revenue

$

2

$

158

$

(156)

 

(99)

%

Operating expenses:

 

  

 

  

 

  

 

  

Research and development

 

20,262

 

29,206

 

(8,944)

 

(31)

%

General and administrative

 

4,492

 

4,156

 

336

 

8

%

Total operating expenses

 

24,754

 

33,362

 

(8,608)

 

(26)

%

Loss from operations

 

(24,752)

 

(33,204)

 

8,452

 

25

%

Other income (expense):

 

  

 

  

 

  

 

  

Interest expense

 

(64)

 

(33)

 

(31)

 

(94)

%

Interest income

 

1,053

 

13

 

1,040

 

8,000

%

Other income (expense), net

 

50

 

(286)

 

336

 

(117)

%

Total other income (expense), net

 

1,039

 

(306)

 

1,345

 

(440)

%

Net loss before income taxes

 

(23,713)

 

(33,510)

 

9,797

 

29

%

Income tax benefit

 

197

 

 

197

 

Net loss

$

(23,516)

$

(33,510)

$

9,994

 

30

%

18

Comparison of the nine months ended September 30, 2022 and 2021:

For the Nine Months Ended

September 30, 

(in thousands)

    

2022

    

2021

    

Increase (Decrease)

 

Revenue

$

42

$

1,133

$

(1,091)

 

(96)

%

Operating expenses:

 

  

 

  

 

  

 

Research and development

 

51,359

 

54,356

 

(2,997)

 

(6)

%

General and administrative

 

13,329

 

11,636

 

1,693

 

15

%

Impairment loss on construction-in-progress

8,070

(8,070)

100

%

Total operating expenses

 

64,688

 

74,062

 

(9,374)

 

(13)

%

Loss from operations

 

(64,646)

 

(72,929)

 

8,283

 

11

%

Other income (expense):

 

  

 

  

 

 

  

Interest expense

 

(191)

 

(67)

 

(124)

 

(185)

%

Interest income

 

1,402

 

88

 

1,314

 

1,493

%

Other income (expense), net

 

185

 

(293)

 

478

 

163

%

Total other income (expense), net

 

1,396

 

(272)

 

1,668

 

613

%

Net loss before income taxes

(63,250)

(73,201)

9,951

 

14

%

Income tax benefit

 

197

 

 

197

 

Net loss

$

(63,053)

$

(73,201)

$

10,148

 

14

%

Revenue

Revenue consists primarily of research grants in the United States from MTEC for our T-COVID product candidate and BARDA for our NasoShield vaccine product candidate. These grants consist of firm fixed fee contracts based on milestones and cost reimbursement contracts, with a fixed fee based on either costs incurred or milestones met. Our T-COVID and NasoShield programs were discontinued as of the end of 2021.

Revenue decreased by $0.2 million, or 99% for the three months ended September 30, 2022 and $1.1 million, or 96%, for the nine months ended September 30, 2022, as compared to the three and nine months ended September 30, 2021. The decrease was primarily the result of the discontinuation of development work on both T-COVID and NasoShield programs as described above.

Research and development expenses

Research and development expense decreased by $8.9 million, or 31%, for the three months ended September 30, 2022, as compared to the three months ended September 30, 2021. The decrease was primarily the result of:

a decrease of $17.9 million due primarily to development activities for our COVID-19 programs, which included AdCOVID and T-COVID (which were discontinued in 2021);
a decrease of $1.7 million due to change in the fair value of contingent consideration liability with respect to the acquisition of pemvidutide, which was fully paid on June 10, 2022;
an increase of $9.1 million due to the development activities for pemvidutide primarily due to the ongoing NAFLD trials and the MOMENTUM Phase 2 trial in obesity;
an increase of $0.2 million due to development activities for HepTcell; and
a net increase of $1.4 million due primarily to costs associated with non-project specific research and development costs including employee compensation and facility costs.

Research and development expense decreased by $3.0 million, or 6%, for the nine months ended September 30, 2022, as compared to the nine months ended September 30, 2021. The decrease was primarily the result of:

a decrease of $32.1 million due primarily to development activities for our COVID-19 programs, which included AdCOVID and T-COVID (which were discontinued in 2021);

19

a decrease of $1.5 million due to change in the fair value of contingent consideration liability with respect to the acquisition of pemvidutide, which was fully paid on June 10, 2022;
an increase of $25.2 million due to the development activities for pemvidutide primarily due to the ongoing NAFLD trials and initiation of the MOMENTUM Phase 2 trial in obesity;
an increase of $2.9 million due to development activities for HepTcell; and
a net increase of $2.5 million due primarily to costs associated with non-project specific research and development costs including employee compensation and facility costs.

General and administrative expenses

General and administrative expense increased by $0.3 million, or 8% for the three months ended September 30, 2022, as compared to the three months ended September 30, 2022, primarily due to increase in stock compensation expense. For the nine months ended September 30, 2022, general and administrative expense increased by $1.7 million, or 15%, as compared to the nine months ended September 30, 2021, due primarily to a $1.2 million increase in stock compensation and other labor related costs and $0.4 million increase in professional fees.

Impairment loss on construction-in-progress

Impairment loss on construction-in-progress of $8.1 million reported during the nine months ended September 30, 2021 represents non-cash impairment charges recorded for assets that were previously capitalized in connection with the construction of the Lonza facility and subsequent discontinuation of AdCOVID. There were no such impairment charges reported during the nine months ended September 30, 2022.

Total other income (expense), net

Total other income (expense), net increased by $1.3 million and $1.7 million for the three and nine months ended September 30, 2022, as compared to the three and nine months ended September 30, 2021, respectively, primarily due to increase in interest income earned on our cash equivalents and short-term investments.

Income tax benefit

Income tax benefit of $0.2 million related to interest received and receivable on income tax refunds was recorded during the three and nine months ended September 30, 2022. Other than the income tax benefit related to interest, we did not record an income tax benefit in the three and nine months ended September 30, 2022 and 2021 due to a full valuation allowance.

Liquidity and Capital Resources

Overview

Our primary sources of cash during the nine months ended September 30, 2022 were from equity transactions. Our cash, cash equivalents, restricted cash and short-term investments were $201.9 million as of September 30, 2022. We believe, based on the operating cash requirements and capital expenditures expected for 2022 and 2023, our cash on hand as of September 30, 2022, together with expected cash receipts from our income tax refunds and R&D incentives, are sufficient to fund operations for at least a twelve-month period from the issuance date of our September 30, 2022 consolidated financial statements.

We have not generated any revenues from the sale of any products to date, and there is no assurance of any future revenues from product sales. Our sources of revenue have consisted of grant revenues under our arrangements with BARDA for the development of NasoShield, MTEC for a clinical trial and development work on T-COVID, and to a lesser degree from other licensing arrangements. We have incurred significant losses since we commenced operations. As of September 30, 2022, we had an accumulated deficit of $356.2 million. In addition, we have not generated positive cash flows from operations. We have had to rely on a variety of financing sources, including the issuance of debt and equity

20

securities. As capital resources are consumed to fund our research and development activities, we may require additional capital beyond our currently anticipated amounts. In order to address our capital needs, including our planned clinical trials, we must continue to actively pursue additional equity or debt financing, government funding, and monetization of our existing programs through partnership arrangements or sales to third parties.

On December 31, 2020, we filed a shelf registration statement on Form S-3, which was declared effective by the SEC on January 11, 2021. This shelf registration statement covered the offering, issuance and sale by us of up to an aggregate of $250.0 million of our common stock, preferred stock, debt securities, warrants, rights and units (the “2021 Shelf”). As of September 30, 2022, approximately $125.0 million remained available to be sold under the 2021 Shelf.  

In June 2020, we were awarded $4.7 million from the U.S. Army Medical Research & Development Command (“USAMRDC”) to fund our Phase 1/2 clinical trial of T-COVID. The competitive award was granted by USAMRDC in collaboration with the Medical Technology Enterprise Consortium (“MTEC”), a 501(c)(3) biomedical technology consortium working in partnership with the Department of Defense (“DoD”). Under the contract, MTEC paid us a firm fixed fee based upon the achievement of certain milestones for conduct and completion of a Phase 1/2 study and research and development work on the replication-deficient adenovirus 5 (“RD-Ad5”) vector vaccine platform. Through September 30, 2022, we have collected approximately $4.7 million in cash under the contract, which completed the full recognition of this award.

In July 2016, we signed a five-year contract with BARDA. The contract, as amended, had a total value of up to $136.8 million to be used to fund clinical development of NasoShield. Under the contract, BARDA paid us a fixed fee and reimbursed certain costs for the research and development of an Ad5-vectored, protective antigen-based intranasal anthrax vaccine through cGMP manufacture and conduct of a Phase 1 clinical trial dose ranging assessment of safety and immunogenicity. The contract consisted of an initial base performance period providing approximately $30.9 million in funding for the period July 2016 through December 2021. BARDA had seven options to extend the contract to fund certain continued development and manufacturing activities for the anthrax vaccine, including Phase 2 clinical trials. Each option, if exercised by BARDA, would have provided additional funding ranging from approximately $1.1 million to $34.4 million for a three-year period beginning in 2021. Through September 30, 2022, we have collected approximately $29.3 million in cash under the BARDA contract. BARDA did not extend the contract beyond the end of December 2021.

Cash Flows

The following table provides information regarding our cash flows for the nine months ended September 30, 2022 and 2021:

Nine Months Ended September 30, 

(in thousands)

    

2022

    

2021

Net cash (used in) provided by:

 

  

 

  

Operating activities

$

(45,280)

$

(56,271)

Investing activities

 

(74,380)

 

62,654

Financing activities

 

56,824

 

52,563

Net (decrease) increase in cash and cash equivalents and restricted cash

$

(62,836)

$

58,946

Operating Activities

Net cash used in operating activities was $45.3 million for the nine months ended September 30, 2022 compared to $56.3 million during the nine months ended September 30, 2021. The primary uses of cash from our operating activities include payments for labor and labor-related costs, professional fees, research and development costs associated with our clinical trials and other general corporate expenditures. The decrease in cash used in operations of $11.0 million year over year is due to changes in working capital accounts of $9.3 million and a decrease in net loss as adjusted for non-cash items of $1.7 million.

21

Investing Activities

Net cash used in investing activities was $74.4 million for the nine months ended September 30, 2022 compared to $62.7 million net cash provided during the nine months ended September 30, 2021. The net cash used in investing activities during the nine months ended September 30, 2022 was primarily due to purchase of short-term investments. The net cash provided by investing activities during the nine months ended September 30, 2021 was primarily due to $74.8 million net proceeds from short-term investment activity, partially offset by a $12.0 million purchases of property and equipment.

Financing Activities

Net cash provided by financing activities during the nine months ended September 30, 2022 was $56.8 million compared to $52.6 million for the nine months ended September 30, 2021. The net cash provided by financing activities during the nine months ended September 30, 2022 was primarily the result of the receipt of $56.2 million in net proceeds from the issuance of common stock from our at-the-market offerings program and $0.5 million in net proceeds from exercise of stock options. The net cash provided by financing activities during the nine months ended September 30, 2021 was primarily the result of the receipt of $52.4 million in net proceeds from the issuance of common stock from our at-the-market offerings program.

Financing

Public Offering

On July 16, 2020, we offered and sold (i) 3,369,564 shares of our common stock, at a price to the public of $23.00 per share, and (ii) pre-funded warrants to purchase 1,630,436 shares of our common stock at an exercise price equal to $0.0001 per share (the “Pre-Funded Warrants”), at a price to the public of $22.9999 per share of common stock underlying the Pre-Funded Warrants (equal to the public offering price per share of Common Stock, minus the exercise price of each Pre-Funded Warrant). The Pre-Funded Warrants are exercisable at any time, provided that each Pre-Funded Warrant holder will be prohibited from exercising such Pre-Funded Warrants into shares of our common stock if, as a result of such exercise, the holder, together with its affiliates, would own more than 4.99% of the total number of shares of our common stock then issued and outstanding, which percentage may change at the holders’ election to any other number less than or equal to 19.99% upon 61 days’ notice to us. The gross proceeds of this offering were approximately $132.2 million, which includes the exercise in full of the underwriters’ option to purchase an additional 750,000 shares of common stock, before deducting underwriting discounts and commissions and offering expenses during the third quarter of 2020. The net proceeds of this offering were approximately $124.0 million, after deducting underwriting discounts and commissions and offering expenses payable by us. As of September 30, 2022, 760,870 of the Pre-Funded Warrants were exercised, leaving 869,566 remaining Pre-Funded Warrants unexercised.

At-the-Market Offerings

On February 25, 2021, we entered into an Equity Distribution Agreement (the “2021 Agreement”) with Piper Sandler & Co., Evercore Group L.L.C. and B. Riley Securities, Inc., serving as sales agents (the “Sales Agents”) with respect to an at-the-market offerings program under which we offered and sold shares of our common stock, par value $0.0001 per share (the “Common Stock”), having an aggregate offering price of up to $125.0 million through the Sales Agents from the 2021 Shelf.

During the nine months ended September 30, 2022, we sold 5,204,415 shares of Common Stock under the 2021 Agreement resulting in approximately $56.2 million in net proceeds. As of September 30, 2022, we sold 10,004,869 shares of Common Stock under the 2021 Agreement resulting in approximately $121.0 million in net proceeds. As of September 30, 2022, there were no remaining shares available for issuance under the 2021 Agreement.

22

Current Resources

We have financed our operations to date principally through our equity offerings and proceeds from issuances of our preferred stock, common stock and warrants. As of September 30, 2022, we had $127.5 million of cash, cash equivalents and restricted cash and $74.4 million of short-term investments. Accordingly, management believes that we have sufficient capital to fund our plan of operations for at least a twelve-month period from the issuance date of our September 30, 2022 financial statements. However, in order to address our capital needs in the long-term, including potential future clinical trials, we must continue to actively pursue additional equity or debt financing, government funding, and monetization of our existing programs through partnership arrangements or sales to third parties.

Off-Balance Sheet Arrangements

We did not have during the periods presented, and we do not currently have, any off-balance sheet arrangements, as defined in the rules and regulations of the Securities and Exchange Commission.

Item 3. Quantitative and Qualitative Disclosures about Market Risk

As a “smaller reporting company” as defined by Item 10 of Regulation S-K, we are not required to provide the information required by this Item.

Item 4. Controls and Procedures

Evaluation of Disclosure Controls and Procedures

Our management, with the participation of our principal executive officer and principal financial officer, evaluated the effectiveness of our disclosure controls and procedures pursuant to Rule 13a-15 under the Securities Exchange Act of 1934, as amended (“the “Exchange Act”) as of the end of the period covered by this Quarterly Report on Form 10-Q.

Based on this evaluation, our principal executive officer and principal financial officer concluded that, as of September 30, 2022, our disclosure controls and procedures were effective to provide reasonable assurance that information we are required to disclose in reports that we file or submit under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate, to allow timely decisions regarding required disclosure.

Changes in Internal Control Over Financial Reporting

There were no changes in our internal control over financial reporting (as defined in Rule 13a-15(f) and Rule 15d-15(f) under the Exchange Act) during the quarter ended September 30, 2022 identified in connection with the evaluation thereof by our management, including the Chief Executive Officer and Chief Financial Officer, that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II. OTHER INFORMATION

Item 1. Legal Proceedings

From time to time, we may be involved in various legal proceedings arising from the normal course of business activities. Defending such proceedings is costly and can impose a significant burden on management and employees. The results of any current or future litigation cannot be predicted with certainty, and regardless of the outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources, and other factors.

23

In December 2019, a complaint was filed by Dr. De-Chu Christopher Tang (“Plaintiff”) against us, which we removed to the United States District Court for the Eastern District of Texas. The Plaintiff amended the complaint in February 2020 to include Vipin K. Garg and David J. Drutz as defendants, in addition to the Company (Dr. Garg, Dr. Drutz, and the Company are collectively referred to as “Defendants”). In December 2021, the Plaintiff refiled the complaint in the United States District Court for the District of Maryland. See Note 14 to the consolidated financial statements appearing in Item 1 of this report for further details.

Item 1A. Risk Factors

There have been no material changes from the risk factors disclosed in our Annual Report on Form 10-K filed with the SEC on March 15, 2022.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

None.

Item 3. Default upon Senior Securities

None.

Item 4. Mine Safety Disclosures

Not applicable.

Item 5. Other Information

None.

24

Item 6. Exhibits

Exhibit Index

Exhibit No.

    

Description

31.1 †

  

Certification of Principal Executive Officer Pursuant to SEC Rule 13a-14(a)/15d-14(a)

31.2 †

  

Certification of Principal Financial Officer Pursuant to SEC Rule 13a-14(a)/15d-14(a)

32.1 †

  

Certification Pursuant to Section 1350 of Chapter 63 of Title 18 of the United States Code

32.2 †

  

Certification Pursuant to Section 1350 of Chapter 63 of Title 18 of the United States Code

101.INS

  

Inline XBRL Instance Document (the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document)

101.SCH

  

Inline XBRL Taxonomy Extension Schema Document

101.CAL

  

Inline XBRL Taxonomy Extension Calculation Linkbase Document

101.DEF

  

Inline XBRL Taxonomy Extension Definition Linkbase Document

101.LAB

  

Inline XBRL Taxonomy Extension Label Linkbase Document

101.PRE

  

Inline XBRL Taxonomy Extension Presentation Linkbase Document

104

Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)

This certification will not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section. Such certification will not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except to the extent specifically incorporated by reference into such filing.

§

Certain portions of this exhibit have been omitted pursuant to a request for confidential treatment.

25

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused the report to be signed on its behalf by the undersigned, thereunto duly authorized.

ALTIMMUNE, INC.

Dated: November 10, 2022

By:

/s/ Vipin K. Garg

Name:

Vipin K. Garg

Title:

President and Chief Executive Officer (Principal Executive Officer)

Dated: November 10, 2022

By:

/s/ Richard Eisenstadt

Name:

Richard Eisenstadt

Title:

Chief Financial Officer (Principal Financial and Accounting Officer)

26

EX-31.1 2 alt-20220930xex31d1.htm EX-31.1

Exhibit 31.1

Certification of Principal Executive Officer

Pursuant to SEC Rule 13a-14(a)/15d-14(a)

I, Vipin K. Garg, certify that:

1.

I have reviewed this report on Form 10-Q of Altimmune, Inc. for the period ended September 30, 2022;

2.

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.

The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a)

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b)

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c)

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d)

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.

The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a)

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Dated: November 10, 2022

/s/ Vipin K. Garg

Name: Vipin K. Garg

Title: President and Chief Executive Officer
(Principal Executive Officer)


EX-31.2 3 alt-20220930xex31d2.htm EX-31.2

Exhibit 31.2

Certification of Principal Financial Officer

Pursuant to SEC Rule 13a-14(a)/15d-14(a)

I, Richard Eisenstadt, certify that:

1.

I have reviewed this report on Form 10-Q of Altimmune, Inc. for the period ended September 30, 2022;

2.

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.

The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a)

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b)

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c)

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d)

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.

The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a)

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Dated: November 10, 2022

/s/ Richard Eisenstadt

Name: Richard Eisenstadt

Title: Chief Financial Officer
(Principal Financial Officer)


EX-32.1 4 alt-20220930xex32d1.htm EX-32.1

Exhibit 32.1

Certification Pursuant to Section 1350 of Chapter 63

of Title 18 of the United States Code

In connection with the quarterly report on Form 10-Q of Altimmune, Inc. (the “Company”) for the period ended September 30, 2022, as filed with the Securities and Exchange Commission (the “Report”), I, Vipin K. Garg, President and Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:

1.

The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934.

2.

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

/s/ Vipin K. Garg

Vipin K. Garg

President and Chief Executive Officer

November 10, 2022

A signed original of this written statement required by Section 906 of the Sarbanes-Oxley Act of 2002 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.

This certification is being furnished pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, or otherwise subject to the liability of that section. This certification will not be deemed to be incorporated by reference into any filing under the Securities Act of 1933 or the Securities Exchange Act of 1934.


EX-32.2 5 alt-20220930xex32d2.htm EX-32.2

Exhibit 32.2

Certification Pursuant to Section 1350 of Chapter 63

of Title 18 of the United States Code

In connection with the quarterly report on Form 10-Q of Altimmune, Inc. (the “Company”) for the period ended September 30, 2022, as filed with the Securities and Exchange Commission (the “Report”), I, Richard Eisenstadt, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:

1.

The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934.

2.

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

/s/ Richard Eisenstadt

Richard Eisenstadt

Chief Financial Officer

November 10, 2022

A signed original of this written statement required by Section 906 of the Sarbanes-Oxley Act of 2002 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.

This certification is being furnished pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, or otherwise subject to the liability of that section. This certification will not be deemed to be incorporated by reference into any filing under the Securities Act of 1933 or the Securities Exchange Act of 1934.


GRAPHIC 6 alt-20220930x10q002.jpg GRAPHIC begin 644 alt-20220930x10q002.jpg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end EX-101.SCH 7 alt-20220930.xsd EX-101.SCH 99900 - Disclosure - Standard And Custom Axis Domain Defaults link:presentationLink link:calculationLink link:definitionLink 00100 - Statement - CONSOLIDATED BALANCE SHEETS link:presentationLink link:calculationLink link:definitionLink 00200 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS link:presentationLink link:calculationLink link:definitionLink 00400 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS link:presentationLink link:calculationLink link:definitionLink 40302 - Disclosure - Fair Value Measurements - Schedule of Short Term Investments (Detail) link:presentationLink link:calculationLink link:definitionLink 40501 - Disclosure - Accrued Expenses - Schedule of Accrued Expenses and Other Current Liabilities (Detail) link:presentationLink link:calculationLink link:definitionLink 40701 - Disclosure - Other Long-Term Liabilities - Summary of Other Long-Term Liabilities (Detail) link:presentationLink link:calculationLink link:definitionLink 00300 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY link:presentationLink link:calculationLink link:definitionLink 40301 - Disclosure - Fair Value Measurements - Schedule of Fair Value Assets and Liabilities Measured on Recurring Basis (Detail) link:presentationLink link:calculationLink link:definitionLink 40303 - Disclosure - Fair Value Measurements - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 40601 - Disclosure - Contingent Consideration - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 40801 - Disclosure - Common Stock - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 40901 - Disclosure - Warrants - Summary of Warrant Activity (Detail) link:presentationLink link:calculationLink link:definitionLink 40902 - Disclosure - Warrants - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 41001 - Disclosure - Stock-Based Compensation - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 41003 - Disclosure - Stock-Based Compensation - Schedule of Stock-based Compensation Expense (Detail) link:presentationLink link:calculationLink link:definitionLink 41101 - Disclosure - U.S. Government Contracts and Grants - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 41301 - Disclosure - Net Loss Per Share - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Detail) link:presentationLink link:calculationLink link:definitionLink 41401 - Disclosure - Commitments and Contingencies - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 00090 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 00105 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 10101 - Disclosure - Nature of Business and Basis of Presentation link:presentationLink link:calculationLink link:definitionLink 10201 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 10301 - Disclosure - Fair Value Measurements link:presentationLink link:calculationLink link:definitionLink 10401 - Disclosure - Operating Leases link:presentationLink link:calculationLink link:definitionLink 10501 - Disclosure - Accrued Expenses link:presentationLink link:calculationLink link:definitionLink 10601 - Disclosure - Contingent Consideration link:presentationLink link:calculationLink link:definitionLink 10701 - Disclosure - Other Long-Term Liabilities link:presentationLink link:calculationLink link:definitionLink 10801 - Disclosure - Common Stock link:presentationLink link:calculationLink link:definitionLink 10901 - Disclosure - Warrants link:presentationLink link:calculationLink link:definitionLink 11001 - Disclosure - Stock-Based Compensation link:presentationLink link:calculationLink link:definitionLink 11101 - Disclosure - U.S. Government Contracts and Grants link:presentationLink link:calculationLink link:definitionLink 11201 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 11301 - Disclosure - Net Loss Per Share link:presentationLink link:calculationLink link:definitionLink 11401 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 20202 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 30303 - Disclosure - Fair Value Measurements (Tables) link:presentationLink link:calculationLink link:definitionLink 30403 - Disclosure - Operating Leases (Tables) link:presentationLink link:calculationLink link:definitionLink 30503 - Disclosure - Accrued Expenses (Tables) link:presentationLink link:calculationLink link:definitionLink 30603 - Disclosure - Contingent Consideration (Tables) link:presentationLink link:calculationLink link:definitionLink 30703 - Disclosure - Other Long-Term Liabilities (Tables) link:presentationLink link:calculationLink link:definitionLink 30903 - Disclosure - Warrants (Tables) link:presentationLink link:calculationLink link:definitionLink 31003 - Disclosure - Stock-Based Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 31303 - Disclosure - Net Loss Per Share (Tables) link:presentationLink link:calculationLink link:definitionLink 40401 - Disclosure - Operating Leases - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 40402 - Disclosure - Operating Leases - Summary of Supplemental other Information Related to Operating Leases Balance Sheet (Detail) link:presentationLink link:calculationLink link:definitionLink 40602 - Disclosure - Contingent Consideration - Summary of Fair Value of Contingent Consideration (Detail) link:presentationLink link:calculationLink link:definitionLink 41002 - Disclosure - Stock-Based Compensation - Schedule of Information Related to Stock Options Outstanding (Detail) link:presentationLink link:calculationLink link:definitionLink 41201 - Disclosure - Income Taxes - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 8 alt-20220930_cal.xml EX-101.CAL EX-101.DEF 9 alt-20220930_def.xml EX-101.DEF EX-101.LAB 10 alt-20220930_lab.xml EX-101.LAB EX-101.PRE 11 alt-20220930_pre.xml EX-101.PRE XML 12 R1.htm IDEA: XBRL DOCUMENT v3.22.2.2
Document and Entity Information - shares
9 Months Ended
Sep. 30, 2022
Nov. 04, 2022
Cover [Abstract]    
Document Type 10-Q  
Amendment Flag false  
Document Quarterly Report true  
Document Period End Date Sep. 30, 2022  
Document Fiscal Year Focus 2022  
Document Fiscal Period Focus Q3  
Trading Symbol ALT  
Entity Registrant Name ALTIMMUNE, INC.  
Entity Central Index Key 0001326190  
Current Fiscal Year End Date --12-31  
Entity Current Reporting Status Yes  
Entity Filer Category Non-accelerated Filer  
Entity Small Business true  
Entity Emerging Growth Company false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   49,159,056
Entity Interactive Data Current Yes  
Title of 12(b) Security Common stock, par value $0.0001 per share  
Security Exchange Name NASDAQ  
Entity File Number 001-32587  
Entity Incorporation, State or Country Code DE  
Entity Tax Identification Number 20-2726770  
Entity Address, Address Line One 910 Clopper Road  
Entity Address, Address Line Two Suite 201S  
Entity Address, City or Town Gaithersburg  
Entity Address, State or Province MD  
Entity Address, Postal Zip Code 20878  
City Area Code 240  
Local Phone Number 654-1450  
Document Transition Report false  
XML 13 R2.htm IDEA: XBRL DOCUMENT v3.22.2.2
CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Sep. 30, 2022
Dec. 31, 2021
Current assets:    
Cash and cash equivalents $ 127,465 $ 190,301
Restricted cash 34 34
Total cash, cash equivalents and restricted cash 127,499 190,335
Short-term investments 74,362  
Accounts receivable 633 429
Income tax and R&D incentive receivables 3,720 5,410
Prepaid expenses and other current assets 4,790 7,952
Total current assets 211,004 204,126
Property and equipment, net 1,172 1,448
Intangible assets, net 12,419 12,419
Other assets 682 872
Total assets 225,277 218,865
Current liabilities:    
Accounts payable 1,419 2,034
Contingent consideration   6,090
Accrued expenses and other current liabilities 14,323 10,152
Total current liabilities 15,742 18,276
Other long-term liabilities 4,506 1,454
Total liabilities 20,248 19,730
Commitments and contingencies (Note 14)
Stockholders' equity:    
Common stock, $0.0001 par value; 200,000,000 shares authorized; 49,161,637 and 40,993,768 shares issued and outstanding as of September 30, 2022 and December 31, 2021, respectively 5 4
Additional paid-in capital 566,551 497,342
Accumulated deficit (356,224) (293,171)
Accumulated other comprehensive loss, net (5,303) (5,040)
Total stockholders' equity 205,029 199,135
Total liabilities and stockholders' equity $ 225,277 $ 218,865
XML 14 R3.htm IDEA: XBRL DOCUMENT v3.22.2.2
CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares
Sep. 30, 2022
Dec. 31, 2021
CONSOLIDATED BALANCE SHEETS    
Common stock, par or stated value per share $ 0.0001 $ 0.0001
Common stock, shares authorized 200,000,000 200,000,000
Common stock, shares issued 49,161,637 40,993,768
Common stock, shares outstanding 49,161,637 40,993,768
XML 15 R4.htm IDEA: XBRL DOCUMENT v3.22.2.2
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS        
Revenues $ 2 $ 158 $ 42 $ 1,133
Operating expenses:        
Research and development 20,262 29,206 51,359 54,356
General and administrative 4,492 4,156 13,329 11,636
Impairment loss on construction-in-progress       8,070
Total operating expenses 24,754 33,362 64,688 74,062
Loss from operations (24,752) (33,204) (64,646) (72,929)
Other income (expense):        
Interest expense (64) (33) (191) (67)
Interest income 1,053 13 1,402 88
Other income (expense), net 50 (286) 185 (293)
Total other income (expense), net 1,039 (306) 1,396 (272)
Net loss before income taxes (23,713) (33,510) (63,250) (73,201)
Income tax benefit 197   197  
Net loss (23,516) (33,510) (63,053) (73,201)
Other comprehensive income - unrealized (loss) gain on short-term investments (143) (2) (263) 4
Comprehensive loss $ (23,659) $ (33,512) $ (63,316) $ (73,197)
Net loss per share, basic $ (0.48) $ (0.81) $ (1.37) $ (1.79)
Net loss per share, diluted $ (0.48) $ (0.81) $ (1.37) $ (1.79)
Weighted-average common shares outstanding, basic 49,286,535 41,370,768 45,881,547 40,843,905
Weighted-average common shares outstanding, diluted 49,286,535 41,370,768 45,881,547 40,843,905
XML 16 R5.htm IDEA: XBRL DOCUMENT v3.22.2.2
CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY - USD ($)
$ in Thousands
Common Stock [Member]
Additional Paid-In Capital [Member]
Accumulated Deficit [Member]
Accumulated Other Comprehensive Loss [Member]
Total
Beginning Balance at Dec. 31, 2020 $ 4 $ 417,337 $ (186,421) $ (5,044) $ 225,876
Beginning Balance (in shares) at Dec. 31, 2020 37,142,946        
Stock-based compensation   1,218     1,218
Vesting of restricted stock awards including withholding, net   (92)     (92)
Vesting of restricted stock awards including withholding, net (in shares) (6,349)        
Issuance of common stock from Employee Stock Purchase Plan   106     106
Issuance of common stock from Employee Stock Purchase Plan (in shares) 8,733        
Issuance of common stock in at the market offerings, net   34,178     34,178
Issuance of common stock in at the market offerings, net (in shares) 2,110,800        
Retirement of common stock in exchange for common stock warrant   (7,540) (9,660)   (17,200)
Retirement of common stock in exchange for common stock warrant (in Shares) (1,000,000)        
Issuance of common stock warrant in exchange for retirement of common stock   17,200     17,200
Issuance of common stock upon cashless exercise of warrants   10     10
Issuance of common stock upon cashless exercise of warrants (in shares) 1,050        
Unrealized (loss) gain on short-term investments       5 5
Net loss     (14,864)   (14,864)
Ending Balance at Mar. 31, 2021 $ 4 462,417 (210,945) (5,039) 246,437
Ending Balance (in shares) at Mar. 31, 2021 38,257,180        
Beginning Balance at Dec. 31, 2020 $ 4 417,337 (186,421) (5,044) 225,876
Beginning Balance (in shares) at Dec. 31, 2020 37,142,946        
Unrealized (loss) gain on short-term investments         4
Net loss         (73,201)
Ending Balance at Sep. 30, 2021 $ 4 483,582 (269,282) (5,040) 209,264
Ending Balance (in shares) at Sep. 30, 2021 39,702,768        
Beginning Balance at Mar. 31, 2021 $ 4 462,417 (210,945) (5,039) 246,437
Beginning Balance (in shares) at Mar. 31, 2021 38,257,180        
Stock-based compensation   1,485     1,485
Exercise of stock options   94     94
Exercise of stock options (in shares) 38,217        
Vesting of restricted stock awards including withholding, net   (90)     (90)
Vesting of restricted stock awards including withholding, net (in shares) (7,583)        
Issuance of common stock in at the market offerings, net   18,178     18,178
Issuance of common stock in at the market offerings, net (in shares) 1,405,710        
Unrealized (loss) gain on short-term investments       1 1
Net loss     (24,827)   (24,827)
Ending Balance at Jun. 30, 2021 $ 4 482,084 (235,772) (5,038) 241,278
Ending Balance (in shares) at Jun. 30, 2021 39,693,524        
Stock-based compensation   1,497     1,497
Exercise of stock options   6     6
Exercise of stock options (in shares) 398        
Vesting of restricted stock awards including withholding, net   (124)     (124)
Vesting of restricted stock awards including withholding, net (in shares) (6,521)        
Issuance of common stock from Employee Stock Purchase Plan   119     119
Issuance of common stock from Employee Stock Purchase Plan (in shares) 15,367        
Unrealized (loss) gain on short-term investments       (2) (2)
Net loss     (33,510)   (33,510)
Ending Balance at Sep. 30, 2021 $ 4 483,582 (269,282) (5,040) 209,264
Ending Balance (in shares) at Sep. 30, 2021 39,702,768        
Beginning Balance at Dec. 31, 2021 $ 4 497,342 (293,171) (5,040) 199,135
Beginning Balance (in shares) at Dec. 31, 2021 40,993,768        
Stock-based compensation   2,033     2,033
Exercise of stock options   197     197
Exercise of stock options (in shares) 95,771        
Vesting of restricted stock awards including withholding, net   (170)     (170)
Vesting of restricted stock awards including withholding, net (in shares) 17,568        
Issuance of common stock from Employee Stock Purchase Plan   113     113
Issuance of common stock from Employee Stock Purchase Plan (in shares) 16,450        
Issuance of common stock in at the market offerings, net   2,990     2,990
Issuance of common stock in at the market offerings, net (in shares) 335,485        
Issuance of common stock upon cashless exercise of warrants (in shares) 1,760,854        
Net loss     (19,430)   (19,430)
Ending Balance at Mar. 31, 2022 $ 4 502,505 (312,601) (5,040) 184,868
Ending Balance (in shares) at Mar. 31, 2022 43,219,896        
Beginning Balance at Dec. 31, 2021 $ 4 497,342 (293,171) (5,040) 199,135
Beginning Balance (in shares) at Dec. 31, 2021 40,993,768        
Unrealized (loss) gain on short-term investments         (263)
Net loss         (63,053)
Ending Balance at Sep. 30, 2022 $ 5 566,551 (356,224) (5,303) 205,029
Ending Balance (in shares) at Sep. 30, 2022 49,161,637        
Beginning Balance at Mar. 31, 2022 $ 4 502,505 (312,601) (5,040) 184,868
Beginning Balance (in shares) at Mar. 31, 2022 43,219,896        
Stock-based compensation   2,048     2,048
Exercise of stock options   403     403
Exercise of stock options (in shares) 152,913        
Vesting of restricted stock awards including withholding, net   (80)     (80)
Vesting of restricted stock awards including withholding, net (in shares) (5,865)        
Issuance of common stock in at the market offerings, net $ 1 21,346     21,347
Issuance of common stock in at the market offerings, net (in shares) 2,157,717        
Issuance of common stock related to contingent consideration liability   6,176     6,176
Issuance of common stock related to contingent consideration liability (in shares) 847,444        
Unrealized (loss) gain on short-term investments       (120) (120)
Net loss     (20,107)   (20,107)
Ending Balance at Jun. 30, 2022 $ 5 532,398 (332,708) (5,160) 194,535
Ending Balance (in shares) at Jun. 30, 2022 46,372,105        
Stock-based compensation   2,128     2,128
Exercise of stock options   268     268
Exercise of stock options (in shares) 76,161        
Vesting of restricted stock awards including withholding, net   (140)     (140)
Vesting of restricted stock awards including withholding, net (in shares) (7,744)        
Issuance of common stock from Employee Stock Purchase Plan   68     68
Issuance of common stock from Employee Stock Purchase Plan (in shares) 9,945        
Issuance of common stock in at the market offerings, net   31,829     31,829
Issuance of common stock in at the market offerings, net (in shares) 2,711,013        
Other increase (in shares) 157        
Unrealized (loss) gain on short-term investments       (143) (143)
Net loss     (23,516)   (23,516)
Ending Balance at Sep. 30, 2022 $ 5 $ 566,551 $ (356,224) $ (5,303) $ 205,029
Ending Balance (in shares) at Sep. 30, 2022 49,161,637        
XML 17 R6.htm IDEA: XBRL DOCUMENT v3.22.2.2
CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
$ in Thousands
9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
CASH FLOWS FROM OPERATING ACTIVITIES:    
Net loss $ (63,053) $ (73,201)
Adjustments to reconcile net loss to net cash used in operating activities:    
Change in fair value of contingent consideration liability 86 1,560
Impairment loss on construction-in-progress   8,070
Stock-based compensation expense 6,209 4,200
Depreciation and amortization 31 434
Unrealized (gains) losses on foreign currency exchange (183) 297
Changes in operating assets and liabilities:    
Accounts receivable (204) 3,036
Prepaid expenses and other assets 3,204 (5,263)
Accounts payable (615) (606)
Accrued expenses and other liabilities 7,555 6,916
Income tax and R&D incentive receivables 1,690 (1,714)
Net cash used in operating activities (45,280) (56,271)
CASH FLOWS FROM INVESTING ACTIVITIES:    
Proceeds from sales and maturities of short-term investments   82,406
Purchases of short-term investments (74,292) (7,592)
Purchases of property and equipment, net (88) (11,970)
Cash paid for internally developed patents   (190)
Net cash (used in) provided by investing activities (74,380) 62,654
CASH FLOWS FROM FINANCING ACTIVITIES:    
Payments of deferred offering costs   (118)
Proceeds from issuance of common stock in at-the-market offerings, net 56,166 52,356
Proceeds from issuance of common stock from Employee Stock Purchase Plan 181 225
Proceeds from exercises of stock options, net 477 100
Net cash provided by financing activities 56,824 52,563
Net (decrease) increase in cash and cash equivalents and restricted cash (62,836) 58,946
Cash, cash equivalents and restricted cash at beginning of period 190,335 115,952
Cash, cash equivalents and restricted cash at end of period 127,499 174,898
SUPPLEMENTAL NON-CASH ACTIVITIES:    
Common stock issued related to contingent consideration liability $ 6,176  
Operating lease liability and right of use asset addition   $ 72
XML 18 R7.htm IDEA: XBRL DOCUMENT v3.22.2.2
Nature of Business and Basis of Presentation
9 Months Ended
Sep. 30, 2022
Nature of Business and Basis of Presentation  
Nature of Business and Basis of Presentation

1. Nature of Business and Basis of Presentation

Nature of Business

Altimmune, Inc., headquartered in Gaithersburg, Maryland, United States, together with its subsidiaries (collectively, the “Company” or “Altimmune”) is a clinical stage biopharmaceutical company incorporated under the laws of the State of Delaware.

The Company is focused on developing treatments for obesity and liver diseases. The Company’s pipeline includes next generation peptide therapeutics for obesity and non-alcoholic steatohepatitis (“NASH”) (for both, pemvidutide, formerly known as ALT-801), and for chronic hepatitis B (HepTcell). Since its inception, the Company has devoted substantially all of its efforts to business planning, research and development, recruiting management and technical staff and raising capital, and has financed its operations through the issuance of common and preferred stock, long-term debt and proceeds from research grants and government contracts. The Company has not generated any revenues from the sale of any products to date, and there is no assurance of any future revenues from product sales.

Basis of Presentation

The accompanying unaudited consolidated financial statements are prepared pursuant to the rules and regulations of the U.S. Securities and Exchange Commission (“SEC”) regarding interim financial reporting. Accordingly, they do not include all of the information and disclosures required by accounting principles generally accepted in the United States (“U.S. GAAP”) for complete consolidated financial statements and should be read in conjunction with the audited consolidated financial statements for the year ended December 31, 2021 included in the Annual Report on Form 10-K which was filed with the SEC on March 15, 2022. In the opinion of management, the Company has prepared the accompanying unaudited consolidated financial statements on the same basis as the audited consolidated financial statements, and these consolidated financial statements include all adjustments, consisting only of normal recurring adjustments, necessary for a fair presentation of the results of the interim periods presented. The operating results for the interim periods presented are not necessarily indicative of the results expected for the full year 2022 or any future years or periods.

The accompanying unaudited consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation.

The accompanying unaudited consolidated financial statements have been prepared on the basis of continuity of operations, realization of assets, and the satisfaction of liabilities in the ordinary course of business. The financial statements do not include any adjustments relating to the recoverability and classification of recorded assets and liabilities that might be necessary should we be unable to continue as a going concern.

XML 19 R8.htm IDEA: XBRL DOCUMENT v3.22.2.2
Summary of Significant Accounting Policies
9 Months Ended
Sep. 30, 2022
Summary of Significant Accounting Policies  
Summary of Significant Accounting Policies

2. Summary of Significant Accounting Policies

During the nine months ended September 30, 2022, there have been no significant changes to the Company’s summary of significant accounting policies contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021 as filed with the SEC.

Use of Estimates

The preparation of these financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. The extent to which the COVID-19 pandemic, including any resurgences or the emergence of new variants, may directly or indirectly impact the Company’s business, financial condition, and results of operations is highly uncertain and subject to change.

The Company considered the potential impact of the COVID-19 pandemic on the Company’s estimates and assumptions and determined that there was not a material impact to the Company’s unaudited consolidated financial statements as of and for the three and nine months ended September 30, 2022. However, actual results could differ from those estimates and there may be changes to the Company’s estimates in future periods.

XML 20 R9.htm IDEA: XBRL DOCUMENT v3.22.2.2
Fair Value Measurements
9 Months Ended
Sep. 30, 2022
Fair Value Measurements  
Fair Value Measurements

3. Fair Value Measurements

The Company’s assets measured at fair value on a recurring basis as of September 30, 2022 consisted of the following (in thousands):

Fair Value Measurement at September 30, 2022

    

Total

    

Level 1

    

Level 2

    

Level 3

Assets:

Cash equivalents - money market funds

$

123,921

$

123,921

$

$

Short-term investments

 

74,362

 

 

74,362

 

Total

$

198,283

$

123,921

$

74,362

$

The Company’s assets and liabilities measured at fair value on a recurring basis as of December 31, 2021 consisted of the following (in thousands):

Fair Value Measurement at December 31, 2021

    

Total

    

Level 1

    

Level 2

    

Level 3

Assets:

Cash equivalents - money market funds

$

65,634

    

$

65,634

    

$

    

$

Total

$

65,634

$

65,634

$

$

Liabilities:

Contingent consideration liability (see Note 6)

$

6,090

$

$

$

6,090

Total

$

6,090

$

$

$

6,090

As described in Note 6 the remaining milestone payment underlying the contingent consideration liability was fully settled in shares of the Company’s common stock. As of September 30, 2022, the Company had no contingent consideration liability.

Short-term investments have been initially valued at the transaction price and subsequently valued, at the end of each reporting period, utilizing third party pricing services or other market observable data (Level 2). The pricing services utilize industry standard valuation models, including both income and market-based approaches and observable market inputs to determine value.

Short-term investments had quoted prices as of September 30, 2022 as shown below (in thousands):

September 30, 2022

Amortized Cost

Unrealized Loss

Market Value

United States treasury securities

    

$

17,784

    

$

(112)

    

$

17,672

Commercial paper and corporate debt securities

49,931

(124)

49,807

Asset backed securities

 

6,910

 

(27)

 

6,883

Total

$

74,625

$

(263)

$

74,362

Separate disclosure is required for assets and liabilities measured at fair value on a recurring basis from those measured at fair value on a non-recurring basis. Assets recorded at fair value on a non-recurring basis, such as property and equipment and intangible assets are recognized at fair value when they are impaired. During the nine months ended September 30, 2022, the Company had no significant assets or liabilities that were measured at fair value on a non-recurring basis. During the year ended December 31, 2021, the Company recorded non-cash impairment charges to property and equipment, net on a non-recurring basis (see below).

Lonza Manufacturing Agreement

In March 2021, the Company expanded its manufacturing collaboration with Lonza Houston, Inc. (“Lonza”) for the manufacture of AdCOVID or other adenovirus-based vaccines. Under the expanded agreement, the Company had committed approximately $23.0 million to Lonza to procure long-lead equipment and construct a dedicated manufacturing suite for clinical and commercial production of adenovirus-based vaccines. In June 2021, the Company announced the discontinuation of further development of AdCOVID following the Company’s review of findings from its Phase 1 clinical trial. Construction continued at Lonza, and the Company assessed its strategic options with respect to the suite. This work was completed during the fourth quarter of 2021. The Company capitalized a total of $11.4 million as construction-in-progress (“CIP”) during the nine months ended September 30, 2021 under this expanded agreement.

In connection with the discontinuation of further development of AdCOVID, the Company recorded a non-cash impairment charge of $8.1 million in the unaudited consolidated statements of operations and comprehensive loss for the nine months ended September 30, 2021 to write-down the CIP associated with the construction of the Lonza facility to its fair value of $3.3 million as of September 30, 2021. As of September 30, 2021, the fair value of the CIP related assets was primarily determined utilizing the cost approach, which reflected the replacement cost of the asset being appraised, adjusted for contractual restrictions on the assets, the probability of satisfying the contractual restrictions, physical deterioration, functional obsolescence and economic obsolescence. The fair value measurement was considered a Level 3 measurement within the valuation hierarchy.

Furthermore, the remaining $3.3 million CIP was fully charged to impairment during the three months ended December 31, 2021 upon termination of the agreement.

XML 21 R10.htm IDEA: XBRL DOCUMENT v3.22.2.2
Operating Leases
9 Months Ended
Sep. 30, 2022
Operating Leases  
Operating Leases

4. Operating Leases

The Company rents office and laboratory space in the United States which expires in April 2025. Rent expense under the Company’s operating leases was $0.1 million and $0.4 million during each of the three and nine months ended September 30, 2022 and 2021, respectively. Rent expense includes short-term leases and variable lease costs that are not included in the lease obligation.

Short-term leases are leases having a term of twelve months or less. The Company recognizes short-term leases on a straight-line basis and does not record a related lease asset or liability for such leases.

The office space lease provides for increases in future minimum annual rental payments as defined in the lease agreement. The office space lease also includes an option to renew the lease as of the end of the term. The Company has determined that the lease renewal option is not reasonably certain of being exercised.

The cash paid for operating lease liabilities for each of the nine months ended September 30, 2022 and 2021 was $0.4 million.

Supplemental other information related to the operating leases balance sheet information is as follows (in thousands):

 

September 30, 2022

December 31, 2021

 

Operating lease obligations (see Note 5 and 7)

    

$

1,230

    

$

1,535

Operating lease right-of-use assets (included in "Other assets" in Balance Sheet)

$

649

$

798

Weighted-average remaining lease term (years)

 

2.6

 

3.3

Weighted-average discount rate

 

7.2

%  

 

7.2

%

XML 22 R11.htm IDEA: XBRL DOCUMENT v3.22.2.2
Accrued Expenses
9 Months Ended
Sep. 30, 2022
Accrued Expenses  
Accrued Expenses

5. Accrued Expenses

Accrued expenses and other current liabilities consist of the following (in thousands):

September 30, 2022

December 31, 2021

Accrued professional services

    

$

624

    

$

396

Accrued payroll and employee benefits

 

2,110

 

2,313

Accrued research and development

 

9,930

 

6,988

Lease obligation, current portion (see Note 4)

 

442

 

411

Income tax payable

1,169

Accrued interest and other

 

48

 

44

Total accrued expenses and other current liabilities

$

14,323

$

10,152

XML 23 R12.htm IDEA: XBRL DOCUMENT v3.22.2.2
Contingent Consideration
9 Months Ended
Sep. 30, 2022
Contingent Consideration  
Contingent consideration

6. Contingent Consideration

The Company entered into an Agreement and Plan of Merger and Reorganization, dated July 8, 2019, by and among the Company, Springfield Merger Sub, Inc., Springfield Merger Sub, LLC, Spitfire Pharma, Inc. and David Collier, as the Stockholder Representative (the “Spitfire Merger Agreement”) to acquire all of the equity interests of Spitfire Pharma, Inc. (“Spitfire”). Spitfire was a privately held, preclinical pharmaceutical company developing a novel GLP-1/glucagon receptor dual agonist for the treatment of NASH.

The transaction closed on July 12, 2019. The Company issued 1,887,250 unregistered shares of its common stock as upfront consideration to certain former securityholders of Spitfire, representing an amount equal to $5.0 million less working capital and transaction expense adjustment amounts as defined in the agreement.

The acquisition of Spitfire was accounted for as an asset acquisition instead of a business combination because substantially all of the fair value of the gross assets acquired was concentrated in a single identifiable asset or group of similar identifiable assets, and therefore, the asset was not considered a business. The Company expensed the acquired intellectual property as of the acquisition date as in-process research and development with no alternative future uses.

The Spitfire Merger Agreement also includes future contingent payments up to $88.0 million in cash and shares of the Company’s common stock as follows:

a one-time payment of $5.0 million (the “IND Milestone Consideration Amount”) within sixty days of the submission of an Investigational New Drug Application (“IND”) to the United States Food and Drug Administration (the “FDA”) or other applicable governmental authority in a foreign jurisdiction, which IND has not been rejected or placed on clinical hold by the FDA or such applicable foreign governmental authority within time specified in the Spitfire Merger Agreement;
a one-time payment of $3.0 million (the “Phase 2 Milestone Consideration Amount” and together with the IND Milestone Consideration Amount, the “Regulatory Milestones”) within sixty days of the initiation (first patient, first dosing) of a Phase 2 clinical trial of a product candidate anywhere in the world (a “Phase 2 Milestone Event”); and
payments of up to $80.0 million upon the achievement of specified worldwide net sales (the “Sales Milestones”) of all products developed using the technology acquired in the Amended and Restated License Agreement, dated July 12, 2019, by and between Mederis Diabetes, LLC and Spitfire, within ten years following the approval of a new drug application filed with the FDA.

The Regulatory Milestones were payable in shares of the Company’s common stock, with the number of shares of the Company’s common stock issued in connection with each milestone amount, if any, dependent on the share price at the time of achievement. The number of shares issued in consideration for the IND Milestone Consideration Amount was determined based on the lower of (A) the average of the closing prices of the Company’s common stock as reported on the Nasdaq Global Market for the twenty (20) consecutive trading days prior to the IND Reference Date or (B) $2.95.

The number of shares issued in consideration for the Phase 2 Milestone Consideration Amount was determined based on the lower of (A) the average of the closing trading prices of the Company’s common stock as reported on the Nasdaq Global Market for the twenty (20) consecutive trading days immediately preceding the date of the occurrence of the Phase 2 Milestone Event or (B) $3.54.

The contingent payments related to the Regulatory Milestones were stock-based payments accounted for under FASB Accounting Standards Codification Topic 480, Distinguishing Liabilities From Equity (“ASC 480”). Such stock-based payments are subject to a lock-up whereby 50% of the shares are released at 3 months following issuance and 50% are released at 6 months following issuance. The future contingent payments related to the Sales Milestones are predominately cash-based payments accounted for under FASB Accounting Standards Codification Topic 450, Contingencies. Accordingly, the Company will recognize the Sales Milestones when the contingency is probable and the amount can be reasonably estimated.

On November 3, 2020, the Company received acknowledgement from the Australian Government Department of Health on the Company’s submitted clinical trial notification (“CTN”) which triggered the obligation to settle the IND Milestone payment to the former owners. As a result, on November 19, 2020, the Company issued 1,694,906 shares of its common stock valued at $9.57 per share for the amount value of $13.6 million to the former Spitfire stockholders. Pursuant to the Spitfire Merger Agreement, the Company issued the shares within sixty days of the submission of the CTN, which was October 29, 2020. From September 30, 2020 through November 19, 2020, the date of issuance, the Company recognized a decrease in the fair value of the IND Milestone payment of $5.4 million to research and development expense and reclassified the balance in the contingent consideration liability associated with the fair value of the IND Milestone payment to equity in the Company’s consolidated balance sheet.

On April 26, 2022, the Company dosed the first patient in the Phase 2 MOMENTUM trial of pemvidutide in obesity, which triggered the obligation to pay the Phase 2 Milestone Consideration Amount to the former owners. As a result, on June 10, 2022, the Company issued 847,444 shares of its common stock valued at $8.55 per share for the amount value of $7.2 million to the former Spitfire stockholders. From the last valuation date on March 31, 2022 through June 10, 2022, the date of issuance, the Company recognized an increase in the fair value of the Phase 2 Milestone Consideration Amount of $1.9 million to research and development expense and reclassified the balance in the contingent consideration liability to equity in the Company’s consolidated balance sheet. As of September 30, 2022, the Company had no contingent consideration liability.

Below is a summary of the contingent consideration activity (in thousands):

Nine Months Ended September 30, 

2022

2021

Beginning balance

    

$

6,090

    

$

5,390

Change in fair value

 

86

 

1,560

Fair value of payments settled in common stock (Phase II Milestone)

 

(6,176)

 

Ending balance

$

$

6,950

XML 24 R13.htm IDEA: XBRL DOCUMENT v3.22.2.2
Other Long-Term Liabilities
9 Months Ended
Sep. 30, 2022
Other Long-Term Liabilities  
Other Long-Term Liabilities

7. Other Long-Term Liabilities

During the nine months ended September 30, 2022, the Company received a total of $3.4 million in cash for research and development (“R&D”) incentive credit that the Company earned during the fiscal years 2021 and 2020 through the participation in the Australian research and development incentive credit program administered through the Australian Tax Office. The Company recorded the receipt as long-term liability until there is reasonable assurance that the Company will comply with the conditions attached to the incentive credit. See Note 2. Summary of Significant Accounting Policies in the Company’s 2021 Annual Report on Form 10-K for accounting policies related to research and development incentive credits.

The Company’s other long-term liabilities are summarized as follows (in thousands):

September 30, 2022

December 31, 2021

Research and development incentive credit

$

3,402

$

Lease obligation, long-term portion (see Note 4)

    

788

    

1,124

Conditional economic incentive grants

 

250

 

250

Other

 

66

 

80

Total other long-term liabilities

$

4,506

$

1,454

XML 25 R14.htm IDEA: XBRL DOCUMENT v3.22.2.2
Common Stock
9 Months Ended
Sep. 30, 2022
Common Stock  
Common Stock

8. Common Stock

Public Offering

On July 16, 2020, the Company offered and sold (i) 3,369,564 shares of common stock, at a price to the public of $23.00 per share, and (ii) pre-funded warrants of the Company to purchase 1,630,436 shares of common stock at an exercise price equal to $0.0001 per share (the “Pre-Funded Warrants”), at a price to the public of $22.9999 per share of common stock underlying the Pre-Funded Warrants (equal to the public offering price per share of Common Stock, minus the exercise price of each Pre-Funded Warrant). The Pre-Funded Warrants are exercisable at any time, provided that each Pre-Funded Warrant holder will be prohibited from exercising such Pre-Funded Warrants into shares of the Company’s common stock if, as a result of such exercise, the holder, together with its affiliates, would own more than 4.99% of the total number of shares of the Company’s common stock then issued and outstanding, which percentage may change at the holders’ election to any other number less than or equal to 19.99% upon 61 days’ notice to the Company. The gross proceeds of this offering were approximately $132.2 million, which includes the exercise in full of the underwriters’ option to purchase an additional 750,000 shares of common stock, before deducting underwriting discounts and commissions and offering expenses during the third quarter of 2020. The net proceeds of this offering were approximately $124.0 million, after deducting underwriting discounts and commissions and offering expenses payable by the Company.

The Company has assessed the Pre-Funded Warrants for appropriate equity or liability classification and determined that the Pre-Funded Warrants are freestanding instruments that do not meet the definition of a liability pursuant to ASC 480 and do not meet the definition of a derivative pursuant to FASB Accounting Standards Codification Topic 815, Derivatives and Hedging (“ASC 815”). The Pre-Funded Warrants are indexed to the Company’s common stock and meet all other conditions for equity classification under ASC 480 and ASC 815. Accordingly, the Pre-Funded Warrants are classified as equity and are accounted for as a component of additional paid-in capital at the time of issuance. As of September 30, 2022, 760,870 of the Pre-Funded Warrants were exercised, leaving 869,566 remaining Pre-Funded Warrants unexercised.

At-the-Market Offerings

On February 25, 2021, the Company entered into an Equity Distribution Agreement (the “2021 Agreement”) with Piper Sandler & Co., Evercore Group L.L.C. and B. Riley Securities, Inc., serving as sales agents (the “Sales Agents”) with respect to an at-the-market offerings program under which the Company offered and sold shares of its common stock, par value $0.0001 per share (the “Common Stock”), having an aggregate offering price of up to $125.0 million (the “Shares”) through the Sales Agents (the “2021 Offering”). All the Shares offered and sold in the 2021 Offering were issued pursuant to the Company’s Registration Statement on Form S-3 filed with the Securities and Exchange Commission (the “SEC”) on December 31, 2020, which was declared effective on January 11, 2021 (“2021 Shelf”), the prospectus supplement relating to the 2021 Offering filed with the SEC on February 25, 2021 and any applicable additional prospectus supplements related to the 2021 Offering that form a part of the Registration Statement.

During the nine months ended September 30, 2022, the Company sold 5,204,415 shares of Common Stock under the 2021 Agreement resulting in approximately $56.2 million in proceeds, net of $1.9 million commission and other offering costs. As of September 30, 2022, the Company has sold 10,004,869 shares of Common Stock under the 2021 Agreement resulting in approximately $121.0 million in proceeds, net of $4.0 million commission and other offering costs, As of September 30, 2022, there were no remaining shares available for issuance under the 2021 Agreement. The Company

recorded approximately $0.3 million of other offering costs which offset the proceeds received from the shares sold through September 30, 2022.

Exchange Agreement

On February 25, 2021, the Company entered into an exchange agreement (the “Exchange Agreement”) with an investor and its affiliates (the “Exchanging Stockholders”), pursuant to which the Company exchanged an aggregate of 1,000,000 shares of the Company’s common stock, par value $0.0001 per share, owned by the Exchanging Stockholders for pre-funded warrants (the “Exchange Warrants”) to purchase an aggregate of 1,000,000 shares of common stock (subject to adjustment in the event of any stock dividends and splits, reverse stock split, recapitalization, reorganization or similar transaction, as described in the Exchange Warrants), with an exercise price of $0.0001 per share. The Exchange Warrants did not have an expiration date and were exercisable at any time except that the Exchange Warrants could not be exercised by the Exchanging Stockholders if, after giving effect thereto, the Exchanging Stockholders would beneficially own more than 9.99% of the Company’s common stock, subject to certain exceptions. In accordance with FASB Accounting Standards Codification Topic 505, Equity, the Company recorded the retirement of the common stock exchanged as a reduction of common shares outstanding and a corresponding debit to additional paid-in-capital and accumulated deficit at the fair value of the Exchange Warrants on the issuance date. The Exchange Warrants were classified as equity in accordance with ASC 480 and the fair value of the Exchange Warrants was recorded as a credit to additional paid-in-capital and is not subject to remeasurement. The Company determined that the fair value of the Exchange Warrants is substantially similar to the fair value of the retired shares on the issuance date due to the negligible exercise price for the Exchange Warrants. On January 24, 2022, the Exchange Warrants to purchase 1,000,000 shares were net exercised, resulting in the issuance of 999,984 shares of common stock, and no Exchange Warrants remain outstanding.

XML 26 R15.htm IDEA: XBRL DOCUMENT v3.22.2.2
Warrants
9 Months Ended
Sep. 30, 2022
Warrants  
Warrants

9. Warrants

A summary of warrant activity during the nine months ended September 30, 2022 is as follows:

Weighted-Average

    

    

Weighted

Remaining

Number of

Average

Contractual Term

Warrants

Exercise Price

(Years)

Warrants outstanding, December 31, 2021

 

2,776,191

 

Expired

(155)

Exercises (see Note 8)

 

(1,760,870)

 

Warrants outstanding, September 30, 2022

 

1,015,166

 

$

0.66

1.2

The warrants outstanding as of September 30, 2022 included 869,566 Pre-Funded Warrants with an exercise price of $0.0001 per-share and no expiration date.

XML 27 R16.htm IDEA: XBRL DOCUMENT v3.22.2.2
Stock-Based Compensation
9 Months Ended
Sep. 30, 2022
Stock-Based Compensation  
Stock-Based Compensation

10. Stock-Based Compensation

Stock Options

The Company’s stock option awards generally vest over four years and typically have a contractual life of ten years. As of September 30, 2022, there was $13.7 million of unrecognized compensation cost related to stock options, which is expected to be recognized over a weighted-average period of 2.6 years. During the nine months ended September 30, 2022, the Company granted 1,433,427 stock options with a weighted average exercise price of $8.39 and per share weighted average grant date fair value of $6.97.

Information related to stock options outstanding as of September 30, 2022 is as follows (in thousands, except share and per share data):

    

    

    

Weighted-Average

    

Weighted-

Remaining

Number of

Average

Contractual Term

Aggregate Intrinsic

Stock Options

Exercise Price

(Years)

Value

Outstanding

 

3,528,473

$

9.09

 

5.9

$

16,975

Exercisable

 

1,382,587

$

8.75

 

5.8

$

7,824

Unvested

 

2,145,886

$

9.31

 

6.0

$

9,151

Restricted Stock

As of September 30, 2022, the Company had unvested restricted stock of 13,454 shares with total unrecognized compensation expense of $47,000, which the Company expects to recognize over a weighted average period of approximately 0.2 years. During the nine months ended September 30, 2022, the Company issued 34,132 of unrestricted common stock as a result of the vesting of 60,546 restricted stock net of 26,414 shares of common stock withheld to satisfy tax withholding obligations.

Restricted Stock Units (RSUs)

During the nine months ended September 30, 2022, the Company granted 285,000 shares of RSUs with a weighted average grant date fair value of $7.11 which vest over four years. As of September 30, 2022, the Company had unvested RSUs of 470,275 shares with total unrecognized compensation expense of $3.4 million, which the Company expects to recognize over a weighted average period of approximately 3.1 years. During the nine months ended September 30, 2022, the Company issued 30,373 shares of unrestricted common stock as a result of the vesting of 46,653 RSUs net of 16,280 shares of common stock withheld to satisfy tax withholding obligations.

2019 Employee Stock Purchase Plan (ESPP)

Under the ESPP, employees purchased 26,395 shares for $0.2 million during the nine months ended September 30, 2022. During the three and nine months ended September 30, 2022, the Company recognized compensation expense of $0.1 million and $0.2 million respectively. During the three and nine months ended September 30, 2021, the Company recognized compensation expense of $29,000 and $0.3 million, respectively.

Stock-based Compensation Expense

Stock-based compensation expense is classified in the unaudited consolidated statements of operations and comprehensive loss for the three and nine months ended September 30, 2022 and 2021 as follows (in thousands):

    

For the Three Months Ended

    

For the Nine Months Ended

September 30, 

September 30, 

2022

    

2021

2022

    

2021

Research and development

$

743

$

449

$

2,024

$

1,211

General and administrative

 

1,385

 

1,048

 

4,185

 

2,989

Total

$

2,128

$

1,497

$

6,209

$

4,200

XML 28 R17.htm IDEA: XBRL DOCUMENT v3.22.2.2
U.S. Government Contracts and Grants
9 Months Ended
Sep. 30, 2022
U.S. Government Contracts and Grants  
U.S. Government Contracts and Grants

11. U.S. Government Contracts and Grants

In June 2020, the Company was awarded $4.7 million from the U.S. Army Medical Research & Development Command (“USAMRDC”) to fund its Phase 1/2 clinical trial of T-COVID. The competitive award was granted by USAMRDC in collaboration with the Medical Technology Enterprise Consortium (“MTEC”), a 501(c)(3) biomedical technology consortium working in partnership with the Department of Defense (“DoD”). Under the contract, MTEC paid the Company a firm fixed fee based upon the achievement of certain milestones for conduct and completion of a Phase 1/2 study and research and development work on the replication-deficient adenovirus 5 (“RD-Ad5”) vector vaccine

platform. For the nine months ended September 30, 2021, the Company recognized approximately $0.5 million of grant revenue under the contract, which completed the full recognition of this award. No revenue was recognized for this contract for the three and nine months ended September 30, 2022.

In July 2016, the Company signed a five-year contract with Biomedical Advanced Research and Development Authority (“BARDA”). The contract, as amended, had a total value of up to $136.8 million to be used to fund clinical development of NasoShield. Under the contract, BARDA paid the Company a fixed fee and reimbursed certain costs for the research and development of an Ad5-vectored, protective antigen-based intranasal anthrax vaccine through cGMP manufacture and conduct of a Phase 1 clinical trial dose ranging assessment of safety and immunogenicity. The contract consisted of an initial base performance period providing approximately $30.9 million in funding for the period July 2016 through December 2021. BARDA had seven options to extend the contract to fund certain continued development and manufacturing activities for the anthrax vaccine, including Phase 2 clinical studies. Each option, if exercised by BARDA, would have provided additional funding ranging from approximately $1.1 million to $34.4 million for a three-year period beginning in 2021. For the three and nine months ended September 30, 2021, the Company recognized approximately $0.1 million and $0.4 million, respectively, of grant revenue under the BARDA contract. For the three and nine months ended September 30, 2022, the Company has recognized de minimis grant revenue related to the close-out of the BARDA contract. BARDA did not extend the contract beyond the end of December 2021.

XML 29 R18.htm IDEA: XBRL DOCUMENT v3.22.2.2
Income Taxes
9 Months Ended
Sep. 30, 2022
Income Taxes  
Income Taxes

12. Income Taxes

During the three and nine months ended September 30, 2022, the Company recorded a total of $0.2 million income tax benefit related to interest received and receivable on income tax refunds. Other than the tax benefit related to interest, the Company did not record an income tax benefit in the three and nine months ended September 30, 2022 and 2021 due to a full valuation allowance.

XML 30 R19.htm IDEA: XBRL DOCUMENT v3.22.2.2
Net Loss Per Share
9 Months Ended
Sep. 30, 2022
Net Loss Per Share  
Net Loss Per Share

13. Net Loss Per Share

Because the Company has reported a net loss attributable to common stockholders for all periods presented, basic and diluted net loss per share attributable to common stockholders are the same for all periods presented.

Basic net loss per share attributable to common stockholders is computed by dividing the net loss attributable to common stockholders by the weighted average numbers of shares of common stock outstanding for the period. Basic shares outstanding includes the weighted average effect of the Company’s outstanding pre-funded warrants, the exercise of which requires little or no consideration for the delivery of shares of common stock.

Diluted net loss per share is calculated by adjusting weighted average shares outstanding for the dilutive effect of common stock equivalents outstanding for the period. As such, all unvested restricted stock, restricted stock units, common stock warrants and stock options have been excluded from the computation of diluted weighted average shares outstanding because such securities would have an anti-dilutive impact for all periods presented.

Potential common shares issuable upon conversion, vesting or exercise of unvested restricted stock, restricted stock units, common stock warrants and stock options that are excluded from the computation of diluted weighted-average shares outstanding, as they are anti-dilutive, are as follows:

For the Three and Nine Months Ended

September 30, 

2022

2021

Common stock warrants

 

145,600

 

145,755

 

Common stock options

 

3,542,534

 

2,626,482

 

Restricted stock units

 

470,275

 

207,529

Restricted stock

 

13,454

 

94,181

 

XML 31 R20.htm IDEA: XBRL DOCUMENT v3.22.2.2
Commitments and Contingencies
9 Months Ended
Sep. 30, 2022
Commitments And Contingencies.  
Commitments and Contingencies

14. Commitments and Contingencies

Spitfire Acquisition

As disclosed in Note 6, the Company is obligated to make payments of up to $80.0 million upon the achievement of specified worldwide net sales of all products developed using the technology acquired from Spitfire Pharma Inc. within ten years following the approval of a new drug application filed with the FDA.

Litigation

In December 2019, a complaint was filed by Dr. De-Chu Christopher Tang (“Plaintiff”) against the Company, which was removed to the United States District Court for the Eastern District of Texas. The Plaintiff amended the complaint in February 2020 to include Vipin K. Garg and David J. Drutz as defendants, in addition to the Company (Dr. Garg, Dr. Drutz, and the Company are collectively referred to as “Defendants”). In March 2020 the Defendants filed a motion to dismiss the complaint. The Court denied the motion without prejudice and allowed Plaintiff an opportunity to file an amended complaint. Plaintiff’s second amended complaint was filed on April 17, 2020, and Defendants filed a motion to dismiss that complaint on May 1, 2020. A hearing on Defendants’ motion to dismiss was held on May 20, 2020. Plaintiff, who is representing himself, alleges five causes of action as follows: (1) Defendants’ alleged retention of Plaintiff’s lab notebooks after the termination of his employment in 2012; (2) alleged plagiarism based on publishing an article without naming Plaintiff as an author; (3) use of the Adhigh System, which Plaintiff alleges he developed; (4) allegations that Defendants manipulated the Company’s stock and caused a decrease in value; and (5) allegations that the Defendants “wast[ed] government grant money and poison[ed] science by leaving data to rot.” On September 30, 2020, Plaintiff filed a motion titled “Motion to Proscribe Defendants’ Allegedly Illegal Use of Plaintiff’s AdHigh System in Altimmune’s Human Clinical Trials,” to which Defendants filed an opposition on October 13, 2020. The court has not yet ruled on that motion, which also remains pending. On November 6, 2020, Defendants filed a motion for summary judgment on the basis of lack of personal jurisdiction, insufficient service of process, and failure to state a claim. The court ruled on that motion on March 25, 2021, which dismissed the case on the basis of lack of personal jurisdiction. On December 1, 2020, the magistrate judge assigned to the case issued a report and recommendation that Defendants’ motion to dismiss of May 1, 2020 be granted and that this action be dismissed for lack of personal jurisdiction. Plaintiff filed objections to the report and recommendation on December 14, 2020, and the resolution of those objections by the district court remains pending.

In December 2021, the Plaintiff refiled the complaint in the United States District Court for the District of Maryland. On February 24, 2022, Defendants filed a memorandum containing a brief description of the planned motion and a concise summary of the factual and legal support for it. On the basis of that memorandum, the Court granted Defendants’ request to file a motion to dismiss and allowed Plaintiff an opportunity to file an amended complaint. Plaintiff’s amended complaint was filed on March 3, 2022, and Defendants filed a motion to dismiss that complaint on April 4, 2022. The Company believes the allegations in the complaint are without merit and intends to vigorously defend the litigation.

The Company is a party in various contracts and subject to disputes, litigation and potential claims arising in the ordinary course of business, none of which are currently reasonably possible or probable of material loss.

XML 32 R21.htm IDEA: XBRL DOCUMENT v3.22.2.2
Summary of Significant Accounting Policies (Policies)
9 Months Ended
Sep. 30, 2022
Summary of Significant Accounting Policies  
Use of Estimates

Use of Estimates

The preparation of these financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. The extent to which the COVID-19 pandemic, including any resurgences or the emergence of new variants, may directly or indirectly impact the Company’s business, financial condition, and results of operations is highly uncertain and subject to change.

The Company considered the potential impact of the COVID-19 pandemic on the Company’s estimates and assumptions and determined that there was not a material impact to the Company’s unaudited consolidated financial statements as of and for the three and nine months ended September 30, 2022. However, actual results could differ from those estimates and there may be changes to the Company’s estimates in future periods.

XML 33 R22.htm IDEA: XBRL DOCUMENT v3.22.2.2
Fair Value Measurements (Tables)
9 Months Ended
Sep. 30, 2022
Fair Value Measurements  
Schedule of Fair Value Assets and Liabilities Measured on Recurring Basis

The Company’s assets measured at fair value on a recurring basis as of September 30, 2022 consisted of the following (in thousands):

Fair Value Measurement at September 30, 2022

    

Total

    

Level 1

    

Level 2

    

Level 3

Assets:

Cash equivalents - money market funds

$

123,921

$

123,921

$

$

Short-term investments

 

74,362

 

 

74,362

 

Total

$

198,283

$

123,921

$

74,362

$

The Company’s assets and liabilities measured at fair value on a recurring basis as of December 31, 2021 consisted of the following (in thousands):

Fair Value Measurement at December 31, 2021

    

Total

    

Level 1

    

Level 2

    

Level 3

Assets:

Cash equivalents - money market funds

$

65,634

    

$

65,634

    

$

    

$

Total

$

65,634

$

65,634

$

$

Liabilities:

Contingent consideration liability (see Note 6)

$

6,090

$

$

$

6,090

Total

$

6,090

$

$

$

6,090

Schedule of Short Term Investments

Short-term investments had quoted prices as of September 30, 2022 as shown below (in thousands):

September 30, 2022

Amortized Cost

Unrealized Loss

Market Value

United States treasury securities

    

$

17,784

    

$

(112)

    

$

17,672

Commercial paper and corporate debt securities

49,931

(124)

49,807

Asset backed securities

 

6,910

 

(27)

 

6,883

Total

$

74,625

$

(263)

$

74,362

XML 34 R23.htm IDEA: XBRL DOCUMENT v3.22.2.2
Operating Leases (Tables)
9 Months Ended
Sep. 30, 2022
Operating Leases  
Summary of Supplemental other Information Related to Operating Leases Balance Sheet

Supplemental other information related to the operating leases balance sheet information is as follows (in thousands):

 

September 30, 2022

December 31, 2021

 

Operating lease obligations (see Note 5 and 7)

    

$

1,230

    

$

1,535

Operating lease right-of-use assets (included in "Other assets" in Balance Sheet)

$

649

$

798

Weighted-average remaining lease term (years)

 

2.6

 

3.3

Weighted-average discount rate

 

7.2

%  

 

7.2

%

XML 35 R24.htm IDEA: XBRL DOCUMENT v3.22.2.2
Accrued Expenses (Tables)
9 Months Ended
Sep. 30, 2022
Accrued Expenses  
Schedule of Accrued Expenses and Other Current Liabilities

Accrued expenses and other current liabilities consist of the following (in thousands):

September 30, 2022

December 31, 2021

Accrued professional services

    

$

624

    

$

396

Accrued payroll and employee benefits

 

2,110

 

2,313

Accrued research and development

 

9,930

 

6,988

Lease obligation, current portion (see Note 4)

 

442

 

411

Income tax payable

1,169

Accrued interest and other

 

48

 

44

Total accrued expenses and other current liabilities

$

14,323

$

10,152

XML 36 R25.htm IDEA: XBRL DOCUMENT v3.22.2.2
Contingent Consideration (Tables)
9 Months Ended
Sep. 30, 2022
Contingent Consideration  
Summary of Fair Value of Contingent Consideration Below is a summary of the contingent consideration activity (in thousands):

Nine Months Ended September 30, 

2022

2021

Beginning balance

    

$

6,090

    

$

5,390

Change in fair value

 

86

 

1,560

Fair value of payments settled in common stock (Phase II Milestone)

 

(6,176)

 

Ending balance

$

$

6,950

XML 37 R26.htm IDEA: XBRL DOCUMENT v3.22.2.2
Other Long-Term Liabilities (Tables)
9 Months Ended
Sep. 30, 2022
Other Long-Term Liabilities  
Summary of Other Long-Term Liabilities

The Company’s other long-term liabilities are summarized as follows (in thousands):

September 30, 2022

December 31, 2021

Research and development incentive credit

$

3,402

$

Lease obligation, long-term portion (see Note 4)

    

788

    

1,124

Conditional economic incentive grants

 

250

 

250

Other

 

66

 

80

Total other long-term liabilities

$

4,506

$

1,454

XML 38 R27.htm IDEA: XBRL DOCUMENT v3.22.2.2
Warrants (Tables)
9 Months Ended
Sep. 30, 2022
Warrants  
Summary of Warrant Activity

A summary of warrant activity during the nine months ended September 30, 2022 is as follows:

Weighted-Average

    

    

Weighted

Remaining

Number of

Average

Contractual Term

Warrants

Exercise Price

(Years)

Warrants outstanding, December 31, 2021

 

2,776,191

 

Expired

(155)

Exercises (see Note 8)

 

(1,760,870)

 

Warrants outstanding, September 30, 2022

 

1,015,166

 

$

0.66

1.2

XML 39 R28.htm IDEA: XBRL DOCUMENT v3.22.2.2
Stock-Based Compensation (Tables)
9 Months Ended
Sep. 30, 2022
Stock-Based Compensation  
Schedule of Information Related to Stock Options Outstanding

Information related to stock options outstanding as of September 30, 2022 is as follows (in thousands, except share and per share data):

    

    

    

Weighted-Average

    

Weighted-

Remaining

Number of

Average

Contractual Term

Aggregate Intrinsic

Stock Options

Exercise Price

(Years)

Value

Outstanding

 

3,528,473

$

9.09

 

5.9

$

16,975

Exercisable

 

1,382,587

$

8.75

 

5.8

$

7,824

Unvested

 

2,145,886

$

9.31

 

6.0

$

9,151

Schedule of Stock-based Compensation Expense

Stock-based compensation expense is classified in the unaudited consolidated statements of operations and comprehensive loss for the three and nine months ended September 30, 2022 and 2021 as follows (in thousands):

    

For the Three Months Ended

    

For the Nine Months Ended

September 30, 

September 30, 

2022

    

2021

2022

    

2021

Research and development

$

743

$

449

$

2,024

$

1,211

General and administrative

 

1,385

 

1,048

 

4,185

 

2,989

Total

$

2,128

$

1,497

$

6,209

$

4,200

XML 40 R29.htm IDEA: XBRL DOCUMENT v3.22.2.2
Net Loss Per Share (Tables)
9 Months Ended
Sep. 30, 2022
Net Loss Per Share  
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share

Potential common shares issuable upon conversion, vesting or exercise of unvested restricted stock, restricted stock units, common stock warrants and stock options that are excluded from the computation of diluted weighted-average shares outstanding, as they are anti-dilutive, are as follows:

For the Three and Nine Months Ended

September 30, 

2022

2021

Common stock warrants

 

145,600

 

145,755

 

Common stock options

 

3,542,534

 

2,626,482

 

Restricted stock units

 

470,275

 

207,529

Restricted stock

 

13,454

 

94,181

 

XML 41 R30.htm IDEA: XBRL DOCUMENT v3.22.2.2
Fair Value Measurements - Schedule of Fair Value Assets and Liabilities Measured on Recurring Basis (Detail) - USD ($)
$ in Thousands
Sep. 30, 2022
Dec. 31, 2021
Sep. 30, 2021
Dec. 31, 2020
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]        
Short-term investments $ 74,362      
Contingent consideration liability (see Note 6)   $ 6,090 $ 6,950 $ 5,390
Fair Value, Measurements, Recurring [Member]        
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]        
Short-term investments 74,362      
Total 198,283 65,634    
Contingent consideration liability (see Note 6) 0 6,090    
Total   6,090    
Fair Value, Measurements, Recurring [Member] | Level 1 [Member]        
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]        
Total 123,921 65,634    
Fair Value, Measurements, Recurring [Member] | Level 2 [Member]        
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]        
Short-term investments 74,362      
Total 74,362      
Fair Value, Measurements, Recurring [Member] | Level 3 [Member]        
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]        
Contingent consideration liability (see Note 6)   6,090    
Total   6,090    
Money Market Funds [Member] | Fair Value, Measurements, Recurring [Member]        
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]        
Cash equivalents 123,921 65,634    
Money Market Funds [Member] | Fair Value, Measurements, Recurring [Member] | Level 1 [Member]        
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]        
Cash equivalents $ 123,921 $ 65,634    
XML 42 R31.htm IDEA: XBRL DOCUMENT v3.22.2.2
Fair Value Measurements - Schedule of Short Term Investments (Detail)
$ in Thousands
Sep. 30, 2022
USD ($)
Schedule Of Available For Sale Securities [Line Items]  
Amortized Cost $ 74,625
Unrealized Loss (263)
Market Value 74,362
United States Treasury Securities [Member]  
Schedule Of Available For Sale Securities [Line Items]  
Amortized Cost 17,784
Unrealized Loss (112)
Market Value 17,672
Commercial Paper and Corporate Debt Securities [Member]  
Schedule Of Available For Sale Securities [Line Items]  
Amortized Cost 49,931
Unrealized Loss (124)
Market Value 49,807
Asset Backed Securities [Member]  
Schedule Of Available For Sale Securities [Line Items]  
Amortized Cost 6,910
Unrealized Loss (27)
Market Value $ 6,883
XML 43 R32.htm IDEA: XBRL DOCUMENT v3.22.2.2
Fair Value Measurements - Additional Information (Detail) - USD ($)
$ in Thousands
1 Months Ended 3 Months Ended 9 Months Ended
Mar. 31, 2021
Dec. 31, 2021
Sep. 30, 2021
Sep. 30, 2022
Assets or liabilities measured at fair value on a non-recurring basis.       $ 0
Non-cash impairment charge     $ 8,070  
Lonza Manufacturing Agreement [Member]        
Non-cash impairment charge     8,100  
Commitment to procure equipment and construction $ 23,000      
Lonza Manufacturing Agreement [Member] | Construction-In-Progress        
Non-cash impairment charge   $ 3,300    
Capitalized costs     11,400  
Lonza Manufacturing Agreement [Member] | Construction-In-Progress | Fair Value, Nonrecurring [Member] | Level 3 [Member]        
Fair value of impaired assets     $ 3,300  
XML 44 R33.htm IDEA: XBRL DOCUMENT v3.22.2.2
Operating Leases - Additional Information (Detail) - USD ($)
$ in Millions
3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Operating Leases        
Cash paid for operating lease liabilities     $ 0.4 $ 0.4
Operating lease rent expense $ 0.1 $ 0.1 $ 0.4 $ 0.4
XML 45 R34.htm IDEA: XBRL DOCUMENT v3.22.2.2
Operating Leases - Summary of Supplemental other Information Related to Operating Leases Balance Sheet (Detail) - USD ($)
$ in Thousands
Sep. 30, 2022
Dec. 31, 2021
Operating Leases    
Operating lease obligations (see Note 5 and 7) $ 1,230 $ 1,535
Operating lease right-of-use assets (included in "Other assets" in Balance Sheet) $ 649 $ 798
Weighted-average remaining lease term (years) 2 years 7 months 6 days 3 years 3 months 18 days
Weighted-average discount rate 7.20% 7.20%
XML 46 R35.htm IDEA: XBRL DOCUMENT v3.22.2.2
Accrued Expenses - Schedule of Accrued Expenses and Other Current Liabilities (Detail) - USD ($)
$ in Thousands
Sep. 30, 2022
Dec. 31, 2021
Accrued Liabilities And Other Liabilities [Abstract]    
Accrued professional services $ 624 $ 396
Accrued payroll and employee benefits 2,110 2,313
Accrued research and development 9,930 6,988
Lease obligation, current portion (see Note 4) 442 411
Income tax payable 1,169  
Accrued interest and other 48 44
Total accrued expenses and other current liabilities $ 14,323 $ 10,152
XML 47 R36.htm IDEA: XBRL DOCUMENT v3.22.2.2
Contingent Consideration - Additional Information (Detail) - USD ($)
$ / shares in Units, $ in Thousands
2 Months Ended 9 Months Ended
Jun. 10, 2022
Nov. 19, 2020
Jul. 12, 2019
Jun. 10, 2022
Nov. 19, 2020
Sep. 30, 2022
Sep. 30, 2021
Dec. 31, 2021
Dec. 31, 2020
Business Acquisition [Line Items]                  
Common stock issued related to contingent consideration liability           $ 6,176      
Estimated future contingent consideration             $ 6,950 $ 6,090 $ 5,390
Change in value of contingent consideration for acquired in-process research and development           86 $ 1,560    
Clinical Trial Notification [Member]                  
Business Acquisition [Line Items]                  
Common stock issued related to contingent consideration liability   $ 13,600              
Shares issued for contingent milestone payment   1,694,906              
Period for submission of clinical trial notification   60 days              
Submission date of clinical trial notification   Oct. 29, 2020              
Clinical Trial Notification [Member] | Regulatory Milestones [Member]                  
Business Acquisition [Line Items]                  
Change in value of contingent consideration for acquired in-process research and development         $ 5,400        
Spitfire Pharma, Inc. [Member]                  
Business Acquisition [Line Items]                  
Agreement date     Jul. 08, 2019            
Unregistered shares of common stock     1,887,250            
Up-front consideration     $ 5,000            
Spitfire Pharma, Inc. [Member] | Investigational New Drug Application Milestone [Member]                  
Business Acquisition [Line Items]                  
Estimated future contingent consideration     $ 5,000            
Estimated future contingent consideration term     60 days            
Number of consecutive trading days     20 days            
Consideration amount     $ 2.95            
Spitfire Pharma, Inc. [Member] | Investigational New Drug Application and Regulatory Milestones [Member]                  
Business Acquisition [Line Items]                  
Estimated future contingent consideration     $ 3,000            
Estimated future contingent consideration term     60 days            
Number of consecutive trading days     20 days            
Consideration amount     $ 3.54            
Spitfire Pharma, Inc. [Member] | Sales Milestones [Member]                  
Business Acquisition [Line Items]                  
Estimated future contingent consideration     $ 80,000            
License agreement term     10 years            
Spitfire Pharma, Inc. [Member] | Regulatory Milestones [Member]                  
Business Acquisition [Line Items]                  
Contingent consideration, percentage of shares released after three months     50.00%            
Contingent consideration, percentage of shares released after six months     50.00%            
Spitfire Pharma, Inc. [Member] | Phase Two Milestone [Member]                  
Business Acquisition [Line Items]                  
Common stock issued related to contingent consideration liability $ 7,200                
Estimated future contingent consideration           $ 0      
Consideration amount $ 8.55     $ 8.55          
Shares issued for contingent milestone payment 847,444                
Change in value of contingent consideration for acquired in-process research and development       $ 1,900          
Spitfire Pharma, Inc. [Member] | Clinical Trial Notification [Member]                  
Business Acquisition [Line Items]                  
Consideration amount   $ 9.57     $ 9.57        
Spitfire Pharma, Inc. [Member] | Common Stock [Member] | Maximum [Member]                  
Business Acquisition [Line Items]                  
Estimated future contingent consideration     $ 88,000            
XML 48 R37.htm IDEA: XBRL DOCUMENT v3.22.2.2
Contingent Consideration - Summary of Fair Value of Contingent Consideration (Detail) - USD ($)
$ in Thousands
9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Contingent Consideration    
Beginning balance $ 6,090 $ 5,390
Change in fair value 86 1,560
Fair value of payments settled in common stock (Phase II Milestone) $ (6,176)  
Ending balance   $ 6,950
XML 49 R38.htm IDEA: XBRL DOCUMENT v3.22.2.2
Other Long-Term Liabilities - Summary of Other Long-Term Liabilities (Detail) - USD ($)
$ in Thousands
9 Months Ended
Sep. 30, 2022
Dec. 31, 2021
Other Long-Term Liabilities    
Research and development incentive credit $ 3,402  
Research and development incentive credit earned 3,400  
Lease obligation, long-term portion (see Note 4) 788 $ 1,124
Conditional economic incentive grants 250 250
Other 66 80
Total other long-term liabilities $ 4,506 $ 1,454
XML 50 R39.htm IDEA: XBRL DOCUMENT v3.22.2.2
Common Stock - Additional Information (Detail) - USD ($)
$ / shares in Units, $ in Thousands
3 Months Ended 9 Months Ended 19 Months Ended
Jan. 24, 2022
Feb. 25, 2021
Jul. 16, 2020
Sep. 30, 2022
Jun. 30, 2022
Mar. 31, 2022
Jun. 30, 2021
Mar. 31, 2021
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Dec. 31, 2021
Changes In Equity And Comprehensive Income Line Items [Line Items]                        
Warrants outstanding       1,015,166         1,015,166   1,015,166 2,776,191
Exercise price of warrants or rights       $ 0.66         $ 0.66   $ 0.66  
Proceeds from issuance of common stock in public offering                 $ 56,166 $ 52,356    
Common stock, par or stated value per share       $ 0.0001         $ 0.0001   $ 0.0001 $ 0.0001
Pre-Funded Warrants [Member]                        
Changes In Equity And Comprehensive Income Line Items [Line Items]                        
Number of securities called by warrants or rights       760,870         760,870   760,870  
Warrants outstanding       869,566         869,566   869,566  
Exercise price of warrants or rights       $ 0.0001         $ 0.0001   $ 0.0001  
Common Stock [Member]                        
Changes In Equity And Comprehensive Income Line Items [Line Items]                        
Shares of common stock sold       2,711,013 2,157,717 335,485 1,405,710 2,110,800        
Exchange Warrants [Member]                        
Changes In Equity And Comprehensive Income Line Items [Line Items]                        
Shares of common stock sold 999,984                      
Number of securities called by warrants or rights   1,000,000                    
Warrants outstanding 0                      
Exercise price of warrants or rights   $ 0.0001                    
Common stock, par or stated value per share   $ 0.0001                    
Common stock exchanged for pre-funded warrants   1,000,000                    
Number of warrants exercised 1,000,000                      
Exchange Warrants [Member] | Exchanging Stockholders [Member]                        
Changes In Equity And Comprehensive Income Line Items [Line Items]                        
Ownership percentage   9.99%                    
Public Offering [Member]                        
Changes In Equity And Comprehensive Income Line Items [Line Items]                        
Gross proceeds from offering including exercise of underwriter's option     $ 132,200                  
Public Offering [Member] | Pre-Funded Warrants [Member]                        
Changes In Equity And Comprehensive Income Line Items [Line Items]                        
Number of securities called by warrants or rights     1,630,436                  
Exercise price of warrants or rights     $ 0.0001                  
Purchase price of warrants issued     $ 22.9999                  
Ownership percentage on exercise of warrants without notice, minimum     4.99%                  
Ownership percentage on exercise of warrants with notice, maximum     19.99%                  
Notice period to increase ownership percentage on exercise of warrants     61 days                  
Public Offering [Member] | Common Stock [Member]                        
Changes In Equity And Comprehensive Income Line Items [Line Items]                        
Shares of common stock sold     3,369,564                  
Public offering price, per share     $ 23.00                  
Over-Allotment Option [Member] | Common Stock [Member]                        
Changes In Equity And Comprehensive Income Line Items [Line Items]                        
Shares of common stock sold     750,000                  
Proceeds from issuance of common stock in public offering     $ 124,000                  
At-The-Market Offering [Member]                        
Changes In Equity And Comprehensive Income Line Items [Line Items]                        
Shares of common stock sold                 5,204,415      
Proceeds from issuance of common stock in public offering                 $ 56,200      
Issuance costs                 1,900      
At-The-Market Offering [Member] | Equity Distribution Agreement [Member]                        
Changes In Equity And Comprehensive Income Line Items [Line Items]                        
Commission and other offering costs       $ 300         $ 300   $ 300  
Remaining shares available for issuance       0         0   0  
At-The-Market Offering [Member] | Equity Distribution Agreement [Member] | Piper Sandler company and evercore group limited liability company and B Riley Securities inc [Member]                        
Changes In Equity And Comprehensive Income Line Items [Line Items]                        
Shares of common stock sold                     10,004,869  
Proceeds from issuance of common stock in public offering                     $ 121,000  
Common stock, par or stated value per share   $ 0.0001                    
Aggregate offering price   $ 125,000                    
Issuance costs                     $ 4,000  
XML 51 R40.htm IDEA: XBRL DOCUMENT v3.22.2.2
Warrants - Summary of Warrant Activity (Detail)
9 Months Ended
Sep. 30, 2022
$ / shares
shares
Warrants  
Warrants outstanding, December 31, 2021 2,776,191
Expired (155)
Exercises (see Note 8) (1,760,870)
Warrants outstanding, September 30, 2022 1,015,166
Weighted Average Exercise Price | $ / shares $ 0.66
Weighted-Average Remaining Contractual Term (Years) 1 year 2 months 12 days
XML 52 R41.htm IDEA: XBRL DOCUMENT v3.22.2.2
Warrants - Additional Information (Detail) - $ / shares
Sep. 30, 2022
Dec. 31, 2021
Class Of Warrant Or Right [Line Items]    
Warrants outstanding 1,015,166 2,776,191
Exercise price of warrants or rights $ 0.66  
Pre-Funded Warrants [Member]    
Class Of Warrant Or Right [Line Items]    
Warrants outstanding 869,566  
Exercise price of warrants or rights $ 0.0001  
XML 53 R42.htm IDEA: XBRL DOCUMENT v3.22.2.2
Stock-Based Compensation - Additional Information (Detail) - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2022
Mar. 31, 2022
Sep. 30, 2021
Mar. 31, 2021
Sep. 30, 2022
Sep. 30, 2021
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]            
Employees purchased, value $ 68,000 $ 113,000 $ 119,000 $ 106,000    
Stock-based compensation expense         $ 6,209,000 $ 4,200,000
2019 Employee Stock Purchase Plan [Member]            
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]            
Employees purchased, shares         26,395  
Employees purchased, value         $ 200,000  
Stock-based compensation expense 100,000   $ 29,000   $ 200,000 $ 300,000
Stock Options [Member]            
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]            
Vesting Period         4 years  
Stock option expiration Period         10 years  
Unrecognized compensation cost, stock options $ 13,700,000       $ 13,700,000  
Number of Stock Options, Granted         1,433,427  
Stock options granted, weighted-average exercise price         $ 8.39  
Weighted-average grant date fair value of stock options granted         $ 6.97  
Unrecognized stock-based compensation expense, period for recognition         2 years 7 months 6 days  
Restricted Stock [Member]            
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]            
Unvested restricted stock, shares 13,454       13,454  
Unrecognized compensation expense $ 47,000       $ 47,000  
Unrecognized stock-based compensation expense, period for recognition         2 months 12 days  
Unrestricted common stock         34,132  
Number of share vested         60,546  
Common stock withheld to satisfy tax withholding obligations.         26,414  
Restricted Stock Units [Member]            
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]            
Shares granted         285,000  
Weighted average grant date fair value         $ 7.11  
Vesting Period         4 years  
Unvested restricted stock, shares 470,275       470,275  
Unrecognized compensation expense $ 3,400,000       $ 3,400,000  
Unrecognized stock-based compensation expense, period for recognition         3 years 1 month 6 days  
Unrestricted common stock         30,373  
Number of share vested         46,653  
Common stock withheld to satisfy tax withholding obligations.         16,280  
XML 54 R43.htm IDEA: XBRL DOCUMENT v3.22.2.2
Stock-Based Compensation - Schedule of Information Related to Stock Options Outstanding (Detail)
9 Months Ended
Sep. 30, 2022
USD ($)
$ / shares
shares
Stock-Based Compensation  
Number of Stock Options, Outstanding | shares 3,528,473
Number of Stock Options, Exercisable | shares 1,382,587
Number of Stock Options, Unvested | shares 2,145,886
Weighted-average Exercise Price, Outstanding | $ / shares $ 9.09
Weighted-average Exercise Price, Exercisable | $ / shares 8.75
Weighted-average Exercise Price, Unvested | $ / shares $ 9.31
Weighted-average Remaining Contractual Term, Outstanding 5 years 10 months 24 days
Weighted-average Remaining Contractual Term, Exercisable 5 years 9 months 18 days
Weighted-average Remaining Contractual Term, Unvested 6 years
Aggregate Intrinsic Value, Outstanding | $ $ 16,975
Aggregate Intrinsic Value, Exercisable | $ 7,824
Aggregate Intrinsic Value, Unvested | $ $ 9,151
XML 55 R44.htm IDEA: XBRL DOCUMENT v3.22.2.2
Stock-Based Compensation - Schedule of Stock-based Compensation Expense (Detail) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]        
Stock based compensation expense $ 2,128 $ 1,497 $ 6,209 $ 4,200
Research and Development [Member]        
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]        
Stock based compensation expense 743 449 2,024 1,211
General and Administrative [Member]        
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]        
Stock based compensation expense $ 1,385 $ 1,048 $ 4,185 $ 2,989
XML 56 R45.htm IDEA: XBRL DOCUMENT v3.22.2.2
U.S. Government Contracts and Grants - Additional Information (Detail) - USD ($)
$ in Thousands
1 Months Ended 3 Months Ended 9 Months Ended
Jan. 01, 2021
Jun. 30, 2020
Jul. 31, 2016
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Revenues       $ 2 $ 158 $ 42 $ 1,133
BARDA Contract [Member]              
Duration of contract 3 years   5 years        
Amount used to fund clinical development     $ 136,800        
BARDA Contract [Member] | Minimum [Member]              
Additional funding for development and manufacturing activities $ 1,100            
BARDA Contract [Member] | Maximum [Member]              
Additional funding for development and manufacturing activities $ 34,400            
MTEC Collaborative Arrangement [Member]              
Revenues   $ 4,700          
Grant [Member] | BARDA Contract [Member]              
Revenues         $ 100   400
Grant [Member] | MTEC Collaborative Arrangement [Member]              
Revenues       $ 0   $ 0 $ 500
Investment Performance [Member] | BARDA Contract [Member]              
Revenues     $ 30,900        
XML 57 R46.htm IDEA: XBRL DOCUMENT v3.22.2.2
Income Taxes - Additional Information (Detail) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Income Taxes        
Income tax benefit $ (197)   $ (197)  
Income tax benefit due to valuation allowance $ 0 $ 0 $ 0 $ 0
XML 58 R47.htm IDEA: XBRL DOCUMENT v3.22.2.2
Net Loss Per Share - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Detail) - shares
3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Common Stock Warrants [Member]        
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]        
Antidilutive securities excluded from computation of earnings per share 145,600 145,755 145,600 145,755
Stock Options [Member]        
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]        
Antidilutive securities excluded from computation of earnings per share 3,542,534 2,626,482 3,542,534 2,626,482
Restricted Stock Units [Member]        
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]        
Antidilutive securities excluded from computation of earnings per share 470,275 207,529 470,275 207,529
Restricted Stock [Member]        
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]        
Antidilutive securities excluded from computation of earnings per share 13,454 94,181 13,454 94,181
XML 59 R48.htm IDEA: XBRL DOCUMENT v3.22.2.2
Commitments and Contingencies - Additional Information (Details) - USD ($)
$ in Thousands
Jul. 12, 2019
Dec. 31, 2021
Sep. 30, 2021
Dec. 31, 2020
Commitments And Contingencies [Line Items]        
Estimated future contingent consideration   $ 6,090 $ 6,950 $ 5,390
Spitfire Pharma, Inc. [Member] | Sales Milestones [Member]        
Commitments And Contingencies [Line Items]        
Estimated future contingent consideration $ 80,000      
License agreement term 10 years      
XML 60 alt-20220930x10q_htm.xml IDEA: XBRL DOCUMENT 0001326190 us-gaap:CommonStockMember us-gaap:IPOMember 2020-07-16 2020-07-16 0001326190 us-gaap:RetainedEarningsMember 2022-09-30 0001326190 us-gaap:AdditionalPaidInCapitalMember 2022-09-30 0001326190 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-09-30 0001326190 us-gaap:RetainedEarningsMember 2022-06-30 0001326190 us-gaap:AdditionalPaidInCapitalMember 2022-06-30 0001326190 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-06-30 0001326190 2022-06-30 0001326190 us-gaap:RetainedEarningsMember 2022-03-31 0001326190 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0001326190 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-03-31 0001326190 2022-03-31 0001326190 us-gaap:RetainedEarningsMember 2021-12-31 0001326190 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001326190 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-12-31 0001326190 us-gaap:RetainedEarningsMember 2021-09-30 0001326190 us-gaap:AdditionalPaidInCapitalMember 2021-09-30 0001326190 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-09-30 0001326190 us-gaap:RetainedEarningsMember 2021-06-30 0001326190 us-gaap:AdditionalPaidInCapitalMember 2021-06-30 0001326190 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-06-30 0001326190 2021-06-30 0001326190 us-gaap:RetainedEarningsMember 2021-03-31 0001326190 us-gaap:AdditionalPaidInCapitalMember 2021-03-31 0001326190 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-03-31 0001326190 2021-03-31 0001326190 us-gaap:RetainedEarningsMember 2020-12-31 0001326190 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001326190 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-12-31 0001326190 us-gaap:CommonStockMember 2022-09-30 0001326190 us-gaap:CommonStockMember 2022-06-30 0001326190 us-gaap:CommonStockMember 2022-03-31 0001326190 us-gaap:CommonStockMember 2021-12-31 0001326190 us-gaap:CommonStockMember 2021-09-30 0001326190 us-gaap:CommonStockMember 2021-06-30 0001326190 us-gaap:CommonStockMember 2021-03-31 0001326190 us-gaap:CommonStockMember 2020-12-31 0001326190 us-gaap:CommonStockMember us-gaap:IPOMember 2020-07-16 0001326190 alt:TwoThousandAndNineteenEmployeeStockPurchasePlanMember 2022-07-01 2022-09-30 0001326190 alt:TwoThousandAndNineteenEmployeeStockPurchasePlanMember 2022-01-01 2022-09-30 0001326190 alt:TwoThousandAndNineteenEmployeeStockPurchasePlanMember 2021-07-01 2021-09-30 0001326190 alt:TwoThousandAndNineteenEmployeeStockPurchasePlanMember 2021-01-01 2021-09-30 0001326190 us-gaap:GrantMember alt:MedicalTechnologyEnterpriseConsortiumCollaborativeArrangementMember 2022-07-01 2022-09-30 0001326190 us-gaap:GrantMember alt:MedicalTechnologyEnterpriseConsortiumCollaborativeArrangementMember 2022-01-01 2022-09-30 0001326190 alt:BARDAContractMember us-gaap:GrantMember 2021-07-01 2021-09-30 0001326190 us-gaap:GrantMember alt:MedicalTechnologyEnterpriseConsortiumCollaborativeArrangementMember 2021-01-01 2021-09-30 0001326190 alt:BARDAContractMember us-gaap:GrantMember 2021-01-01 2021-09-30 0001326190 alt:MedicalTechnologyEnterpriseConsortiumCollaborativeArrangementMember 2020-06-01 2020-06-30 0001326190 alt:BARDAContractMember us-gaap:InvestmentPerformanceMember 2016-07-01 2016-07-31 0001326190 us-gaap:CommonStockMember 2022-07-01 2022-09-30 0001326190 us-gaap:CommonStockMember 2022-04-01 2022-06-30 0001326190 us-gaap:CommonStockMember 2021-07-01 2021-09-30 0001326190 us-gaap:CommonStockMember 2021-04-01 2021-06-30 0001326190 alt:BARDAContractMember 2016-07-31 0001326190 alt:LonzaManufacturingAgreementMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsNonrecurringMember us-gaap:ConstructionInProgressMember 2021-09-30 0001326190 alt:LonzaManufacturingAgreementMember us-gaap:ConstructionInProgressMember 2021-01-01 2021-09-30 0001326190 us-gaap:IPOMember 2020-07-16 2020-07-16 0001326190 us-gaap:CommonStockMember us-gaap:OverAllotmentOptionMember 2020-07-16 2020-07-16 0001326190 alt:AtTheMarketOfferingMember 2022-01-01 2022-09-30 0001326190 alt:PiperSandlerCompanyAndEvercoreGroupLimitedLiabilityCompanyAndBRileySecuritiesIncMember alt:AtTheMarketOfferingMember alt:EquityDistributionAgreementMember 2021-02-25 2022-09-30 0001326190 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-07-01 2022-09-30 0001326190 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-04-01 2022-06-30 0001326190 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-07-01 2021-09-30 0001326190 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-04-01 2021-06-30 0001326190 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-01-01 2021-03-31 0001326190 us-gaap:RetainedEarningsMember 2022-07-01 2022-09-30 0001326190 us-gaap:RetainedEarningsMember 2022-04-01 2022-06-30 0001326190 us-gaap:RetainedEarningsMember 2022-01-01 2022-03-31 0001326190 us-gaap:RetainedEarningsMember 2021-07-01 2021-09-30 0001326190 us-gaap:RetainedEarningsMember 2021-04-01 2021-06-30 0001326190 alt:ExchangingStockholdersMember alt:ExchangeWarrantsMember 2021-02-25 0001326190 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2022-09-30 0001326190 us-gaap:MoneyMarketFundsMember us-gaap:FairValueMeasurementsRecurringMember 2022-09-30 0001326190 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001326190 us-gaap:MoneyMarketFundsMember us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001326190 alt:LonzaManufacturingAgreementMember us-gaap:ConstructionInProgressMember 2021-10-01 2021-12-31 0001326190 alt:LonzaManufacturingAgreementMember 2021-01-01 2021-09-30 0001326190 alt:BARDAContractMember srt:MinimumMember 2021-01-01 0001326190 alt:BARDAContractMember srt:MaximumMember 2021-01-01 0001326190 us-gaap:EmployeeStockOptionMember 2022-09-30 0001326190 us-gaap:RestrictedStockUnitsRSUMember 2022-09-30 0001326190 us-gaap:RestrictedStockMember 2022-09-30 0001326190 us-gaap:RestrictedStockUnitsRSUMember 2022-01-01 2022-09-30 0001326190 us-gaap:RestrictedStockMember 2022-01-01 2022-09-30 0001326190 us-gaap:EmployeeStockOptionMember 2022-01-01 2022-09-30 0001326190 alt:PiperSandlerCompanyAndEvercoreGroupLimitedLiabilityCompanyAndBRileySecuritiesIncMember alt:AtTheMarketOfferingMember alt:EquityDistributionAgreementMember 2021-02-25 0001326190 alt:ExchangeWarrantsMember 2022-01-24 0001326190 alt:PreFundedWarrantsMember 2022-09-30 0001326190 alt:ExchangeWarrantsMember 2021-02-25 0001326190 alt:PreFundedWarrantsMember us-gaap:IPOMember 2020-07-16 0001326190 alt:SpitfirePharmaIncMember alt:PhaseTwoMilestoneMember 2022-09-30 0001326190 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001326190 2021-09-30 0001326190 2020-12-31 0001326190 srt:MaximumMember alt:SpitfirePharmaIncMember us-gaap:CommonStockMember 2019-07-12 0001326190 alt:SpitfirePharmaIncMember alt:SalesMilestoneMember 2019-07-12 0001326190 alt:SpitfirePharmaIncMember alt:PhaseTwoMilestoneMember 2022-04-01 2022-06-10 0001326190 alt:RegulatoryMilestoneMember alt:ClinicalTrialNotificationMember 2020-09-30 2020-11-19 0001326190 alt:SpitfirePharmaIncMember alt:PhaseTwoMilestoneMember 2022-06-10 0001326190 alt:SpitfirePharmaIncMember alt:ClinicalTrialNotificationMember 2020-11-19 0001326190 alt:SpitfirePharmaIncMember alt:InvestigationalNewDrugApplicationMilestoneMember 2019-07-12 0001326190 alt:SpitfirePharmaIncMember alt:InvestigationalNewDrugApplicationAndRegulatoryMilestonesMember 2019-07-12 0001326190 alt:SpitfirePharmaIncMember 2019-07-12 2019-07-12 0001326190 us-gaap:USTreasurySecuritiesMember 2022-09-30 0001326190 us-gaap:AssetBackedSecuritiesMember 2022-09-30 0001326190 alt:CommercialPaperAndCorporateDebtSecuritiesMember 2022-09-30 0001326190 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2022-09-30 0001326190 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2022-09-30 0001326190 us-gaap:FairValueMeasurementsRecurringMember 2022-09-30 0001326190 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001326190 us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001326190 us-gaap:WarrantMember 2022-07-01 2022-09-30 0001326190 us-gaap:RestrictedStockUnitsRSUMember 2022-07-01 2022-09-30 0001326190 us-gaap:RestrictedStockMember 2022-07-01 2022-09-30 0001326190 us-gaap:EmployeeStockOptionMember 2022-07-01 2022-09-30 0001326190 us-gaap:WarrantMember 2022-01-01 2022-09-30 0001326190 us-gaap:RestrictedStockUnitsRSUMember 2022-01-01 2022-09-30 0001326190 us-gaap:RestrictedStockMember 2022-01-01 2022-09-30 0001326190 us-gaap:EmployeeStockOptionMember 2022-01-01 2022-09-30 0001326190 us-gaap:WarrantMember 2021-07-01 2021-09-30 0001326190 us-gaap:RestrictedStockUnitsRSUMember 2021-07-01 2021-09-30 0001326190 us-gaap:RestrictedStockMember 2021-07-01 2021-09-30 0001326190 us-gaap:EmployeeStockOptionMember 2021-07-01 2021-09-30 0001326190 us-gaap:WarrantMember 2021-01-01 2021-09-30 0001326190 us-gaap:RestrictedStockUnitsRSUMember 2021-01-01 2021-09-30 0001326190 us-gaap:RestrictedStockMember 2021-01-01 2021-09-30 0001326190 us-gaap:EmployeeStockOptionMember 2021-01-01 2021-09-30 0001326190 us-gaap:ResearchAndDevelopmentExpenseMember 2022-07-01 2022-09-30 0001326190 us-gaap:GeneralAndAdministrativeExpenseMember 2022-07-01 2022-09-30 0001326190 us-gaap:ResearchAndDevelopmentExpenseMember 2022-01-01 2022-09-30 0001326190 us-gaap:GeneralAndAdministrativeExpenseMember 2022-01-01 2022-09-30 0001326190 us-gaap:ResearchAndDevelopmentExpenseMember 2021-07-01 2021-09-30 0001326190 us-gaap:GeneralAndAdministrativeExpenseMember 2021-07-01 2021-09-30 0001326190 us-gaap:ResearchAndDevelopmentExpenseMember 2021-01-01 2021-09-30 0001326190 us-gaap:GeneralAndAdministrativeExpenseMember 2021-01-01 2021-09-30 0001326190 us-gaap:AdditionalPaidInCapitalMember 2022-07-01 2022-09-30 0001326190 2022-07-01 2022-09-30 0001326190 us-gaap:AdditionalPaidInCapitalMember 2022-04-01 2022-06-30 0001326190 2022-04-01 2022-06-30 0001326190 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-03-31 0001326190 2022-01-01 2022-03-31 0001326190 us-gaap:AdditionalPaidInCapitalMember 2021-07-01 2021-09-30 0001326190 2021-07-01 2021-09-30 0001326190 us-gaap:AdditionalPaidInCapitalMember 2021-04-01 2021-06-30 0001326190 2021-04-01 2021-06-30 0001326190 2022-11-04 0001326190 us-gaap:CommonStockMember 2022-01-01 2022-03-31 0001326190 alt:ExchangeWarrantsMember 2021-02-25 2021-02-25 0001326190 us-gaap:CommonStockMember 2021-01-01 2021-03-31 0001326190 us-gaap:RetainedEarningsMember 2021-01-01 2021-03-31 0001326190 alt:ExchangeWarrantsMember 2022-01-24 2022-01-24 0001326190 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-03-31 0001326190 2021-01-01 2021-03-31 0001326190 alt:BARDAContractMember 2021-01-01 2021-01-01 0001326190 alt:BARDAContractMember 2016-07-01 2016-07-31 0001326190 alt:AtTheMarketOfferingMember alt:EquityDistributionAgreementMember 2022-09-30 0001326190 alt:SpitfirePharmaIncMember alt:RegulatoryMilestoneMember 2019-07-12 2019-07-12 0001326190 alt:SpitfirePharmaIncMember alt:PhaseTwoMilestoneMember 2022-06-10 2022-06-10 0001326190 2022-01-01 2022-09-30 0001326190 alt:ClinicalTrialNotificationMember 2020-11-19 2020-11-19 0001326190 alt:LonzaManufacturingAgreementMember 2021-03-01 2021-03-31 0001326190 alt:PreFundedWarrantsMember us-gaap:IPOMember 2020-07-16 2020-07-16 0001326190 alt:SpitfirePharmaIncMember alt:InvestigationalNewDrugApplicationMilestoneMember 2019-07-12 2019-07-12 0001326190 alt:SpitfirePharmaIncMember alt:InvestigationalNewDrugApplicationAndRegulatoryMilestonesMember 2019-07-12 2019-07-12 0001326190 alt:SpitfirePharmaIncMember alt:SalesMilestoneMember 2019-07-12 2019-07-12 0001326190 alt:PiperSandlerCompanyAndEvercoreGroupLimitedLiabilityCompanyAndBRileySecuritiesIncMember alt:AtTheMarketOfferingMember alt:EquityDistributionAgreementMember 2021-02-25 2021-02-25 0001326190 2021-01-01 2021-09-30 0001326190 2022-09-30 0001326190 2021-12-31 iso4217:USD iso4217:USD shares pure shares 49286535 41370768 45881547 40843905 0001326190 --12-31 2022 Q3 49161637 40993768 -0.48 -0.81 -1.37 -1.79 P20D P20D false 10-Q true 2022-09-30 false 001-32587 ALTIMMUNE, INC. DE 20-2726770 910 Clopper Road Suite 201S Gaithersburg MD 20878 240 654-1450 Common stock, par value $0.0001 per share ALT NASDAQ Yes Yes Non-accelerated Filer true false false 49159056 127465000 190301000 34000 34000 127499000 190335000 74362000 633000 429000 3720000 5410000 4790000 7952000 211004000 204126000 1172000 1448000 12419000 12419000 682000 872000 225277000 218865000 1419000 2034000 6090000 14323000 10152000 15742000 18276000 4506000 1454000 20248000 19730000 0.0001 0.0001 200000000 200000000 49161637 40993768 5000 4000 566551000 497342000 -356224000 -293171000 -5303000 -5040000 205029000 199135000 225277000 218865000 2000 158000 42000 1133000 20262000 29206000 51359000 54356000 4492000 4156000 13329000 11636000 8070000 24754000 33362000 64688000 74062000 -24752000 -33204000 -64646000 -72929000 64000 33000 191000 67000 1053000 13000 1402000 88000 50000 -286000 185000 -293000 1039000 -306000 1396000 -272000 -23713000 -33510000 -63250000 -73201000 -197000 -197000 -23516000 -33510000 -63053000 -73201000 -143000 -2000 -263000 4000 -23659000 -33512000 -63316000 -73197000 -0.48 -0.81 -1.37 -1.79 49286535 41370768 45881547 40843905 40993768 4000 497342000 -293171000 -5040000 199135000 2033000 2033000 95771 197000 197000 17568 -170000 -170000 16450 113000 113000 335485 2990000 2990000 1760854 -19430000 -19430000 43219896 4000 502505000 -312601000 -5040000 184868000 2048000 2048000 152913 403000 403000 -5865 -80000 -80000 2157717 1000 21346000 21347000 847444 6176000 6176000 -120000 -120000 -20107000 -20107000 46372105 5000 532398000 -332708000 -5160000 194535000 2128000 2128000 76161 268000 268000 -7744 -140000 -140000 2711013 31829000 31829000 9945 68000 68000 157 -143000 -143000 -23516000 -23516000 49161637 5000 566551000 -356224000 -5303000 205029000 37142946 4000 417337000 -186421000 -5044000 225876000 1218000 1218000 -6349 -92000 -92000 8733 106000 106000 -1000000 -7540000 -9660000 -17200000 17200000 17200000 2110800 34178000 34178000 1050 10000 10000 5000 5000 -14864000 -14864000 38257180 4000 462417000 -210945000 -5039000 246437000 1485000 1485000 38217 94000 94000 -7583 -90000 -90000 1405710 18178000 18178000 1000 1000 -24827000 -24827000 39693524 4000 482084000 -235772000 -5038000 241278000 1497000 1497000 398 6000 6000 -6521 -124000 -124000 15367 119000 119000 -2000 -2000 -33510000 -33510000 39702768 4000 483582000 -269282000 -5040000 209264000 -63053000 -73201000 86000 1560000 8070000 6209000 4200000 31000 434000 183000 -297000 204000 -3036000 -3204000 5263000 -615000 -606000 7555000 6916000 -1690000 1714000 -45280000 -56271000 82406000 74292000 7592000 88000 11970000 190000 -74380000 62654000 118000 56166000 52356000 181000 225000 477000 100000 56824000 52563000 -62836000 58946000 190335000 115952000 127499000 174898000 6176000 72000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">1. Nature of Business and Basis of Presentation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Nature of Business</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Altimmune, Inc., headquartered in Gaithersburg, Maryland, United States, together with its subsidiaries (collectively, the “Company” or “Altimmune”) is a clinical stage biopharmaceutical company incorporated under the laws of the State of Delaware.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company is focused on developing treatments for obesity and liver diseases. The Company’s pipeline includes next generation peptide therapeutics for obesity and non-alcoholic steatohepatitis (“NASH”) (for both, pemvidutide, formerly known as ALT-801), and for chronic hepatitis B (HepTcell). Since its inception, the Company has devoted substantially all of its efforts to business planning, research and development, recruiting management and technical staff and raising capital, and has financed its operations through the issuance of common and preferred stock, long-term debt and proceeds from research grants and government contracts. The Company has not generated any revenues from the sale of any products to date, and there is no assurance of any future revenues from product sales.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Basis of Presentation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The accompanying unaudited consolidated financial statements are prepared pursuant to the rules and regulations of the U.S. Securities and Exchange Commission (“SEC”) regarding interim financial reporting. Accordingly, they do not include all of the information and disclosures required by accounting principles generally accepted in the United States (“U.S. GAAP”) for complete consolidated financial statements and should be read in conjunction with the audited consolidated financial statements for the year ended December 31, 2021 included in the Annual Report on Form 10-K which was filed with the SEC on March 15, 2022. In the opinion of management, the Company has prepared the accompanying unaudited consolidated financial statements on the same basis as the audited consolidated financial statements, and these consolidated financial statements include all adjustments, consisting only of normal recurring adjustments, necessary for a fair presentation of the results of the interim periods presented. The operating results for the interim periods presented are not necessarily indicative of the results expected for the full year 2022 or any future years or periods.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The accompanying unaudited consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The accompanying unaudited consolidated financial statements have been prepared on the basis of continuity of operations, realization of assets, and the satisfaction of liabilities in the ordinary course of business. The financial statements do not include any adjustments relating to the recoverability and classification of recorded assets and liabilities that might be necessary should we be unable to continue as a going concern.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">2. Summary of Significant Accounting Policies</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">During the nine months ended September 30, 2022, there have been no significant changes to the Company’s summary of significant accounting policies contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021 as filed with the SEC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The preparation of these financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. The extent to which the COVID-19 pandemic, including any resurgences or the emergence of new variants, may directly or indirectly impact the Company’s business, financial condition, and results of operations is highly uncertain and subject to change. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company considered the potential impact of the COVID-19 pandemic on the Company’s estimates and assumptions and determined that there was not a material impact to the Company’s unaudited consolidated financial statements as of and for the three and nine months ended September 30, 2022. However, actual results could differ from those estimates and there may be changes to the Company’s estimates in future periods.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The preparation of these financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. The extent to which the COVID-19 pandemic, including any resurgences or the emergence of new variants, may directly or indirectly impact the Company’s business, financial condition, and results of operations is highly uncertain and subject to change. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company considered the potential impact of the COVID-19 pandemic on the Company’s estimates and assumptions and determined that there was not a material impact to the Company’s unaudited consolidated financial statements as of and for the three and nine months ended September 30, 2022. However, actual results could differ from those estimates and there may be changes to the Company’s estimates in future periods.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">3. Fair Value Measurements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company’s assets measured at fair value on a recurring basis as of September 30, 2022 consisted of the following (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:42.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:42.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:55.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair Value Measurement at September 30, 2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:42.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Level 1</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Level 2</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Level 3</b></p></td></tr><tr><td style="vertical-align:bottom;width:42.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:42.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash equivalents - money market funds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 123,921</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 123,921</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:42.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Short-term investments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 74,362</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 74,362</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:42.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 198,283</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 123,921</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 74,362</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company’s assets and liabilities measured at fair value on a recurring basis as of December 31, 2021 consisted of the following (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:42.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:42.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:55.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair Value Measurement at December 31, 2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:42.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Level 1</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Level 2</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Level 3</b></p></td></tr><tr><td style="vertical-align:bottom;width:42.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:42.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash equivalents - money market funds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 65,634</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 65,634</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:42.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 65,634</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 65,634</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:42.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:42.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Contingent consideration liability (see Note 6)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,090</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,090</p></td></tr><tr><td style="vertical-align:bottom;width:42.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,090</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,090</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"> <span style="margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As described in Note 6 the remaining milestone payment underlying the contingent consideration liability was fully settled in shares of the Company’s common stock. As of September 30, 2022, the Company had no contingent consideration liability.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Short-term investments have been initially valued at the transaction price and subsequently valued, at the end of each reporting period, utilizing third party pricing services or other market observable data (Level 2). The pricing services utilize industry standard valuation models, including both income and market-based approaches and observable market inputs to determine value.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Short-term investments had quoted prices as of September 30, 2022 as shown below (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:56.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:41.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September 30, 2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:56.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Amortized Cost</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Unrealized Loss</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Market Value</b></p></td></tr><tr><td style="vertical-align:bottom;width:56.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">United States treasury securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 17,784</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (112)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 17,672</p></td></tr><tr><td style="vertical-align:bottom;width:56.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Commercial paper and corporate debt securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 49,931</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (124)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 49,807</p></td></tr><tr><td style="vertical-align:bottom;width:56.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Asset backed securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,910</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (27)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.83%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,883</p></td></tr><tr><td style="vertical-align:bottom;width:56.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 74,625</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (263)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.83%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 74,362</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Separate disclosure is required for assets and liabilities measured at fair value on a recurring basis from those measured at fair value on a non-recurring basis. Assets recorded at fair value on a non-recurring basis, such as property and equipment and intangible assets are recognized at fair value when they are impaired. During the nine months ended September 30, 2022, the Company had no significant assets or liabilities that were measured at fair value on a non-recurring basis. During the year ended December 31, 2021, the Company recorded non-cash impairment charges to property and equipment, net on a non-recurring basis (see below).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><i style="font-style:italic;">Lonza Manufacturing Agreement </i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">In March 2021, the Company expanded its manufacturing collaboration with Lonza Houston, Inc. (“Lonza”) for the manufacture of AdCOVID or other adenovirus-based vaccines. Under the expanded agreement, the Company had committed approximately $23.0 million to Lonza to procure long-lead equipment and construct a dedicated manufacturing suite for clinical and commercial production of adenovirus-based vaccines. In June 2021, the Company announced the discontinuation of further development of AdCOVID following the Company’s review of findings from its Phase 1 clinical trial. Construction continued at Lonza, and the Company assessed its strategic options with respect to the suite. This work was completed during the fourth quarter of 2021. The Company capitalized a total of $11.4 million as construction-in-progress (“CIP”) during the nine months ended September 30, 2021 under this expanded agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">In connection with the discontinuation of further development of AdCOVID, the Company recorded a non-cash impairment charge of $8.1 million in the unaudited consolidated statements of operations and comprehensive loss for the nine months ended September 30, 2021 to write-down the CIP associated with the construction of the Lonza facility to its fair value of $3.3 million as of September 30, 2021. As of September 30, 2021, the fair value of the CIP related assets was primarily determined utilizing the cost approach, which reflected the replacement cost of the asset being appraised, adjusted for contractual restrictions on the assets, the probability of satisfying the contractual restrictions, physical deterioration, functional obsolescence and economic obsolescence. The fair value measurement was considered a Level 3 measurement within the valuation hierarchy.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">Furthermore, the remaining $3.3 million CIP was fully charged to impairment during the three months ended December 31, 2021 upon termination of the agreement. </p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company’s assets measured at fair value on a recurring basis as of September 30, 2022 consisted of the following (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:42.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:42.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:55.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair Value Measurement at September 30, 2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:42.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Level 1</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Level 2</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Level 3</b></p></td></tr><tr><td style="vertical-align:bottom;width:42.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:42.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash equivalents - money market funds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 123,921</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 123,921</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:42.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Short-term investments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 74,362</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 74,362</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:42.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 198,283</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 123,921</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 74,362</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company’s assets and liabilities measured at fair value on a recurring basis as of December 31, 2021 consisted of the following (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:42.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:42.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:55.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair Value Measurement at December 31, 2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:42.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Level 1</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Level 2</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Level 3</b></p></td></tr><tr><td style="vertical-align:bottom;width:42.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:42.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash equivalents - money market funds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 65,634</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 65,634</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:42.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 65,634</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 65,634</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:42.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:42.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Contingent consideration liability (see Note 6)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,090</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,090</p></td></tr><tr><td style="vertical-align:bottom;width:42.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,090</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,090</p></td></tr></table> 123921000 123921000 74362000 74362000 198283000 123921000 74362000 65634000 65634000 65634000 65634000 6090000 6090000 6090000 6090000 0 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Short-term investments had quoted prices as of September 30, 2022 as shown below (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:56.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:41.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September 30, 2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:56.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Amortized Cost</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Unrealized Loss</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Market Value</b></p></td></tr><tr><td style="vertical-align:bottom;width:56.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">United States treasury securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 17,784</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (112)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 17,672</p></td></tr><tr><td style="vertical-align:bottom;width:56.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Commercial paper and corporate debt securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 49,931</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (124)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 49,807</p></td></tr><tr><td style="vertical-align:bottom;width:56.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Asset backed securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,910</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (27)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.83%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,883</p></td></tr><tr><td style="vertical-align:bottom;width:56.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 74,625</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (263)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.83%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 74,362</p></td></tr></table> 17784000 -112000 17672000 49931000 -124000 49807000 6910000 -27000 6883000 74625000 -263000 74362000 0 23000000.0 11400000 8100000 3300000 3300000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">4. Operating Leases</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company rents office and laboratory space in the United States which expires in April 2025. Rent expense under the Company’s operating leases was $0.1 million and $0.4 million during each of the three and nine months ended September 30, 2022 and 2021, respectively. Rent expense includes short-term leases and variable lease costs that are not included in the lease obligation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Short-term leases are leases having a term of twelve months or less. The Company recognizes short-term leases on a straight-line basis and does not record a related lease asset or liability for such leases.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The office space lease provides for increases in future minimum annual rental payments as defined in the lease agreement. The office space lease also includes an option to renew the lease as of the end of the term. The Company has determined that the lease renewal option is not reasonably certain of being exercised.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The cash paid for operating lease liabilities for each of the nine months ended September 30, 2022 and 2021 was $0.4 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 6pt 0pt;">Supplemental other information related to the operating leases balance sheet information is as follows (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:66.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:66.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td></tr><tr><td style="vertical-align:bottom;width:66.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September 30, 2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31, 2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td></tr><tr><td style="vertical-align:bottom;width:66.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating lease obligations (see Note 5 and 7)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,230</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,535</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating lease right-of-use assets (included in "Other assets" in Balance Sheet)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 649</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 798</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted-average remaining lease term (years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2.6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3.3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted-average discount rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7.2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7.2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">​</span></p> 100000 100000 400000 400000 400000 400000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 6pt 0pt;">Supplemental other information related to the operating leases balance sheet information is as follows (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:66.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:66.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td></tr><tr><td style="vertical-align:bottom;width:66.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September 30, 2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31, 2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td></tr><tr><td style="vertical-align:bottom;width:66.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating lease obligations (see Note 5 and 7)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,230</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,535</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating lease right-of-use assets (included in "Other assets" in Balance Sheet)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 649</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 798</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted-average remaining lease term (years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2.6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3.3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted-average discount rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7.2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7.2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr></table> 1230000 1535000 649000 798000 P2Y7M6D P3Y3M18D 0.072 0.072 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">5. Accrued Expenses</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 6pt 0pt;">Accrued expenses and other current liabilities consist of the following (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:68.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:68.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September 30, 2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31, 2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued professional services</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 624</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 396</p></td></tr><tr><td style="vertical-align:bottom;width:68.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued payroll and employee benefits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,110</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,313</p></td></tr><tr><td style="vertical-align:bottom;width:68.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9,930</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,988</p></td></tr><tr><td style="vertical-align:bottom;width:68.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Lease obligation, current portion (see Note 4)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 442</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 411</p></td></tr><tr><td style="vertical-align:bottom;width:68.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Income tax payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,169</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:68.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued interest and other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 48</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 44</p></td></tr><tr><td style="vertical-align:bottom;width:68.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Total accrued expenses and other current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 14,323</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 10,152</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">​</span></p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 6pt 0pt;">Accrued expenses and other current liabilities consist of the following (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:68.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:68.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September 30, 2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31, 2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued professional services</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 624</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 396</p></td></tr><tr><td style="vertical-align:bottom;width:68.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued payroll and employee benefits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,110</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,313</p></td></tr><tr><td style="vertical-align:bottom;width:68.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9,930</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,988</p></td></tr><tr><td style="vertical-align:bottom;width:68.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Lease obligation, current portion (see Note 4)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 442</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 411</p></td></tr><tr><td style="vertical-align:bottom;width:68.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Income tax payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,169</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:68.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued interest and other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 48</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 44</p></td></tr><tr><td style="vertical-align:bottom;width:68.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Total accrued expenses and other current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 14,323</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 10,152</p></td></tr></table> 624000 396000 2110000 2313000 9930000 6988000 442000 411000 1169000 48000 44000 14323000 10152000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">6. Contingent Consideration</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company entered into an Agreement and Plan of Merger and Reorganization, dated July 8, 2019, by and among the Company, Springfield Merger Sub, Inc., Springfield Merger Sub, LLC, Spitfire Pharma, Inc. and David Collier, as the Stockholder Representative (the “Spitfire Merger Agreement”) to acquire all of the equity interests of Spitfire Pharma, Inc. (“Spitfire”). Spitfire was a privately held, preclinical pharmaceutical company developing a novel GLP-1/glucagon receptor dual agonist for the treatment of NASH.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The transaction closed on July 12, 2019. The Company issued 1,887,250 unregistered shares of its common stock as upfront consideration to certain former securityholders of Spitfire, representing an amount equal to $5.0 million less working capital and transaction expense adjustment amounts as defined in the agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The acquisition of Spitfire was accounted for as an asset acquisition instead of a business combination because substantially all of the fair value of the gross assets acquired was concentrated in a single identifiable asset or group of similar identifiable assets, and therefore, the asset was not considered a business. The Company expensed the acquired intellectual property as of the acquisition date as in-process research and development with no alternative future uses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Spitfire Merger Agreement also includes future contingent payments up to $88.0 million in cash and shares of the Company’s common stock as follows:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a one-time payment of </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$5.0</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> million (the “IND Milestone Consideration Amount”) within </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">sixty days</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> of the submission of an Investigational New Drug Application (“IND”) to the United States Food and Drug Administration (the “FDA”) or other applicable governmental authority in a foreign jurisdiction, which IND has not been rejected or placed on clinical hold by the FDA or such applicable foreign governmental authority within time specified in the Spitfire Merger Agreement;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a one-time payment of </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$3.0</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> million (the “Phase 2 Milestone Consideration Amount” and together with the IND Milestone Consideration Amount, the “Regulatory Milestones”) within </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">sixty days</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> of the initiation (first patient, first dosing) of a Phase 2 clinical trial of a product candidate anywhere in the world (a “Phase 2 Milestone Event”); and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">payments of up to </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$80.0</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> million upon the achievement of specified worldwide net sales (the “Sales Milestones”) of all products developed using the technology acquired in the Amended and Restated License Agreement, dated July 12, 2019, by and between Mederis Diabetes, LLC and Spitfire, within </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">ten years</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> following the approval of a new drug application filed with the FDA.</span></td></tr></table><div style="margin-top:12pt;"/><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Regulatory Milestones were payable in shares of the Company’s common stock, with the number of shares of the Company’s common stock issued in connection with each milestone amount, if any, dependent on the share price at the time of achievement. The number of shares issued in consideration for the IND Milestone Consideration Amount was determined based on the lower of (A) the average of the closing prices of the Company’s common stock as reported on the Nasdaq Global Market for the <span style="-sec-ix-hidden:Hidden_g7Mf_SBOZ0y5rJszHkVZ3Q;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">twenty</span></span> (20) consecutive trading days prior to the IND Reference Date or (B) $2.95. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The number of shares issued in consideration for the Phase 2 Milestone Consideration Amount was determined based on the lower of (A) the average of the closing trading prices of the Company’s common stock as reported on the Nasdaq Global Market for the <span style="-sec-ix-hidden:Hidden_M2AdECxb5USsTtOnrXY-Dg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">twenty</span></span> (20) consecutive trading days immediately preceding the date of the occurrence of the Phase 2 Milestone Event or (B) $3.54.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The contingent payments related to the Regulatory Milestones were stock-based payments accounted for under FASB Accounting Standards Codification Topic 480, <i style="font-style:italic;">Distinguishing Liabilities From Equity</i> (“ASC 480”). Such stock-based payments are subject to a lock-up whereby 50% of the shares are released at 3 months following issuance and 50% are released at 6 months following issuance. The future contingent payments related to the Sales Milestones are predominately cash-based payments accounted for under FASB Accounting Standards Codification Topic 450, <i style="font-style:italic;">Contingencies</i>. Accordingly, the Company will recognize the Sales Milestones when the contingency is probable and the amount can be reasonably estimated.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On November 3, 2020, the Company received acknowledgement from the Australian Government Department of Health on the Company’s submitted clinical trial notification (“CTN”) which triggered the obligation to settle the IND Milestone payment to the former owners. As a result, on November 19, 2020, the Company issued 1,694,906 shares of its common stock valued at $9.57 per share for the amount value of $13.6 million to the former Spitfire stockholders. Pursuant to the Spitfire Merger Agreement, the Company issued the shares within sixty days of the submission of the CTN, which was October 29, 2020. From September 30, 2020 through November 19, 2020, the date of issuance, the Company recognized a decrease in the fair value of the IND Milestone payment of $5.4 million to research and development expense and reclassified the balance in the contingent consideration liability associated with the fair value of the IND Milestone payment to equity in the Company’s consolidated balance sheet.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On April 26, 2022, the Company dosed the first patient in the Phase 2 MOMENTUM trial of pemvidutide in obesity, which triggered the obligation to pay the Phase 2 Milestone Consideration Amount to the former owners. As a result, on June 10, 2022, the Company issued 847,444 shares of its common stock valued at $8.55 per share for the amount value of $7.2 million to the former Spitfire stockholders. From the last valuation date on March 31, 2022 through June 10, 2022, the date of issuance, the Company recognized an increase in the fair value of the Phase 2 Milestone Consideration Amount of $1.9 million to research and development expense and reclassified the balance in the contingent consideration liability to equity in the Company’s consolidated balance sheet. As of September 30, 2022, the Company had no contingent consideration liability.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"> Below is a summary of the contingent consideration activity (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-size:12pt;margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:63.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:63.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:33.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Nine Months Ended September 30, </b></p></td></tr><tr><td style="vertical-align:bottom;width:63.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:63.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Beginning balance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,090</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,390</p></td></tr><tr><td style="vertical-align:bottom;width:63.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Change in fair value</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 86</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,560</p></td></tr><tr><td style="vertical-align:bottom;width:63.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Fair value of payments settled in common stock (Phase II Milestone)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (6,176)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:63.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Ending balance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.4%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,950</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">​</span></p> 2019-07-08 1887250 5000000.0 88000000.0 5000000.0 P60D 3000000.0 P60D 80000000.0 P10Y 2.95 3.54 0.50 0.50 1694906 9.57 13600000 P60D 2020-10-29 5400000 847444 8.55 7200000 1900000 0 Below is a summary of the contingent consideration activity (in thousands):<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-size:12pt;margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:63.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:63.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:33.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Nine Months Ended September 30, </b></p></td></tr><tr><td style="vertical-align:bottom;width:63.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:63.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Beginning balance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,090</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,390</p></td></tr><tr><td style="vertical-align:bottom;width:63.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Change in fair value</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 86</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,560</p></td></tr><tr><td style="vertical-align:bottom;width:63.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Fair value of payments settled in common stock (Phase II Milestone)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (6,176)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:63.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Ending balance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.4%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,950</p></td></tr></table> 6090000 5390000 86000 1560000 6176000 6950000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">7. Other Long-Term Liabilities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 6pt 0pt;">During the nine months ended September 30, 2022, the Company received a total of $3.4 million in cash for research and development (“R&amp;D”) incentive credit that the Company earned during the fiscal years 2021 and 2020 through the participation in the Australian research and development incentive credit program administered through the Australian Tax Office. The Company recorded the receipt as long-term liability until there is reasonable assurance that the Company will comply with the conditions attached to the incentive credit. See <a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1326190/000155837022003659/alt-20211231x10k.htm#Item8FinancialStatementsandSupplem" style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;"><i style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:normal;">Note 2. Summary of Significant Accounting Policies in the Company’s 2021 Annual Report on Form 10-K</i></a> for accounting policies related to research and development incentive credits.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 6pt 0pt;">The Company’s other long-term liabilities are summarized as follows (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:63.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:63.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September 30, 2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31, 2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:63.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Research and development incentive credit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,402</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:63.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Lease obligation, long-term portion (see Note 4)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 788</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,124</p></td></tr><tr><td style="vertical-align:bottom;width:63.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Conditional economic incentive grants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 250</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 250</p></td></tr><tr><td style="vertical-align:bottom;width:63.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 66</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 80</p></td></tr><tr><td style="vertical-align:bottom;width:63.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Total other long-term liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,506</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,454</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">​</span></p> 3400000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 6pt 0pt;">The Company’s other long-term liabilities are summarized as follows (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:63.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:63.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September 30, 2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31, 2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:63.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Research and development incentive credit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,402</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:63.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Lease obligation, long-term portion (see Note 4)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 788</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,124</p></td></tr><tr><td style="vertical-align:bottom;width:63.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Conditional economic incentive grants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 250</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 250</p></td></tr><tr><td style="vertical-align:bottom;width:63.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 66</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 80</p></td></tr><tr><td style="vertical-align:bottom;width:63.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Total other long-term liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,506</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,454</p></td></tr></table> 3402000 788000 1124000 250000 250000 66000 80000 4506000 1454000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">8. Common Stock</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Public Offering</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On July 16, 2020, the Company offered and sold (i) 3,369,564 shares of common stock, at a price to the public of $23.00 per share, and (ii) pre-funded warrants of the Company to purchase 1,630,436 shares of common stock at an exercise price equal to $0.0001 per share (the “Pre-Funded Warrants”), at a price to the public of $22.9999 per share of common stock underlying the Pre-Funded Warrants (equal to the public offering price per share of Common Stock, minus the exercise price of each Pre-Funded Warrant). The Pre-Funded Warrants are exercisable at any time, provided that each Pre-Funded Warrant holder will be prohibited from exercising such Pre-Funded Warrants into shares of the Company’s common stock if, as a result of such exercise, the holder, together with its affiliates, would own more than 4.99% of the total number of shares of the Company’s common stock then issued and outstanding, which percentage may change at the holders’ election to any other number less than or equal to 19.99% upon 61 days’ notice to the Company. The gross proceeds of this offering were approximately $132.2 million, which includes the exercise in full of the underwriters’ option to purchase an additional 750,000 shares of common stock, before deducting underwriting discounts and commissions and offering expenses during the third quarter of 2020. The net proceeds of this offering were approximately $124.0 million, after deducting underwriting discounts and commissions and offering expenses payable by the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company has assessed the Pre-Funded Warrants for appropriate equity or liability classification and determined that the Pre-Funded Warrants are freestanding instruments that do not meet the definition of a liability pursuant to ASC 480 and do not meet the definition of a derivative pursuant to FASB Accounting Standards Codification Topic 815, <i style="font-style:italic;">Derivatives and Hedging</i> (“ASC 815”). The Pre-Funded Warrants are indexed to the Company’s common stock and meet all other conditions for equity classification under ASC 480 and ASC 815. Accordingly, the Pre-Funded Warrants are classified as equity and are accounted for as a component of additional paid-in capital at the time of issuance. As of September 30, 2022, 760,870 of the Pre-Funded Warrants were exercised, leaving 869,566 remaining Pre-Funded Warrants unexercised.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">At-the-Market Offerings</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On February 25, 2021, the Company entered into an Equity Distribution Agreement (the “2021 Agreement”) with Piper Sandler &amp; Co., Evercore Group L.L.C. and B. Riley Securities, Inc., serving as sales agents (the “Sales Agents”) with respect to an at-the-market offerings program under which the Company offered and sold shares of its common stock, par value $0.0001 per share (the “Common Stock”), having an aggregate offering price of up to $125.0 million (the “Shares”) through the Sales Agents (the “2021 Offering”). All the Shares offered and sold in the 2021 Offering were issued pursuant to the Company’s Registration Statement on Form S-3 filed with the Securities and Exchange Commission (the “SEC”) on December 31, 2020, which was declared effective on January 11, 2021 (“2021 Shelf”), the prospectus supplement relating to the 2021 Offering filed with the SEC on February 25, 2021 and any applicable additional prospectus supplements related to the 2021 Offering that form a part of the Registration Statement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">During the nine months ended September 30, 2022, the Company sold 5,204,415 shares of Common Stock under the 2021 Agreement resulting in approximately $56.2 million in proceeds, net of $1.9 million commission and other offering costs. As of September 30, 2022, the Company has sold 10,004,869 shares of Common Stock under the 2021 Agreement resulting in approximately $121.0 million in proceeds, net of $4.0 million commission and other offering costs, As of September 30, 2022, there were no remaining shares available for issuance under the 2021 Agreement. The Company </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">recorded approximately $0.3 million of other offering costs which offset the proceeds received from the shares sold through September 30, 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Exchange Agreement</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On February 25, 2021, the Company entered into an exchange agreement (the “Exchange Agreement”) with an investor and its affiliates (the “Exchanging Stockholders”), pursuant to which the Company exchanged an aggregate of 1,000,000 shares of the Company’s common stock, par value $0.0001 per share, owned by the Exchanging Stockholders for pre-funded warrants (the “Exchange Warrants”) to purchase an aggregate of 1,000,000 shares of common stock (subject to adjustment in the event of any stock dividends and splits, reverse stock split, recapitalization, reorganization or similar transaction, as described in the Exchange Warrants), with an exercise price of $0.0001 per share. The Exchange Warrants did not have an expiration date and were exercisable at any time except that the Exchange Warrants could not be exercised by the Exchanging Stockholders if, after giving effect thereto, the Exchanging Stockholders would beneficially own more than 9.99% of the Company’s common stock, subject to certain exceptions. In accordance with FASB Accounting Standards Codification Topic 505, <i style="font-style:italic;">Equity</i>, the Company recorded the retirement of the common stock exchanged as a reduction of common shares outstanding and a corresponding debit to additional paid-in-capital and accumulated deficit at the fair value of the Exchange Warrants on the issuance date. The Exchange Warrants were classified as equity in accordance with ASC 480 and the fair value of the Exchange Warrants was recorded as a credit to additional paid-in-capital and is not subject to remeasurement. The Company determined that the fair value of the Exchange Warrants is substantially similar to the fair value of the retired shares on the issuance date due to the negligible exercise price for the Exchange Warrants. On January 24, 2022, the Exchange Warrants to purchase 1,000,000 shares were net exercised, resulting in the issuance of 999,984 shares of common stock, and no Exchange Warrants remain outstanding.</p> 3369564 23.00 1630436 0.0001 22.9999 0.0499 0.1999 P61D 132200000 750000 124000000.0 760870 869566 0.0001 125000000.0 5204415 56200000 1900000 10004869 121000000.0 4000000.0 0 300000 1000000 0.0001 1000000 0.0001 0.0999 1000000 999984 0 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">9. Warrants</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 6pt 0pt;">A summary of warrant activity during the nine months ended September 30, 2022 is as follows:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:62.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;width:0.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:62.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted-Average</b></p></td></tr><tr><td style="vertical-align:bottom;width:62.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Remaining</b></p></td></tr><tr><td style="vertical-align:bottom;width:62.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Contractual Term</b></p></td></tr><tr><td style="vertical-align:bottom;width:62.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Warrants</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercise Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Years)</b></p></td></tr><tr><td style="vertical-align:bottom;width:62.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Warrants outstanding, December 31, 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,776,191</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Expired</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (155)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Exercises (see Note 8)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,760,870)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Warrants outstanding, September 30, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,015,166</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">0.66</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">1.2</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The warrants outstanding as of September 30, 2022 included 869,566 Pre-Funded Warrants with an exercise price of $0.0001 per-share and no expiration date. </p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 6pt 0pt;">A summary of warrant activity during the nine months ended September 30, 2022 is as follows:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:62.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;width:0.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:62.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted-Average</b></p></td></tr><tr><td style="vertical-align:bottom;width:62.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Remaining</b></p></td></tr><tr><td style="vertical-align:bottom;width:62.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Contractual Term</b></p></td></tr><tr><td style="vertical-align:bottom;width:62.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Warrants</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercise Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Years)</b></p></td></tr><tr><td style="vertical-align:bottom;width:62.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Warrants outstanding, December 31, 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,776,191</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Expired</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (155)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Exercises (see Note 8)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,760,870)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Warrants outstanding, September 30, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,015,166</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">0.66</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">1.2</p></td></tr></table> 2776191 155 1760870 1015166 0.66 P1Y2M12D 869566 0.0001 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:12pt 0pt 12pt 0pt;">10. Stock-Based Compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Stock Options</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company’s stock option awards generally vest over four years and typically have a contractual life of ten years. As of September 30, 2022, there was $13.7 million of unrecognized compensation cost related to stock options, which is expected to be recognized over a weighted-average period of 2.6 years. During the nine months ended September 30, 2022, the Company granted 1,433,427 stock options with a weighted average exercise price of $8.39 and per share weighted average grant date fair value of $6.97.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 6pt 0pt;">Information related to stock options outstanding as of September 30, 2022 is as follows (in thousands, except share and per share data):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:46.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:46.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted-Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted-</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Remaining</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Contractual Term</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Aggregate Intrinsic</b></p></td></tr><tr><td style="vertical-align:bottom;width:46.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Stock Options</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercise Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Years)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Value</b></p></td></tr><tr><td style="vertical-align:bottom;width:46.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,528,473</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9.09</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.18%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5.9</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 16,975</p></td></tr><tr><td style="vertical-align:bottom;width:46.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Exercisable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,382,587</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8.75</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5.8</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,824</p></td></tr><tr><td style="vertical-align:bottom;width:46.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Unvested </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,145,886</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9.31</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.18%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9,151</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Restricted Stock</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of September 30, 2022, the Company had unvested restricted stock of 13,454 shares with total unrecognized compensation expense of $47,000, which the Company expects to recognize over a weighted average period of approximately 0.2 years. During the nine months ended September 30, 2022, the Company issued 34,132 of unrestricted common stock as a result of the vesting of 60,546 restricted stock net of 26,414 shares of common stock withheld to satisfy tax withholding obligations. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Restricted Stock Units (RSUs)</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">During the nine months ended September 30, 2022, the Company granted 285,000 shares of RSUs with a weighted average grant date fair value of $7.11 which vest over four years. As of September 30, 2022, the Company had unvested RSUs of 470,275 shares with total unrecognized compensation expense of $3.4 million, which the Company expects to recognize over a weighted average period of approximately 3.1 years. During the nine months ended September 30, 2022, the Company issued 30,373 shares of unrestricted common stock as a result of the vesting of 46,653 RSUs net of 16,280 shares of common stock withheld to satisfy tax withholding obligations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">2019 Employee Stock Purchase Plan (ESPP)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Under the ESPP, employees purchased 26,395 shares for $0.2 million during the nine months ended September 30, 2022. During the three and nine months ended September 30, 2022, the Company recognized compensation expense of $0.1 million and $0.2 million respectively. During the three and nine months ended September 30, 2021, the Company recognized compensation expense of $29,000 and $0.3 million, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Stock-based Compensation Expense</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 6pt 0pt;">Stock-based compensation expense is classified in the unaudited consolidated statements of operations and comprehensive loss for the three and nine months ended September 30, 2022 and 2021 as follows (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:55.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:55.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:20.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For the Three Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:20.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For the Nine Months Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:55.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:20.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September 30, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:20.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September 30, </b></p></td></tr><tr><td style="vertical-align:bottom;width:55.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:55.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 743</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 449</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,211</p></td></tr><tr><td style="vertical-align:bottom;width:55.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,385</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,048</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,185</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,989</p></td></tr><tr><td style="vertical-align:bottom;width:55.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,128</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,497</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,209</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.19%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,200</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">​</span></p> P4Y P10Y 13700000 P2Y7M6D 1433427 8.39 6.97 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 6pt 0pt;">Information related to stock options outstanding as of September 30, 2022 is as follows (in thousands, except share and per share data):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:46.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:46.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted-Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted-</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Remaining</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Contractual Term</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Aggregate Intrinsic</b></p></td></tr><tr><td style="vertical-align:bottom;width:46.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Stock Options</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercise Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Years)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Value</b></p></td></tr><tr><td style="vertical-align:bottom;width:46.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,528,473</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9.09</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.18%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5.9</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 16,975</p></td></tr><tr><td style="vertical-align:bottom;width:46.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Exercisable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,382,587</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8.75</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5.8</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,824</p></td></tr><tr><td style="vertical-align:bottom;width:46.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Unvested </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,145,886</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9.31</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.18%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9,151</p></td></tr></table> 3528473 9.09 P5Y10M24D 16975 1382587 8.75 P5Y9M18D 7824 2145886 9.31 P6Y 9151 13454 47000 P0Y2M12D 34132 60546 26414 285000 7.11 P4Y 470275 3400000 P3Y1M6D 30373 46653 16280 26395 200000 100000 200000 29000 300000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 6pt 0pt;">Stock-based compensation expense is classified in the unaudited consolidated statements of operations and comprehensive loss for the three and nine months ended September 30, 2022 and 2021 as follows (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:55.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:55.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:20.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For the Three Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:20.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For the Nine Months Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:55.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:20.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September 30, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:20.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September 30, </b></p></td></tr><tr><td style="vertical-align:bottom;width:55.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:55.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 743</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 449</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,211</p></td></tr><tr><td style="vertical-align:bottom;width:55.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,385</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,048</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,185</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,989</p></td></tr><tr><td style="vertical-align:bottom;width:55.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,128</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,497</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,209</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.19%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,200</p></td></tr></table> 743000 449000 2024000 1211000 1385000 1048000 4185000 2989000 2128000 1497000 6209000 4200000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">11. U.S. Government Contracts and Grants</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">In June 2020, the Company was awarded $4.7 million from the U.S. Army Medical Research &amp; Development Command (“USAMRDC”) to fund its Phase 1/2 clinical trial of T-COVID. The competitive award was granted by USAMRDC in collaboration with the Medical Technology Enterprise Consortium (“MTEC”), a 501(c)(3) biomedical technology consortium working in partnership with the Department of Defense (“DoD”). Under the contract, MTEC paid the Company a firm fixed fee based upon the achievement of certain milestones for conduct and completion of a Phase 1/2 study and research and development work on the replication-deficient adenovirus 5 (“RD-Ad5”) vector vaccine </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">platform. For the nine months ended September 30, 2021, the Company recognized approximately $0.5 million of grant revenue under the contract, which completed the full recognition of this award. No revenue was recognized for this contract for the three and nine months ended September 30, 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">In July 2016, the Company signed a five-year contract with Biomedical Advanced Research and Development Authority (“BARDA”). The contract, as amended, had a total value of up to $136.8 million to be used to fund clinical development of NasoShield. Under the contract, BARDA paid the Company a fixed fee and reimbursed certain costs for the research and development of an Ad5-vectored, protective antigen-based intranasal anthrax vaccine through cGMP manufacture and conduct of a Phase 1 clinical trial dose ranging assessment of safety and immunogenicity. The contract consisted of an initial base performance period providing approximately $30.9 million in funding for the period July 2016 through December 2021. BARDA had seven options to extend the contract to fund certain continued development and manufacturing activities for the anthrax vaccine, including Phase 2 clinical studies. Each option, if exercised by BARDA, would have provided additional funding ranging from approximately $1.1 million to $34.4 million for a three-year period beginning in 2021. For the three and nine months ended September 30, 2021, the Company recognized approximately $0.1 million and $0.4 million, respectively, of grant revenue under the BARDA contract. For the three and nine months ended September 30, 2022, the Company has recognized de minimis grant revenue related to the close-out of the BARDA contract. BARDA did not extend the contract beyond the end of December 2021.</p> 4700000 500000 0 0 P5Y 136800000 30900000 1100000 34400000 P3Y 100000 400000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">12. Income Taxes</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">During the three and nine months ended September 30, 2022, the Company recorded a total of $0.2 million income tax benefit related to interest received and receivable on income tax refunds. Other than the tax benefit related to interest, the Company did not record an income tax benefit in the three and nine months ended September 30, 2022 and 2021 due to a full valuation allowance.</p> -200000 -200000 0 0 0 0 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">13. Net Loss Per Share</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Because the Company has reported a net loss attributable to common stockholders for all periods presented, basic and diluted net loss per share attributable to common stockholders are the same for all periods presented.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Basic net loss per share attributable to common stockholders is computed by dividing the net loss attributable to common stockholders by the weighted average numbers of shares of common stock outstanding for the period. Basic shares outstanding includes the weighted average effect of the Company’s outstanding pre-funded warrants, the exercise of which requires little or no consideration for the delivery of shares of common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Diluted net loss per share is calculated by adjusting weighted average shares outstanding for the dilutive effect of common stock equivalents outstanding for the period. As such, all unvested restricted stock, restricted stock units, common stock warrants and stock options have been excluded from the computation of diluted weighted average shares outstanding because such securities would have an anti-dilutive impact for all periods presented.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 6pt 0pt;">Potential common shares issuable upon conversion, vesting or exercise of unvested restricted stock, restricted stock units, common stock warrants and stock options that are excluded from the computation of diluted weighted-average shares outstanding, as they are anti-dilutive, are as follows:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:27.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For the Three and Nine Months Ended</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:27.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September 30, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Common stock warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 145,600</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 145,755</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td></tr><tr><td style="vertical-align:bottom;width:71.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Common stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,542,534</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,626,482</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td></tr><tr><td style="vertical-align:bottom;width:71.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Restricted stock units</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 470,275</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 207,529</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Restricted stock </p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 13,454</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 94,181</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">​</span></p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 6pt 0pt;">Potential common shares issuable upon conversion, vesting or exercise of unvested restricted stock, restricted stock units, common stock warrants and stock options that are excluded from the computation of diluted weighted-average shares outstanding, as they are anti-dilutive, are as follows:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:27.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For the Three and Nine Months Ended</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:27.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September 30, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Common stock warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 145,600</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 145,755</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td></tr><tr><td style="vertical-align:bottom;width:71.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Common stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,542,534</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,626,482</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td></tr><tr><td style="vertical-align:bottom;width:71.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Restricted stock units</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 470,275</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 207,529</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Restricted stock </p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 13,454</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 94,181</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td></tr></table> 145600 145600 145755 145755 3542534 3542534 2626482 2626482 470275 470275 207529 207529 13454 13454 94181 94181 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">14. Commitments and Contingencies</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Spitfire Acquisition</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As disclosed in Note 6, the Company is obligated to make payments of up to $80.0 million upon the achievement of specified worldwide net sales of all products developed using the technology acquired from Spitfire Pharma Inc. within ten years following the approval of a new drug application filed with the FDA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Litigation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In December 2019, a complaint was filed by Dr. De-Chu Christopher Tang (“Plaintiff”) against the Company, which was removed to the United States District Court for the Eastern District of Texas. The Plaintiff amended the complaint in February 2020 to include Vipin K. Garg and David J. Drutz as defendants, in addition to the Company (Dr. Garg, Dr. Drutz, and the Company are collectively referred to as “Defendants”). In March 2020 the Defendants filed a motion to dismiss the complaint. The Court denied the motion without prejudice and allowed Plaintiff an opportunity to file an amended complaint. Plaintiff’s second amended complaint was filed on April 17, 2020, and Defendants filed a motion to dismiss that complaint on May 1, 2020. A hearing on Defendants’ motion to dismiss was held on May 20, 2020. Plaintiff, who is representing himself, alleges five causes of action as follows: (1) Defendants’ alleged retention of Plaintiff’s lab notebooks after the termination of his employment in 2012; (2) alleged plagiarism based on publishing an article without naming Plaintiff as an author; (3) use of the Adhigh System, which Plaintiff alleges he developed; (4) allegations that Defendants manipulated the Company’s stock and caused a decrease in value; and (5) allegations that the Defendants “wast[ed] government grant money and poison[ed] science by leaving data to rot.” On September 30, 2020, Plaintiff filed a motion titled “Motion to Proscribe Defendants’ Allegedly Illegal Use of Plaintiff’s AdHigh System in Altimmune’s Human Clinical Trials,” to which Defendants filed an opposition on October 13, 2020. The court has not yet ruled on that motion, which also remains pending. On November 6, 2020, Defendants filed a motion for summary judgment on the basis of lack of personal jurisdiction, insufficient service of process, and failure to state a claim. The court ruled on that motion on March 25, 2021, which dismissed the case on the basis of lack of personal jurisdiction. On December 1, 2020, the magistrate judge assigned to the case issued a report and recommendation that Defendants’ motion to dismiss of May 1, 2020 be granted and that this action be dismissed for lack of personal jurisdiction. Plaintiff filed objections to the report and recommendation on December 14, 2020, and the resolution of those objections by the district court remains pending. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In December 2021, the Plaintiff refiled the complaint in the United States District Court for the District of Maryland. On February 24, 2022, Defendants filed a memorandum containing a brief description of the planned motion and a concise summary of the factual and legal support for it. On the basis of that memorandum, the Court granted Defendants’ request to file a motion to dismiss and allowed Plaintiff an opportunity to file an amended complaint. Plaintiff’s amended complaint was filed on March 3, 2022, and Defendants filed a motion to dismiss that complaint on April 4, 2022. The Company believes the allegations in the complaint are without merit and intends to vigorously defend the litigation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company is a party in various contracts and subject to disputes, litigation and potential claims arising in the ordinary course of business, none of which are currently reasonably possible or probable of material loss.</p> 80000000.0 P10Y EXCEL 61 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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

E+W6*Q MFM.YNY9YR\JUTJ[0ZX2;O57NI5DXB&/_'V;92ZMMX?MAEB9AUD\A"0?)($S/ M$KC?>YB0#N,P&684>AAFR7D7_95YKQ^F60KG:=@[Z\&^WHIVYEZ%>NFGNZ&C M;J1M1V"G[1Z0JW9N_C5O7Y];II><$A&X(-?X=)@%H-N)W@I6U7Z*SI6EF>R7 M)3V"J)T![2\4]<=&< &Z9W7R!U!+ P04 " "<@6I5UVVXCE0% 7+0 M&0 'AL+W=O92OOCUQ *N"%.Z)Y*N6E#\'EL MW@,^>6T&:\:?Q)Q2B7[%42*&UES*Q;EMB^FZF 5F+[R%=B\IG ME%[*/6-/Z<&7V=!RTA'1B$YEBB#JWXJ.:12E)#6.GSG4*OI, ZN?7^A7V<6K MB[DG@HY9]' MK$80A\GF/_F5"U$)<%L[ G >@ \-\/( []" 5A[0.C2@G0=DEVYOKCT3SB>2 MC :H5)>J-,)%=G0Q4G1UZ\+#P[OW='#;96^(H>XR"'.>-[^ M'.;9N=B5G;^JV4E;_U<+,B4#BTU M:,RT^2\E@])RLJ9/90 MUB5CP^EDG+0HK$;=EM=1C\2JJK*QMZ8J0\("()BFH9D11U/M;);^R@Z;/0VLIEQ^D[>BK]FD;]]JM& MP7:CME94*Q6GE1GEQPV-[RFOG3:,]*920<)\2%@ !--2 MU"E2U#FF0M"!S"@DS(>$!4 P+:/=(J-=H$*PX;3W% )C;TU5AH0%0#!-Y5ZA M_D*O_WG6S MOZ78JQ(VWFY14PR-XVPJ*1!,D]1U2A_FO.T>-,E!5 T/7>ELW6/RMJZH-X6E.:#T@(H MFI[7TM^Z9H.[>[;SMDLN]OKI,HM6'FK:U=5<\S :B_8>;M4M[:IK]JMOFLBP M>2(#-;"@-!^4%D#1]-R5YMEM']5$!NJV06D^*"V HNEY+1VW:[1_#0Q:#MKG MT,S]-=8:U E#T72M2R_LFLWP[J)QF/DUXQM+"VI_H6BZM*4!=LT.^$VEQ3.7 M%DB_.P:E^:"T (JFYZYTXV[_J$H+I.D>@])\4%H 1=,W]

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how.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 63 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 64 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.2.2 html 169 237 1 false 46 0 false 4 false false R1.htm 00090 - Document - Document and Entity Information Sheet http://www.altimmune.com/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 00100 - Statement - CONSOLIDATED BALANCE SHEETS Sheet http://www.altimmune.com/role/StatementConsolidatedBalanceSheets CONSOLIDATED BALANCE SHEETS Statements 2 false false R3.htm 00105 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical) Sheet http://www.altimmune.com/role/StatementConsolidatedBalanceSheetsParenthetical CONSOLIDATED BALANCE SHEETS (Parenthetical) Statements 3 false false R4.htm 00200 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS Sheet http://www.altimmune.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS Statements 4 false false R5.htm 00300 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY Sheet http://www.altimmune.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY Statements 5 false false R6.htm 00400 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS Sheet http://www.altimmune.com/role/StatementConsolidatedStatementsOfCashFlows CONSOLIDATED STATEMENTS OF CASH FLOWS Statements 6 false false R7.htm 10101 - Disclosure - Nature of Business and Basis of Presentation Sheet http://www.altimmune.com/role/DisclosureNatureOfBusinessAndBasisOfPresentation Nature of Business and Basis of Presentation Notes 7 false false R8.htm 10201 - Disclosure - Summary of Significant Accounting Policies Sheet http://www.altimmune.com/role/DisclosureSummaryOfSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 8 false false R9.htm 10301 - Disclosure - Fair Value Measurements Sheet http://www.altimmune.com/role/DisclosureFairValueMeasurements Fair Value Measurements Notes 9 false false R10.htm 10401 - Disclosure - Operating Leases Sheet http://www.altimmune.com/role/DisclosureOperatingLeases Operating Leases Notes 10 false false R11.htm 10501 - Disclosure - Accrued Expenses Sheet http://www.altimmune.com/role/DisclosureAccruedExpenses Accrued Expenses Notes 11 false false R12.htm 10601 - Disclosure - Contingent Consideration Sheet http://www.altimmune.com/role/DisclosureContingentConsideration Contingent Consideration Notes 12 false false R13.htm 10701 - Disclosure - Other Long-Term Liabilities Sheet http://www.altimmune.com/role/DisclosureOtherLongTermLiabilities Other Long-Term Liabilities Notes 13 false false R14.htm 10801 - Disclosure - Common Stock Sheet http://www.altimmune.com/role/DisclosureCommonStock Common Stock Notes 14 false false R15.htm 10901 - Disclosure - Warrants Sheet http://www.altimmune.com/role/DisclosureWarrants Warrants Notes 15 false false R16.htm 11001 - Disclosure - Stock-Based Compensation Sheet http://www.altimmune.com/role/DisclosureStockBasedCompensation Stock-Based Compensation Notes 16 false false R17.htm 11101 - Disclosure - U.S. Government Contracts and Grants Sheet http://www.altimmune.com/role/DisclosureUsGovernmentContractsAndGrants U.S. Government Contracts and Grants Notes 17 false false R18.htm 11201 - Disclosure - Income Taxes Sheet http://www.altimmune.com/role/DisclosureIncomeTaxes Income Taxes Notes 18 false false R19.htm 11301 - Disclosure - Net Loss Per Share Sheet http://www.altimmune.com/role/DisclosureNetLossPerShare Net Loss Per Share Notes 19 false false R20.htm 11401 - Disclosure - Commitments and Contingencies Sheet http://www.altimmune.com/role/DisclosureCommitmentsAndContingencies Commitments and Contingencies Notes 20 false false R21.htm 20202 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://www.altimmune.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://www.altimmune.com/role/DisclosureSummaryOfSignificantAccountingPolicies 21 false false R22.htm 30303 - Disclosure - Fair Value Measurements (Tables) Sheet http://www.altimmune.com/role/DisclosureFairValueMeasurementsTables Fair Value Measurements (Tables) Tables http://www.altimmune.com/role/DisclosureFairValueMeasurements 22 false false R23.htm 30403 - Disclosure - Operating Leases (Tables) Sheet http://www.altimmune.com/role/DisclosureOperatingLeasesTables Operating Leases (Tables) Tables http://www.altimmune.com/role/DisclosureOperatingLeases 23 false false R24.htm 30503 - Disclosure - Accrued Expenses (Tables) Sheet http://www.altimmune.com/role/DisclosureAccruedExpensesTables Accrued Expenses (Tables) Tables http://www.altimmune.com/role/DisclosureAccruedExpenses 24 false false R25.htm 30603 - Disclosure - Contingent Consideration (Tables) Sheet http://www.altimmune.com/role/DisclosureContingentConsiderationTables Contingent Consideration (Tables) Tables http://www.altimmune.com/role/DisclosureContingentConsideration 25 false false R26.htm 30703 - Disclosure - Other Long-Term Liabilities (Tables) Sheet http://www.altimmune.com/role/DisclosureOtherLongTermLiabilitiesTables Other Long-Term Liabilities (Tables) Tables http://www.altimmune.com/role/DisclosureOtherLongTermLiabilities 26 false false R27.htm 30903 - Disclosure - Warrants (Tables) Sheet http://www.altimmune.com/role/DisclosureWarrantsTables Warrants (Tables) Tables http://www.altimmune.com/role/DisclosureWarrants 27 false false R28.htm 31003 - Disclosure - Stock-Based Compensation (Tables) Sheet http://www.altimmune.com/role/DisclosureStockBasedCompensationTables Stock-Based Compensation (Tables) Tables http://www.altimmune.com/role/DisclosureStockBasedCompensation 28 false false R29.htm 31303 - Disclosure - Net Loss Per Share (Tables) Sheet http://www.altimmune.com/role/DisclosureNetLossPerShareTables Net Loss Per Share (Tables) Tables http://www.altimmune.com/role/DisclosureNetLossPerShare 29 false false R30.htm 40301 - Disclosure - Fair Value Measurements - Schedule of Fair Value Assets and Liabilities Measured on Recurring Basis (Detail) Sheet http://www.altimmune.com/role/DisclosureFairValueMeasurementsScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetail Fair Value Measurements - Schedule of Fair Value Assets and Liabilities Measured on Recurring Basis (Detail) Details 30 false false R31.htm 40302 - Disclosure - Fair Value Measurements - Schedule of Short Term Investments (Detail) Sheet http://www.altimmune.com/role/DisclosureFairValueMeasurementsScheduleOfShortTermInvestmentsDetail Fair Value Measurements - Schedule of Short Term Investments (Detail) Details 31 false false R32.htm 40303 - Disclosure - Fair Value Measurements - Additional Information (Detail) Sheet http://www.altimmune.com/role/DisclosureFairValueMeasurementsAdditionalInformationDetail Fair Value Measurements - Additional Information (Detail) Details 32 false false R33.htm 40401 - Disclosure - Operating Leases - Additional Information (Detail) Sheet http://www.altimmune.com/role/DisclosureOperatingLeasesAdditionalInformationDetail Operating Leases - Additional Information (Detail) Details 33 false false R34.htm 40402 - Disclosure - Operating Leases - Summary of Supplemental other Information Related to Operating Leases Balance Sheet (Detail) Sheet http://www.altimmune.com/role/DisclosureOperatingLeasesSummaryOfSupplementalOtherInformationRelatedToOperatingLeasesBalanceSheetDetail Operating Leases - Summary of Supplemental other Information Related to Operating Leases Balance Sheet (Detail) Details 34 false false R35.htm 40501 - Disclosure - Accrued Expenses - Schedule of Accrued Expenses and Other Current Liabilities (Detail) Sheet http://www.altimmune.com/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetail Accrued Expenses - Schedule of Accrued Expenses and Other Current Liabilities (Detail) Details 35 false false R36.htm 40601 - Disclosure - Contingent Consideration - Additional Information (Detail) Sheet http://www.altimmune.com/role/DisclosureContingentConsiderationAdditionalInformationDetail Contingent Consideration - Additional Information (Detail) Details 36 false false R37.htm 40602 - Disclosure - Contingent Consideration - Summary of Fair Value of Contingent Consideration (Detail) Sheet http://www.altimmune.com/role/DisclosureContingentConsiderationSummaryOfFairValueOfContingentConsiderationDetail Contingent Consideration - Summary of Fair Value of Contingent Consideration (Detail) Details 37 false false R38.htm 40701 - Disclosure - Other Long-Term Liabilities - Summary of Other Long-Term Liabilities (Detail) Sheet http://www.altimmune.com/role/DisclosureOtherLongTermLiabilitiesSummaryOfOtherLongTermLiabilitiesDetail Other Long-Term Liabilities - Summary of Other Long-Term Liabilities (Detail) Details 38 false false R39.htm 40801 - Disclosure - Common Stock - Additional Information (Detail) Sheet http://www.altimmune.com/role/DisclosureCommonStockAdditionalInformationDetail Common Stock - Additional Information (Detail) Details 39 false false R40.htm 40901 - Disclosure - Warrants - Summary of Warrant Activity (Detail) Sheet http://www.altimmune.com/role/DisclosureWarrantsSummaryOfWarrantActivityDetail Warrants - Summary of Warrant Activity (Detail) Details 40 false false R41.htm 40902 - Disclosure - Warrants - Additional Information (Detail) Sheet http://www.altimmune.com/role/DisclosureWarrantsAdditionalInformationDetail Warrants - Additional Information (Detail) Details 41 false false R42.htm 41001 - Disclosure - Stock-Based Compensation - Additional Information (Detail) Sheet http://www.altimmune.com/role/DisclosureStockBasedCompensationAdditionalInformationDetail Stock-Based Compensation - Additional Information (Detail) Details 42 false false R43.htm 41002 - Disclosure - Stock-Based Compensation - Schedule of Information Related to Stock Options Outstanding (Detail) Sheet http://www.altimmune.com/role/DisclosureStockBasedCompensationScheduleOfInformationRelatedToStockOptionsOutstandingDetail Stock-Based Compensation - Schedule of Information Related to Stock Options Outstanding (Detail) Details 43 false false R44.htm 41003 - Disclosure - Stock-Based Compensation - Schedule of Stock-based Compensation Expense (Detail) Sheet http://www.altimmune.com/role/DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseDetail Stock-Based Compensation - Schedule of Stock-based Compensation Expense (Detail) Details 44 false false R45.htm 41101 - Disclosure - U.S. Government Contracts and Grants - Additional Information (Detail) Sheet http://www.altimmune.com/role/DisclosureUsGovernmentContractsAndGrantsAdditionalInformationDetail U.S. Government Contracts and Grants - Additional Information (Detail) Details 45 false false R46.htm 41201 - Disclosure - Income Taxes - Additional Information (Detail) Sheet http://www.altimmune.com/role/DisclosureIncomeTaxesAdditionalInformationDetail Income Taxes - Additional Information (Detail) Details 46 false false R47.htm 41301 - Disclosure - Net Loss Per Share - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Detail) Sheet http://www.altimmune.com/role/DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetail Net Loss Per Share - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Detail) Details 47 false false R48.htm 41401 - Disclosure - Commitments and Contingencies - Additional Information (Details) Sheet http://www.altimmune.com/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails Commitments and Contingencies - Additional Information (Details) Details 48 false false All Reports Book All Reports [ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 12 fact(s) appearing in ix:hidden were eligible for transformation: alt:NumberOfConsecutiveTradingDays, us-gaap:CommonStockSharesOutstanding, us-gaap:EarningsPerShareDiluted, us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding - alt-20220930x10q.htm 9 [ix-0514-Hidden-Fact-Not-Referenced] WARN: 2 fact(s) appearing in ix:hidden were not referenced by any -sec-ix-hidden style property: us-gaap:CommitmentsAndContingencies - alt-20220930x10q.htm 9 alt-20220930x10q.htm alt-20220930.xsd alt-20220930_cal.xml alt-20220930_def.xml alt-20220930_lab.xml alt-20220930_pre.xml alt-20220930xex31d1.htm alt-20220930xex31d2.htm alt-20220930xex32d1.htm alt-20220930xex32d2.htm alt-20220930x10q002.jpg http://fasb.org/us-gaap/2021-01-31 http://xbrl.sec.gov/dei/2021q4 true true JSON 67 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "alt-20220930x10q.htm": { "axisCustom": 0, "axisStandard": 19, "contextCount": 169, "dts": { "calculationLink": { "local": [ "alt-20220930_cal.xml" ] }, "definitionLink": { "local": [ "alt-20220930_def.xml" ] }, "inline": { "local": [ "alt-20220930x10q.htm" ] }, "labelLink": { "local": [ "alt-20220930_lab.xml" ] }, "presentationLink": { "local": [ "alt-20220930_pre.xml" ] }, "schema": { "local": [ "alt-20220930.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" ] } }, "elementCount": 371, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2021-01-31": 12, "http://www.altimmune.com/20220930": 2, "http://xbrl.sec.gov/dei/2021q4": 5, "total": 19 }, "keyCustom": 42, "keyStandard": 195, "memberCustom": 18, "memberStandard": 25, "nsprefix": "alt", "nsuri": "http://www.altimmune.com/20220930", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "div", "div", "body", "html" ], "baseRef": "alt-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_Nh6OhqMuZkWQYwOmO2JLFg", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00090 - Document - Document and Entity Information", "role": "http://www.altimmune.com/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "div", "div", "body", "html" ], "baseRef": "alt-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_Nh6OhqMuZkWQYwOmO2JLFg", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "alt-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_Nh6OhqMuZkWQYwOmO2JLFg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10401 - Disclosure - Operating Leases", "role": "http://www.altimmune.com/role/DisclosureOperatingLeases", "shortName": "Operating Leases", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "alt-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_Nh6OhqMuZkWQYwOmO2JLFg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "alt-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_Nh6OhqMuZkWQYwOmO2JLFg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10501 - Disclosure - Accrued Expenses", "role": "http://www.altimmune.com/role/DisclosureAccruedExpenses", "shortName": "Accrued Expenses", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "alt-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_Nh6OhqMuZkWQYwOmO2JLFg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "alt-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_Nh6OhqMuZkWQYwOmO2JLFg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10601 - Disclosure - Contingent Consideration", "role": "http://www.altimmune.com/role/DisclosureContingentConsideration", "shortName": "Contingent Consideration", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "alt-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_Nh6OhqMuZkWQYwOmO2JLFg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "alt-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_Nh6OhqMuZkWQYwOmO2JLFg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OtherLiabilitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10701 - Disclosure - Other Long-Term Liabilities", "role": "http://www.altimmune.com/role/DisclosureOtherLongTermLiabilities", "shortName": "Other Long-Term Liabilities", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "alt-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_Nh6OhqMuZkWQYwOmO2JLFg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OtherLiabilitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "alt-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_Nh6OhqMuZkWQYwOmO2JLFg", "decimals": null, "first": true, "lang": "en-US", "name": "alt:CommonStockTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10801 - Disclosure - Common Stock", "role": "http://www.altimmune.com/role/DisclosureCommonStock", "shortName": "Common Stock", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "alt-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_Nh6OhqMuZkWQYwOmO2JLFg", "decimals": null, "first": true, "lang": "en-US", "name": "alt:CommonStockTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "alt-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_Nh6OhqMuZkWQYwOmO2JLFg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10901 - Disclosure - Warrants", "role": "http://www.altimmune.com/role/DisclosureWarrants", "shortName": "Warrants", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "alt-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_Nh6OhqMuZkWQYwOmO2JLFg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "alt-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_Nh6OhqMuZkWQYwOmO2JLFg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "11001 - Disclosure - Stock-Based Compensation", "role": "http://www.altimmune.com/role/DisclosureStockBasedCompensation", "shortName": "Stock-Based Compensation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "alt-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_Nh6OhqMuZkWQYwOmO2JLFg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "alt-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_Nh6OhqMuZkWQYwOmO2JLFg", "decimals": null, "first": true, "lang": "en-US", "name": "alt:USGovernmentContractsAndGrantsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "11101 - Disclosure - U.S. Government Contracts and Grants", "role": "http://www.altimmune.com/role/DisclosureUsGovernmentContractsAndGrants", "shortName": "U.S. Government Contracts and Grants", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "alt-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_Nh6OhqMuZkWQYwOmO2JLFg", "decimals": null, "first": true, "lang": "en-US", "name": "alt:USGovernmentContractsAndGrantsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "alt-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_Nh6OhqMuZkWQYwOmO2JLFg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "11201 - Disclosure - Income Taxes", "role": "http://www.altimmune.com/role/DisclosureIncomeTaxes", "shortName": "Income Taxes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "alt-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_Nh6OhqMuZkWQYwOmO2JLFg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "alt-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_Nh6OhqMuZkWQYwOmO2JLFg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "11301 - Disclosure - Net Loss Per Share", "role": "http://www.altimmune.com/role/DisclosureNetLossPerShare", "shortName": "Net Loss Per Share", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "alt-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_Nh6OhqMuZkWQYwOmO2JLFg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "alt-20220930x10q.htm", "contextRef": "As_Of_9_30_2022_TQg6B5BW90OukNNTbJ71gw", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_I-4CVpypV0KZWdE1iSXy5Q", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00100 - Statement - CONSOLIDATED BALANCE SHEETS", "role": "http://www.altimmune.com/role/StatementConsolidatedBalanceSheets", "shortName": "CONSOLIDATED BALANCE SHEETS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "alt-20220930x10q.htm", "contextRef": "As_Of_9_30_2022_TQg6B5BW90OukNNTbJ71gw", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_I-4CVpypV0KZWdE1iSXy5Q", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "alt-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_Nh6OhqMuZkWQYwOmO2JLFg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "11401 - Disclosure - Commitments and Contingencies", "role": "http://www.altimmune.com/role/DisclosureCommitmentsAndContingencies", "shortName": "Commitments and Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "alt-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_Nh6OhqMuZkWQYwOmO2JLFg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "div", "body", "html" ], "baseRef": "alt-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_Nh6OhqMuZkWQYwOmO2JLFg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:UseOfEstimates", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "20202 - Disclosure - Summary of Significant Accounting Policies (Policies)", "role": "http://www.altimmune.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies", "shortName": "Summary of Significant Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "div", "body", "html" ], "baseRef": "alt-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_Nh6OhqMuZkWQYwOmO2JLFg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:UseOfEstimates", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "us-gaap:FairValueDisclosuresTextBlock", "div", "div", "body", "html" ], "baseRef": "alt-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_Nh6OhqMuZkWQYwOmO2JLFg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "30303 - Disclosure - Fair Value Measurements (Tables)", "role": "http://www.altimmune.com/role/DisclosureFairValueMeasurementsTables", "shortName": "Fair Value Measurements (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:FairValueDisclosuresTextBlock", "div", "div", "body", "html" ], "baseRef": "alt-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_Nh6OhqMuZkWQYwOmO2JLFg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "us-gaap:LesseeOperatingLeasesTextBlock", "div", "div", "body", "html" ], "baseRef": "alt-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_Nh6OhqMuZkWQYwOmO2JLFg", "decimals": null, "first": true, "lang": "en-US", "name": "alt:ScheduleOfSupplementalBalanceSheetInformationRelatedToOperatingLeasesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "30403 - Disclosure - Operating Leases (Tables)", "role": "http://www.altimmune.com/role/DisclosureOperatingLeasesTables", "shortName": "Operating Leases (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:LesseeOperatingLeasesTextBlock", "div", "div", "body", "html" ], "baseRef": "alt-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_Nh6OhqMuZkWQYwOmO2JLFg", "decimals": null, "first": true, "lang": "en-US", "name": "alt:ScheduleOfSupplementalBalanceSheetInformationRelatedToOperatingLeasesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "alt-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_Nh6OhqMuZkWQYwOmO2JLFg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "30503 - Disclosure - Accrued Expenses (Tables)", "role": "http://www.altimmune.com/role/DisclosureAccruedExpensesTables", "shortName": "Accrued Expenses (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "alt-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_Nh6OhqMuZkWQYwOmO2JLFg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "alt-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_Nh6OhqMuZkWQYwOmO2JLFg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "30603 - Disclosure - Contingent Consideration (Tables)", "role": "http://www.altimmune.com/role/DisclosureContingentConsiderationTables", "shortName": "Contingent Consideration (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "alt-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_Nh6OhqMuZkWQYwOmO2JLFg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "baseRef": "alt-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_Nh6OhqMuZkWQYwOmO2JLFg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OtherNoncurrentLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "30703 - Disclosure - Other Long-Term Liabilities (Tables)", "role": "http://www.altimmune.com/role/DisclosureOtherLongTermLiabilitiesTables", "shortName": "Other Long-Term Liabilities (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "baseRef": "alt-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_Nh6OhqMuZkWQYwOmO2JLFg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OtherNoncurrentLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "alt-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_Nh6OhqMuZkWQYwOmO2JLFg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "30903 - Disclosure - Warrants (Tables)", "role": "http://www.altimmune.com/role/DisclosureWarrantsTables", "shortName": "Warrants (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "alt-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_Nh6OhqMuZkWQYwOmO2JLFg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "baseRef": "alt-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_Nh6OhqMuZkWQYwOmO2JLFg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfOtherShareBasedCompensationActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "31003 - Disclosure - Stock-Based Compensation (Tables)", "role": "http://www.altimmune.com/role/DisclosureStockBasedCompensationTables", "shortName": "Stock-Based Compensation (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "baseRef": "alt-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_Nh6OhqMuZkWQYwOmO2JLFg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfOtherShareBasedCompensationActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "us-gaap:EarningsPerShareTextBlock", "div", "div", "body", "html" ], "baseRef": "alt-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_Nh6OhqMuZkWQYwOmO2JLFg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "31303 - Disclosure - Net Loss Per Share (Tables)", "role": "http://www.altimmune.com/role/DisclosureNetLossPerShareTables", "shortName": "Net Loss Per Share (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:EarningsPerShareTextBlock", "div", "div", "body", "html" ], "baseRef": "alt-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_Nh6OhqMuZkWQYwOmO2JLFg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "alt-20220930x10q.htm", "contextRef": "As_Of_9_30_2022_TQg6B5BW90OukNNTbJ71gw", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockParOrStatedValuePerShare", "reportCount": 1, "unitRef": "Unit_Divide_USD_shares_qGKdwya1O0uTV3c0_SM4ig", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00105 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)", "role": "http://www.altimmune.com/role/StatementConsolidatedBalanceSheetsParenthetical", "shortName": "CONSOLIDATED BALANCE SHEETS (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "alt-20220930x10q.htm", "contextRef": "As_Of_9_30_2022_TQg6B5BW90OukNNTbJ71gw", "decimals": "INF", "lang": null, "name": "us-gaap:CommonStockSharesAuthorized", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_C7PsNJDVF0OEmvb2RnrBfQ", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "alt-20220930x10q.htm", "contextRef": "As_Of_9_30_2022_TQg6B5BW90OukNNTbJ71gw", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ShortTermInvestments", "reportCount": 1, "unitRef": "Unit_Standard_USD_I-4CVpypV0KZWdE1iSXy5Q", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40301 - Disclosure - Fair Value Measurements - Schedule of Fair Value Assets and Liabilities Measured on Recurring Basis (Detail)", "role": "http://www.altimmune.com/role/DisclosureFairValueMeasurementsScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetail", "shortName": "Fair Value Measurements - Schedule of Fair Value Assets and Liabilities Measured on Recurring Basis (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "div", "div", "body", "html" ], "baseRef": "alt-20220930x10q.htm", "contextRef": "As_Of_9_30_2022_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_Wu_La9F_8UepHHwlhdi5oQ", "decimals": "-3", "lang": null, "name": "us-gaap:ShortTermInvestments", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_I-4CVpypV0KZWdE1iSXy5Q", "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "div", "div", "body", "html" ], "baseRef": "alt-20220930x10q.htm", "contextRef": "As_Of_9_30_2022_TQg6B5BW90OukNNTbJ71gw", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_I-4CVpypV0KZWdE1iSXy5Q", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40302 - Disclosure - Fair Value Measurements - Schedule of Short Term Investments (Detail)", "role": "http://www.altimmune.com/role/DisclosureFairValueMeasurementsScheduleOfShortTermInvestmentsDetail", "shortName": "Fair Value Measurements - Schedule of Short Term Investments (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "div", "div", "body", "html" ], "baseRef": "alt-20220930x10q.htm", "contextRef": "As_Of_9_30_2022_TQg6B5BW90OukNNTbJ71gw", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_I-4CVpypV0KZWdE1iSXy5Q", "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "p", "us-gaap:FairValueDisclosuresTextBlock", "div", "div", "body", "html" ], "baseRef": "alt-20220930x10q.htm", "contextRef": "As_Of_9_30_2022_TQg6B5BW90OukNNTbJ71gw", "decimals": "-6", "first": true, "lang": null, "name": "alt:AssetsOrLiabilitiesMeasuredAtFairValueOnNonRecurringBasis", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_I-4CVpypV0KZWdE1iSXy5Q", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40303 - Disclosure - Fair Value Measurements - Additional Information (Detail)", "role": "http://www.altimmune.com/role/DisclosureFairValueMeasurementsAdditionalInformationDetail", "shortName": "Fair Value Measurements - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:FairValueDisclosuresTextBlock", "div", "div", "body", "html" ], "baseRef": "alt-20220930x10q.htm", "contextRef": "As_Of_9_30_2022_TQg6B5BW90OukNNTbJ71gw", "decimals": "-6", "first": true, "lang": null, "name": "alt:AssetsOrLiabilitiesMeasuredAtFairValueOnNonRecurringBasis", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_I-4CVpypV0KZWdE1iSXy5Q", "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "us-gaap:OperatingLeasePayments", "p", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "div", "body", "html" ], "baseRef": "alt-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_Nh6OhqMuZkWQYwOmO2JLFg", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:OperatingLeasePayments", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_I-4CVpypV0KZWdE1iSXy5Q", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40401 - Disclosure - Operating Leases - Additional Information (Detail)", "role": "http://www.altimmune.com/role/DisclosureOperatingLeasesAdditionalInformationDetail", "shortName": "Operating Leases - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "us-gaap:OperatingLeasePayments", "p", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "div", "body", "html" ], "baseRef": "alt-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_Nh6OhqMuZkWQYwOmO2JLFg", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:OperatingLeasePayments", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_I-4CVpypV0KZWdE1iSXy5Q", "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "alt:ScheduleOfSupplementalBalanceSheetInformationRelatedToOperatingLeasesTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "div", "body", "html" ], "baseRef": "alt-20220930x10q.htm", "contextRef": "As_Of_9_30_2022_TQg6B5BW90OukNNTbJ71gw", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseLiability", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_I-4CVpypV0KZWdE1iSXy5Q", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40402 - Disclosure - Operating Leases - Summary of Supplemental other Information Related to Operating Leases Balance Sheet (Detail)", "role": "http://www.altimmune.com/role/DisclosureOperatingLeasesSummaryOfSupplementalOtherInformationRelatedToOperatingLeasesBalanceSheetDetail", "shortName": "Operating Leases - Summary of Supplemental other Information Related to Operating Leases Balance Sheet (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "alt:ScheduleOfSupplementalBalanceSheetInformationRelatedToOperatingLeasesTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "div", "body", "html" ], "baseRef": "alt-20220930x10q.htm", "contextRef": "As_Of_9_30_2022_TQg6B5BW90OukNNTbJ71gw", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseLiability", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_I-4CVpypV0KZWdE1iSXy5Q", "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "alt-20220930x10q.htm", "contextRef": "As_Of_9_30_2022_TQg6B5BW90OukNNTbJ71gw", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AccruedProfessionalFeesCurrent", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_I-4CVpypV0KZWdE1iSXy5Q", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40501 - Disclosure - Accrued Expenses - Schedule of Accrued Expenses and Other Current Liabilities (Detail)", "role": "http://www.altimmune.com/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetail", "shortName": "Accrued Expenses - Schedule of Accrued Expenses and Other Current Liabilities (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "alt-20220930x10q.htm", "contextRef": "As_Of_9_30_2022_TQg6B5BW90OukNNTbJ71gw", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AccruedProfessionalFeesCurrent", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_I-4CVpypV0KZWdE1iSXy5Q", "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "alt-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_Nh6OhqMuZkWQYwOmO2JLFg", "decimals": "-3", "first": true, "lang": null, "name": "alt:CommonStockIssuedRelatedToContingentConsiderationLiability", "reportCount": 1, "unitRef": "Unit_Standard_USD_I-4CVpypV0KZWdE1iSXy5Q", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40601 - Disclosure - Contingent Consideration - Additional Information (Detail)", "role": "http://www.altimmune.com/role/DisclosureContingentConsiderationAdditionalInformationDetail", "shortName": "Contingent Consideration - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "alt-20220930x10q.htm", "contextRef": "Duration_11_19_2020_To_11_19_2020_us-gaap_SubsidiarySaleOfStockAxis_alt_ClinicalTrialNotificationMember_NbB5i3MoX0m3TrmfKAn33Q", "decimals": "-5", "lang": null, "name": "alt:CommonStockIssuedRelatedToContingentConsiderationLiability", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_I-4CVpypV0KZWdE1iSXy5Q", "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "alt-20220930x10q.htm", "contextRef": "As_Of_12_31_2021_N1yzRxVtSUehNNpcNrvaiQ", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:BusinessCombinationContingentConsiderationLiability", "reportCount": 1, "unitRef": "Unit_Standard_USD_I-4CVpypV0KZWdE1iSXy5Q", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40602 - Disclosure - Contingent Consideration - Summary of Fair Value of Contingent Consideration (Detail)", "role": "http://www.altimmune.com/role/DisclosureContingentConsiderationSummaryOfFairValueOfContingentConsiderationDetail", "shortName": "Contingent Consideration - Summary of Fair Value of Contingent Consideration (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "alt-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_Nh6OhqMuZkWQYwOmO2JLFg", "decimals": "-3", "lang": null, "name": "us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_I-4CVpypV0KZWdE1iSXy5Q", "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:OtherNoncurrentLiabilitiesTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "alt-20220930x10q.htm", "contextRef": "As_Of_9_30_2022_TQg6B5BW90OukNNTbJ71gw", "decimals": "-3", "first": true, "lang": null, "name": "alt:ResearchAndDevelopmentIncentiveCredit", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_I-4CVpypV0KZWdE1iSXy5Q", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40701 - Disclosure - Other Long-Term Liabilities - Summary of Other Long-Term Liabilities (Detail)", "role": "http://www.altimmune.com/role/DisclosureOtherLongTermLiabilitiesSummaryOfOtherLongTermLiabilitiesDetail", "shortName": "Other Long-Term Liabilities - Summary of Other Long-Term Liabilities (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:OtherNoncurrentLiabilitiesTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "alt-20220930x10q.htm", "contextRef": "As_Of_9_30_2022_TQg6B5BW90OukNNTbJ71gw", "decimals": "-3", "first": true, "lang": null, "name": "alt:ResearchAndDevelopmentIncentiveCredit", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_I-4CVpypV0KZWdE1iSXy5Q", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "alt-20220930x10q.htm", "contextRef": "As_Of_9_30_2022_TQg6B5BW90OukNNTbJ71gw", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ClassOfWarrantOrRightOutstanding", "reportCount": 1, "unitRef": "Unit_Standard_shares_C7PsNJDVF0OEmvb2RnrBfQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40801 - Disclosure - Common Stock - Additional Information (Detail)", "role": "http://www.altimmune.com/role/DisclosureCommonStockAdditionalInformationDetail", "shortName": "Common Stock - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "alt-20220930x10q.htm", "contextRef": "Duration_1_24_2022_To_1_24_2022_us-gaap_StatementEquityComponentsAxis_alt_ExchangeWarrantsMember_zub2EHhayk24W6FboCBNDQ", "decimals": "INF", "lang": null, "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_C7PsNJDVF0OEmvb2RnrBfQ", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "alt-20220930x10q.htm", "contextRef": "Duration_7_1_2022_To_9_30_2022_Uf5Jq1cZcUK2MSXcxyHW2A", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "Unit_Standard_USD_I-4CVpypV0KZWdE1iSXy5Q", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00200 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS", "role": "http://www.altimmune.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss", "shortName": "CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "alt-20220930x10q.htm", "contextRef": "Duration_7_1_2022_To_9_30_2022_Uf5Jq1cZcUK2MSXcxyHW2A", "decimals": "-3", "lang": null, "name": "us-gaap:ResearchAndDevelopmentExpense", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_I-4CVpypV0KZWdE1iSXy5Q", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "alt-20220930x10q.htm", "contextRef": "As_Of_12_31_2021_N1yzRxVtSUehNNpcNrvaiQ", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ClassOfWarrantOrRightOutstanding", "reportCount": 1, "unitRef": "Unit_Standard_shares_C7PsNJDVF0OEmvb2RnrBfQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40901 - Disclosure - Warrants - Summary of Warrant Activity (Detail)", "role": "http://www.altimmune.com/role/DisclosureWarrantsSummaryOfWarrantActivityDetail", "shortName": "Warrants - Summary of Warrant Activity (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "alt-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_Nh6OhqMuZkWQYwOmO2JLFg", "decimals": "INF", "lang": null, "name": "alt:WarrantsExpired", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_C7PsNJDVF0OEmvb2RnrBfQ", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "alt-20220930x10q.htm", "contextRef": "As_Of_9_30_2022_TQg6B5BW90OukNNTbJ71gw", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ClassOfWarrantOrRightOutstanding", "reportCount": 1, "unitRef": "Unit_Standard_shares_C7PsNJDVF0OEmvb2RnrBfQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40902 - Disclosure - Warrants - Additional Information (Detail)", "role": "http://www.altimmune.com/role/DisclosureWarrantsAdditionalInformationDetail", "shortName": "Warrants - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": null }, "R42": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "alt-20220930x10q.htm", "contextRef": "Duration_7_1_2022_To_9_30_2022_Uf5Jq1cZcUK2MSXcxyHW2A", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan", "reportCount": 1, "unitRef": "Unit_Standard_USD_I-4CVpypV0KZWdE1iSXy5Q", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41001 - Disclosure - Stock-Based Compensation - Additional Information (Detail)", "role": "http://www.altimmune.com/role/DisclosureStockBasedCompensationAdditionalInformationDetail", "shortName": "Stock-Based Compensation - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "alt-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_us-gaap_PlanNameAxis_alt_TwoThousandAndNineteenEmployeeStockPurchasePlanMember_cn5PBTbrY0q14Zj-KpLgmQ", "decimals": "INF", "lang": null, "name": "us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_C7PsNJDVF0OEmvb2RnrBfQ", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfOtherShareBasedCompensationActivityTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "alt-20220930x10q.htm", "contextRef": "As_Of_9_30_2022_TQg6B5BW90OukNNTbJ71gw", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_C7PsNJDVF0OEmvb2RnrBfQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41002 - Disclosure - Stock-Based Compensation - Schedule of Information Related to Stock Options Outstanding (Detail)", "role": "http://www.altimmune.com/role/DisclosureStockBasedCompensationScheduleOfInformationRelatedToStockOptionsOutstandingDetail", "shortName": "Stock-Based Compensation - Schedule of Information Related to Stock Options Outstanding (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfOtherShareBasedCompensationActivityTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "alt-20220930x10q.htm", "contextRef": "As_Of_9_30_2022_TQg6B5BW90OukNNTbJ71gw", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_C7PsNJDVF0OEmvb2RnrBfQ", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "alt-20220930x10q.htm", "contextRef": "Duration_7_1_2022_To_9_30_2022_Uf5Jq1cZcUK2MSXcxyHW2A", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_I-4CVpypV0KZWdE1iSXy5Q", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41003 - Disclosure - Stock-Based Compensation - Schedule of Stock-based Compensation Expense (Detail)", "role": "http://www.altimmune.com/role/DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseDetail", "shortName": "Stock-Based Compensation - Schedule of Stock-based Compensation Expense (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "alt-20220930x10q.htm", "contextRef": "Duration_7_1_2022_To_9_30_2022_Uf5Jq1cZcUK2MSXcxyHW2A", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_I-4CVpypV0KZWdE1iSXy5Q", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "alt-20220930x10q.htm", "contextRef": "Duration_7_1_2022_To_9_30_2022_Uf5Jq1cZcUK2MSXcxyHW2A", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "Unit_Standard_USD_I-4CVpypV0KZWdE1iSXy5Q", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41101 - Disclosure - U.S. Government Contracts and Grants - Additional Information (Detail)", "role": "http://www.altimmune.com/role/DisclosureUsGovernmentContractsAndGrantsAdditionalInformationDetail", "shortName": "U.S. Government Contracts and Grants - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "alt-20220930x10q.htm", "contextRef": "Duration_1_1_2021_To_1_1_2021_srt_CounterpartyNameAxis_alt_BARDAContractMember_T1ow2DJPKkKzWKOaNnsb7g", "decimals": null, "lang": "en-US", "name": "alt:DurationOfContract", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "alt-20220930x10q.htm", "contextRef": "Duration_7_1_2022_To_9_30_2022_Uf5Jq1cZcUK2MSXcxyHW2A", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:IncomeTaxExpenseBenefit", "reportCount": 1, "unitRef": "Unit_Standard_USD_I-4CVpypV0KZWdE1iSXy5Q", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41201 - Disclosure - Income Taxes - Additional Information (Detail)", "role": "http://www.altimmune.com/role/DisclosureIncomeTaxesAdditionalInformationDetail", "shortName": "Income Taxes - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "us-gaap:OtherTaxExpenseBenefit", "us-gaap:OtherTaxExpenseBenefit", "us-gaap:OtherTaxExpenseBenefit", "p", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "alt-20220930x10q.htm", "contextRef": "Duration_7_1_2022_To_9_30_2022_Uf5Jq1cZcUK2MSXcxyHW2A", "decimals": "-5", "lang": null, "name": "us-gaap:OtherTaxExpenseBenefit", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_I-4CVpypV0KZWdE1iSXy5Q", "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "p", "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerShareTextBlock", "div", "div", "body", "html" ], "baseRef": "alt-20220930x10q.htm", "contextRef": "Duration_7_1_2022_To_9_30_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_VUpClJ0xZkqNVQ3R_GJzkw", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_C7PsNJDVF0OEmvb2RnrBfQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41301 - Disclosure - Net Loss Per Share - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Detail)", "role": "http://www.altimmune.com/role/DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetail", "shortName": "Net Loss Per Share - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "p", "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerShareTextBlock", "div", "div", "body", "html" ], "baseRef": "alt-20220930x10q.htm", "contextRef": "Duration_7_1_2022_To_9_30_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_VUpClJ0xZkqNVQ3R_GJzkw", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_C7PsNJDVF0OEmvb2RnrBfQ", "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "alt-20220930x10q.htm", "contextRef": "As_Of_12_31_2021_N1yzRxVtSUehNNpcNrvaiQ", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:BusinessCombinationContingentConsiderationLiability", "reportCount": 1, "unitRef": "Unit_Standard_USD_I-4CVpypV0KZWdE1iSXy5Q", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41401 - Disclosure - Commitments and Contingencies - Additional Information (Details)", "role": "http://www.altimmune.com/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "shortName": "Commitments and Contingencies - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R5": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "alt-20220930x10q.htm", "contextRef": "As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_AzHr-u4yg0aZjmlS-hihSg", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unitRef": "Unit_Standard_USD_I-4CVpypV0KZWdE1iSXy5Q", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00300 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY", "role": "http://www.altimmune.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity", "shortName": "CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "alt-20220930x10q.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_wbF29e_M3UWcXqKOl_ojEw", "decimals": "-3", "lang": null, "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_I-4CVpypV0KZWdE1iSXy5Q", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "alt-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_Nh6OhqMuZkWQYwOmO2JLFg", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_I-4CVpypV0KZWdE1iSXy5Q", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00400 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS", "role": "http://www.altimmune.com/role/StatementConsolidatedStatementsOfCashFlows", "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "alt-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_Nh6OhqMuZkWQYwOmO2JLFg", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_I-4CVpypV0KZWdE1iSXy5Q", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "alt-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_Nh6OhqMuZkWQYwOmO2JLFg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10101 - Disclosure - Nature of Business and Basis of Presentation", "role": "http://www.altimmune.com/role/DisclosureNatureOfBusinessAndBasisOfPresentation", "shortName": "Nature of Business and Basis of Presentation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "alt-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_Nh6OhqMuZkWQYwOmO2JLFg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "alt-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_Nh6OhqMuZkWQYwOmO2JLFg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10201 - Disclosure - Summary of Significant Accounting Policies", "role": "http://www.altimmune.com/role/DisclosureSummaryOfSignificantAccountingPolicies", "shortName": "Summary of Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "alt-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_Nh6OhqMuZkWQYwOmO2JLFg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "alt-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_Nh6OhqMuZkWQYwOmO2JLFg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10301 - Disclosure - Fair Value Measurements", "role": "http://www.altimmune.com/role/DisclosureFairValueMeasurements", "shortName": "Fair Value Measurements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "alt-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_Nh6OhqMuZkWQYwOmO2JLFg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 46, "tag": { "alt_AccruedExpensesAndOtherCurrentLiabilities": { "auth_ref": [], "calculation": { "http://www.altimmune.com/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetail": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.altimmune.com/role/StatementConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). Also includes the aggregate carrying amount, as of the balance sheet date, of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered and of liabilities not separately disclosed in the balance sheet. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Expenses And Other Current Liabilities", "terseLabel": "Accrued expenses and other current liabilities", "totalLabel": "Total accrued expenses and other current liabilities" } } }, "localname": "AccruedExpensesAndOtherCurrentLiabilities", "nsuri": "http://www.altimmune.com/20220930", "presentation": [ "http://www.altimmune.com/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetail", "http://www.altimmune.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "alt_AccruedResearchAndDevelopment": { "auth_ref": [], "calculation": { "http://www.altimmune.com/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetail": { "order": 3.0, "parentTag": "alt_AccruedExpensesAndOtherCurrentLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accrued research and development.", "label": "Accrued Research And Development", "terseLabel": "Accrued research and development" } } }, "localname": "AccruedResearchAndDevelopment", "nsuri": "http://www.altimmune.com/20220930", "presentation": [ "http://www.altimmune.com/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "alt_AdditionOperatingLeaseLiabilityAndRightOfUseAsset": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Operating lease liability and right of use asset addition.", "label": "Addition Operating Lease Liability And Right Of Use Asset", "terseLabel": "Operating lease liability and right of use asset addition" } } }, "localname": "AdditionOperatingLeaseLiabilityAndRightOfUseAsset", "nsuri": "http://www.altimmune.com/20220930", "presentation": [ "http://www.altimmune.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "alt_AggregateOfferingPrice": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate offering price.", "label": "Aggregate Offering Price", "terseLabel": "Aggregate offering price" } } }, "localname": "AggregateOfferingPrice", "nsuri": "http://www.altimmune.com/20220930", "presentation": [ "http://www.altimmune.com/role/DisclosureCommonStockAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "alt_AssetsOrLiabilitiesMeasuredAtFairValueOnNonRecurringBasis": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Assets or liabilities that were measured at fair value on a non-recurring basis.", "label": "Assets Or Liabilities Measured At Fair Value On Non Recurring Basis", "terseLabel": "Assets or liabilities measured at fair value on a non-recurring basis." } } }, "localname": "AssetsOrLiabilitiesMeasuredAtFairValueOnNonRecurringBasis", "nsuri": "http://www.altimmune.com/20220930", "presentation": [ "http://www.altimmune.com/role/DisclosureFairValueMeasurementsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "alt_AtTheMarketOfferingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "At-the-market offering.", "label": "At-The-Market Offering [Member]" } } }, "localname": "AtTheMarketOfferingMember", "nsuri": "http://www.altimmune.com/20220930", "presentation": [ "http://www.altimmune.com/role/DisclosureCommonStockAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "alt_BARDAContractMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "BARDA Contract [Member].", "label": "BARDA Contract [Member]" } } }, "localname": "BARDAContractMember", "nsuri": "http://www.altimmune.com/20220930", "presentation": [ "http://www.altimmune.com/role/DisclosureUsGovernmentContractsAndGrantsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "alt_BusinessAcquisitionTermOfLicenseAgreement": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Business acquisition term of license agreement.", "label": "Business Acquisition Term Of License Agreement", "terseLabel": "License agreement term", "verboseLabel": "License agreement term" } } }, "localname": "BusinessAcquisitionTermOfLicenseAgreement", "nsuri": "http://www.altimmune.com/20220930", "presentation": [ "http://www.altimmune.com/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "http://www.altimmune.com/role/DisclosureContingentConsiderationAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "alt_BusinessCombinationContingentConsiderationPaymentTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Business combination contingent consideration payment term.", "label": "Business Combination Contingent Consideration Payment Term", "terseLabel": "Estimated future contingent consideration term" } } }, "localname": "BusinessCombinationContingentConsiderationPaymentTerm", "nsuri": "http://www.altimmune.com/20220930", "presentation": [ "http://www.altimmune.com/role/DisclosureContingentConsiderationAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "alt_ChangesInEquityAndComprehensiveIncomeLineItemsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Changes In Equity And Comprehensive Income Line Items [Line Items]", "label": "Changes In Equity And Comprehensive Income Line Items [Line Items]", "terseLabel": "Changes In Equity And Comprehensive Income Line Items [Line Items]" } } }, "localname": "ChangesInEquityAndComprehensiveIncomeLineItemsLineItems", "nsuri": "http://www.altimmune.com/20220930", "presentation": [ "http://www.altimmune.com/role/DisclosureCommonStockAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "alt_ClassOfWarrantOrRightIssuancePricePerWarrantOrRight": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Class of warrant or right, issuance price per warrant or right.", "label": "Class Of Warrant Or Right Issuance Price Per Warrant Or Right", "terseLabel": "Purchase price of warrants issued" } } }, "localname": "ClassOfWarrantOrRightIssuancePricePerWarrantOrRight", "nsuri": "http://www.altimmune.com/20220930", "presentation": [ "http://www.altimmune.com/role/DisclosureCommonStockAdditionalInformationDetail" ], "xbrltype": "perShareItemType" }, "alt_ClinicalTrialNotificationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Clinical trial notification.", "label": "Clinical Trial Notification [Member]" } } }, "localname": "ClinicalTrialNotificationMember", "nsuri": "http://www.altimmune.com/20220930", "presentation": [ "http://www.altimmune.com/role/DisclosureContingentConsiderationAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "alt_CommercialPaperAndCorporateDebtSecuritiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commercial Paper And Corporate Debt Securities [Member].", "label": "Commercial Paper and Corporate Debt Securities [Member]" } } }, "localname": "CommercialPaperAndCorporateDebtSecuritiesMember", "nsuri": "http://www.altimmune.com/20220930", "presentation": [ "http://www.altimmune.com/role/DisclosureFairValueMeasurementsScheduleOfShortTermInvestmentsDetail" ], "xbrltype": "domainItemType" }, "alt_CommitmentToProcureEquipmentAndConstruction": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Commitment to procure equipment and construction", "label": "Commitment To Procure Equipment And Construction" } } }, "localname": "CommitmentToProcureEquipmentAndConstruction", "nsuri": "http://www.altimmune.com/20220930", "presentation": [ "http://www.altimmune.com/role/DisclosureFairValueMeasurementsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "alt_CommitmentsAndContingenciesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commitments and contingencies.", "label": "Commitments And Contingencies [Line Items]", "terseLabel": "Commitments And Contingencies [Line Items]" } } }, "localname": "CommitmentsAndContingenciesLineItems", "nsuri": "http://www.altimmune.com/20220930", "presentation": [ "http://www.altimmune.com/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "alt_CommitmentsAndContingenciesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commitments and contingencies.", "label": "Commitments And Contingencies [Table]", "terseLabel": "Commitments And Contingencies [Table]" } } }, "localname": "CommitmentsAndContingenciesTable", "nsuri": "http://www.altimmune.com/20220930", "presentation": [ "http://www.altimmune.com/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "alt_CommonStockIssuedRelatedToContingentConsiderationLiability": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Common stock issued related to contingent consideration liability.", "label": "Common Stock Issued Related To Contingent Consideration Liability", "terseLabel": "Common stock issued related to contingent consideration liability" } } }, "localname": "CommonStockIssuedRelatedToContingentConsiderationLiability", "nsuri": "http://www.altimmune.com/20220930", "presentation": [ "http://www.altimmune.com/role/DisclosureContingentConsiderationAdditionalInformationDetail", "http://www.altimmune.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "alt_CommonStockTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The entire disclosure of common stock.", "label": "Common Stock [Text Block]", "terseLabel": "Common Stock" } } }, "localname": "CommonStockTextBlock", "nsuri": "http://www.altimmune.com/20220930", "presentation": [ "http://www.altimmune.com/role/DisclosureCommonStock" ], "xbrltype": "textBlockItemType" }, "alt_ContingentConsiderationPercentageOfSharesReleaseAfterSixMonths": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of shares that will be issued upon satisfaction of the milestones that are subject to lock-up period of six months.", "label": "Contingent Consideration, Percentage Of Shares Release After Six Months", "terseLabel": "Contingent consideration, percentage of shares released after six months" } } }, "localname": "ContingentConsiderationPercentageOfSharesReleaseAfterSixMonths", "nsuri": "http://www.altimmune.com/20220930", "presentation": [ "http://www.altimmune.com/role/DisclosureContingentConsiderationAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "alt_ContingentConsiderationPercentageOfSharesReleaseAfterThreeMonths": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of shares that will be issued upon satisfaction of the milestones that are subject to lock-up period of three months.", "label": "Contingent Consideration, Percentage Of Shares Release After Three Months", "terseLabel": "Contingent consideration, percentage of shares released after three months" } } }, "localname": "ContingentConsiderationPercentageOfSharesReleaseAfterThreeMonths", "nsuri": "http://www.altimmune.com/20220930", "presentation": [ "http://www.altimmune.com/role/DisclosureContingentConsiderationAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "alt_DeferredOfferingCostsAppliedToProceeds": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Deferred offering costs applied to the proceeds.", "label": "Deferred Offering Costs Applied To The Proceeds", "terseLabel": "Commission and other offering costs" } } }, "localname": "DeferredOfferingCostsAppliedToProceeds", "nsuri": "http://www.altimmune.com/20220930", "presentation": [ "http://www.altimmune.com/role/DisclosureCommonStockAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "alt_DurationOfContract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Duration of contract.", "label": "Duration Of Contract", "terseLabel": "Duration of contract" } } }, "localname": "DurationOfContract", "nsuri": "http://www.altimmune.com/20220930", "presentation": [ "http://www.altimmune.com/role/DisclosureUsGovernmentContractsAndGrantsAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "alt_EconomicConditionalIncentiveGrants": { "auth_ref": [], "calculation": { "http://www.altimmune.com/role/DisclosureOtherLongTermLiabilitiesSummaryOfOtherLongTermLiabilitiesDetail": { "order": 2.0, "parentTag": "us-gaap_LongTermDebtNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Economic conditional incentive grants.", "label": "Economic Conditional Incentive Grants", "verboseLabel": "Conditional economic incentive grants" } } }, "localname": "EconomicConditionalIncentiveGrants", "nsuri": "http://www.altimmune.com/20220930", "presentation": [ "http://www.altimmune.com/role/DisclosureOtherLongTermLiabilitiesSummaryOfOtherLongTermLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "alt_EquityDistributionAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Equity Distribution Agreement.", "label": "Equity Distribution Agreement [Member]" } } }, "localname": "EquityDistributionAgreementMember", "nsuri": "http://www.altimmune.com/20220930", "presentation": [ "http://www.altimmune.com/role/DisclosureCommonStockAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "alt_ExchangeWarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Exchange Warrants [Member].", "label": "Exchange Warrants [Member]" } } }, "localname": "ExchangeWarrantsMember", "nsuri": "http://www.altimmune.com/20220930", "presentation": [ "http://www.altimmune.com/role/DisclosureCommonStockAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "alt_ExchangingStockholdersMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represent the information pertaining to investors and its affiliates (the Exchanging Stockholders).", "label": "Exchanging Stockholders [Member]" } } }, "localname": "ExchangingStockholdersMember", "nsuri": "http://www.altimmune.com/20220930", "presentation": [ "http://www.altimmune.com/role/DisclosureCommonStockAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "alt_IncomeTaxesAndResearchDevelopmentIncentiveReceivableCurrent": { "auth_ref": [], "calculation": { "http://www.altimmune.com/role/StatementConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount due within one year of the balance sheet date (or one operating cycle, if longer) from tax authorities as of the balance sheet date representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes and research & development incentives.", "label": "Income Taxes and Research & Development Incentive Receivable, Current", "terseLabel": "Income tax and R&D incentive receivables" } } }, "localname": "IncomeTaxesAndResearchDevelopmentIncentiveReceivableCurrent", "nsuri": "http://www.altimmune.com/20220930", "presentation": [ "http://www.altimmune.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "alt_IncreaseDecreaseInIncomeTaxesAndTaxIncentiveReceivable": { "auth_ref": [], "calculation": { "http://www.altimmune.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in income taxes receivable, which represents the amount due from tax authorities for refunds of overpayments or recoveries of income taxes paid.", "label": "Increase (Decrease) in Income Taxes and Tax Incentive Receivable", "negatedLabel": "Income tax and R&D incentive receivables" } } }, "localname": "IncreaseDecreaseInIncomeTaxesAndTaxIncentiveReceivable", "nsuri": "http://www.altimmune.com/20220930", "presentation": [ "http://www.altimmune.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "alt_InvestigationalNewDrugApplicationAndRegulatoryMilestonesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Investigational New Drug Application and Regulatory milestones.", "label": "Investigational New Drug Application and Regulatory Milestones [Member]" } } }, "localname": "InvestigationalNewDrugApplicationAndRegulatoryMilestonesMember", "nsuri": "http://www.altimmune.com/20220930", "presentation": [ "http://www.altimmune.com/role/DisclosureContingentConsiderationAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "alt_InvestigationalNewDrugApplicationMilestoneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Investigational New Drug Application milestone.", "label": "Investigational New Drug Application Milestone [Member]" } } }, "localname": "InvestigationalNewDrugApplicationMilestoneMember", "nsuri": "http://www.altimmune.com/20220930", "presentation": [ "http://www.altimmune.com/role/DisclosureContingentConsiderationAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "alt_IssuanceOfCommonStockWarrantInExchangeForRetirementOfCommonStock": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Issuance of common stock warrant in exchange for retirement of common stock.", "label": "Issuance Of Common Stock Warrant In Exchange For Retirement Of Common Stock", "verboseLabel": "Issuance of common stock warrant in exchange for retirement of common stock" } } }, "localname": "IssuanceOfCommonStockWarrantInExchangeForRetirementOfCommonStock", "nsuri": "http://www.altimmune.com/20220930", "presentation": [ "http://www.altimmune.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "alt_LonzaManufacturingAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lonza manufacturing agreement member", "label": "Lonza Manufacturing Agreement [Member]" } } }, "localname": "LonzaManufacturingAgreementMember", "nsuri": "http://www.altimmune.com/20220930", "presentation": [ "http://www.altimmune.com/role/DisclosureFairValueMeasurementsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "alt_MedicalTechnologyEnterpriseConsortiumCollaborativeArrangementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Medical Technology Enterprise Consortium collaborative arrangement.", "label": "MTEC Collaborative Arrangement [Member]" } } }, "localname": "MedicalTechnologyEnterpriseConsortiumCollaborativeArrangementMember", "nsuri": "http://www.altimmune.com/20220930", "presentation": [ "http://www.altimmune.com/role/DisclosureUsGovernmentContractsAndGrantsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "alt_NoticePeriodToIncreaseOwnershipPercentageOnExerciseOfWarrants": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Notice period to increase ownership percentage on exercise of warrants.", "label": "Notice Period To Increase Ownership Percentage On Exercise Of Warrants", "terseLabel": "Notice period to increase ownership percentage on exercise of warrants" } } }, "localname": "NoticePeriodToIncreaseOwnershipPercentageOnExerciseOfWarrants", "nsuri": "http://www.altimmune.com/20220930", "presentation": [ "http://www.altimmune.com/role/DisclosureCommonStockAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "alt_NumberOfConsecutiveTradingDays": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of consecutive trading days.", "label": "Number Of Consecutive Trading Days", "terseLabel": "Number of consecutive trading days" } } }, "localname": "NumberOfConsecutiveTradingDays", "nsuri": "http://www.altimmune.com/20220930", "presentation": [ "http://www.altimmune.com/role/DisclosureContingentConsiderationAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "alt_NumberOfWarrantsExercised": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of warrants exercised.", "label": "Number Of Warrants Exercised", "terseLabel": "Number of warrants exercised" } } }, "localname": "NumberOfWarrantsExercised", "nsuri": "http://www.altimmune.com/20220930", "presentation": [ "http://www.altimmune.com/role/DisclosureCommonStockAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "alt_NumberOfWarrantsExercisedForConversionOfSecurities": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of warrants exercised for conversion of securities.", "label": "Number Of Warrants Exercised For Conversion Of Securities", "negatedLabel": "Exercises (see Note 8)" } } }, "localname": "NumberOfWarrantsExercisedForConversionOfSecurities", "nsuri": "http://www.altimmune.com/20220930", "presentation": [ "http://www.altimmune.com/role/DisclosureWarrantsSummaryOfWarrantActivityDetail" ], "xbrltype": "sharesItemType" }, "alt_OwnershipPercentageOnExerciseOfWarrantsWithNoticeMaximum": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Ownership percentage on exercise of warrants with notice, maximum.", "label": "Ownership Percentage On Exercise Of Warrants With Notice Maximum", "terseLabel": "Ownership percentage on exercise of warrants with notice, maximum" } } }, "localname": "OwnershipPercentageOnExerciseOfWarrantsWithNoticeMaximum", "nsuri": "http://www.altimmune.com/20220930", "presentation": [ "http://www.altimmune.com/role/DisclosureCommonStockAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "alt_OwnershipPercentageOnExerciseOfWarrantsWithoutNoticeMinimum": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Ownership percentage on exercise of warrants without notice, minimum.", "label": "Ownership Percentage On Exercise Of Warrants Without Notice Minimum", "terseLabel": "Ownership percentage on exercise of warrants without notice, minimum" } } }, "localname": "OwnershipPercentageOnExerciseOfWarrantsWithoutNoticeMinimum", "nsuri": "http://www.altimmune.com/20220930", "presentation": [ "http://www.altimmune.com/role/DisclosureCommonStockAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "alt_PaymentsOfDeferredOfferingCosts": { "auth_ref": [], "calculation": { "http://www.altimmune.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Payments of deferred offering costs.", "label": "Payments Of Deferred Offering Costs", "negatedLabel": "Payments of deferred offering costs" } } }, "localname": "PaymentsOfDeferredOfferingCosts", "nsuri": "http://www.altimmune.com/20220930", "presentation": [ "http://www.altimmune.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "alt_PeriodForSubmissionOfClinicalTrialNotification": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Period for submission of clinical trial notification.", "label": "Period For Submission Of Clinical Trial Notification", "terseLabel": "Period for submission of clinical trial notification" } } }, "localname": "PeriodForSubmissionOfClinicalTrialNotification", "nsuri": "http://www.altimmune.com/20220930", "presentation": [ "http://www.altimmune.com/role/DisclosureContingentConsiderationAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "alt_PhaseTwoMilestoneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Phase 2 Milestone", "label": "Phase Two Milestone [Member]" } } }, "localname": "PhaseTwoMilestoneMember", "nsuri": "http://www.altimmune.com/20220930", "presentation": [ "http://www.altimmune.com/role/DisclosureContingentConsiderationAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "alt_PiperSandlerCompanyAndEvercoreGroupLimitedLiabilityCompanyAndBRileySecuritiesIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Piper Sandler company and evercore group limited liability company and B Riley Securities inc Member.", "label": "Piper Sandler company and evercore group limited liability company and B Riley Securities inc [Member]" } } }, "localname": "PiperSandlerCompanyAndEvercoreGroupLimitedLiabilityCompanyAndBRileySecuritiesIncMember", "nsuri": "http://www.altimmune.com/20220930", "presentation": [ "http://www.altimmune.com/role/DisclosureCommonStockAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "alt_PreFundedWarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Pre-funded warrants.", "label": "Pre-Funded Warrants [Member]" } } }, "localname": "PreFundedWarrantsMember", "nsuri": "http://www.altimmune.com/20220930", "presentation": [ "http://www.altimmune.com/role/DisclosureCommonStockAdditionalInformationDetail", "http://www.altimmune.com/role/DisclosureWarrantsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "alt_RegulatoryMilestoneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Regulatory milestone.", "label": "Regulatory Milestones [Member]" } } }, "localname": "RegulatoryMilestoneMember", "nsuri": "http://www.altimmune.com/20220930", "presentation": [ "http://www.altimmune.com/role/DisclosureContingentConsiderationAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "alt_ResearchAndDevelopmentIncentiveCredit": { "auth_ref": [], "calculation": { "http://www.altimmune.com/role/DisclosureOtherLongTermLiabilitiesSummaryOfOtherLongTermLiabilitiesDetail": { "order": 4.0, "parentTag": "us-gaap_LongTermDebtNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of research and development incentive credit.", "label": "Research and Development Incentive Credit", "terseLabel": "Research and development incentive credit" } } }, "localname": "ResearchAndDevelopmentIncentiveCredit", "nsuri": "http://www.altimmune.com/20220930", "presentation": [ "http://www.altimmune.com/role/DisclosureOtherLongTermLiabilitiesSummaryOfOtherLongTermLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "alt_ResearchAndDevelopmentIncentiveCreditEarned": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of research and development incentive credit earned.", "label": "Research and Development Incentive Credit Earned", "terseLabel": "Research and development incentive credit earned" } } }, "localname": "ResearchAndDevelopmentIncentiveCreditEarned", "nsuri": "http://www.altimmune.com/20220930", "presentation": [ "http://www.altimmune.com/role/DisclosureOtherLongTermLiabilitiesSummaryOfOtherLongTermLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "alt_RetirementOfCommonSockInExchangeForCommonStockWarrant": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Retirement of common stock in exchange for common stock warrant.", "label": "Retirement Of Common Sock In Exchange For Common Stock Warrant", "terseLabel": "Retirement of common stock in exchange for common stock warrant" } } }, "localname": "RetirementOfCommonSockInExchangeForCommonStockWarrant", "nsuri": "http://www.altimmune.com/20220930", "presentation": [ "http://www.altimmune.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "alt_RetirementOfCommonSockInExchangeForCommonStockWarrantShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Retirement of common stock in exchange for common stock warrant shares.", "label": "Retirement Of Common Sock In Exchange For Common Stock Warrant Shares", "terseLabel": "Retirement of common stock in exchange for common stock warrant (in Shares)" } } }, "localname": "RetirementOfCommonSockInExchangeForCommonStockWarrantShares", "nsuri": "http://www.altimmune.com/20220930", "presentation": [ "http://www.altimmune.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "sharesItemType" }, "alt_SalesMilestoneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sales milestone.", "label": "Sales Milestones [Member]" } } }, "localname": "SalesMilestoneMember", "nsuri": "http://www.altimmune.com/20220930", "presentation": [ "http://www.altimmune.com/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "http://www.altimmune.com/role/DisclosureContingentConsiderationAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "alt_ScheduleOfSupplementalBalanceSheetInformationRelatedToOperatingLeasesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of supplemental balance sheet information related to Operating leases.", "label": "Schedule Of Supplemental Balance Sheet Information Related To Operating Leases Table [Text Block]", "terseLabel": "Summary of Supplemental other Information Related to Operating Leases Balance Sheet" } } }, "localname": "ScheduleOfSupplementalBalanceSheetInformationRelatedToOperatingLeasesTableTextBlock", "nsuri": "http://www.altimmune.com/20220930", "presentation": [ "http://www.altimmune.com/role/DisclosureOperatingLeasesTables" ], "xbrltype": "textBlockItemType" }, "alt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedOutstandingIntrinsicValue": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Share based compensation arrangement by share based payment award options nonvested outstanding intrinsic value.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Nonvested Outstanding Intrinsic Value", "terseLabel": "Aggregate Intrinsic Value, Unvested" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedOutstandingIntrinsicValue", "nsuri": "http://www.altimmune.com/20220930", "presentation": [ "http://www.altimmune.com/role/DisclosureStockBasedCompensationScheduleOfInformationRelatedToStockOptionsOutstandingDetail" ], "xbrltype": "monetaryItemType" }, "alt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedOutstandingWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share based compensation arrangement by share based payment award options unvested outstanding weighted average exercise price.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Unvested Outstanding Weighted Average Exercise Price", "terseLabel": "Weighted-average Exercise Price, Unvested" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedOutstandingWeightedAverageExercisePrice", "nsuri": "http://www.altimmune.com/20220930", "presentation": [ "http://www.altimmune.com/role/DisclosureStockBasedCompensationScheduleOfInformationRelatedToStockOptionsOutstandingDetail" ], "xbrltype": "perShareItemType" }, "alt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedOutstandingWeightedAverageRemainingContractualTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share based compensation arrangement by share based payment award options unvested outstanding weighted average remaining contractual term.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Unvested Outstanding Weighted Average Remaining Contractual Term", "terseLabel": "Weighted-average Remaining Contractual Term, Unvested" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedOutstandingWeightedAverageRemainingContractualTerm", "nsuri": "http://www.altimmune.com/20220930", "presentation": [ "http://www.altimmune.com/role/DisclosureStockBasedCompensationScheduleOfInformationRelatedToStockOptionsOutstandingDetail" ], "xbrltype": "durationItemType" }, "alt_SharesIssuedForContingentMilestonePayment": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Shares issued for contingent milestone payment.", "label": "Shares Issued For Contingent Milestone Payment", "terseLabel": "Shares issued for contingent milestone payment" } } }, "localname": "SharesIssuedForContingentMilestonePayment", "nsuri": "http://www.altimmune.com/20220930", "presentation": [ "http://www.altimmune.com/role/DisclosureContingentConsiderationAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "alt_SpitfirePharmaIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Spitfire Pharma, Inc.", "label": "Spitfire Pharma, Inc. [Member]" } } }, "localname": "SpitfirePharmaIncMember", "nsuri": "http://www.altimmune.com/20220930", "presentation": [ "http://www.altimmune.com/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "http://www.altimmune.com/role/DisclosureContingentConsiderationAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "alt_StockExchangedForPreFundedWarrants": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of shares exchanged for pre-funded warrants.", "label": "Stock Exchanged For Pre Funded Warrants", "terseLabel": "Common stock exchanged for pre-funded warrants" } } }, "localname": "StockExchangedForPreFundedWarrants", "nsuri": "http://www.altimmune.com/20220930", "presentation": [ "http://www.altimmune.com/role/DisclosureCommonStockAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "alt_StockIssuedDuringPeriodShareExerciseOfWarrants": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Stock issued during period share exercise of warrants.", "label": "Stock Issued During Period Share Exercise Of Warrants", "terseLabel": "Issuance of common stock upon cashless exercise of warrants (in shares)" } } }, "localname": "StockIssuedDuringPeriodShareExerciseOfWarrants", "nsuri": "http://www.altimmune.com/20220930", "presentation": [ "http://www.altimmune.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "sharesItemType" }, "alt_StockIssuedDuringPeriodValueExerciseOfWarrants": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Stock issued during period value exercise of warrants.", "label": "Stock Issued During Period Value Exercise Of Warrants", "terseLabel": "Issuance of common stock upon cashless exercise of warrants" } } }, "localname": "StockIssuedDuringPeriodValueExerciseOfWarrants", "nsuri": "http://www.altimmune.com/20220930", "presentation": [ "http://www.altimmune.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "alt_SubmissionDateOfClinicalTrialNotification": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Submission date of clinical trial notification.", "label": "Submission Date Of Clinical Trial Notification", "terseLabel": "Submission date of clinical trial notification" } } }, "localname": "SubmissionDateOfClinicalTrialNotification", "nsuri": "http://www.altimmune.com/20220930", "presentation": [ "http://www.altimmune.com/role/DisclosureContingentConsiderationAdditionalInformationDetail" ], "xbrltype": "dateItemType" }, "alt_TwoThousandAndNineteenEmployeeStockPurchasePlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two thousand and nineteen employee stock purchase plan.", "label": "2019 Employee Stock Purchase Plan [Member]" } } }, "localname": "TwoThousandAndNineteenEmployeeStockPurchasePlanMember", "nsuri": "http://www.altimmune.com/20220930", "presentation": [ "http://www.altimmune.com/role/DisclosureStockBasedCompensationAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "alt_USGovernmentContractsAndGrantsDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "U.S. government contracts and grants disclosures abstract.", "label": "U.S. Government Contracts and Grants" } } }, "localname": "USGovernmentContractsAndGrantsDisclosuresAbstract", "nsuri": "http://www.altimmune.com/20220930", "xbrltype": "stringItemType" }, "alt_USGovernmentContractsAndGrantsTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "U.S. government contracts and grants.", "label": "U S Government Contracts And Grants [Text Block]", "terseLabel": "U.S. Government Contracts and Grants" } } }, "localname": "USGovernmentContractsAndGrantsTextBlock", "nsuri": "http://www.altimmune.com/20220930", "presentation": [ "http://www.altimmune.com/role/DisclosureUsGovernmentContractsAndGrants" ], "xbrltype": "textBlockItemType" }, "alt_WarrantsExpired": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of warrants expired.", "label": "Warrants Expired", "negatedLabel": "Expired" } } }, "localname": "WarrantsExpired", "nsuri": "http://www.altimmune.com/20220930", "presentation": [ "http://www.altimmune.com/role/DisclosureWarrantsSummaryOfWarrantActivityDetail" ], "xbrltype": "sharesItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.altimmune.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.altimmune.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.altimmune.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.altimmune.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.altimmune.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.altimmune.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r438" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.altimmune.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r439" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.altimmune.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.altimmune.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address Address Line1", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.altimmune.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address Address Line2", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.altimmune.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address City Or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.altimmune.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.altimmune.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address State Or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.altimmune.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r436" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.altimmune.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.altimmune.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.altimmune.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r436" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.altimmune.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.altimmune.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r436" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.altimmune.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.altimmune.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r447" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.altimmune.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r436" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.altimmune.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r436" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.altimmune.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r436" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.altimmune.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r436" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.altimmune.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.altimmune.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r435" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security12b Title", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.altimmune.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r437" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.altimmune.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.altimmune.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "srt_CounterpartyNameAxis": { "auth_ref": [ "r40", "r42", "r89", "r90", "r199", "r210" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Axis]" } } }, "localname": "CounterpartyNameAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.altimmune.com/role/DisclosureCommonStockAdditionalInformationDetail", "http://www.altimmune.com/role/DisclosureFairValueMeasurementsAdditionalInformationDetail", "http://www.altimmune.com/role/DisclosureUsGovernmentContractsAndGrantsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "srt_MaximumMember": { "auth_ref": [ "r198", "r209", "r246", "r248", "r362", "r363", "r364", "r365", "r366", "r367", "r386", "r422", "r424", "r432", "r433" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.altimmune.com/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "http://www.altimmune.com/role/DisclosureContingentConsiderationAdditionalInformationDetail", "http://www.altimmune.com/role/DisclosureUsGovernmentContractsAndGrantsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r198", "r209", "r246", "r248", "r362", "r363", "r364", "r365", "r366", "r367", "r386", "r422", "r424", "r432", "r433" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.altimmune.com/role/DisclosureUsGovernmentContractsAndGrantsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "srt_OwnershipAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Ownership [Axis]" } } }, "localname": "OwnershipAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.altimmune.com/role/DisclosureCommonStockAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "srt_OwnershipDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Ownership [Domain]" } } }, "localname": "OwnershipDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.altimmune.com/role/DisclosureCommonStockAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r146", "r234", "r235", "r389", "r421", "r423" ], "lang": { "en-us": { "role": { "label": "Product Or Service [Axis]" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.altimmune.com/role/DisclosureUsGovernmentContractsAndGrantsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [ "r146", "r234", "r235", "r389", "r421", "r423" ], "lang": { "en-us": { "role": { "label": "Product and Service" } } }, "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.altimmune.com/role/DisclosureUsGovernmentContractsAndGrantsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r198", "r209", "r236", "r246", "r248", "r362", "r363", "r364", "r365", "r366", "r367", "r386", "r422", "r424", "r432", "r433" ], "lang": { "en-us": { "role": { "label": "Range [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.altimmune.com/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "http://www.altimmune.com/role/DisclosureContingentConsiderationAdditionalInformationDetail", "http://www.altimmune.com/role/DisclosureUsGovernmentContractsAndGrantsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r198", "r209", "r236", "r246", "r248", "r362", "r363", "r364", "r365", "r366", "r367", "r386", "r422", "r424", "r432", "r433" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.altimmune.com/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "http://www.altimmune.com/role/DisclosureContingentConsiderationAdditionalInformationDetail", "http://www.altimmune.com/role/DisclosureUsGovernmentContractsAndGrantsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "auth_ref": [ "r41", "r42", "r89", "r90", "r199", "r210" ], "lang": { "en-us": { "role": { "label": "Counterparty Name" } } }, "localname": "RepurchaseAgreementCounterpartyNameDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.altimmune.com/role/DisclosureCommonStockAdditionalInformationDetail", "http://www.altimmune.com/role/DisclosureFairValueMeasurementsAdditionalInformationDetail", "http://www.altimmune.com/role/DisclosureUsGovernmentContractsAndGrantsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Summary of Significant Accounting Policies" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": { "auth_ref": [ "r28" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.", "label": "Accounts Payable And Accrued Liabilities Disclosure [Text Block]", "terseLabel": "Accrued Expenses" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altimmune.com/role/DisclosureAccruedExpenses" ], "xbrltype": "textBlockItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r27", "r355" ], "calculation": { "http://www.altimmune.com/role/StatementConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable Current", "terseLabel": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altimmune.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableGrossCurrent": { "auth_ref": [ "r149", "r150" ], "calculation": { "http://www.altimmune.com/role/StatementConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts Receivable Gross Current", "terseLabel": "Accounts receivable" } } }, "localname": "AccountsReceivableGrossCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altimmune.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedIncomeTaxesCurrent": { "auth_ref": [ "r12", "r392", "r409" ], "calculation": { "http://www.altimmune.com/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetail": { "order": 6.0, "parentTag": "alt_AccruedExpensesAndOtherCurrentLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.", "label": "Accrued Income Taxes, Current", "terseLabel": "Income tax payable" } } }, "localname": "AccruedIncomeTaxesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altimmune.com/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesAndOtherLiabilities": { "auth_ref": [], "calculation": { "http://www.altimmune.com/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetail": { "order": 5.0, "parentTag": "alt_AccruedExpensesAndOtherCurrentLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.", "label": "Accrued Liabilities and Other Liabilities", "terseLabel": "Accrued interest and other" } } }, "localname": "AccruedLiabilitiesAndOtherLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altimmune.com/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accrued Liabilities And Other Liabilities [Abstract]" } } }, "localname": "AccruedLiabilitiesAndOtherLiabilitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccruedProfessionalFeesCurrent": { "auth_ref": [ "r6", "r7", "r30" ], "calculation": { "http://www.altimmune.com/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetail": { "order": 1.0, "parentTag": "alt_AccruedExpensesAndOtherCurrentLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Professional Fees Current", "terseLabel": "Accrued professional services" } } }, "localname": "AccruedProfessionalFeesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altimmune.com/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r18", "r46", "r47", "r48", "r411", "r429", "r430" ], "calculation": { "http://www.altimmune.com/role/StatementConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated Other Comprehensive Income Loss Net Of Tax", "terseLabel": "Accumulated other comprehensive loss, net" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altimmune.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r45", "r48", "r53", "r54", "r55", "r92", "r93", "r94", "r313", "r425", "r426", "r448" ], "lang": { "en-us": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "Accumulated Other Comprehensive Loss [Member]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altimmune.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r16", "r275", "r355" ], "calculation": { "http://www.altimmune.com/role/StatementConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.", "label": "Additional Paid In Capital", "terseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altimmune.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r92", "r93", "r94", "r272", "r273", "r274", "r319" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-In Capital [Member]" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altimmune.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r249", "r251", "r277", "r278" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.", "label": "Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value", "terseLabel": "Stock-based compensation" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altimmune.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altimmune.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r251", "r268", "r276" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Allocated Share Based Compensation Expense", "terseLabel": "Stock based compensation expense" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altimmune.com/role/DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r112" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount", "terseLabel": "Antidilutive securities excluded from computation of earnings per share" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altimmune.com/role/DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "auth_ref": [ "r112" ], "lang": { "en-us": { "role": { "documentation": "Information by type of antidilutive security.", "label": "Antidilutive Securities Excluded From Computation Of Earnings Per Share By Antidilutive Securities [Axis]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altimmune.com/role/DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetail" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]", "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altimmune.com/role/DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetail" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "auth_ref": [ "r112" ], "lang": { "en-us": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.", "label": "Antidilutive Securities, Name" } } }, "localname": "AntidilutiveSecuritiesNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altimmune.com/role/DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative" } } }, "localname": "ArrangementsAndNonarrangementTransactionsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altimmune.com/role/DisclosureCommonStockAdditionalInformationDetail", "http://www.altimmune.com/role/DisclosureUsGovernmentContractsAndGrantsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_AssetBackedSecuritiesMember": { "auth_ref": [ "r156", "r237" ], "lang": { "en-us": { "role": { "documentation": "Securities that are primarily serviced by the cash flows of a discrete pool of receivables or other financial assets for example, but not limited to, credit card receivables, car loans, recreational vehicle loans, and mobile home loans.", "label": "Asset Backed Securities [Member]" } } }, "localname": "AssetBackedSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altimmune.com/role/DisclosureFairValueMeasurementsScheduleOfShortTermInvestmentsDetail" ], "xbrltype": "domainItemType" }, "us-gaap_Assets": { "auth_ref": [ "r84", "r135", "r138", "r144", "r162", "r187", "r188", "r189", "r190", "r191", "r192", "r193", "r194", "r195", "r196", "r197", "r309", "r314", "r332", "r353", "r355", "r391", "r408" ], "calculation": { "http://www.altimmune.com/role/StatementConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altimmune.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "ASSETS" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altimmune.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r4", "r5", "r39", "r84", "r162", "r187", "r188", "r189", "r190", "r191", "r192", "r193", "r194", "r195", "r196", "r197", "r309", "r314", "r332", "r353", "r355" ], "calculation": { "http://www.altimmune.com/role/StatementConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altimmune.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets Current [Abstract]", "terseLabel": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altimmune.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsFairValueDisclosure": { "auth_ref": [ "r322" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets Fair Value Disclosure", "terseLabel": "Total" } } }, "localname": "AssetsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altimmune.com/role/DisclosureFairValueMeasurementsScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": { "auth_ref": [ "r154", "r169" ], "calculation": { "http://www.altimmune.com/role/DisclosureFairValueMeasurementsScheduleOfShortTermInvestmentsDetail": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Available For Sale Debt Securities Amortized Cost Basis", "totalLabel": "Amortized Cost" } } }, "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altimmune.com/role/DisclosureFairValueMeasurementsScheduleOfShortTermInvestmentsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtSecurities": { "auth_ref": [ "r152", "r155", "r169", "r397" ], "calculation": { "http://www.altimmune.com/role/DisclosureFairValueMeasurementsScheduleOfShortTermInvestmentsDetail": { "order": 2.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Available For Sale Securities Debt Securities", "terseLabel": "Market Value" } } }, "localname": "AvailableForSaleSecuritiesDebtSecurities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altimmune.com/role/DisclosureFairValueMeasurementsScheduleOfShortTermInvestmentsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r252", "r270" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altimmune.com/role/DisclosureStockBasedCompensationAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "auth_ref": [ "r245", "r247" ], "lang": { "en-us": { "role": { "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.", "label": "Business Acquisition, Acquiree" } } }, "localname": "BusinessAcquisitionAcquireeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altimmune.com/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "http://www.altimmune.com/role/DisclosureContingentConsiderationAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAxis": { "auth_ref": [ "r245", "r247", "r295", "r296" ], "lang": { "en-us": { "role": { "documentation": "Information by business combination or series of individually immaterial business combinations.", "label": "Business Acquisition [Axis]" } } }, "localname": "BusinessAcquisitionAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altimmune.com/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "http://www.altimmune.com/role/DisclosureContingentConsiderationAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionDateOfAcquisitionAgreement1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Date when the business acquisition agreement was executed, in YYYY-MM-DD format.", "label": "Business Acquisition Date Of Acquisition Agreement1", "terseLabel": "Agreement date" } } }, "localname": "BusinessAcquisitionDateOfAcquisitionAgreement1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altimmune.com/role/DisclosureContingentConsiderationAdditionalInformationDetail" ], "xbrltype": "dateItemType" }, "us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued": { "auth_ref": [ "r303" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of equity interests issued or issuable to acquire entity.", "label": "Business Acquisition Equity Interests Issued Or Issuable Number Of Shares Issued", "terseLabel": "Unregistered shares of common stock" } } }, "localname": "BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altimmune.com/role/DisclosureContingentConsiderationAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_BusinessAcquisitionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Business Acquisition [Line Items]", "terseLabel": "Business Acquisition [Line Items]" } } }, "localname": "BusinessAcquisitionLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altimmune.com/role/DisclosureContingentConsiderationAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionSharePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Price of a single share of a number of saleable stocks paid or offered to be paid in a business combination.", "label": "Business Acquisition Share Price", "terseLabel": "Consideration amount" } } }, "localname": "BusinessAcquisitionSharePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altimmune.com/role/DisclosureContingentConsiderationAdditionalInformationDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable": { "auth_ref": [ "r298", "r299" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of equity interests of the acquirer, including instruments or interests issued or issuable in consideration for the business combination.", "label": "Business Combination Consideration Transferred Equity Interests Issued And Issuable", "negatedLabel": "Fair value of payments settled in common stock (Phase II Milestone)" } } }, "localname": "BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altimmune.com/role/DisclosureContingentConsiderationSummaryOfFairValueOfContingentConsiderationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": { "auth_ref": [ "r76", "r305" ], "calculation": { "http://www.altimmune.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.", "label": "Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1", "netLabel": "Change in fair value", "terseLabel": "Change in fair value of contingent consideration liability", "verboseLabel": "Change in value of contingent consideration for acquired in-process research and development" } } }, "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altimmune.com/role/DisclosureContingentConsiderationAdditionalInformationDetail", "http://www.altimmune.com/role/DisclosureContingentConsiderationSummaryOfFairValueOfContingentConsiderationDetail", "http://www.altimmune.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationLiability": { "auth_ref": [ "r297", "r300", "r304" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liability recognized arising from contingent consideration in a business combination.", "label": "Business Combination Contingent Consideration Liability", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance", "terseLabel": "Estimated future contingent consideration", "verboseLabel": "Contingent consideration liability (see Note 6)" } } }, "localname": "BusinessCombinationContingentConsiderationLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altimmune.com/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "http://www.altimmune.com/role/DisclosureContingentConsiderationAdditionalInformationDetail", "http://www.altimmune.com/role/DisclosureContingentConsiderationSummaryOfFairValueOfContingentConsiderationDetail", "http://www.altimmune.com/role/DisclosureFairValueMeasurementsScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent": { "auth_ref": [ "r297", "r301" ], "calculation": { "http://www.altimmune.com/role/StatementConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer.", "label": "Business Combination, Contingent Consideration, Liability, Current", "verboseLabel": "Contingent consideration" } } }, "localname": "BusinessCombinationContingentConsiderationLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altimmune.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationDisclosureTextBlock": { "auth_ref": [ "r306" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).", "label": "Business Combination Disclosure [Text Block]", "terseLabel": "Contingent consideration" } } }, "localname": "BusinessCombinationDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altimmune.com/role/DisclosureContingentConsideration" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessCombinationsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Contingent Consideration" } } }, "localname": "BusinessCombinationsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": { "auth_ref": [ "r2", "r91", "r128" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Nature of Business and Basis of Presentation.", "terseLabel": "Nature of Business and Basis of Presentation" } } }, "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altimmune.com/role/DisclosureNatureOfBusinessAndBasisOfPresentation" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r3", "r24", "r79" ], "calculation": { "http://www.altimmune.com/role/StatementConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash And Cash Equivalents At Carrying Value", "terseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altimmune.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of cash and cash equivalent balance.", "label": "Cash And Cash Equivalents [Axis]" } } }, "localname": "CashAndCashEquivalentsAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altimmune.com/role/DisclosureFairValueMeasurementsScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetail" ], "xbrltype": "stringItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r74", "r79", "r80" ], "calculation": { "http://www.altimmune.com/role/StatementConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents", "periodEndLabel": "Cash, cash equivalents and restricted cash at end of period", "periodStartLabel": "Cash, cash equivalents and restricted cash at beginning of period", "totalLabel": "Total cash, cash equivalents and restricted cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altimmune.com/role/StatementConsolidatedBalanceSheets", "http://www.altimmune.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r74", "r335" ], "calculation": { "http://www.altimmune.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect", "totalLabel": "Net (decrease) increase in cash and cash equivalents and restricted cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altimmune.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash Flow Noncash Investing And Financing Activities Disclosure [Abstract]", "terseLabel": "SUPPLEMENTAL NON-CASH ACTIVITIES:" } } }, "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altimmune.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfWarrantOrRightAxis": { "auth_ref": [ "r231", "r250" ], "lang": { "en-us": { "role": { "documentation": "Information by type of warrant or right issued.", "label": "Class Of Warrant Or Right [Axis]" } } }, "localname": "ClassOfWarrantOrRightAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altimmune.com/role/DisclosureCommonStockAdditionalInformationDetail", "http://www.altimmune.com/role/DisclosureWarrantsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfWarrantOrRightDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months.", "label": "Class of Warrant or Right" } } }, "localname": "ClassOfWarrantOrRightDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altimmune.com/role/DisclosureCommonStockAdditionalInformationDetail", "http://www.altimmune.com/role/DisclosureWarrantsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "auth_ref": [ "r224" ], "lang": { "en-us": { "role": { "documentation": "Exercise price per share or per unit of warrants or rights outstanding.", "label": "Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1", "terseLabel": "Exercise price of warrants or rights", "verboseLabel": "Weighted Average Exercise Price" } } }, "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altimmune.com/role/DisclosureCommonStockAdditionalInformationDetail", "http://www.altimmune.com/role/DisclosureWarrantsAdditionalInformationDetail", "http://www.altimmune.com/role/DisclosureWarrantsSummaryOfWarrantActivityDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ClassOfWarrantOrRightLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Class Of Warrant Or Right [Line Items]" } } }, "localname": "ClassOfWarrantOrRightLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altimmune.com/role/DisclosureWarrantsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": { "auth_ref": [ "r224" ], "lang": { "en-us": { "role": { "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.", "label": "Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights", "terseLabel": "Number of securities called by warrants or rights" } } }, "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altimmune.com/role/DisclosureCommonStockAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ClassOfWarrantOrRightOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of warrants or rights outstanding.", "label": "Class Of Warrant Or Right Outstanding", "periodEndLabel": "Warrants outstanding, September 30, 2022", "periodStartLabel": "Warrants outstanding, December 31, 2021", "verboseLabel": "Warrants outstanding" } } }, "localname": "ClassOfWarrantOrRightOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altimmune.com/role/DisclosureCommonStockAdditionalInformationDetail", "http://www.altimmune.com/role/DisclosureWarrantsAdditionalInformationDetail", "http://www.altimmune.com/role/DisclosureWarrantsSummaryOfWarrantActivityDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ClassOfWarrantOrRightTable": { "auth_ref": [ "r231", "r250" ], "lang": { "en-us": { "role": { "documentation": "Disclosure for warrants or rights issued, which includes the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.", "label": "Class Of Warrant Or Right [Table]" } } }, "localname": "ClassOfWarrantOrRightTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altimmune.com/role/DisclosureWarrantsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r35", "r185", "r398", "r415" ], "calculation": { "http://www.altimmune.com/role/StatementConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments And Contingencies", "terseLabel": "Commitments and contingencies (Note 14)" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altimmune.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments And Contingencies." } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r182", "r183", "r184", "r186", "r431" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments And Contingencies Disclosure [Text Block]", "verboseLabel": "Commitments and Contingencies" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altimmune.com/role/DisclosureCommitmentsAndContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": { "auth_ref": [ "r37" ], "lang": { "en-us": { "role": { "documentation": "Aggregate number of common shares reserved for future issuance.", "label": "Common Stock Capital Shares Reserved For Future Issuance", "terseLabel": "Remaining shares available for issuance" } } }, "localname": "CommonStockCapitalSharesReservedForFutureIssuance", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altimmune.com/role/DisclosureCommonStockAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r92", "r93", "r319" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altimmune.com/role/DisclosureCommonStockAdditionalInformationDetail", "http://www.altimmune.com/role/DisclosureContingentConsiderationAdditionalInformationDetail", "http://www.altimmune.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock Par Or Stated Value Per Share", "terseLabel": "Common stock, par or stated value per share", "verboseLabel": "Common stock, par or stated value per share" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altimmune.com/role/DisclosureCommonStockAdditionalInformationDetail", "http://www.altimmune.com/role/StatementConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock Shares Authorized", "terseLabel": "Common stock, shares authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altimmune.com/role/StatementConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock Shares Issued", "terseLabel": "Common stock, shares issued" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altimmune.com/role/StatementConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r15", "r223" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock Shares Outstanding", "terseLabel": "Common stock, shares outstanding" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altimmune.com/role/StatementConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r15", "r355" ], "calculation": { "http://www.altimmune.com/role/StatementConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock Value", "terseLabel": "Common stock, $0.0001 par value; 200,000,000 shares authorized; 49,161,637 and 40,993,768 shares issued and outstanding as of September 30, 2022 and December 31, 2021, respectively" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altimmune.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": { "auth_ref": [ "r50", "r52", "r59", "r308", "r317", "r401", "r417" ], "calculation": { "http://www.altimmune.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest", "totalLabel": "Comprehensive loss" } } }, "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altimmune.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConstructionInProgressMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.", "label": "Construction-In-Progress" } } }, "localname": "ConstructionInProgressMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altimmune.com/role/DisclosureFairValueMeasurementsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ContingentConsiderationByTypeAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of contingent consideration.", "label": "Contingent Consideration By Type [Axis]" } } }, "localname": "ContingentConsiderationByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altimmune.com/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "http://www.altimmune.com/role/DisclosureContingentConsiderationAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ContingentConsiderationTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of contingent payment arrangement.", "label": "Contingent Consideration Type" } } }, "localname": "ContingentConsiderationTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altimmune.com/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "http://www.altimmune.com/role/DisclosureContingentConsiderationAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax": { "auth_ref": [], "calculation": { "http://www.altimmune.com/role/DisclosureFairValueMeasurementsScheduleOfShortTermInvestmentsDetail": { "order": 1.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of unrealized gain (loss) in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities Available For Sale Accumulated Gross Unrealized Gain Loss Before Tax", "terseLabel": "Unrealized Loss" } } }, "localname": "DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altimmune.com/role/DisclosureFairValueMeasurementsScheduleOfShortTermInvestmentsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleTable": { "auth_ref": [ "r158" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities Available For Sale [Table]", "terseLabel": "Debt Securities Available For Sale [Table]" } } }, "localname": "DebtSecuritiesAvailableForSaleTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altimmune.com/role/DisclosureFairValueMeasurementsScheduleOfShortTermInvestmentsDetail" ], "xbrltype": "stringItemType" }, "us-gaap_DepreciationDepletionAndAmortization": { "auth_ref": [ "r77", "r133" ], "calculation": { "http://www.altimmune.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.", "label": "Depreciation Depletion And Amortization", "terseLabel": "Depreciation and amortization" } } }, "localname": "DepreciationDepletionAndAmortization", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altimmune.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r279" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "Disclosure Of Compensation Related Costs Share Based Payments [Text Block]", "terseLabel": "Stock-Based Compensation" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altimmune.com/role/DisclosureStockBasedCompensation" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stock-Based Compensation" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Loss Per Share" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r60", "r97", "r98", "r99", "r100", "r101", "r105", "r107", "r109", "r110", "r111", "r115", "r116", "r320", "r321", "r402", "r418" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Net loss per share, basic" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altimmune.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r60", "r97", "r98", "r99", "r100", "r101", "r107", "r109", "r110", "r111", "r115", "r116", "r320", "r321", "r402", "r418" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Net loss per share, diluted" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altimmune.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r112", "r113", "r114", "r117" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]", "terseLabel": "Net Loss Per Share" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altimmune.com/role/DisclosureNetLossPerShare" ], "xbrltype": "textBlockItemType" }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "auth_ref": [ "r30" ], "calculation": { "http://www.altimmune.com/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetail": { "order": 2.0, "parentTag": "alt_AccruedExpensesAndOtherCurrentLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Employee Related Liabilities Current", "terseLabel": "Accrued payroll and employee benefits" } } }, "localname": "EmployeeRelatedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altimmune.com/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]", "terseLabel": "Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]" } } }, "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altimmune.com/role/DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseDetail" ], "xbrltype": "stringItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "auth_ref": [ "r269" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1", "terseLabel": "Unrecognized stock-based compensation expense, period for recognition" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altimmune.com/role/DisclosureStockBasedCompensationAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": { "auth_ref": [ "r269" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.", "label": "Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Share Based Awards Other Than Options", "terseLabel": "Unrecognized compensation expense" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altimmune.com/role/DisclosureStockBasedCompensationAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": { "auth_ref": [ "r269" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.", "label": "Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options", "terseLabel": "Unrecognized compensation cost, stock options" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altimmune.com/role/DisclosureStockBasedCompensationAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [ "r266" ], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "label": "Stock Options [Member]" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altimmune.com/role/DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetail", "http://www.altimmune.com/role/DisclosureStockBasedCompensationAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Common Stock" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r0", "r53", "r54", "r55", "r92", "r93", "r94", "r96", "r102", "r104", "r118", "r163", "r223", "r230", "r272", "r273", "r274", "r286", "r287", "r319", "r336", "r337", "r338", "r339", "r340", "r341", "r425", "r426", "r427", "r448" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altimmune.com/role/DisclosureCommonStockAdditionalInformationDetail", "http://www.altimmune.com/role/DisclosureContingentConsiderationAdditionalInformationDetail", "http://www.altimmune.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]", "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altimmune.com/role/DisclosureFairValueMeasurementsScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "auth_ref": [ "r322", "r323", "r324", "r330" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.", "label": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]", "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altimmune.com/role/DisclosureFairValueMeasurementsScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock": { "auth_ref": [ "r322", "r323", "r324", "r329", "r330" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.", "label": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Table [Text Block]", "terseLabel": "Schedule of Fair Value Assets and Liabilities Measured on Recurring Basis" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altimmune.com/role/DisclosureFairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r200", "r202", "r203", "r237", "r238", "r239", "r240", "r241", "r242", "r243", "r244", "r323", "r359", "r360", "r361" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value By Fair Value Hierarchy Level [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altimmune.com/role/DisclosureFairValueMeasurementsAdditionalInformationDetail", "http://www.altimmune.com/role/DisclosureFairValueMeasurementsScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "auth_ref": [ "r322", "r323", "r325", "r326", "r331" ], "lang": { "en-us": { "role": { "documentation": "Information by measurement frequency.", "label": "Fair Value By Measurement Frequency [Axis]" } } }, "localname": "FairValueByMeasurementFrequencyAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altimmune.com/role/DisclosureFairValueMeasurementsAdditionalInformationDetail", "http://www.altimmune.com/role/DisclosureFairValueMeasurementsScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value Measurements" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r328" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "Fair Value Disclosures [Text Block]", "terseLabel": "Fair Value Measurements" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altimmune.com/role/DisclosureFairValueMeasurements" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r200", "r237", "r238", "r243", "r244", "r323", "r359" ], "lang": { "en-us": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Level 1 [Member]" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altimmune.com/role/DisclosureFairValueMeasurementsScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r200", "r202", "r203", "r237", "r238", "r243", "r244", "r323", "r360" ], "lang": { "en-us": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Level 2 [Member]" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altimmune.com/role/DisclosureFairValueMeasurementsScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r200", "r202", "r203", "r237", "r238", "r239", "r240", "r241", "r242", "r243", "r244", "r323", "r361" ], "lang": { "en-us": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Level 3 [Member]" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altimmune.com/role/DisclosureFairValueMeasurementsAdditionalInformationDetail", "http://www.altimmune.com/role/DisclosureFairValueMeasurementsScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementFrequencyDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement frequency.", "label": "Measurement Frequency" } } }, "localname": "FairValueMeasurementFrequencyDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altimmune.com/role/DisclosureFairValueMeasurementsAdditionalInformationDetail", "http://www.altimmune.com/role/DisclosureFairValueMeasurementsScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r200", "r202", "r203", "r237", "r238", "r239", "r240", "r241", "r242", "r243", "r244", "r359", "r360", "r361" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Hierarchy and NAV" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altimmune.com/role/DisclosureFairValueMeasurementsAdditionalInformationDetail", "http://www.altimmune.com/role/DisclosureFairValueMeasurementsScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsNonrecurringMember": { "auth_ref": [ "r322", "r323", "r325", "r326", "r327", "r331" ], "lang": { "en-us": { "role": { "documentation": "Infrequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, not frequently measured at fair value.", "label": "Fair Value, Nonrecurring [Member]" } } }, "localname": "FairValueMeasurementsNonrecurringMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altimmune.com/role/DisclosureFairValueMeasurementsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsRecurringMember": { "auth_ref": [ "r328", "r331" ], "lang": { "en-us": { "role": { "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.", "label": "Fair Value, Measurements, Recurring [Member]" } } }, "localname": "FairValueMeasurementsRecurringMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altimmune.com/role/DisclosureFairValueMeasurementsScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FinancialInstrumentAxis": { "auth_ref": [ "r156", "r157", "r159", "r160", "r161", "r164", "r165", "r166", "r167", "r168", "r170", "r171", "r172", "r173", "r201", "r221", "r318", "r356", "r357", "r358", "r359", "r360", "r361", "r362", "r363", "r364", "r365", "r366", "r367", "r368", "r369", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r383", "r384", "r385", "r440", "r441", "r442", "r443", "r444", "r445", "r446" ], "lang": { "en-us": { "role": { "documentation": "Information by type of financial instrument.", "label": "Financial Instrument [Axis]" } } }, "localname": "FinancialInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altimmune.com/role/DisclosureFairValueMeasurementsScheduleOfShortTermInvestmentsDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ForeignCurrencyTransactionGainLossUnrealized": { "auth_ref": [ "r78", "r333", "r334" ], "calculation": { "http://www.altimmune.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount before tax of foreign currency transaction unrealized gain (loss) recognized in the income statement.", "label": "Foreign Currency Transaction Gain Loss Unrealized", "negatedLabel": "Unrealized (gains) losses on foreign currency exchange" } } }, "localname": "ForeignCurrencyTransactionGainLossUnrealized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altimmune.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r62" ], "calculation": { "http://www.altimmune.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 2.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General And Administrative Expense", "terseLabel": "General and administrative" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altimmune.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "auth_ref": [ "r61" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing general and administrative expense.", "label": "General and Administrative [Member]" } } }, "localname": "GeneralAndAdministrativeExpenseMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altimmune.com/role/DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseDetail" ], "xbrltype": "domainItemType" }, "us-gaap_GovernmentContractReceivable": { "auth_ref": [ "r387" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of receivables that are derived from government contracts.", "label": "Government Contract Receivable", "terseLabel": "Additional funding for development and manufacturing activities" } } }, "localname": "GovernmentContractReceivable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altimmune.com/role/DisclosureUsGovernmentContractsAndGrantsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_GrantMember": { "auth_ref": [ "r235" ], "lang": { "en-us": { "role": { "documentation": "Award of money not required to be repaid.", "label": "Grant [Member]" } } }, "localname": "GrantMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altimmune.com/role/DisclosureUsGovernmentContractsAndGrantsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_IPOMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "First sale of stock by a private company to the public.", "label": "Public Offering [Member]" } } }, "localname": "IPOMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altimmune.com/role/DisclosureCommonStockAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ImpairmentOfLongLivedAssetsHeldForUse": { "auth_ref": [ "r77", "r176", "r179" ], "calculation": { "http://www.altimmune.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.altimmune.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 3.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).", "label": "Impairment of Long-Lived Assets Held-for-use", "terseLabel": "Impairment loss on construction-in-progress", "verboseLabel": "Non-cash impairment charge" } } }, "localname": "ImpairmentOfLongLivedAssetsHeldForUse", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altimmune.com/role/DisclosureFairValueMeasurementsAdditionalInformationDetail", "http://www.altimmune.com/role/StatementConsolidatedStatementsOfCashFlows", "http://www.altimmune.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r57", "r135", "r137", "r140", "r143", "r145", "r390", "r399", "r404", "r419" ], "calculation": { "http://www.altimmune.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest", "totalLabel": "Net loss before income taxes" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altimmune.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r180", "r181" ], "lang": { "en-us": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altimmune.com/role/DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseDetail" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [ "r181" ], "lang": { "en-us": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altimmune.com/role/DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseDetail" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Taxes" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r86", "r282", "r283", "r284", "r288", "r290", "r292", "r293", "r294" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]", "terseLabel": "Income Taxes" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altimmune.com/role/DisclosureIncomeTaxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r87", "r103", "r104", "r134", "r281", "r289", "r291", "r420" ], "calculation": { "http://www.altimmune.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense Benefit", "negatedLabel": "Income tax benefit", "terseLabel": "Income tax benefit" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altimmune.com/role/DisclosureIncomeTaxesAdditionalInformationDetail", "http://www.altimmune.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "auth_ref": [ "r76" ], "calculation": { "http://www.altimmune.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.", "label": "Increase Decrease In Accounts Payable", "terseLabel": "Accounts payable" } } }, "localname": "IncreaseDecreaseInAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altimmune.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "auth_ref": [ "r76" ], "calculation": { "http://www.altimmune.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.", "label": "Increase Decrease In Accounts Receivable", "negatedLabel": "Accounts receivable" } } }, "localname": "IncreaseDecreaseInAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altimmune.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities": { "auth_ref": [ "r76" ], "calculation": { "http://www.altimmune.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in accrued expenses, and obligations classified as other.", "label": "Increase Decrease In Accrued Liabilities And Other Operating Liabilities", "terseLabel": "Accrued expenses and other liabilities" } } }, "localname": "IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altimmune.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Increase Decrease In Operating Capital [Abstract]", "terseLabel": "Changes in operating assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altimmune.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "auth_ref": [ "r76" ], "calculation": { "http://www.altimmune.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.", "label": "Increase Decrease In Prepaid Deferred Expense And Other Assets", "negatedLabel": "Prepaid expenses and other assets" } } }, "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altimmune.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "auth_ref": [ "r174", "r175" ], "calculation": { "http://www.altimmune.com/role/StatementConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.", "label": "Intangible Assets Net Excluding Goodwill", "terseLabel": "Intangible assets, net" } } }, "localname": "IntangibleAssetsNetExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altimmune.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpense": { "auth_ref": [ "r56", "r132", "r342", "r343", "r403" ], "calculation": { "http://www.altimmune.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.", "label": "Interest Expense", "negatedLabel": "Interest expense" } } }, "localname": "InterestExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altimmune.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentIncomeInterest": { "auth_ref": [ "r63", "r131" ], "calculation": { "http://www.altimmune.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 2.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.", "label": "Investment Income Interest", "terseLabel": "Interest income" } } }, "localname": "InvestmentIncomeInterest", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altimmune.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentPerformanceMember": { "auth_ref": [ "r235" ], "lang": { "en-us": { "role": { "documentation": "Result achieved from investment. Excludes non-performance related result from asset under management.", "label": "Investment Performance [Member]" } } }, "localname": "InvestmentPerformanceMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altimmune.com/role/DisclosureUsGovernmentContractsAndGrantsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_InvestmentsFairValueDisclosure": { "auth_ref": [ "r322" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.", "label": "Investments Fair Value Disclosure", "terseLabel": "Cash equivalents" } } }, "localname": "InvestmentsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altimmune.com/role/DisclosureFairValueMeasurementsScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeasesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating Leases" } } }, "localname": "LeasesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_LesseeOperatingLeasesTextBlock": { "auth_ref": [ "r352" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.", "label": "Lessee Operating Leases [Text Block]", "terseLabel": "Operating Leases" } } }, "localname": "LesseeOperatingLeasesTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altimmune.com/role/DisclosureOperatingLeases" ], "xbrltype": "textBlockItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r29", "r84", "r139", "r162", "r187", "r188", "r189", "r191", "r192", "r193", "r194", "r195", "r196", "r197", "r310", "r314", "r315", "r332", "r353", "r354" ], "calculation": { "http://www.altimmune.com/role/StatementConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altimmune.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r21", "r84", "r162", "r332", "r355", "r394", "r413" ], "calculation": { "http://www.altimmune.com/role/StatementConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities And Stockholders Equity", "totalLabel": "Total liabilities and stockholders' equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altimmune.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities And Stockholders Equity [Abstract]", "terseLabel": "LIABILITIES AND STOCKHOLDERS' EQUITY" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altimmune.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r32", "r84", "r162", "r187", "r188", "r189", "r191", "r192", "r193", "r194", "r195", "r196", "r197", "r310", "r314", "r315", "r332", "r353", "r354", "r355" ], "calculation": { "http://www.altimmune.com/role/StatementConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altimmune.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities Current [Abstract]", "terseLabel": "Current liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altimmune.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesFairValueDisclosure": { "auth_ref": [ "r322" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of financial and nonfinancial obligations.", "label": "Liabilities Fair Value Disclosure", "terseLabel": "Total" } } }, "localname": "LiabilitiesFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altimmune.com/role/DisclosureFairValueMeasurementsScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtNoncurrent": { "auth_ref": [ "r33" ], "calculation": { "http://www.altimmune.com/role/DisclosureOtherLongTermLiabilitiesSummaryOfOtherLongTermLiabilitiesDetail": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long Term Debt Noncurrent", "totalLabel": "Total other long-term liabilities" } } }, "localname": "LongTermDebtNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altimmune.com/role/DisclosureOtherLongTermLiabilitiesSummaryOfOtherLongTermLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity.", "label": "Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners", "terseLabel": "Ownership percentage" } } }, "localname": "MinorityInterestOwnershipPercentageByNoncontrollingOwners", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altimmune.com/role/DisclosureCommonStockAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "us-gaap_MoneyMarketFundsMember": { "auth_ref": [ "r237" ], "lang": { "en-us": { "role": { "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.", "label": "Money Market Funds [Member]" } } }, "localname": "MoneyMarketFundsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altimmune.com/role/DisclosureFairValueMeasurementsScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetail" ], "xbrltype": "domainItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r74" ], "calculation": { "http://www.altimmune.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided By Used In Financing Activities", "totalLabel": "Net cash provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altimmune.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided By Used In Financing Activities [Abstract]", "terseLabel": "CASH FLOWS FROM FINANCING ACTIVITIES:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altimmune.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r74" ], "calculation": { "http://www.altimmune.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided By Used In Investing Activities", "totalLabel": "Net cash (used in) provided by investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altimmune.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided By Used In Investing Activities [Abstract]", "terseLabel": "CASH FLOWS FROM INVESTING ACTIVITIES:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altimmune.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r74", "r75", "r78" ], "calculation": { "http://www.altimmune.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided By Used In Operating Activities", "totalLabel": "Net cash used in operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altimmune.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided By Used In Operating Activities [Abstract]", "terseLabel": "CASH FLOWS FROM OPERATING ACTIVITIES:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altimmune.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r1", "r49", "r51", "r55", "r58", "r78", "r84", "r95", "r97", "r98", "r99", "r100", "r103", "r104", "r108", "r135", "r137", "r140", "r143", "r145", "r162", "r187", "r188", "r189", "r191", "r192", "r193", "r194", "r195", "r196", "r197", "r321", "r332", "r400", "r416" ], "calculation": { "http://www.altimmune.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income Loss", "terseLabel": "Net loss", "totalLabel": "Net loss" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altimmune.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity", "http://www.altimmune.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_NonoperatingIncomeExpense": { "auth_ref": [ "r64" ], "calculation": { "http://www.altimmune.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).", "label": "Nonoperating Income Expense", "totalLabel": "Total other income (expense), net" } } }, "localname": "NonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altimmune.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Nonoperating Income Expense [Abstract]", "terseLabel": "Other income (expense):" } } }, "localname": "NonoperatingIncomeExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altimmune.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://www.altimmune.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating Expenses", "totalLabel": "Total operating expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altimmune.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating Expenses [Abstract]", "terseLabel": "Operating expenses:" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altimmune.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r135", "r137", "r140", "r143", "r145" ], "calculation": { "http://www.altimmune.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income Loss", "totalLabel": "Loss from operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altimmune.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseExpense": { "auth_ref": [ "r346" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of operating lease expense. Excludes sublease income.", "label": "Operating lease rent expense" } } }, "localname": "OperatingLeaseExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altimmune.com/role/DisclosureOperatingLeasesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiability": { "auth_ref": [ "r345" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "label": "Operating Lease Liability", "terseLabel": "Operating lease obligations (see Note 5 and 7)" } } }, "localname": "OperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altimmune.com/role/DisclosureOperatingLeasesSummaryOfSupplementalOtherInformationRelatedToOperatingLeasesBalanceSheetDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r345" ], "calculation": { "http://www.altimmune.com/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetail": { "order": 4.0, "parentTag": "alt_AccruedExpensesAndOtherCurrentLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating Lease Liability Current", "terseLabel": "Lease obligation, current portion (see Note 4)" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altimmune.com/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r345" ], "calculation": { "http://www.altimmune.com/role/DisclosureOtherLongTermLiabilitiesSummaryOfOtherLongTermLiabilitiesDetail": { "order": 1.0, "parentTag": "us-gaap_LongTermDebtNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating Lease Liability Noncurrent", "terseLabel": "Lease obligation, long-term portion (see Note 4)" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altimmune.com/role/DisclosureOtherLongTermLiabilitiesSummaryOfOtherLongTermLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasePayments": { "auth_ref": [ "r347", "r348" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.", "label": "Operating Lease Payments", "terseLabel": "Cash paid for operating lease liabilities" } } }, "localname": "OperatingLeasePayments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altimmune.com/role/DisclosureOperatingLeasesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r344" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating Lease Right Of Use Asset", "verboseLabel": "Operating lease right-of-use assets (included in \"Other assets\" in Balance Sheet)" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altimmune.com/role/DisclosureOperatingLeasesSummaryOfSupplementalOtherInformationRelatedToOperatingLeasesBalanceSheetDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r350", "r351" ], "lang": { "en-us": { "role": { "documentation": "Weighted average discount rate for operating lease calculated at point in time.", "label": "Operating Lease Weighted Average Discount Rate Percent", "terseLabel": "Weighted-average discount rate" } } }, "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altimmune.com/role/DisclosureOperatingLeasesSummaryOfSupplementalOtherInformationRelatedToOperatingLeasesBalanceSheetDetail" ], "xbrltype": "percentItemType" }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r349", "r351" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Operating Lease Weighted Average Remaining Lease Term1", "terseLabel": "Weighted-average remaining lease term (years)" } } }, "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altimmune.com/role/DisclosureOperatingLeasesSummaryOfSupplementalOtherInformationRelatedToOperatingLeasesBalanceSheetDetail" ], "xbrltype": "durationItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Nature of Business and Basis of Presentation" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r26" ], "calculation": { "http://www.altimmune.com/role/StatementConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other Assets Noncurrent", "terseLabel": "Other assets" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altimmune.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": { "auth_ref": [ "r43", "r44", "r46" ], "calculation": { "http://www.altimmune.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.", "label": "Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax", "terseLabel": "Other comprehensive income - unrealized (loss) gain on short-term investments", "verboseLabel": "Unrealized (loss) gain on short-term investments" } } }, "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altimmune.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity", "http://www.altimmune.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilitiesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Long-Term Liabilities" } } }, "localname": "OtherLiabilitiesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_OtherLiabilitiesDisclosureTextBlock": { "auth_ref": [ "r31" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for other liabilities.", "label": "Other Liabilities Disclosure [Text Block]", "terseLabel": "Other Long-Term Liabilities" } } }, "localname": "OtherLiabilitiesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altimmune.com/role/DisclosureOtherLongTermLiabilities" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherLiabilitiesNoncurrent": { "auth_ref": [ "r34" ], "calculation": { "http://www.altimmune.com/role/DisclosureOtherLongTermLiabilitiesSummaryOfOtherLongTermLiabilitiesDetail": { "order": 3.0, "parentTag": "us-gaap_LongTermDebtNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.", "label": "Other Liabilities Noncurrent", "terseLabel": "Other" } } }, "localname": "OtherLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altimmune.com/role/DisclosureOtherLongTermLiabilitiesSummaryOfOtherLongTermLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLongTermDebtNoncurrent": { "auth_ref": [ "r33" ], "calculation": { "http://www.altimmune.com/role/StatementConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt classified as other, payable after one year or the operating cycle, if longer.", "label": "Other Long Term Debt Noncurrent", "terseLabel": "Other long-term liabilities" } } }, "localname": "OtherLongTermDebtNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altimmune.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNoncurrentLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of other noncurrent liabilities.", "label": "Other Noncurrent Liabilities Table [Text Block]", "terseLabel": "Summary of Other Long-Term Liabilities" } } }, "localname": "OtherNoncurrentLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altimmune.com/role/DisclosureOtherLongTermLiabilitiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherNonoperatingIncomeExpense": { "auth_ref": [ "r65" ], "calculation": { "http://www.altimmune.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 3.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.", "label": "Other Nonoperating Income Expense", "terseLabel": "Other income (expense), net" } } }, "localname": "OtherNonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altimmune.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherTaxExpenseBenefit": { "auth_ref": [ "r85", "r281", "r285" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of other income tax expense (benefit).", "label": "Other Tax Expense (Benefit)", "terseLabel": "Income tax benefit due to valuation allowance" } } }, "localname": "OtherTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altimmune.com/role/DisclosureIncomeTaxesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OverAllotmentOptionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Right given to the underwriter to sell additional shares over the initial allotment.", "label": "Over-Allotment Option [Member]" } } }, "localname": "OverAllotmentOptionMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altimmune.com/role/DisclosureCommonStockAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_PayablesAndAccrualsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accrued Expenses" } } }, "localname": "PayablesAndAccrualsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_PaymentsOfStockIssuanceCosts": { "auth_ref": [ "r72" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.", "label": "Payments Of Stock Issuance Costs", "terseLabel": "Issuance costs" } } }, "localname": "PaymentsOfStockIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altimmune.com/role/DisclosureCommonStockAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": { "auth_ref": [ "r66", "r68", "r153" ], "calculation": { "http://www.altimmune.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Payments To Acquire Available For Sale Securities Debt", "negatedLabel": "Purchases of short-term investments" } } }, "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altimmune.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireBusinessesGross": { "auth_ref": [ "r69", "r302" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.", "label": "Payments To Acquire Businesses Gross", "terseLabel": "Up-front consideration" } } }, "localname": "PaymentsToAcquireBusinessesGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altimmune.com/role/DisclosureContingentConsiderationAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireIntangibleAssets": { "auth_ref": [ "r70" ], "calculation": { "http://www.altimmune.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.", "label": "Payments To Acquire Intangible Assets", "negatedLabel": "Cash paid for internally developed patents" } } }, "localname": "PaymentsToAcquireIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altimmune.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r70" ], "calculation": { "http://www.altimmune.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments To Acquire Property Plant And Equipment", "negatedLabel": "Purchases of property and equipment, net" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altimmune.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r252", "r270" ], "lang": { "en-us": { "role": { "documentation": "Information by plan name for share-based payment arrangement.", "label": "Plan Name [Axis]" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altimmune.com/role/DisclosureStockBasedCompensationAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Plan name for share-based payment arrangement.", "label": "Plan Name" } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altimmune.com/role/DisclosureStockBasedCompensationAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r4", "r22", "r23" ], "calculation": { "http://www.altimmune.com/role/StatementConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepaid Expense And Other Assets Current", "terseLabel": "Prepaid expenses and other current assets" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altimmune.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "auth_ref": [ "r71" ], "calculation": { "http://www.altimmune.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the additional capital contribution to the entity.", "label": "Proceeds From Issuance Of Common Stock", "terseLabel": "Proceeds from issuance of common stock in at-the-market offerings, net", "verboseLabel": "Proceeds from issuance of common stock in public offering" } } }, "localname": "ProceedsFromIssuanceOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altimmune.com/role/DisclosureCommonStockAdditionalInformationDetail", "http://www.altimmune.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": { "auth_ref": [ "r71" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.", "label": "Proceeds From Issuance Or Sale Of Equity", "terseLabel": "Gross proceeds from offering including exercise of underwriter's option" } } }, "localname": "ProceedsFromIssuanceOrSaleOfEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altimmune.com/role/DisclosureCommonStockAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities": { "auth_ref": [ "r66", "r67", "r153" ], "calculation": { "http://www.altimmune.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Proceeds From Sale And Maturity Of Available For Sale Securities", "terseLabel": "Proceeds from sales and maturities of short-term investments" } } }, "localname": "ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altimmune.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromStockOptionsExercised": { "auth_ref": [ "r71", "r271" ], "calculation": { "http://www.altimmune.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.", "label": "Proceeds from Stock Options Exercised", "verboseLabel": "Proceeds from exercises of stock options, net" } } }, "localname": "ProceedsFromStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altimmune.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromStockPlans": { "auth_ref": [ "r71" ], "calculation": { "http://www.altimmune.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the amount received from the stock plan during the period.", "label": "Proceeds From Stock Plans", "terseLabel": "Proceeds from issuance of common stock from Employee Stock Purchase Plan" } } }, "localname": "ProceedsFromStockPlans", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altimmune.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProfitLoss": { "auth_ref": [ "r1", "r49", "r51", "r55", "r73", "r84", "r95", "r103", "r104", "r135", "r137", "r140", "r143", "r145", "r162", "r187", "r188", "r189", "r191", "r192", "r193", "r194", "r195", "r196", "r197", "r308", "r311", "r312", "r316", "r317", "r321", "r332", "r404" ], "calculation": { "http://www.altimmune.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.", "label": "Profit Loss", "terseLabel": "Net loss" } } }, "localname": "ProfitLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altimmune.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentAdditions": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of acquisition of long-lived, physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.", "label": "Property, Plant and Equipment, Additions", "verboseLabel": "Capitalized costs" } } }, "localname": "PropertyPlantAndEquipmentAdditions", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altimmune.com/role/DisclosureFairValueMeasurementsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r25", "r178" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Property Plant And Equipment By Type [Axis]" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altimmune.com/role/DisclosureFairValueMeasurementsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentFairValueDisclosure": { "auth_ref": [ "r322" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant, and Equipment, Fair Value Disclosure", "terseLabel": "Fair value of impaired assets" } } }, "localname": "PropertyPlantAndEquipmentFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altimmune.com/role/DisclosureFairValueMeasurementsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r9", "r10", "r178", "r355", "r406", "r414" ], "calculation": { "http://www.altimmune.com/role/StatementConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property Plant And Equipment Net", "terseLabel": "Property and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altimmune.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r9", "r177" ], "lang": { "en-us": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.", "label": "Long-Lived Tangible Asset" } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altimmune.com/role/DisclosureFairValueMeasurementsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted": { "auth_ref": [ "r13", "r393", "r410" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Minimum amount to be expended to satisfy the terms of arrangements in which the entity has agreed to expend funds to procure goods or services, excluding long-term purchase commitments or unconditional purchase obligations.", "label": "Purchase Commitment Remaining Minimum Amount Committed", "terseLabel": "Amount used to fund clinical development" } } }, "localname": "PurchaseCommitmentRemainingMinimumAmountCommitted", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altimmune.com/role/DisclosureUsGovernmentContractsAndGrantsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r280", "r388", "r434" ], "calculation": { "http://www.altimmune.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research And Development Expense", "terseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altimmune.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.", "label": "Research and Development [Member]" } } }, "localname": "ResearchAndDevelopmentExpenseMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altimmune.com/role/DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseDetail" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash and Cash Equivalents" } } }, "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altimmune.com/role/DisclosureFairValueMeasurementsScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetail" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedCashCurrent": { "auth_ref": [ "r3", "r8", "r80" ], "calculation": { "http://www.altimmune.com/role/StatementConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.", "label": "Restricted Cash Current", "terseLabel": "Restricted cash" } } }, "localname": "RestrictedCashCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altimmune.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedStockMember": { "auth_ref": [ "r112" ], "lang": { "en-us": { "role": { "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.", "label": "Restricted Stock [Member]" } } }, "localname": "RestrictedStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altimmune.com/role/DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetail", "http://www.altimmune.com/role/DisclosureStockBasedCompensationAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number, after shares used to satisfy grantee's tax withholding obligation for award under share-based payment arrangement, of restricted shares issued. Excludes cash used to satisfy grantee's tax withholding obligation.", "label": "Restricted Stock Shares Issued Net Of Shares For Tax Withholdings", "terseLabel": "Unrestricted common stock", "verboseLabel": "Vesting of restricted stock awards including withholding, net (in shares)" } } }, "localname": "RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altimmune.com/role/DisclosureStockBasedCompensationAdditionalInformationDetail", "http://www.altimmune.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_RestrictedStockUnitsRSUMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.", "label": "Restricted Stock Units [Member]" } } }, "localname": "RestrictedStockUnitsRSUMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altimmune.com/role/DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetail", "http://www.altimmune.com/role/DisclosureStockBasedCompensationAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value, after value of shares used to satisfy grantee's tax withholding obligation for award under share-based payment arrangement, of restricted shares issued. Excludes cash used to satisfy grantee's tax withholding obligation.", "label": "Restricted Stock Value Shares Issued Net Of Tax Withholdings", "terseLabel": "Vesting of restricted stock awards including withholding, net" } } }, "localname": "RestrictedStockValueSharesIssuedNetOfTaxWithholdings", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altimmune.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r17", "r230", "r275", "r355", "r412", "r428", "r430" ], "calculation": { "http://www.altimmune.com/role/StatementConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings Accumulated Deficit", "terseLabel": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altimmune.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r0", "r92", "r93", "r94", "r96", "r102", "r104", "r163", "r272", "r273", "r274", "r286", "r287", "r319", "r425", "r427" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Accumulated Deficit [Member]" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altimmune.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [ "r129", "r130", "r136", "r141", "r142", "r146", "r147", "r148", "r233", "r234", "r389" ], "calculation": { "http://www.altimmune.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "label": "Revenue From Contract With Customer Excluding Assessed Tax", "terseLabel": "Revenues" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altimmune.com/role/DisclosureUsGovernmentContractsAndGrantsAdditionalInformationDetail", "http://www.altimmune.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.", "label": "Sale of Stock" } } }, "localname": "SaleOfStockNameOfTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altimmune.com/role/DisclosureCommonStockAdditionalInformationDetail", "http://www.altimmune.com/role/DisclosureContingentConsiderationAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of accrued liabilities.", "label": "Schedule Of Accrued Liabilities Table [Text Block]", "terseLabel": "Schedule of Accrued Expenses and Other Current Liabilities" } } }, "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altimmune.com/role/DisclosureAccruedExpensesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "auth_ref": [ "r112" ], "lang": { "en-us": { "role": { "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.", "label": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]", "terseLabel": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altimmune.com/role/DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "auth_ref": [ "r112" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.", "label": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Text Block]", "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altimmune.com/role/DisclosureNetLossPerShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Schedule Of Available For Sale Securities [Line Items]", "terseLabel": "Schedule Of Available For Sale Securities [Line Items]" } } }, "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altimmune.com/role/DisclosureFairValueMeasurementsScheduleOfShortTermInvestmentsDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.", "label": "Schedule Of Available For Sale Securities Reconciliation Table [Text Block]", "terseLabel": "Schedule of Short Term Investments" } } }, "localname": "ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altimmune.com/role/DisclosureFairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of contingent payment arrangements including the terms that will result in payment and the accounting treatment that will be followed if such contingencies occur, including the potential impact on earnings per share if contingencies are to be settled in common stock of the entity. The description also may include the period over which amounts are expected to be paid, and changes in the amount since the previous reporting period. This also includes contingent options and commitments.", "label": "Schedule Of Business Acquisitions By Acquisition Contingent Consideration [Text Block]", "terseLabel": "Summary of Fair Value of Contingent Consideration" } } }, "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altimmune.com/role/DisclosureContingentConsiderationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": { "auth_ref": [ "r295", "r296" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.", "label": "Schedule Of Business Acquisitions By Acquisition [Table]", "terseLabel": "Schedule Of Business Acquisitions By Acquisition [Table]" } } }, "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altimmune.com/role/DisclosureContingentConsiderationAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": { "auth_ref": [ "r251", "r267", "r276" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.", "label": "Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]", "terseLabel": "Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altimmune.com/role/DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "auth_ref": [ "r251", "r267", "r276" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.", "label": "Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Text Block]", "terseLabel": "Schedule of Stock-based Compensation Expense" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altimmune.com/role/DisclosureStockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock": { "auth_ref": [ "r260" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of activity for outstanding award under share-based payment arrangement excluding share and unit options and nonvested award.", "label": "Schedule Of Other Share Based Compensation Activity Table [Text Block]", "terseLabel": "Schedule of Information Related to Stock Options Outstanding" } } }, "localname": "ScheduleOfOtherShareBasedCompensationActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altimmune.com/role/DisclosureStockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r252", "r270" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]", "terseLabel": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altimmune.com/role/DisclosureStockBasedCompensationAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfStockByClassTable": { "auth_ref": [ "r36", "r82", "r119", "r120", "r204", "r205", "r206", "r207", "r208", "r209", "r210", "r212", "r216", "r221", "r224", "r225", "r226", "r227", "r228", "r229", "r230" ], "lang": { "en-us": { "role": { "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.", "label": "Schedule Of Stock By Class [Table]", "terseLabel": "Schedule Of Stock By Class [Table]" } } }, "localname": "ScheduleOfStockByClassTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altimmune.com/role/DisclosureCommonStockAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": { "auth_ref": [ "r231", "r250" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.", "label": "Schedule Of Stockholders Equity Note Warrants Or Rights [Text Block]", "terseLabel": "Summary of Warrant Activity" } } }, "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altimmune.com/role/DisclosureWarrantsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r76" ], "calculation": { "http://www.altimmune.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share Based Compensation", "terseLabel": "Stock-based compensation expense" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altimmune.com/role/DisclosureStockBasedCompensationAdditionalInformationDetail", "http://www.altimmune.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "auth_ref": [ "r253" ], "lang": { "en-us": { "role": { "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1", "terseLabel": "Vesting Period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altimmune.com/role/DisclosureStockBasedCompensationAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "auth_ref": [ "r262" ], "lang": { "en-us": { "role": { "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period", "terseLabel": "Shares granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altimmune.com/role/DisclosureStockBasedCompensationAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r262" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value", "verboseLabel": "Weighted average grant date fair value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altimmune.com/role/DisclosureStockBasedCompensationAdditionalInformationDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "auth_ref": [ "r261" ], "lang": { "en-us": { "role": { "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number", "terseLabel": "Unvested restricted stock, shares" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altimmune.com/role/DisclosureStockBasedCompensationAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "auth_ref": [ "r263" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period", "terseLabel": "Number of share vested" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altimmune.com/role/DisclosureStockBasedCompensationAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share Based Compensation Arrangement By Share Based Payment Award [Line Items]", "terseLabel": "Share Based Compensation Arrangement By Share Based Payment Award [Line Items]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altimmune.com/role/DisclosureStockBasedCompensationAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "auth_ref": [ "r258" ], "lang": { "en-us": { "role": { "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number", "verboseLabel": "Number of Stock Options, Exercisable" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altimmune.com/role/DisclosureStockBasedCompensationScheduleOfInformationRelatedToStockOptionsOutstandingDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "auth_ref": [ "r258" ], "lang": { "en-us": { "role": { "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price", "terseLabel": "Weighted-average Exercise Price, Exercisable" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altimmune.com/role/DisclosureStockBasedCompensationScheduleOfInformationRelatedToStockOptionsOutstandingDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross", "terseLabel": "Number of Stock Options, Granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altimmune.com/role/DisclosureStockBasedCompensationAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r264" ], "lang": { "en-us": { "role": { "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value", "terseLabel": "Weighted-average grant date fair value of stock options granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altimmune.com/role/DisclosureStockBasedCompensationAdditionalInformationDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "auth_ref": [ "r270" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value", "terseLabel": "Aggregate Intrinsic Value, Outstanding" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altimmune.com/role/DisclosureStockBasedCompensationScheduleOfInformationRelatedToStockOptionsOutstandingDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r257", "r270" ], "lang": { "en-us": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number", "terseLabel": "Number of Stock Options, Outstanding" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altimmune.com/role/DisclosureStockBasedCompensationScheduleOfInformationRelatedToStockOptionsOutstandingDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r256" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price", "terseLabel": "Weighted-average Exercise Price, Outstanding" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altimmune.com/role/DisclosureStockBasedCompensationScheduleOfInformationRelatedToStockOptionsOutstandingDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r250", "r255" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Award Type" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altimmune.com/role/DisclosureStockBasedCompensationAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price", "terseLabel": "Stock options granted, weighted-average exercise price" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altimmune.com/role/DisclosureStockBasedCompensationAdditionalInformationDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": { "auth_ref": [ "r254" ], "lang": { "en-us": { "role": { "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period", "terseLabel": "Stock option expiration Period" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altimmune.com/role/DisclosureStockBasedCompensationAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "auth_ref": [ "r270" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.", "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1", "terseLabel": "Aggregate Intrinsic Value, Exercisable" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altimmune.com/role/DisclosureStockBasedCompensationScheduleOfInformationRelatedToStockOptionsOutstandingDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r270" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1", "terseLabel": "Weighted-average Remaining Contractual Term, Exercisable" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altimmune.com/role/DisclosureStockBasedCompensationScheduleOfInformationRelatedToStockOptionsOutstandingDetail" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of non-vested options outstanding.", "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares", "terseLabel": "Number of Stock Options, Unvested" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altimmune.com/role/DisclosureStockBasedCompensationScheduleOfInformationRelatedToStockOptionsOutstandingDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r265" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2", "terseLabel": "Weighted-average Remaining Contractual Term, Outstanding" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altimmune.com/role/DisclosureStockBasedCompensationScheduleOfInformationRelatedToStockOptionsOutstandingDetail" ], "xbrltype": "durationItemType" }, "us-gaap_SharesIssuedPricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Per share or per unit amount of equity securities issued.", "label": "Shares Issued Price Per Share", "terseLabel": "Public offering price, per share" } } }, "localname": "SharesIssuedPricePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altimmune.com/role/DisclosureCommonStockAdditionalInformationDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Shares Outstanding", "periodEndLabel": "Ending Balance (in shares)", "periodStartLabel": "Beginning Balance (in shares)" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altimmune.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement.", "label": "Share-based Payment Arrangement, Shares Withheld for Tax Withholding Obligation", "terseLabel": "Common stock withheld to satisfy tax withholding obligations." } } }, "localname": "SharesPaidForTaxWithholdingForShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altimmune.com/role/DisclosureStockBasedCompensationAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShortTermInvestments": { "auth_ref": [ "r11", "r395", "r396", "r407" ], "calculation": { "http://www.altimmune.com/role/StatementConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.", "label": "Short Term Investments", "terseLabel": "Short-term investments" } } }, "localname": "ShortTermInvestments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altimmune.com/role/DisclosureFairValueMeasurementsScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetail", "http://www.altimmune.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r81", "r91" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "Significant Accounting Policies [Text Block]", "terseLabel": "Summary of Significant Accounting Policies" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altimmune.com/role/DisclosureSummaryOfSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r0", "r38", "r53", "r54", "r55", "r92", "r93", "r94", "r96", "r102", "r104", "r118", "r163", "r223", "r230", "r272", "r273", "r274", "r286", "r287", "r319", "r336", "r337", "r338", "r339", "r340", "r341", "r425", "r426", "r427", "r448" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Statement Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altimmune.com/role/DisclosureCommonStockAdditionalInformationDetail", "http://www.altimmune.com/role/DisclosureContingentConsiderationAdditionalInformationDetail", "http://www.altimmune.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "terseLabel": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altimmune.com/role/DisclosureFairValueMeasurementsAdditionalInformationDetail", "http://www.altimmune.com/role/DisclosureUsGovernmentContractsAndGrantsAdditionalInformationDetail", "http://www.altimmune.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CONSOLIDATED STATEMENTS OF CASH FLOWS" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CONSOLIDATED BALANCE SHEETS" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r92", "r93", "r94", "r118", "r389" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]", "terseLabel": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altimmune.com/role/DisclosureFairValueMeasurementsAdditionalInformationDetail", "http://www.altimmune.com/role/DisclosureUsGovernmentContractsAndGrantsAdditionalInformationDetail", "http://www.altimmune.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesAcquisitions": { "auth_ref": [ "r14", "r15", "r230" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of stock issued during the period pursuant to acquisitions.", "label": "Stock Issued During Period Shares Acquisitions", "terseLabel": "Issuance of common stock related to contingent consideration liability (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesAcquisitions", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altimmune.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": { "auth_ref": [ "r14", "r15", "r223", "r230" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.", "label": "Stock Issued During Period Shares Employee Stock Purchase Plans", "terseLabel": "Issuance of common stock from Employee Stock Purchase Plan (in shares)", "verboseLabel": "Employees purchased, shares" } } }, "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altimmune.com/role/DisclosureStockBasedCompensationAdditionalInformationDetail", "http://www.altimmune.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r14", "r15", "r223", "r230" ], "lang": { "en-us": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Stock Issued During Period Shares New Issues", "terseLabel": "Issuance of common stock in at the market offerings, net (in shares)", "verboseLabel": "Shares of common stock sold" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altimmune.com/role/DisclosureCommonStockAdditionalInformationDetail", "http://www.altimmune.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesOther": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares of stock issued attributable to transactions classified as other.", "label": "Stock Issued During Period, Shares, Other", "terseLabel": "Other increase (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesOther", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altimmune.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r14", "r15", "r223", "r230", "r259" ], "lang": { "en-us": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Stock Issued During Period Shares Stock Options Exercised", "terseLabel": "Exercise of stock options (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altimmune.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueAcquisitions": { "auth_ref": [ "r38", "r223", "r230" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued pursuant to acquisitions during the period.", "label": "Stock Issued During Period Value Acquisitions", "terseLabel": "Issuance of common stock related to contingent consideration liability" } } }, "localname": "StockIssuedDuringPeriodValueAcquisitions", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altimmune.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": { "auth_ref": [ "r14", "r15", "r223", "r230" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.", "label": "Stock Issued During Period Value Employee Stock Purchase Plan", "terseLabel": "Issuance of common stock from Employee Stock Purchase Plan", "verboseLabel": "Employees purchased, value" } } }, "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altimmune.com/role/DisclosureStockBasedCompensationAdditionalInformationDetail", "http://www.altimmune.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "auth_ref": [ "r14", "r15", "r223", "r230" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.", "label": "Stock Issued During Period Value New Issues", "terseLabel": "Issuance of common stock in at the market offerings, net" } } }, "localname": "StockIssuedDuringPeriodValueNewIssues", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altimmune.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "auth_ref": [ "r38", "r223", "r230" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued as a result of the exercise of stock options.", "label": "Stock Issued During Period Value Stock Options Exercised", "terseLabel": "Exercise of stock options" } } }, "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altimmune.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r15", "r19", "r20", "r84", "r151", "r162", "r332", "r355" ], "calculation": { "http://www.altimmune.com/role/StatementConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders Equity", "periodEndLabel": "Ending Balance", "periodStartLabel": "Beginning Balance", "totalLabel": "Total stockholders' equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altimmune.com/role/StatementConsolidatedBalanceSheets", "http://www.altimmune.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders Equity [Abstract]", "terseLabel": "Stockholders' equity:" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altimmune.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r83", "r208", "r211", "r212", "r213", "r214", "r215", "r216", "r217", "r218", "r219", "r220", "r222", "r230", "r232" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "Stockholders Equity Note Disclosure [Text Block]", "terseLabel": "Warrants" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altimmune.com/role/DisclosureWarrants" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsidiarySaleOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of sale of the entity's stock.", "label": "Subsidiary Sale Of Stock [Axis]" } } }, "localname": "SubsidiarySaleOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altimmune.com/role/DisclosureCommonStockAdditionalInformationDetail", "http://www.altimmune.com/role/DisclosureContingentConsiderationAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "auth_ref": [ "r156", "r157", "r159", "r160", "r161", "r201", "r221", "r318", "r356", "r357", "r358", "r359", "r360", "r361", "r362", "r363", "r364", "r365", "r366", "r367", "r368", "r369", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r383", "r384", "r385", "r440", "r441", "r442", "r443", "r444", "r445", "r446" ], "lang": { "en-us": { "role": { "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.", "label": "Financial Instruments" } } }, "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altimmune.com/role/DisclosureFairValueMeasurementsScheduleOfShortTermInvestmentsDetail" ], "xbrltype": "domainItemType" }, "us-gaap_TypeOfArrangementAxis": { "auth_ref": [ "r307" ], "lang": { "en-us": { "role": { "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Type Of Arrangement [Axis]" } } }, "localname": "TypeOfArrangementAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altimmune.com/role/DisclosureCommonStockAdditionalInformationDetail", "http://www.altimmune.com/role/DisclosureUsGovernmentContractsAndGrantsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_USTreasurySecuritiesMember": { "auth_ref": [ "r88", "r237", "r244", "r405" ], "lang": { "en-us": { "role": { "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years).", "label": "United States Treasury Securities [Member]" } } }, "localname": "USTreasurySecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altimmune.com/role/DisclosureFairValueMeasurementsScheduleOfShortTermInvestmentsDetail" ], "xbrltype": "domainItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r121", "r122", "r123", "r124", "r125", "r126", "r127" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use Of Estimates", "terseLabel": "Use of Estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altimmune.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_WarrantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.", "label": "Common Stock Warrants [Member]" } } }, "localname": "WarrantMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altimmune.com/role/DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetail" ], "xbrltype": "domainItemType" }, "us-gaap_WarrantsAndRightsNoteDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Warrants" } } }, "localname": "WarrantsAndRightsNoteDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_WarrantsAndRightsOutstandingTerm": { "auth_ref": [ "r326" ], "lang": { "en-us": { "role": { "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Warrants and Rights Outstanding, Term", "terseLabel": "Weighted-Average Remaining Contractual Term (Years)" } } }, "localname": "WarrantsAndRightsOutstandingTerm", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altimmune.com/role/DisclosureWarrantsSummaryOfWarrantActivityDetail" ], "xbrltype": "durationItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r106", "r111" ], "lang": { "en-us": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted", "terseLabel": "Weighted-average common shares outstanding, diluted" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altimmune.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r105", "r111" ], "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number Of Share Outstanding Basic And Diluted", "terseLabel": "Weighted-average common shares outstanding, basic" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.altimmune.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "sharesItemType" } }, "unitCount": 4 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1505-109256" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(2))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e4984-109258" }, "r117": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "http://asc.fasb.org/topic&trid=2144383" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592" }, "r128": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "http://asc.fasb.org/topic&trid=2134479" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(25))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(aa)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27232-111563" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=SL120269820-111563" }, "r158": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "320", "URI": "http://asc.fasb.org/topic&trid=2196928" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "321", "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "321", "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "321", "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "((a)(1),(b))", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=123351718&loc=d3e2420-110228" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2921-110230" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r184": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "http://asc.fasb.org/topic&trid=2144648" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349" }, "r186": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "http://asc.fasb.org/topic&trid=2127136" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r2": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "http://asc.fasb.org/topic&trid=2122149" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(CFRR 211.02)", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21553-112644" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(7))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21484-112644" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21488-112644" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21521-112644" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21538-112644" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(8))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "50", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775" }, "r232": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "http://asc.fasb.org/topic&trid=2208762" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=d3e4534-113899" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.14)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.17)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "2A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11149-113907" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11178-113907" }, "r279": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "http://asc.fasb.org/topic&trid=2228938" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a),20,24)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331" }, "r294": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "http://asc.fasb.org/topic&trid=2144680" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "25", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "30", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6578-128477" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "30", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6613-128477" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "30", "Subparagraph": "b", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)(1)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)(4)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)(1)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e7008-128479" }, "r306": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "805", "URI": "http://asc.fasb.org/topic&trid=2303972" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "808", "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569616-111683" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20,24)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "4J", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123477628&loc=d3e90205-114008" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(1)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "2C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=SL7498348-110258" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19279-110258" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=SL6742756-110258" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=125521441&loc=d3e30690-110894" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=124440516&loc=d3e30840-110895" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.24)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(4)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971" }, "r352": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/subtopic&trid=77888251" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(i)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(ii)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.28,29)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)(i)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(5)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(6)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(7)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(b)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "310", "Topic": "912", "URI": "http://asc.fasb.org/extlink&oid=123371682&loc=d3e55295-109406" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "730", "Topic": "912", "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "http://asc.fasb.org/extlink&oid=123384075&loc=d3e41242-110953" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(15)(1))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(17))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(4))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(5))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(6))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(24))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.9)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Subparagraph": "(b)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=d3e62557-112803" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(1)(g))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(15)(b)(1))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(19))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(20))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(a)", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r435": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r436": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r437": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r438": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r439": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580" }, "r440": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402" }, "r441": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(1)" }, "r442": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)" }, "r443": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(3)" }, "r444": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(i)" }, "r445": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(ii)" }, "r446": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(iii)" }, "r447": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e637-108580" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e681-108580" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669686-108580" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(210.5-03(11))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(22))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6911-107765" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(4))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7(b))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3151-108585" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3000-108585" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18726-107790" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(2))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(2)(ii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r91": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "http://asc.fasb.org/topic&trid=2122369" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794" } }, "version": "2.1" } ZIP 68 0001326190-22-000013-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001326190-22-000013-xbrl.zip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

40+&JCN-%!Q-R!.D:VH7:7@ _Y5:P)F MAX%BHB9A>D7&*T)#=D:X!L]1)1+HC0>. @FB5$6X4PO8='-RS+U-:EZTYIQ6 MM :/;Y$/#+Y03>*Y8ISV#O_8+LE#Y)&HLNPDZ^8T]+XBP%VI")L:5);.]N;*5([FSK'WC:+8"WVWX)X@F M"V0>N/Z2F62,V;9(PM?1YT^?!RXU>7+;R.(WC")/.LB[N1$E3>_QU'/20<#2 MXBF+6)Q2C7=:1?6<-!"IN#C*HA2CKK/4R#>O#@E1^]V&Q,?.W$'I#8T0C21Y M&FM/LG=,%BD1$_CD+E<1KW(!J[UV=$-S&V$%?J6H9+81BOCGJEMI6.[$V5[7B M='97-TM:L/DP_K$_?T#SVO\F=RBGK^.:HV@'!G%1EF&@@O;N#&%B.%Z[803= MYYAP.,N8Q;:)J_IH)TX5(CDPG&OQ0+/R;%?X=0Z B'_1%GO=& 4/:W?LTFR/F/ST 0Q7[H:Q.13^KHW\U>P*U;0I"KI3 M6*U&3JC,S>&@A3:"%1,+0XSU-'SK@N1YJ%U_29"["CPTP4H_-;6YGL(3UKW2 MI&DGR^0Y/-+[:>R@/\>; P0KX(?N"T#[0; &]UD:G-T/%#'7'$D;!#37RZJY MH%<*:&7Q [OR#MUY8'ZYS6Y(TH92 MM[GBHQ;9?S$ZO>@IUV/[$&R#4WH].FT3J),X"B/;Q[4%9)"8ZU9@X,7YZ/3\ MTU%!K8H5+3]J[>N5.Y47-Z\ .FZ8U![8_7&WUECYRFJ-=>RXJ\4?O5[4TL^5 M-&))YBK? 9F-4?PK[4PI/\H1 $HE9P90?&KGELD5'_"S=;-?,K^[T2J((YPR MV@'?7=]=Q[3B90U&*S(0&1GGQIT(VN"07FZ,IA!+Z;5?F^.K,-0;N.39HU>Y M+'J--$)$XI69!8AQ$*?-$>0"!5Z-QCL2C*GGD5ZUMA39_H\P< "8A[=())GE M,('):[=$)@Q#O[KC$0"M(3/:+;&E%:06N0+Y>09*S.WE;3:HNR&QX! M#B2);[?<5F_;4U*&+DRO]C/M>A6$S!L<7I2+0=" MS7BS\5R S@W9/DS1(F(=\WQ!!"&^?#$-'@V9H:ID5:M%_3#>L[?(N(9AZ94< M!2#5G8X$'#49D0%#9[=T=CF=$9*Y$FAYQ)EMCP0&5-AK]V_,I]7?5_=WTR@ZR@$,4? M>DG2N =^A*:/)K!,FC!P6'N\(\*C6AYEN&S'#=U-?<]L!]A5W$E_,78B]P4_ M6Y7)HWQ1SJ.CJ2O?\P.)3M]&0T M.CL[[4>_U)!#LVBU';6MU>148#?O;<"-"ZG6\D$+,^0I2IBRRI+Y GYM'G>0 M3745^"]H3T$3SGU.:E?BY.3CE' MU&&7^>GF="I]U]?FML.K$,3N,%@]<":\@;#I[#/E@I+*H*DK<#RMY?OYD.L%BM:33/3 MS65WDD ,'<])4 'PPT2<39T*HY/RO3?YU'OR+2O_L<$[&?94DD@(>"E8V;C:^- M1E.#&4;=Y!9X9&25Y81F]!F.HZ301AOX="/T,LBJN:%QU97Z+-J3[<\?/=MG M9H9O\U/:@:\:#!0MU15C-,;AS7KC!5N0V%X"U8.9[;5#1&?2+0-+CDD:H^,) MX*HH#C("JJM>4MN^H:(.@S0NT'A Q _?C<*GZ0\99!3[O"&D":,TKO*8<8!C MS^:;Z(>#CLW92F9HK!6$[%#-+JSJ\K#YP-HA MJ&OUWQ(+C4SJ79M7R:O%.Q^967&2H"-: 3A;V7YR2@N_D9N6.S_)AJ<:[9*? MUV]-M(-1A8M!!8>-="]WQ='? ;ZC!//Q"X#V$I _7ML1N+5=2-)G];RF*N?W MMNCT%(&B^VW=XBIJ,YW\SS] &.VJ&+'"+51^XFUUM,9%$LB&PO_W<< M5O$01/\#HB?@!$O?_2MU^Z:;9M4%7)O?/M[5T!][]:I2T[=Y0[4%=!5\S4JYQ.[Z$](L>E0G"P\H@?Z1F\K9&^F*Q7G2 M]XO.G5%O+J<^ M]YE&CB5-JB+UO8XJ?7D[VS=)T-2Y._?@^V]KIQ\6&UGBJ;W#WVZDI-,AQSL_ MZU?,IRCR3_WEG#7H_%^'Y6:6O6J-QXD9X'>M6I-M)O"VH'OFLJMB7 M7JOH(%@XR=R.$[6C?1M$:=A2B/@SLU]Q?=!5X.%'ZZR]INYPQXMLI1Q353A, MKR3Z[=FH_R#JHK= K>+GCW<-],KA=JNN];IFPD?;G9=4!_H%G>$\_$L.=>18 M5L&M=HNY]8;+K)(=F%_'73&DP^K89WM#FA MMW-ER/I.43M\[J_>= OYM3KAU=M#* KKTL <_+*S53B7OO,&YX:\:OD%T>"> M6-!O^S._M>H'%_ROF0[NCCAF[ALB-9M=&[&T:KYN^@+HB8-&/C]2N%WVL" $ MO_ZV(%KAH%ZOC*B9C)JRYT>Z7];3^SW,P$"HZ\)% 3F<:VAVL5GK9T&J@Q$P,7BV[<-/=E40/FLC==%G.Y^3BZG#A@PU\H&00E?&'6*AZX>NT^9#5.;WBB+[@D1V,?0U MT _/S'RAHW!3+?*P YOHX(.F([T[IFGVC*85$V=WV2*JJ;OYJ($@[I%Q[;ZU MT2-"C/[WFU?\(Y","3NK&1.6-'LN-TNG\18#-I@8L!VNA)YSCCTR&?339''X M8),0*%9?4>&W#%2@W?/+R'BP.Q]I5Z1.$? /3QQI-=,(9H%TER?([GA*??24,J/-3H9'?JQ?GR8 M?K#V7[5VG[5L?VXE'T;-]M\N/'-LVWM%=7#_F/*XM*>.Y7ZJT;^GI_RI#<)U M%14:%1?&U]$93@S3AQ:I+:/B@_I*VH;@CPEAE!,Z^M>AP-&O_GB$P3QVH@E, M]2W%^<)JIHW0)>2V%[845=V=E&2$AH&=SCRD^D.X;;41GY0DJ (4)$[G\R[6 M3_Q3[;Z%CI(3% 'ES%I!E\9"NR-7H%CA(,N3&">^PW=-<'H8)519.C5V/\S0 M%R:+W,4XYWJ"VE8;P=;:)N5)TUB6^0HAN-0XFM?^-S/T4X@L0AS=P%W$DJ-H M)W]Q45+.R0IH;T.C4P]LW\'<=7"P#;"H"0LH-M1%9(T>.(%UZ):M1%EKX OP8W"(N9L81KC1P M%8=1L ;PYM7Q8OR091R& /W??&:_,D,-I4?2%SY\))0AI(IXO2Y1J4>+ZQBF M8289I9231;G1\&4M09>1H5=9KORK8+UVR4W&[@E^:IB,U_ATEOP]V@>]'"@* MZ7&&#QVUI!N95[,%W,P8PTE=UDF6PU^BZ)_$:;)% 0:G=: M#K5+QK?(!_H+J5/Z' C1LB>1$6[';=GC4R8THS2<]!+X8.$>SKNB=7$57" S MOZ<4.@*2*+]1$B-'+\-0D?23*GN"PJ%IZ8A0:TR(@'20/R\[/V$[2R&5I8^%9NCKA3-LO2ET MS6"-0W[IE# C1D2[:8>SKD4N"KH*EFF,G-])1!T_QK_09B"8J)!(6;#51"K: M%[UD2^SWT?J^,B17\LSVIJ) CF!%I\(^$?$$D*WI.OB),2;YA^]&X=/T1U5" M$W8?4Y$A3[2B*P*-T"&#"@IC1B>CL[.>ZQ.W@P8.L=W%S75])JH*55$UO'88 M&N)IA\]-(^_*&W(LN05N!]O)V-H!NU6,*8[WL%>!TXT8+-)E'9+*L[3O?8;X$9+0VFC8 4Z+9&-'?S#JYK&DZ:$Z_HDO4% MP.= ^EKJ[Q\32:97,/_^_P%02P,$% @ G(%J53K4-P6(K@$ O6D4 !0 M !A;'0M,C R,C Y,S!X,3!Q+FAT;>R]:7/JN+_@)^>>\^^N"MF> ML'%V][YEP,PSF.F-R]@"C(T-'I@^_2,92" AA"20F,1=U3L,0I:6UOJM04M+ M__R_Q=C 9L!V-,O\]S_$'?X?#)B*I6KFX-__B(U4)/:?__?GOS#XG_\/AOWS M_T4BF-:.UPJ8:BG>&)@NIMA =H&*S35W>(\UK,E$-K$BL&W-,+"XK:D#L/D) M@=_!9]Q16"3R9[?#N.S WUOF_;;='?&T26+S$-2(('X1^"\2)TF,OB?Q>YK! M*L6G/UCW5-!ZMFPOMW.$OX7/CY$,=4?2+/WL*>L?U8$]TQ2 Y:P>EDW>8U1, M[A,QE8F0+(=':):)16(@AD<8AI%)CJ4!Q;$[/<$__PQ=2%A(7-.Y]YS(0)8G M_]X,77=R_^M77W9Z=Y8]^+7Y DV$B.!$A")N-C\Q-%-_:#^?S^\6/=OP?T/B M./4+?=V#)-LV7SC:7NLYM6U+_&H7"W5E",9R1#,=5S:5QU_!/E7WX8>[CXC^ M6G^Y;:HMW(@#E+V'P/=W VOV2S/A< "BVR_7EDVG;]ECV86TAAT1T0@>VYF7 M8[O/R0 _/$ ";?$2 0AJYYG;YC;HOT@PYA?\=G?6VA':/J62"K1]$FWG#;_P MASVEMTUEP]WK&+[7QF//!'>*-?;9%>? M7]N_Z[YZEKK\\X^JS3#'71K@WYNQ; \T,^):DWL*G[B_X5-_P:_WVJB:,S'D MY;UIF0 UT!;WJ#=@KU]JJ@I,_R5LD+)E!1JN0-,Z]J1EPBK8'Y^#/:+'N@W>DJ B4?C+0XO>WJIU.CE6&(PO\%,>0S'NT&5^X0U'FLN FB'-]4$[ ^" M.@1W#3@WF*;^>Y/QARX-VI'VM)X>R5KUO9/,.40ULO":-3V/F_FVZK2<1HU__R2= MH6P#1TJP%:>42S93>%D8SWIDS;3C_>K^S)*>[:C4Y $H>>,>L,O]I&9X M\-.Z/[2RYR+!18I\CQ#)5K=6+*2F*9R<5>11?,86NJG!S1^:(V-,E(I^ 4&( M78(04JS)TV 0Z\Z$LN$55M-N@1/E^<4(0C2:Q8:WZG7T2#W5=Y>S1&U1@)Q! M$Q2+0TW_F00A#G)(:I3IS?"J55G&R$J<<=B"1$G'S!X>*G2(9@L.W ]X, M\*+C37BV#0>;TAQ%-CI M@5334)#_F'(=:Y"I/4,Y>*M',!9);]PJMVJ1*$A M1R($"4W"SQQOC$6:3.GDL D[%/J)/#^0HFBT5>J%L9Y1D$^U7!XE-UM* M'=+QEEEW+44_+JB]>I5M]XV"#4?$=HK0-ROB"U^W$0S!4)^!7">;,>>9<7,8 M*\]BJV9%3Q1D8UAD .$UYPB:.(YZN_)*:C--!;X%MYGS-)U7YTN9*.->HTDI MN%0OTAH<@Z,-S']O(F>V=,BGA!!DVX1S=B!O^X38X/4>#=1Q7);244H3EU16 M8.->4JQ(D ;X'?W%\W^S8?.N^7/BL)EU'2LA>&HEE:$GY4E3\>;+>^:_Z(RKU!&6AP* M^;CJ2;3:;\EV%PYT]!V'5Z#O[6CH)_Q" MBX/_22-6? M<;6!_YULE, \:7L#?C(Q-,7_K*@9L 'TQS?=*_U9MYTU:Q4AH34Y'H>KJ/0? M'&+8Y?W6X$./!8KG:C/0L&6$ITEY^<0?9HM]J1XO=_%EU,XYJXS>[%*0GA42 M3[Y'NP>?G-!SKH&!9\BN92\?:.ML'E:NTI'EE'![(J@P!N[ARGSHOI>X19)7 MA<2B%Q7K3L,MFW:[$TD.WD_<]YI./+2;5-]V,N2-2BW)MBU)Q;9=R:L+%2^S M9+(K>KE1= +!M _E$SP;X*_] ) -^@ :NPIP_OR# FWWCA]#@R/&_,#;/0I/ M_7OC:..)@0)J_F=#/W()R1C9!@CO%HZ*(A/[7:R?MOL(_ZUC>;;_SH]KWF^( MY$]HEP,91!A\PX&;-ULN@G:."Q M!,B!T+>PQA.X_"BB@CCHD=<>;)(G7%CW M>I#W--E>UF4#E/M^F[W?9BOES6](R!*]GN8M!6].U/EIO%PELRC8M!X^\+V; M[3O(T/!]7P,VYI,!'(P_)[+Y?>?FZ8^WW3E@@&:Y?JO"ARV0!&CN>FB8JL%O M_7V0!_@]2IF;/P?,M75?__PZ^(BW//DEFCX^]8&H+S[MUY-Y_SI$Y(GO-CS0 MR)5M%_EGR)G!(S@;(9B'?AZ^>U@M]86FVV^V[[8]JG'\#8FK0%7 MAFBJ;O7FEE/K=DHJVO4Q+G=C.;UA5_I)<.U<=WBNYV2&=>S?]?W:",Y%J,=I M;K[Y[/7E555;:[&*K*E9,R%##2D;FV66J&96MV<12DQ$V[EV>[X&L IMN]+ ,2\E083W6=R/*T M;)/7+N G3_\ZN( Y+Z8/W$$U82\3CE[&C5:KU!M.%.K:A?VS,9T)P/H>QW1O M8FE3 P=9O-P#O7Y)-<128W#ER_Q%F!Z(U3X9TXL1+SFBIXN56)YWR[K;&D:' M\K4+> P_3)<4%FF1UI?'0N"W&LWNRL7">O%5^M+)T]M@OQG4FA]A2RF%G-V MILNZ9<3,6R^.A-@T5 MVO6N]LD*C8M;4Z]) DVTF8PWZN5HJ- "R@6%*3/P[.Z*UL>Z,FN7:DPK M7PF>0COGY'>VK<^BT<8YMRCERM,"7D[D/)HK4&F;OW:O_%,U&K%-@/GB!3ZN MTD2Z6\P5<+6FUVMC04LX\4S6O';+Y2M46F"6^V2=%A]D 1,9@9S@.46MSWB, M)W6O?NF_6*>=F0T>,Q#.@NKY3E3C1,N)X*U$HBCGYSFU.;CV)?]D5+](>/V\ MH"Y5LBLF'E,$G'3H56%12O/3X;4O\]> >C!6^V1,[Q8S7';5B9?%\JAOX$W2 ML4OIT$\)%!$0>I M57$\I_5\P74LH]MI5;AK=\B^"-,#L=HG8WI!++2ZKFR-=-!-9?%*C.]5R:O7 MYE^/Z9?A@@@7S>0B8Q<=-C?&4UQ-3LJ#@,6>SCQYZKRAITZ7&66Z>=W0M66J M%Z]D>,KRKAWI/ENA72*P>EZ%-JIJFI10+ )/&T0Y02J.KH:;*5>\VBQ,<12QIH+)D=]R\NIU\Z^8?@ MZUL3[5_0:*+>9' Y3CCBLC?-E%.-=FT1#S7:&Q88OU!T_:T+?%RE=<5(<5DW MVC*^Y)4QF9;%7-&X>F#[ I46F.4^6:-,AX_EK#YY_XJH&(4'S^:H.^WHS%S7BC-XJ=VJFNXR[ MJ>6U*^5/7-5 9"D]7]9(M#G4B&@V+]8[N:CLR,/.7 F7]:JR% X(*SLPW<5@ M18AENPT2Z=702LOAJE[5/N4!Q=KQJ@U;'3=TK[9*FSS5+!5;#^^:JV MIJ! 2&5\KI-BI<%8I#BD"Z$1?%T1J^?+RJ\R=L2CEP-<[H[&1CTRU(;U<%F_ MQ&/]VH(?>:+G=E1GS.L,W0.MZD;_Z@ZDGOFO4Y6<#9K?E"(B; '\#'.5+S MY4D,YOTU7UZIYG1F?E',:"7>Z-D=?$K0W5$D/RD,QH&-T%P!OQ!?QB^'ZRR> MF5]Z^9BV<-+X2FA-Y181 YSCV2&_O)-?B-/QA;@4OER67YAZ5!-'=J^G+[UR M2B_I"MW VOQ7 &_G(HOY^>7P_:+8[M2Q;943W'+]N:JF#WK-VU#N^F)S8PJ M,I;[O V_&O@6Y@.7%8&J*;+1 ,K0M QKL!3@2.R)K3D %52T;%?SQ@G+,.2> MA<8U SN];)[BLD9>[XYSIBA'\Z#).6*EOPI<< 02[OX0X1Y-W!W*?=RD/DCR M-8^?@>8_R0(+(,?W4NHJEA\9D@"BM)!))V/-@14XE TY_DIM2,3Q"BTZFNHQ,YP+GLB+F/42# M-4,=(,+[&?@\.OZ98Z_ M'/)6C69<$-A^51@/2#&SR";Q6"5$W@ @[]?Q(2,1#]71M_O5^">!J4*ZY:'= M6_7$933#:NE)SLD%SQ*X[W:=R%[V^4G\V^))AU[7UJ\^;\*+>^Y0$1 MJ )L__)-4]DF%N-CBT^##*4(+3863];,7&)5"Z2S%!C4.T+.2_$IP9QL?ZZ; M/NX17RS6]=$MXTXGVJA&RD55!R)#%TI"=^J!P 6F@I0($)Q8$+W#$>=+D.YS M"R(SCU%1$:3QQ20_C"9 (G!8%&2.H$_GB(OHLI?V3][+$;)4&*5PA^Y/NC MZU:PS)5B"\?7F8@Q65;&2X+8 :, M/0AX:),U)Y[K^ VHE[LL MGQ;/^Y*1M B])4EH?[VVGIE"S3!HIGHW$_Z1OZ M I!D[A)M:+N\J2))GJ ?[5RE]PA7D-BVY]^GF#7A+R$)G.TI[9[2&G'P>7$A M71F)>3QMC/M"X*R;XUS\ZBI_/%QZ&GL\8N<1_CCK8%YBK ,C.YLG+(-#Y#HI\)!Y\.B"=3<*C/)^7XF89%](\WN5%,3N)9:Y,3WV"A >2 M?8,3QEF? Y@W# M\J.;Y8E_H?*ZCU%64-VB/%OA8!#-,F4RD9[0/\<3/R<3OTCD[\G4QS/W7^9) MI,1YMS$$1=G6@5ON]\&.>5XE 8W'IJ"LDW9-=773K=;=P.G:$[@"*=T7I_D] M\ZI(B8P^,^?(X^9<18,/JLNF:JSKQ,CF$ID.4)04RP9IV_(F!6VLN4 M:')/ M,S92OVX6KVD&6-:1':ZY&G">7Y?^7C9\?2MXC4!)#5HQ6L_S[U1_8H=.LD0^ M.DT4VSHC<]((M+P!';QRZL?-QLLLST7A^'V"=_*3CVR(O\H2ES1LR0@9_1JQ M/\1;?6*.@U3"JVA3DEX9@0NW7$/%K.^U[7@Z!Y'586P\JB\X M,3U=,&IW(%OE47!-C"OBH.O>ICR=@_J59",=24]P'?!Q:SB"[7I,X#3[U7'0 MU6]KGLY!;%-.S%J-;$=(<(Y1$#N"UPY>>M8U#&9?OAIVIFQ*4LO! MH.=V(T7HDZ3(5B5V1K>JU&SV7 MKR7]O6SD%WBC:X 4[:W,M,@,!FVGW[&$%!7<[82@\L;76;^[H=@S7U'O9$MI MSL&74Y$QO%2S[>,-0=G+Z)0/>48O\$9IL:SDQD4S)^3C_+Q= MSPR9IASJE)_E\[S &XQ0L.%DAE,\#2IN9]BKYW.UD#<"[\VLDP,?=W+0YDUY M;@+;&6J3Q\V/A3*4S0&D@1]X'UJ&"EL\W7LYRC\[W8"6C,+I[L,E\JU5WE6: MCB-$G$FFSPBMHC@,G#V"-D[V*+/9!#A"FC/L>QQGU)T!/"'J.9ET/R5L=^/A M_%+%-7F$RL.+\G$!.$<:*1&<--+:B3FD'Y/2 M,U^=<6$I/8](,9W*:-&/U0C!BU(C*BL)FFJ:1YZN+H8"G)^GG M8^4K@Y"+,\PNQ:Z#89['I/BY;*O/+)^]HO9[)^$*I+Q4YERKAR\'ZDROEKH> M6 9VIWMO=H]VQHO3NXZ8S*FK6 /HC(7B M6?J&AJT"VHBP\0D&M7073.Z&FU M[@WH4M9.MP+KC+VPDD>G^*U7<[.*HRRKF^F%/-27E8&=&Q <.5/-;*JN=Y*3E7RN X(C\TNC(HU"N[)F:\TLKZ< PYE M OW$8]QQH3&ATJ(S$Y;YR(KVY'@\40X<8(7'N-_VY* !' M$O( @5>]#BYQHK<0-4=,E7I3(["H';0<.1^\2?J"V3>&[#CE_F8R9;NF#8:/ M"%>Q =K ^J318TK)AN;R=&YCA+.%B(>+S;3@8UWO#C'#< =GF30/:VG.O;# MDIKG\/XTH:5S>)W$5PIK2RI!!DY9!552SXS SRM]O4]27[>"MBT>2\2)U7P\ M(W*"C8^;.E?HZ<(\T0HL9)]9NL]A?VR;7,T5["]IA[CG:"9P'%Z!0N9HOCVS MY;CZ1'/[F@TJ0]D>R\_M;K3' (TN.!6T@0U7>NT4[F04^'R++H9MS*TBM!,= M%TKPIA=J/, 7%9=@=6;6675-"L287&#!Z 4ZK3GP!4)]G -?I?!& @Z3^#KT MVX$4KB 6BWZ:TY7E.,D0$IV6R"2$(NBZ?)42 PNAWZR^\I4E>3VMJ:X6JCPY MR].>3E;Y:DXB[#HA7)QWWFSM7$3*<:G@,/RJQ35P,;^LIS4!X1QZ^;T58T&2%[.-)9D6Y952Y#D1"-%*X"#MW1D) =?U M0;@U9.="">FIV3!5UI49E(=%=]2:S4/^#*A;]*$J+\0Y=V*Y MAXMJT?D!0H)(NQ]<.HDK:V" "FQ9]O(I7YZVV98P--._]M769*-D(?92Y)T= MWJ+>&N2D:-32&5S 1ZR24>;UP*;MG,AG+Q+MXEM@KY#[8IR.[SL'QTO+$]"/ MXLZUXQPDJ.X[2K4P&W83 D/PTBAFYJ-4<-.5?CI4[T>P=M'WP[[M<[3]D/OV M(825965("<28@,-AFCVVF&P*O9 I XJJ^R&'7:"\1H=K?4>V-O"_@Z0#\Z3M M#?@)(M.:@$\0M+&<-3OSO"<)D8[5CN24+#Z(A<;N>Q#TK;0/NJ,68"[F3?6 MR;?=C[48OB*MNM&NGA[6^J66E>\-,R%/7X2GCZY$T#E\MPCCALG7%X"=@>.Y M1:*4-N-J41R+3KPI1^;5,ODSF/"#OLW3]3WBVSQM^E'?YOGN?$HS95.!5DC6 M/R#^D)NZ_5ZL-VQ_6VPG 7/# 5*9FZO]4,\NKB'IGJ M=UM=WX6SQF-@HR\K,GP2JK5BV1,+:@.0!#WWV6J;JWZAFU?)$4XV2Y.\60#3 M!'5]HNR[5F^;^M6N_L<36,A+)[!T<^F$(Y;;"6BGZO6AJP^Z>#^X&'*&!!;R MIR6P7 .?7[R@'5<;X.RPU5/PJ39,+.KRJ)Q2@HN>85&Y8//Y>9BRY4D%F4M) M,1%,,IFY,52UJ!78*.T/Y8/+9*9>'/"TI=4JR.9DJ3.F1&:+4^C])4+ ^TZ, M?ODJFF?G2JFBDW%]IEBXW&*GE6Z.4.?E:S W?P8CG'C+& ^'I6J&YVHS\.BL M"0O%\%2@IFQKC/(6/=?OJ]S?7H51 79]*-N0FH<[V&.GS3&>#=\TQ4G"R.&+ MKCXM-:M434KG5GI@T>R"]'GDMST"73*;Z>ON,_MZ+CQ>J8;D-27*Y?B$7LX. MW7;&8BG._-E<^65U;T(N?5I%AZ:M;K.9CDE""Y\EVS%G\R5 M+U?XX7"S5FW.N*:@:7QGUD^Y^:07V'W)3^',+ZD7]'7<^4K%J$^W+TG2B-;+ M.=75F8%93>;4V%2)_&RL_#3[,K!UR[[V+T,N?6I?BI36%'I2*2DR@[)6*AC:O)#^V5H\K/D8"/M25N0%/8TN&&&: MS3*3>AUWVY.?C9L_HQ[EB3=:?[Y]6>"CU78K9F@B*%5225!(*6WY9V/EY]B7 M7WIW]M=SX7'[D($=C?F&]N7(9<>L"_GM%K6QOF: M();Q63V:7?4IA@ZY\_/LRQ_.E4?LRWXDVUMFG1D^G5G+1JF3II?9G\V9GV]? M?BEW'KZY[NOL2\,L1)M#E8J*"RIF*- MP4.IR(*U.0?_!/, RI[FX6!0=K3EWSLM+"9P^;:%-]AD)LZ Z:"-U\?C:JK) MSLOR(+!6XY%9[R'8:]/^GAD5'^>8-#"!+1N0W+-\5V\<^',:JI3,Z>W@MC?7F1 H\M5 MV,O7>O[..!/4?=_SX8Q=C;B9;'0V$>I*;R6I6:T]ZUPWSWPYS@1U/_9<.,/T MJG-3YIR:R&3)$1L96ZVT<]T\\Y4X$^#X__EP1LA76FYM*#HBZ%?&H_HP4B+3 M@8T"7 '.!#@N?S:WJ%5Y5M75)PXJLJ5DS(4\T5S8>LFM7 M>J[2M&51*ZE18VBM5DLCL'KIQ&M+CD[Y>WK8ASE%[$=S4T+I*F*>+-;;RF*9 M:5V^,N-5$6[_:HY+B%AZ-%EUEXUR7]?J%=/.%?EH0PY%[#,NO?@$3J&(4E?( MSBP!;U6S-+/,$[-6-X@B]G6$VXWE4)OB'^<5,7,NT^HLTR,4XA2Y-;-L<3*MB:VSGYO$ASLL@"'?X!8=PQ\,8YQ"Q M&8AV$PH[D?%TOJ" V% GV!*?$L1"V# *];D:3"(=6="V? *JVFWP(ERX$3L M2PE'[Q".N8B(Q3M>3Q\FZWV1C P,*9K):.ENJ,7>*6*GVCO$I0S%)YS2G5'= MN>O.9Q! (]U*2J\8S.4+*U\#X1XN-J+7^K[&$M%T9EACA7R]%F-[TX7:+P7! MI-ZK_D@@4CUT]/%::.>PDI]?LYLCQ$Z!L=J4KAEF1512V1P>OW:U?=%K:8-C MU)$2&7T DL%,L"4RO[K6 M@ 0J]'YXGI=4+F2$C)Z(D;M-S[R10#VKI/E>F(CE5*(;X?B(G@<:2$P71:M0 MN';3X_-@XFV;!)=QFC_$$37@RIH)U&W6[(8M)&TYSKMT<8%/B9;29]AL5A*O MG2T.S_6[\@9)/U@5CV\^K$)67H\4,D-YJ9-TBTGUK$2\E Q5R-OL"I(^T:[8 M;1H0P#CNR;&Y/X&"6)7G\>!%DG*\E>715H2TKV^.V#<*: MD\E<):_G5ZU\62Z93H\-7 (0G-;]H6FM@?7 O (B*[M-SQ98)9CUO8K4YLV; MUWS%)*W4K#1T\'I-67&-6G:D9\(U?_$&1>;DF/"ZZ3G$_*6;6XY?ILV[C2$H MRK8.W'*_#W:N*]C^'EU(6N[SR (9^ KIT0SS-5,2Y3YI/<_/D1K8P&^SZ8,N M*YK%BEI"]#*67&$'Q=[0#1S?/*C':DFYPXK*DQ(,;:0CTC<4O$OEB M8/L5U]4^,#4C$?A. @[Q!'POS]3PUPYHS*VG+,VE^*;MM<%5PF!6['C%E'IELA>3+!QMD!+<*0SRI.D9&(0Z&+7-AX.EO5G(C 30=XX"SLXY[9J[.\I&].?5DX M!IK S ->/+YY4/^&[#CE_B;V6[9KVF#XZ'M5;)#R3!6H3V+@KX/-P_&>2GGS M&S*33Y7J&3HGU!,1#I8"M:#) M/E>?%J>=H59J3&;ZE?F9EUF> MBWH6/V3?*9B9K(\GD5)FJA#+=W@@I.L9QZ7;,VUU^=2ARV8:G"?\^737N5$= M,/%HO,7A94\OE1J]'$L,@D"I2VQM;LZ(D _!O!*Q7-463;E+*1NA$<[*<-/%\MZ4* MA%9O+Z./// ?YZ#ZN8XT M3>?5^5(FRKC7:%(*+M6+M/:HEU3_![N=E;PQLFTL^YT#>_9[]&$2F-98,P]U MNY%%?[3'^MWKXM?^Z%^ER\-"3&"W$I-.6V)OU.K@P#%*A#)MU_.C^;.5V*PW M?/GVA7AXX&89$FS%*>62S11>%L:S'EDS[7C_^>*?2@SX1EO?66OC&C[&\$OW_+YYTJL]T,R(:TWNV3MRXOZ&JQ,9 K\'$K\CHO"C MG:?"'T^V/^U#H8GTY;%F+.__TX!JU\&@>XC5K+%L_N=V_0G\ZT!1Z__GM]_: MT58 =H0>XS_W'K[$T/_,^B_J7\:&-NC_>_/?C7("OG6@9;+W1/_UO6E!S\!8 M]SI?#W?ST_GY+Y M&?UV",10=VQT/>KS4&6[@G DKC6^)W8^0BN$WB.H0^H.$7__Z\>5^7V0_/Y@X9>[I.]9 MAKKYX<-S$3/-H&NW-C'OAYH*1PB[_-__CI$X]?MA32;G(M[KE#EE:M'S3DWV MT43JRRHGXPI4H#VE++F MCUC*-H0D5F_P#:'^SZ_>5Z[A&X9=%Q)B+=O("G6,+R4QH9W(\*6T@"7*Q6*V M7L^62U\X%Q\$HX\@N#^O_8FT9&<($<&US%LL>9>XPT@\2G-G'#S]GL$SIPT^ M5:X5__>_"0;_[0\8*CS3,GUK0U.PC1E60_#_OE0-S)21A:D"[3YI*1YRS9#W M=^-+84FV;6G FTPT KPEOA06=KM4G,[E^N"541-XI+HF\-Z S\XM)_+Y_N#^ M0EXS5C;!WP\\X/H:_Y4'-!!**;@C3PW)8G&^. I.^BC\IJ.^ISF@I;\&4>/T$:;/TD M[ DC]9$IX/Y[H\%Q0Q<#4LHR>K)A6&[/6MQX.RT'[ ML6?FT^.B[F73%6:: MB>I@8 %,S&+UY1BN\G]\W<*Q-/.H6PXP MXB]7W5W$KUJ,H\Q:%?E:0Z@5.EA-J)1K#:PBUNHB7VI@C3(&(;H!<7B-#P2% ME6L8$?U+_7O]03F%-3("MH/C#QC.)QH8_)K@*/I!!GQJ_$)\_LJR M,7<(L.F6C["UDXH!M,^/'8#+'2Z_5]$Y*MCI4)672VC, O-";%[Q!R6L0RD[ M3$XLJ,&<<$ "U]QH*:/8? 4O\Z_,N0XF[CIL1^&W&!K)9Z#L!1;/LD/L_4+L M;=BRN?;3GH&O(C4C);VKY$5FR9!:L\>!DO&9H)[E+UEHU?/OEX' M.'RGW&<]1/U+_/O*G+:/QESK)T\_4 [N_@!1D0W-07M=6%^#.L?T?%5Z:<=* M\"/P*?C$DO_ ';!--!?Q7%HA76%,::MYOS8C!'7^RC1PG(A09#3&OJC[=R)U M[R4^=_<"@#Y&\X@[@@/C Q&__?CGSF!ZLJ(/; OR\A.6W_:(U/*S[GRPOF/@ MHS;Z.WH'>]X8!'#JX($%,-ES+?3,=^'^9#[H'NOC0>88RO_WLB&&T$\ M@W,4OB#P*8Z3=Z,)Y!7XQ;\W:6BA##7E9CM<57,FAKR\UTPD]I&>82GZ[R>! MU U!./J.CJ&'8;_.)7NQ]TR:W)GTI>6I!@9^>7W31=OYNP;,K+*4F\5A2?>, MU6 :=?/I%?>:3/&%1K98%$O"[1K%LJ7$W>5,Z[<2]]6(AK"0%1=#A$!A_$?2 M8+*#U2= 05N"*J:9F.8Z6&+H.TR/T8\?#Q>;H',TIO8XBNU)?8H@)1HHE"3' MHK(4PRF65N0834>W0>?U+QJ*5%W-2HR]J-6%::K=G]3E9H2(\1(IX4];+O%4 MU%-99X*GA_VLD/:(7B4_0$E$3UOJ6D]:N0*=%+P84W0&=BL9;PXD^GF?W297 M[T0'=@W/3ZCN.%GLD7)C($6?MW2T2LD8*'P"+\\3&6^@VI4FAUING[X+F:>Y M9#MH@99ZLRAH/TA9[R/M[[GM[M>L=]SP9WMEKKU]ZLX2WQSS]JRM5Q>%/>Q( MS-G]B:<"^;*9]-RY>3+HM7QLIW['L)<=^:D[.<3INS3'Y_>X*'3LCB*O0_AXD,%!=80FMC5#:O7LL:^UAD8WYMB3C9OB%R[RD_#L9<)2 M-PH; E-EN)#:I&1WA B(CY+9'FO1?1X^&#^\7<4=WJU*0OB?RRAIX06E'221 M?+ H7UJ]#X#+IPO?QQCS GS7D!?931[4.N5^U^V"'&# MK/[Y0@&'!W[Z0/>@R!^O/9!-;>6__WL_"!<0C&!.PXB (<+9.2Q[5[NKWV&; MR^[M +'4'L1@)>ON[P/!W&#(_1G3?9CSIOL$2>).2"MXF2:7(D'@U?GGL56UT1&S]IZ"9@-B)BXT;N5*_*X.VL&2-O*KDZXLD]SR1YYC)PQ$X MEC"LR03J^IHEJP<-G].[^Z3(^W.RD#MD:=FUM&!4!Q6=[%;UEJQ-Z6JL^B:R MU#W-!6MU3.)$_8-4N?UFD98U9!,Z/<\>7((B7^'1;DCF6[UENP(?IIG*;NS9F.=::D=J$R*9<+/Y M+-&,+Z9OD[&B;"\-V3PL6T%3F:$C^PD26K$@;QM=;;(7-S$:FDP.>DI;3%<+ M[$I=Y;AR;H[NI7FC%QMC8S_7@=V0&.V:5&PHS-I$-C!A 10/[25@Y3XT\($3 M>H@!7D(H&!B2C$/NUWES:4XQ?.G3C=H@)$@<@X:_+FV'(-.#MX'\B&N^$HV, MJ6*3I0L1?9EJB@,[4^IJL;_+VZ%H1ODC&'AL_$Z4C!!U].389/$%^W+9&PD*POQVL 0PP023" MUC2ZQ;*F8G@(D##$.4\$_T(;V?XG5[&1_:5Y+Z\M\&.5!,SVEQK80,4FGNUX M*%7!M3#8 I%@DU%)_M7;Y%)"[8QR#7G%O?_B]+*70?_#1]X R_2YF*Q*)*M0 M$AU3%:E']""B<*Q"QAC ,+CR;%<_(:@:F\?3>D*+23//IBR^7]ULGNVU]!I9 M%JQZ.(.7W;%"+3.EIML:(/!ZVC+:'93LJ-9C=;DM-'F^5++P0G6S/8):GBL[ M8$,Q/SG 9^#-!^OD /^3_02"W;3M;0K!W6,:5.R=.01CN#;&5GHI]HZE7S* M,/]QV,,K7^2.6E9[?:/$<^)"?:-Q4V_N>V/:/R48?4>_@V8GGJ/UU_+%;^W- MDATYA/O\RQ=G33Y.FSS7P>/W)&]I^YCA9^RB"WDT!669:^[Z^#60E2&FH$*6 M4&.?XF\SX>/L2Y"F:,PJN]6AE/#/AL1<@[3%^< M;Q(L#YMCG#_:]96:\%M+T6^QB6QC,]GP /9_\3M4. <=5\'\FB-O.*44XF]0 M^6<#WVOT?F >:!JGP+#3; OE1:LZKC.C3G^%F(=XA7GX0N-,;/&S5,(%4A61 M'KC(GLX6(T"9U68A)C7R>4$$TU593>KZO!K?9FL?XYP&=%1+?#W) M5[&T8?5D UL7Z7N5G7Y4P'+#"YNCN"^?(3Y&Z:RIHNP;@/66F#($BHZ-46&' M^1#XR6@H8F _GH3XB]@$$X:RXQ__4C'9,& +=/X5122FGH;B$:Z%]<"F >QX M/R1!H=RQG4.>F\#$3F1CRTPH6(%,&73($U/]ZPO\IA,;*, W- ERW8=_"MW! M_H(]0];'' ]:.L[00D=L>RFIUF2;&\U#%T]%/Q>/W\]YB',>]W-$+#][]MX1.G'Y\'!Q+?B.!1_P.67VLN2Z4 M$&! EKN4%'O!ZRH1QK87^@ENUDDDB+O-FW=H>; &<@3= SK4]!A/8D'>0?.WU\D MR#LD1Q3?R/5N"H4J2EDG&7'P_'2\)%I&5&%[!^L/?$M!/M]@SB_-3[,]G@GS MFV44BH&,&?#W ),5!6-'/C"&4/1AL^PMTH"\J]? MI_D6:6W8&=1M:*0#;&!;X_?H.ZF_@CTP%?[7!R^/;-D3Z>M/XA;%N6VKF#@)!GSE"8AM;9-< N;O,3LG()26)4#$"(GF8JH4Z\N$%(MQ/2I*D(K"1I]N:Y1'I6E72G<< M0;:ME35?Q56J<7"KI"LUO$1FNA!%+S;C6^,ZV=7K_*&M$BFSXG2NHQC",A,K M9%M&:6(7Y[ E];2E8BA<:YZ-=G52X0RR&_6&>0UMOSP[4%I/-F*9$ML0A):' M7+H.$XDZ6Y=UKV5\F,[1];D\$2+NN-YK&J/N1$)'3Y\]G4A4^RN],3=PTBVJ MB=R@I6?[!3SGQ]!J;X5^/7 M"6?\7MF-\*,8_K(C-W=@VJ1=R37Z?12^H-\DDJ_$5C]P5ND*-- E(F?! M1O/@$^7+8@R!IDH@$5_8A,[7P?%U_'S]^FL]/ZA[;4_8UTZ#^8EK\/[CGKK3,XFO6]"P<*@ENV_RQCB1X^U^"CX6,Q M$\[40G89I)KOCYBRJ6BR@8)'J$X<:NQL+I1S,'2R7U./GA>B_I+WTW+VML*P MCWJX5YT,X6^T.D-@&-MEQ_Z"B^EO>*XKP[ZPG0A)]R15H . M>RCD9Q),.=!I=^J\*N1'QJ ?=RK,@#V8$O3B30:',.C(O08?V?*_4!;">?'F MY?W?UWB9]W?42];,O[YDDSFSOL+D%C&:#; Y^F?#1RD_1P1B"+KWT>>5MUPP MN<=^IC=6+5<%B@8=EAO,@4H>D@+?Y\3-G:T$JI^ 6*_&$M%T9EACA7R]%F-[ MTX7:+_$WV*8;Y]^;;"EU($W-SSGW;VJN^R,L>ZZ/81#,=CB3)(?,O%Q/+46Y MP(_-:5VUN@9_\X?F;HDH=XM'F2UK;>GP9YVJ[FS%TGY^5E8Y-=_]%K,>1W7. M%($+W,9XZ,+%4[.=C^[6O-\\?J#5MD"[?Q3W;83S*[IO=GU.-3#P-UCPC\> M_\]_G700>>="S^UEIO[J#4"D9P-9C\A]N%CWLC&7E\[&+.:(.YSYG\>;>3:3 MH-"*^9>I8H\O'P\GGWA#*X'[1O=^ X9R#%:5GH2JY#09F<)5>)HA9:(&$FSO6BL'\-CF[21\U!M=[:/ MUZ.\7);Q<*W^A^R@-8&_:'C^NA./]R T^'A!0)?]),JEAE!JU-]PY=7KZ39O M.A[-L7<,^=$JZ[&[-QU@WF'&G4=!(\#N&]9\BV';]Q%T2=?]&F_FD"JO"OK# M]W(/:@'/W=1,N+ATGR<18*=6PZGE>6+,'?ZF4][A IQW :)WL1="02']/TS_ MMQ0:>R,0?1X!8N<*M'Y ZJ]ZMFL1>^V\Y"<2X_ Q]]/KWE2@%?W^TM"!973F M1S'Z!6:[Q^AO/+M[(4J\QN;GH%-MGDNPQX,C M5^%KC6PJ6^)+B2Q?R);03>T\NA!4BN%1ZADFO.C@;5$"=K?Q9^ZPAVZQG7[7 M&"*?PF1[VU=OM5G.SDJ^+W*$DRY5!#R$SN\UV^OBZO/@XQ7P^ ,B9ETP)E+; M?3R_2K9_FESB&(*-'=S]?3WLA3K=[$O=/8MX79-P7)9,#_UACQV^C5R!ER[B M:B4DU *A%OCN6N#G\/@VT0M[K##W@.V)+F23?$-(QOD"-.*%>D80&G6) MI$DZ=KAXT*O@GK!,WR_T$_?CL@&1'F#U(0"N@V[XM?I8'4Q3PZ!TAKE"=@G8#G^!H"I=#98 A, M!Q5$*EC.8QTP%PX5^(U,S038IBK1.N/S@.Y!#9%VV55"WTS3D-]"S$)-$VJ: M4--\=Z9_5=,D,GPI+=2SI7JCG,AGRF?7- D_$=]!B>9^=NS0,E1@.YOD54R8 M>I#^H;9Y44RI;R%JH;8)M?/"1. M/2J6P\?.7U.'$]J/#_!=BNTC MD&ORJ%&@HE'7Y3-0FQIP/./I9LTW4R]$J%^N0W)"_?+C]0M51;5W--<_C @! M"KXU-N\0NAF6X]D?U2_4-](OEZ/7;L>^JMCI&GOH&\Y#[EF>N[F$#JMICO[- MU <9[HUH_9IWWS\QGRXV,4-L],,\R.!?C M;CYP9#Y[A_F]AN?EK]M:#'5@J -_E$=$%,! -GQSW+_XV9%0A>%8[*/.T+R'8F*XC&*^S#R\]\)^L]& M(-0/MNGHNR$^_5IJ/+.N>7V5J?&A(@@5P;=7!*1HKJ]T #90Z[(!'*N_/A17 M!XIG:ZX&G#!OZS/HM=LQYO>,DJ\V!Q0?._=W443'+\B_\25^@%JY%MD*]4>H M/WZ4_J"2H"][ANM-++,.3,VR'Z%*H@F2(\*LK,M3:].M@XFP8VS=\X[."/5# M4&0GU ^A?OA1^H$N:B:HRWW@+G=R0R6&8CG\G44)OVGBU?D)A7K$UEWN)N:& MVB HDA)J@U ;_"AM$"VC&U>SYOJ:5'0!+Q7E"/;#&;C1;Z0(SDLCOS-LI[<0 M_8,B&2'ZA^C_H]"?$19#.%'7D:(<17$?-O^9;X3ZYZ'-MI/O!O)AE:CK8.D0 MY,\)\D]R*0CJCKO:9(KOR.T/ %[/IDM\0ZP)=8DE"/\.OG> =QU.47:_8X0F MK+-Q'0P=PO?YX/N7*_<,$!A@/3OY1I[C:OWE^B/-A ]V[RGF1)8B'MH]7+1, MGD[D3YG+<:J?8?"JYDP,>0GQWP2_WS830S-!9&,5G"K%^!N8V+\9?>>V=\4 MLHW$=_ADU2C4Z^?>^/[V.][_SW_MSJ4G*_K MCQ3C2B68=GWVRN/=R:Y(2WI MH]( 1'HVD/6(W'>!?2\;>HQ?+N9&$VLTW(ONW(^?E.;%WOV4J.<>)^)U$"8ZE=4AM\>O&GR*.OND_H0 M!65,4_^]D3@JIO29'BGU9)R6:,!0$D<#59)9G%)IENK'%'0("#UU_8M7[V1& M3<]#X%W"^.=1GU <@=&&XJ=<[3S93N'UVT&_9 Z[)\L.UC\]HTIX-JQ7KB7G M"XULL2B6A-L-E4N)NQV*GG GWP5)^LK8=P>';4:'K8=W&26[&<3+.O;IRC\Y ME+U_!/NOK(FY0\M#=4J<6PPL% !_Z QE>UV4:@+LS3M5=N6_UT>R/VE:3\R@ M9_-ZASK;X!(>93F9(R :J6Q,HF5"EF)])BK%");#V2A'X%1_#Y<:BI2+Z]Q, M8Q<)@1R8]'"<5D2:G4N$1#YM2>0 72^,2%.HYXPZJ"='U;1;A2VC3UM&HD65 M9K3\%)=SY1'H3?"FW)Q+Y/,^*^F43#6*:077%FZ2,TO%:C:"6C[KD](RTV&V M6>X(M"HE8;M3DROVNDQE(M(0_;;D8E+)V M/;[(B7(VV[/5F3;!I;D4?=X2;U0C(\Y.1P2O:A>C>C0Y65;G$O.\92W;K--S M-5;3O8Z693(QT).I*FSY;)RIBFAGNPF6$D"OSM= )Y]>#%#+9W-/&*-DJ=1A M-3PR8Y-.TIDEIBXOL0=FU.G4S6)J7L3'B0GK56.M\C0YEV+/6[8TO1#+Q.*V MGM<:3;/3]"J#WESBGK<<*JL8( A%%"-3*YY4H_&EC%=A2^9IRY*H7.>DV#*:8'D)?PYYU.I2K9;:E"%X\,[-BX:?.K20(V)9XWYSW )K4V.Z7K[7$5GPYXR-1@F.[HD/$/\$FGZHY'BUE"%)F" MVA#Z<]"QB[#7 XP2GS.S7+Q6HX7R@C#S%;N06%9AKP=6=YD5)ZP.1+)6*8-, MR=CAB?*%)JAWO1Z=D=LB6;#C6 TR8+4WH :L)8W'*ID8]SV(' MW 12X 3MC.ZD8,&O1TT@^NZ1%36I,=3:2ZQHY MV.L!)BSD"W$CUQI-\;%;'=ETS:;4"236 2:T^9(Y%X>SICYN>7QS4C [-!KK M 29L) IN(E.>VWJ:4'*3[C"O3(:PZ0%V*;F26^@Y\D#W5NTDN5 C/(]6ZP"[ M4.G6R.Q4)4L$Q08MC')N6X%-J0/L,C.2]0A?HV21J>=]V/3 PBIR MI1'GQJ6DD$YFQUEZFI0[;=CTP&HY\5J)5N M?5#5\W@^&B>6G8DCSE-SU/09O];;F6Z=U[I9D8DT/4O46H,8X?>ZY5<__O/@ M=?HN(O(X#7GB@/OMBUW# ED-&P<-N2K*VL79=PEW F4;?_"Y!_Y\X^"538.] MN!Q+W-$OUNUYXF3N]&_!/ON&-=]:,=OWD;DM3^[7#O0<$N%5QW436? ?O&TJ M]QS+\%SP&0XK?H='#YMJ^^&KM\D/ V\_C+B! [ M% 0^Z[[]>Q']PR2)O4:18Y'B=6C^^;\/(>'MY%^O;OJJJ))W^%$,/0LEC@7V MWTB;ASM'-T>M\=L7:!-0QOA*6?F![)($RBZW$ >Y)0344&X^16XV,;5M#LYD M@?D796+;A([KD2MTV7,(N2'KO(]UB!!_0_P-[99CR2+BS@W)(1FA>BQ]= M*O/FNHCT2C#G.Q'I?8KH,3_W_K\5!8!^_VO%[!BN\/6ZGRYW1D@)V/2W#MZ9 MT"%@LWO.^=NG)."L>K8&>\T 8P;03-$39-.);![SB7 14BV4I&N2I.\M&D>. MD+VTZD_7_OIN9O$ MK/6#[ S]@&FGC:3C8?36=_0G/L"A@ZBW?=_OZLE1SV=*?:/MD!GM5.V MK* D&,PS-;>&CK.*\(54=R'WR[8JB?6DE(W0B>9D.6GB>70$AM#J[66T>H/Y M*=V+]:]X1RKW)0XEPJ/M'ZE1'3#Q:+S%X65/+Y4:O1Q+#.8WF H4;2P;SK\W M$>H&6Y?Q^_=&6[CWIC=6+7?S_0UFRF-($,^)#&1Y37ML9U6/.;D6+HE:?SP?ZPFKD2WS$H,.3! D>TLS MT7]^[5/BV[ILH8R',GX&&2=(=(0%;=1))6*YJBV:;ET$PU)IHI3LF:Q5/UW( M-4M0C$(Q5\#SA4ET1II,EY\B(6>@D'/X+8431X3\FKS7M752 XYK:XH+UO;) MMW .O@RCH3U"T9XOVY0 RC;SBFQ?>Y.@ XC9(M3?!)LB/4 MTW.C'>M.IO$QCX9U\X>E;RF&#,,IH71>@72B]2+([Y9"P2L*' MT_6V@ &@W M] P0&ORAP1\:_%^D5;?R6'L0Q[1M.<[+XY$2.2MGT;P>R0J$SA I+SVM(OF&'CM-'HO7 M79^WGC45:PPP5U[X6Q&U_Y7'D]])Z+FC X7:#.Q8*0X6N@FAFQ \-^$ZS W9 M<._7PM:0%\!9!Q&!;"O#))@!PYH@=SZ[%;M'L'H9IVBNG&[VQKD]C'7T$T'N&R'6#X"?R^T#O8(S4:(6Q\-S*J%@_EC!O. .SBN2&1M9)@"\6-0]RQR( MVC0BS"S_LD@&%=% M;@GV@KF; >/K4+Q#\0Z^;?)&^9['&%X=$;DE7B^R;$H6:GIE[E]6C4Z#W-)T M[)L$*_!-=@E92+9#$G($C5'L !-H=C1P.@U!4[VLCS"[(XS%SND MH.RJEH<"4D& KC.67/[J:08 HRZ<&G)HYWE2HB##2X1? MMI0DH[428)$;N- M';T6X5O$6X[>A%G(\O%L(=O("G6,+R6Q>J.U/ZB].Y&58?/';FW+AK79!#:INY+"R%L,C M!WQ9)AO/%&1;)'DY@AOJ-*6GYW!,ZYSXBZ:L!8R90YD.93K8D=53A7J6BUE@ MV1A)0CW66DSJ<[5-N#P2:A1IO<4O<"_45QH="=@4/A YIW Y'$T%MHPF%1K_ M5VK\_\2+[D^HT!YR<+;'V7>(#M@:,E"'?BR:%G M$>::AKFF5Q9R0)5;-V*^*2[F;*N+;9"Q\"CA!T!RV&BY5L=;U770!UVCY;%T M(3.02+\2(4'?4F1XZ4,(%"%07+^-]5&D6*4DN]091[K".-98E)79PFOVJ@@I MT'D]_);XWM4(+V$H_42P^T;(]0-@Z&);)#M8\[('I]5:T2DQ7:FZEP8\$^'R M>+PSETB_+B$1O67I\+['4#A_K'!>+@YSDG3F$^5%/\+A%3%!J_$^WF7U8;.* MI!,9!+%;DOWVI0G7!_@-RQRL;X4.HRFADQ0Z2==OG?AR78!BC:ZD3H*>>_3X MKJ;+6DZ<>U/<<],ET*YT5LT$-%/H]6T.4?P8#H;H$*)#B [791Z]#1[D6C9; M[D4X1M?H<78R<_5F?E)%\+ NC!C]+OD@>W&3,%YRB5/!WQO&0LSZC'C+H=K, M;*]HC):2K(^;I69)%9MLMP ARJ^=2.*WY-'BK:%4AU(=2O57!VH.B/6 S\NC M>:]0%ABMM4HD5]I4,.=(K)'EP=VRU#=.@5D_(F&-QYJ+JE:OLU^4;3J1 DF& M_56R7( 1]-^A/_:ML^K#0\\A9X><_6TY^YJZA);::I MP/=/G:%L T>:IO/J?"D39=QK-"D%E^I%6AM\-/B4+:7>X*:NI^ KO8ILEVWH M1[M ;Y:I2:T[J8:%CE).\.JW2:O_D#F03'B0,._),/L(EL8S/TF-^G MAC42S93>%D8SWIDS;3C_0_'+=]--9]$#N^Y0\N&DJ,>I%9<2+1S M9FPXT9E>,2DW>0WGY_/76.;],_\Y]8/)7T'CCI"ED9>2,[F?7LN:MG2N%5P1$)(0>RE\5N.HVY9YOF6 MP)9W]HRKB .4B+:(K"VK^XS_1^K5JVR[;Q1L2 ZV4V1DLH@O!D\-LP_IU/5; MU!$<)"20L?YD4_5S\]'-'\TGP8.=Y_]9K^_KLV@.8^59;-6LZ(F"; R+#""\ MYOPK9F%YKH,X#EHF3Z?B8%8?JX.)"\8]8*]-) J_7;] TN?/-@F4W>^)Q^^) M6PPNZ@3 -9X!8QD&E+YU0.FKSDT'+/)T[?N].TCO6Y@'=H>Z2UXLD[E>51\O MFJW1P,:S3F4ND3&TZ7NL%G0H]Z'6@2L@&]8$V-:":FR!/-E8TPBAE&,;\ZBGGM1L:C M=%6@<&7-Q%JT#D#.E)%7_1C'.&(D1DX;FL2TZ>A (CG?UF"8VVCT4"0K%-%0 M1'^$B%ZP;.'),II&//0(%Y2/"^IFANZ/=\:[_GAR708']=EXE1 ZZLF4 59-N$E'-V!#2YED^( M9'#JL-L#D%9,%)>]=,[5\'+<4R(24&(B/4!CA68'%65N2?*YOQ,F@X82'TK\ MUUDL'Q/Y$9\K1[U5M8N/55_FJ%N"?>YI_'W5,8X=FV53 MW-$:3VPP!*:CS0!F6(YSBYG@?);,CP2Q\,1.$$[L7+U!LR.MZ]IKN[*:-:'H M@@(4V!)PR_V&O#@&=?,\L9S3T5Y>8%*#?,%+91:N/$>PC((JMQ3^O'3C^6R; M$ -"#/CF&'#1NR3.!0(,6#9G=I92Q,2D79M+!.O,:1X-G$$@@-//<[X^;.T$ MQJ#?JSC@O'BF(G3HPFHK8;65*]UDVCTJ)?CB? %^SL742+AC91%^JC@:2OAQ(*\T91E2][^." M7P&!NR6H8YENUQ0,>JGZDI_=^PFVT8]$O#T!IZ" JY;7,T @\.V,5PE^]30# M &2?49F)-]634 U/M;IY:AH%HMQ-"^-I;BCH 2G6=*JD5YE.N1%/REV\-:K5]9A;Y?NU.9)TM)M%Q&YCS*OVRR\7W5=Z M@14:>8ZK]9?KCS03"J![O\^K3R5V_9/-_Y^]+VU.7$G6_GXC[G\@>NY$S$18 M/=J7GO-VA "Q@P AMB\*(162T(H6!/SZ5Q)VM[OE=B_'V(#KQ(2'QFDIJRKS MR:S,K*Q#IA<5SX]SYRO,OO8J5O8R(RRJD,,X/X\59^2)IR:ZE:?M\HM3\YU! MD<-;6Y[J:581T'B2Y@ US('' M_.^WZT[DKWV '?2?9T&/^^6]'R=./N#FE]7$'C%=_/S?_WG,_-?='*+YCA]^ M>D# 1Z,R3V?P\ (,#8"L0J#:B+K.7OQ)=5+U$#WL"[B/Q .X?OH"HD0A7^A' M@OIGY='G?#I*<^FJ>^31C-UC+^* =?SI_L\>OBMP\\N7?E14_WT*@:/FY_?R MIW_SW&)A8C_XA&,?"_G/_GD_,!+[R%!G6JKOU(SXNC!_J14SS.'X'Q.Q]F/A M?.XPY"0'O%S+\LLC<_7Y(J?JK\CJMU/]U RJ!3XK. X Q:%K945KM$+2[$I9 MD1RM$!RMJBA* ISB/IS>^C*S]GBTJ\QT_%CB3W/)]R;M?E\>"/>G.=N#VL=B M DX#J(D#2>RUZ_Q$J$N3[&=?&$PDL2$.A3$_:6>_Y0?UFMA_TS$\9K+REG53$<94U??O/7Q>#]\_I?\@/S__NL_ MJ]PUD?UB<]RX"# $([_^5&3'UC,/Z MN=-1&E<)01X/[1>MVX/&K\"*9G5-85!UI9 8JRJK-88J'+?"2(K1&8Y:W6N+ M^N7L@[1(O-!I)W*B30G42Z(9VTR5S,?\GE+ W D-5&,N(*U5LS'3-[1ZR"G9 M[RFY&C6<326Q+D@HHU)'9AW@**_@Y6>.DZ[#M;OKAIU0BC>;;#"WD_< +3\S M%97#UB8C8(N=!M";^XVB=$<*47ZF8C,;-L;\F@#,.B,IC"GXC9R2^IZRND5" MJK;3:D(3G:=8$M8EL,]VJN6WMQ4-F80J7160M#NE'8R.C+ V)[NRZ[H0=KF0P85%,1/%IN,B?61I2BVP>N\#L M' 0'K=3 QCKN3N=-F1Q9H-)X H*)AL*51[2O#EDHEA8UP5Z MT;2BQ7(^DPZ\0I5,(56Z0#A:=G$*.T M/N"5XHSAMY1L<\]&'GJ8RUU![)O=GF6$NYR2^YY2XPZDNC /D0V2P;];&?H@4/*V/2T;8^R M-2J3'BA\3]7!IB=;NHQ,;:M#]@ZC?,=8(EVMF_UFW1H(*(X'"L=$C-&W,P:( M,JFT3HD=,U_NA5EJ5^DZ"Q:29RC8$_(LT[.=5P?TRI8("VLPX7X33'@%>T). M!O5XK:^KXYTP0QR4%AKXF.IGI$\(RI# 6&/N+YKR3&+(=DH.AD[.ZQ.2PL^3 M4;()-I@-#D37T3J-A886I*5E%7;UQ4K?!KB=:'1SVF!J-6%1D&(E[5-Q$^V1 M77(N)\/>ZCC$ZX>CD$WL$Q(H-FJ#07/>T6T0CB9.B-$)06:/?4((%'HZ[PUK MM9U=HQM4->X&_1F=@>030M!?KXV&S,_V]DS'%N0<#';IW,A)2[QN*(7D#GNY M+;C,(5D26[[O.8I*&V MNQ2Z:CL(V-ZLX+4,%ON%+>B-]!"AB: OA^LMWFN!-+_8O#2N9OTP4CNT@ K; M&M%AG=I^53VF^:6=#Z1%<.#+KN<4_\EV/(X:1.#3PX?']CC?)-QO$')763NY MV-]N21[%A^[W(]]L^3XR9+&5B,.'%]\_$#L9[%_+MI#<1^K9TV&/_/M'S_>S M9ZX=/WTP]P__1O)HV*?3'B[-YN&G>Z?[W6SQX@=2=97MXY,8O,:>Z<>!T4=_ M]^L1ED=;X;\92\P8@^MR@>N"?42?/1@*U^6-U@7]2,"%N<2%^4@3<%TN<5T@ MD%WDND @N]"%@4!VH>L"@>PBUP4"V84N# 2R"UT7"&07N2X0R"YS86",[*SK M\IN%^S\-);_9)+"_,0EG%<@WG8$_S=H_3(GF._F7_^\#]>%/2Y_)C\1YCW:P M3Y9O/#MASQ5L3,P0@$H_^X49501/!WKE2U'&>7TP*"G7)2D#RSN/H-PNI$#S M F7A'*#QA@=&7QA4?G3?"+1!4)PN3YQN%YV@I8*R\!2TX'\*+1A6'"RY'6C) MS_1>BU5B?R8YSPWT\16IWUZ7NH)"\G,AP:Y)2%YPZ%!L(+9 (;D.;+E=W^7/ M_-@+:\PU!CO@)2!ZL96^L/&]17<.]/(:S+]0/P[B;4;VIBTXZDFHYL]1& 6[ M[[;C/VJ](Z^ISA;3EIKYRL_IV+95Y"]TVL MQ@X[EHG:35IH61WQJ,ZU7/?S]H)4^8;T:];^WVK)#>$ PL$+P0'VI"LP,&G1 MW/:3I3T;+5+1%?%.KV&\,1PLQP;0V!;2MF>MZK'K^'+"HVD&!]R'S\]>GG=] M: "5'RK_ZRG_=[Y PVOTV.Z"!T)3:D4Q.=]91^&M?8%):K H7>7W*%C@NW"@ MV4SC6+3[P#-GX XCRM>QP$# U:>0J9OD\A M1T --;-HNJIG^U;'#_(.X7 G>=.AI)>&J'<;3WJEO/))27E/KW]54>$4'W@B MK8SGNZ%I?7W>$T#!U#?8?Z?L&YY-_3=YDR&&.T M,PFAM@7ZC%W-/9-(,WW/+W7A[G"4OBE]OXHM,@2 VP2 5\H>_QX "*C(8?V- M(Z"SR%YV&,%.N<+@"!_-*W/%:CZJ[E65$< M%NV8WGD=P9PRY0;Z'>7HW>GC=Z\OMZ2V\<(\)6"HO.%EHW6K!=J3DPE.(2 M(O(..X\S!8^?,:( M.P(_8QP$6F"HN%>CN.<-9_R^XJYP@-@'K6')R#JQC7Z?234V]YR+6G?LCB;. M&-"X2LV]B>J3MANH5IC'NBJ.'T653-#SJ^OC,"F6&+$\) A](P01['%P_GCU M&[9 N81X]EL/__<,1"X6&/YR1:)0+:!:7.3PWYU:7,66_0(%!>K)^](3J!90 M+>"V^]&V^^MN2ESW?,_H95MN/3]C'DT!Y"^VO5 M(GSI"G$?0HV>@/%:&U5-,V2//G"KZAZ54ZZ S-JC67+E)@ZUF#T8X//>*(_?":(.^*T-SCS:Q P8\F].+&6G'TP]7ZG MEAY4/2X@X#Y00Y9+VJ\: J#&0XU_;8U_I1C-KVF\OJ"K8V$+(KEK4[-:XG8" M(C9RC2_B-?@=]\3YLY=0^=O:V5]3*+[D_/9GC@$4?Q0M0]W MD3!P! -'EY(??M#.'S<\<7KRD=01<6%W!X>:3O,KT112!'^4*7F2 ;TO!KV+S"S7^1C7^5;*_ M/]?X9&!2+"?0A+ -D!A+V21(NGRN\7GW00Z[+96'&@XU_+:RO3_7\/K*-"?J M8J/)(AW.TYDR6C*+PFG/$[PT Y.[-Y7<_2[2>.:4Z'-@\H] <&]R6"_R0;91Z71;.KV"3[6UX:"$7G_S>2*BDT/.![_G?'DWZ<,*'. MTMD7YJ0@6EPI6KQB3NMUVA;\#"Y^>)C16-#;Y0#1QZ^PKGSU,[> M5HCCFLILOKV.Y!7B6%>YHK"+,>QB?'GAJ-]Q".=Q@V[Y_'J )M/VL+NI3NK- MO#Z:NB_=(>#E[%#E;U#E;RVF]$=.W;2:.'AT]"UA"WI[2B2&?7ENY,J?'X=" MSQE.NJBUAV#POL'@QJ)"OV/_$6&J=(9(8V1;O17I4+N:RR&%_2\*B0BN# )7 M@P%0Y:'*7X#]?Y7(SA_9_S1=4K8?MPRNY:GAH1T#-\HL0SZ"T'>< MPC9\J5#]H5FHSZ7JG-(9&@5U-HEF WO-U4J0D,KL"X+(S+7LH./-/* M7[L[&^RPF8BV%TU471P&=!<9-[=S7L'8^T(0"KNQCA-0UZ&NWU8AR"_KNMV- MO.E\(:UL1.<.B4QS86(5N@Y+-Z#R0^6_QAC$+RL_-=A7IYUT9LHB.$R:K$.. MC$VA_*=BBZ>UQVK^U3#P.]5RU)4#&GXH M989! EH26K$%(E[?)">MSBR)N)ZH^^>,"-FVMTFPW#5LI'\45'J>U%TP4C"N MJ,@@S^DM0JB 4/%^H.(5.A&?&2IJP3Q4ZNS$D1,J,!=]M98H0R.'BKQG\14# MQ74$D"!RO#?D>+W.PV=&#AIK<'$S:*_1FEI%F6[8#/S\E@0NCTKA-'0R(%3< M(E3J)#"UU/\FT]B),P_^]8G?Z-QCZA3B5KQ*Y>L)*/*!_]B\GR6=WZ(]:@P)Y381$&G:Y M!IB9-$2[.ZAJKKU3FJ.VD4/-?5W94R=885W9]=>5?>DG'8"P$IEJ".XJ*S6R MM$JF&A7=J*DV*L.0# MT1:8:E*7ATKZ_=_^+0Y/_\P?E$U@!H[.Z9L4Y C_\%5AVNZ7YL56Z*F$TK5; MM;JULW10V+1"H2-EV^SJZ4'%1#293 D-5:0^:1DO'"S$?\.R"6KH99,8#4$H MY2Q6<\0IVR?TBWVJ]FK!*!W9(Z%&VUMAM]OM12*S3U@>\4,_DBQ,)T/0>@1: MG&Q.VW'DUX1$'S9:9" &4PV"UJV#UF^''<\*6B-^%@0+5-K)EMQG.J963=;$ M* >("T/6Z5M#:#],AX31E4^A6]40A M]?5,#4<0M&XX([5=3(1FTAGT=<\T94H!6'L_$/C+G*1"Y MXBC73108S@H$ #JB9KRK!L@/S+K% =A M"6\^_K.4KM];C1HSC :=^K2!BH*[6^%C+ZRN7[HD$?T-J_& !OP)# :)NP*A MN"XL2"1^Q8(':_*]$1D>]_IU&_%#0"B&=!"I5,GX)#Y\)KD[G*7O*((Z M7V=7""002"YT_)<&)+\=^7M-()$FP_JX*9 K03W2?5SM#W:Q,7X:. MD2,+ER$+=<>RV!U%GK'Y/'11()!=+3FH.JC4BW4S M7DJ>4^=S("E.XZ)W+$G<<>A9-CNW%34I FG_*2HQSR#)^<%J:WTX?65Y&2OQ MIV^'\CWOI]]\.2V/9Q2_.)P79UX#>2GJ-[P3='D=,M$OI*-W\I>9H2J4PG4,*[XZTJ>FNB9 M'.JYJA9M ]3\'VO+4SW-RH@S18E!T1_O8R;K+SD1/UZBQ]F+E>_HO[U NA4% MCGK(%1/\]_>8="P/(.;IW;_ 93&<+SF8/^#Y/[JU^_Q7]N/AL9H#U##'"/._ MWXHJD;_FPC-)>NND<>S=@]:"(.6,>?Z(\$_?6KPB(^?.='5H[EGT+@9!9K!_)G M/WYJMB;W@Z")[-UG6I;O4(#XN@A_J14SS$WJ/R9B[4FI_&DN<)+C<0X"^4VV MI^Z7]S*I_HIO\ M1*A+D^QG7QA,)+%1:_&#IB"U!U(F"=V6^*9C>,QDY2N7%;%1N>>STAY4[CGM MU86Q5+1J9?Y;$49R>[)X-2-;EJS5#TW/A\__DA]LY+__^L_J]5R!)S#@L2?P M+,MM+[/N?A)E3FYT5P%[#61_6/CJ%=7-X#F.WG(L/[7W?^ZCW>O[BB5(:D6J MN:J3"JF2*V6U)C1%I0B. AA@652]UQ7UP>7'%9M7]U7-D:7VF$[%>,TD@,]W M*\3WI"MU9\K.?E&?#ERD(W0G"*[I4<-N-OB,LL3I5 HM?(@M)O:L(1,''$O-=3U_)H9^ M3]KMU_>K-3MP[>9JCO=CL"740YJ3E@8E-L?;A6C9*\%2Q@=RMTL7>C#*24N# M"MNCB&V@]9W-I>FH9#E0;DK?]+J)\L-*JI(E.[E'E/?YI3D]Y0. MSNZX(\VK\D%#O=V4EXA8Y#/*TO!G!J)LMCH3"RHGTF+0HB.LD3^S//PDZG0] MM]5I".[A2$3:;F51_8*T-'QZ6F\CT7+8%D0T=*359K%IZ 5I:?BHPT3]^7@M MH$W3;.TH$QW;@:%02NG] DU/0&=]L 2WLSML/'G"MO=I1ED:?FL^F S'U685 M==U^&&8RH"3]G+(T?&D]$EU2'6]0-5'APPG"@=F- M6!D,)&.0/[0\_(-HH0M9Y'VAF>F*S6KK)3/D<]+2\-NMWDXFJ45?D !R](_3 M/< C7J'+P^]'1$O14D>SW180F&6O1TW=G+(D)[YF$EXV*; M4U*E=4(M7]\0"U86@S;)RC-! \N<$L-*8CKCNAO& TUAEO2JYK2Z$5G"R$E+ MTT^!8.L<$D*05:\C#CM+8C451PI3'M.1(+#J4=@C=E?%KIF*AD9VUGS(U)S%9#!2U(2YP&UF91 M7>X21,93L;I'+8[BK)'"ECGM]G9=GJ\"W+;D3JM%FCW3,'+*$J?U%3^QYE'7 M%\ TXIB1W.CQJ)%1ECF="E4$B'$&3K/F@*]MG,[6-/B@;"C%C-E>"Y_?9G3>4T^+OW%@I,SRX9Y$]9, MZ9Z1*5295=JJ^:;I3D@T,5J+ 9"%?J2/:F@E+;4>-]%Y;8.GLN5B9 M6Z/6W5:C69L6)-)M2RHU1&:'@K3$+5BH+F?WHZY\8-9VV\97O5Y^Z1JFL"6; MBK"TP W' 0JX-E)M:;48"XJGE@=&(\*PI34,2FZ.F>5XWIC;WB@M:$L#&RY) MGPIM7)D\S4E+\[7D!I%=];V!;+&S+1K5NLL#5SRU/ =UQ!'B S9NVC06 MHZG9W@L])J,ERN/R)4NTNT:&68>Z' 52K\$?ED9.6GJJ95@F(#KH4#Y0JY%1 M8_T#GHYRTM+$NNH"7?!"=65;M,G*KK"?3]=I3EJV+\L).^UE)E61$\8) < W M$H,5')0-C"6/:U5G9MH"TFG1*TW@MSPH6"A;&%/".-%F3%K8]FMU+EM?KGW, M)H$L3X)IDGQ";Y88NFW[HS0P=J;CC7+2TN*&356;--H1+N#N1&DU 6%$^8H] MX8QTL''05L=H=MD(.P'O=9BGA2\EJ:V MN:,;]3&BS6PK'.^T@;;6T(&1DY:G-I7D'DVONW5Y%E8=A!CTN\O9B;:D8\>= MKBT'RV$5E<0Y"#R:'_5GQ1R4E\'O[1W$/ZR'*((..^-!,EQF4E[0EF8AZDF* M7IWNNW*WM=$6HC]*>J 86GG)HDF+'K<'FBV X8:2(YL.],H M$A@C-T-MI''JK,=E/FE&6II;V7:/.[1@/;YVKYX:GD6@L-(LA12 M:MA=K]ZL:T9ON==.M*61(=V5/D"%+2^+H&+(@"](RM[WFZDC.D65+.*23 M5A7$8S#2TX*VQ.W6,S;&V1Y",-RAZ054E\\OZ"YQRSK+!MD(8A'M=EM& MRYZLA" T>M+\[M0YD3G1EKAMDER7PZHF(301;['?S^I#/BJN MB2AQV\ [C#P&^Z;LMI/XJ#1%!XD+TA)^T,O=NIN,=KZ@'C94#9_2Z&1:](4N M.U3Z 1MLNJ(O6\.P?613ZM >%!UB2\9A8(P2=3,;TNC6KLZ17E6><_OBJ>4Y M6!,+A'W FSB_LQJ9XZ\)3&U:(; MN]:<.DS19)7,C+GA=+OM@K0T+F(,JGMSCW11X Y&6\+LS!FI:%]8&E= Q)+J MK)HK&1DBYFHI]Y)P7)"6UPL%&+6=SG< M=;+.>.Z\G9S3/.:]]*XYJFT\H&N M>C98QO4!VZ:&5E"4QY<]9=Y!13+4UB@RG_:3;FK16Z4@+2%S?SGAN[0\M&7$ MHNISEN^UQ4W!0!F9=[M6T&N-Z+V\Y=ICK8>)8'6J/2V&[J8W#1-X.ALIH1-:"("B8?0(/=C@(NJ3&"Y(QZX(8APR]F$X;8M!V'>6]6S&GG#6%D8GD-!JR@E2,!E,N.&<)^=&3EI&11 . M.[7JH"[,<(;;IGTJ[M0+TO(L6.T0S)9+"Y&;@EJW&$?N+ILGVM+(!HM$\+&1 M[=H@B%F'P>3#H)FMQ!->U39JB_'!CJHD? M^&6W28YRTC*W.VK@D5A+&:$(UU6-@Z#&VQ,'96Z7:I,D]^Y^@V:;Z(9N#[;; M0YRQ\(1#L2#DV:ZY&P%!'$\:=2/>)B J2$O<+B2\1V,U/;J[S3!5,V M#E,TXU1>C%7!'>W[S0FG$OJP("T/+'%&W&8]8F?R3-WV?6W.4?UAP6QY8.&T M25!18@2H-'653H3UVF;G]-P2,"D)2@Y$9/ M'E?9*FQW'A)O*=;&>T3S@_-2V:]L^T1F9KW]9!O#1:MS+W&GW!^K-5QN>,];R;@ MF';PS/9./H0%:6E<^IY"QSU"',K20B.(+2Z'1Z<@+8W+"PS3ZC?<6';-JJ6% M?F8CML9SA?H+(P-X:A-TP=J/X1%NR3AN/'#X_S/'EMRGWB.T\!:Z?4\;=I]4?%2?=) M]7+90AP^O/7^:=@I)_2+1^VPCR3^W*G"1TGK1\_WLV>N'3]]2!\]_!O)*Z\^ MG8H0TFP2?IK^O\]*%2]^(%57D9\?FGN-0H ?EV4]^KM?SY@]JN7XVZ6?& 77 MY?+6A?V(LW!=+F]=T(\L"<>RLZ_*['4%_EJ9\LTE@?V,2S@K@;SH#?WQ@_ZRYN#.?Z+](,?F9/7F' M8O(Z4W)=8O*S],^%SJ#E2=[Z=$\YW\R^*& MCC]U^L\L,NSO2\QS[6-X34O$GLC#QXY*)A?O]B],!]F<3\-P:G[JPEW^6 ."+^)-_*OX8^_T-VEBP MKQ1W<;S&W4 OK!RUTPW#4NQK]K6@Y2M+RKL!RJ%JZ4C;@V+POL7@"M-)4!3. M9AV"$)C BZP=N!5A^/%ZO^NU+EP ,_L,PNC^HA?H,U^XJ%_\#)Q28K?C+I\N MI'PA)+SHW-@;A!7R%-#MB I?7-QT+4;SRD0E-ZVW(RHU-<@O!86R F7EI[)2 M!VM+LR"N0%GYN:ST_.BE?!4H*+-Y(;Z?E\I? MUCZ_C;P1JEI>HE-)/"L>YU7S7\&CMFZ M9A3HAR]M^'?K*='S)PY:Z[?=YL&IY3G]*\_-^+581>V$C_&"ADJ:ZT$;(V#0[!%.TN9[J 6=+\0+T] M2B#$[X#$HR#QB9,O*$%\00D><4: &]O9J.=HDUK7,6W1R:^1I3*4. \^ZG0/%#*Y['=ZJ#ZVI;$K6+6HVFI[9P:*J#\V MK3&Z1NS:>N$.QO$^T&8Y4+ 94'#,'4'B$"X@7-PF7)1&6OG79>'%&,2JY0%= M4$,OFYGH'BC<3MQ7.N*VAXJU3D)R/:(9\NG+ D4V8=ECGD ,FJ+L2%GT5G)B MB6P@UT>]MCE23C>WX=GV V.P$F3\&V(&Q R(&:_B8WRM'2LJ\+\I(&I[FN^" M>QBI&FU (QO0$9*H;ZWIA$Z4Y0O[&S^$$:+.^:0^W+("+:G;?8AHR5$TE-.E MCM0=2J(01""(W"B(O/X^98 =CN/]-)9D8 X&@38(=ZHU.N_>HG\($F8=KW04 MS'E9%Y66,-(+3X'Y\!GCN#N,H)[97%Q3L1M=O**8%62E1B#/<+E!AKEJ/JB; M2/X]4:'Y=_(/EZ5^1;4E_A*C>_N*LA=;J%<_N/MSB_#ZEO+5VR*\JK3>$*Q M:7V+<^6O[]K4D[ PJ@JF%+X-KDQ\A;AW=/ 7#,53IJJ3@"=H#9MW-=EET'M[%[U"".%]P%X(*!!5H M J&T0FF%T@JE]9JD]74=-G(0A*%G;$?RS T[:=5$>15U(=5OA#)> MFS9%80*J>I@[67FUI77^)X"7\(>A)H5@8J_SM[E:W;%#_)Q1K<:L7_A M8-BMA*=_HQCW1;=QY:*[#B8O>K0_)VS+\8:RUFAWT.K?*?9 M:IS0X52Q6_Q2/$G\@RKH3]3NNLLJ6ML/$D*FB>%Z2?%.K6GR"I/7[G+4'?-$ MXOR: A ]$69=)@TPD<-I0P9.8[>1N7$= M68T4-@^S8LP==<[V".]+DV *%U:(0K&^5;%^Z\J$TB2\^%&[ZXVC?F!ROVV1B,FE.)^@6J]Y*H/XZR65U%C M)#8!DOVY#>*,8 WR68UNIU#UIAM@POCI<_'3;-:+7ST5+I43'_?2%6NCS69B MDHW=@G;W(P5#\W@I05!W)/M@M-Y64!QHN7)\@J%PHJ%R; M";SP)89R#N4,31ZQU)GN4'\(@M X+WD'W!*WX!DW0?(;K@2;KMK"M4BPM5"_K")PFJ!50+J!:7U_7J]Q*;8Q"K ME@=T00V]_.#/?78S:@^:7(0>MC+M)(WI/%*59>O/:R>RK4/;TWP7]++]PW,] ML=IQ;(DX$@WLICOG<'6Y:COKD8+A"H;EUPC_ZA/4B:JX-2L[OTG&^8ZX75 M!FD.'U0&'[")'D2-E\_Y7_147#AJ/'_6?=^3ID=2TP69'F_HN"^ZIK4USHL@ MV^;,P_;,/)"1S?&P]KMR;[#A M>H\O7-7?)E,<6/*VN2.]>G4BB3DOKX(OD]U"JQU;,VT)T>6B5>K]HLNK;WEZ6]I(PN61M%U;V\T'8WK6';XP")1ZR38U M;8;I-5Q&S!F*V@1%A=N3[N?Y%I:\8Y^]N_SZ*L&+:4%6:@3TO)]#D*%QD0B[ MB83S33>,O:6"[EON%_1RL?5;E;\; HJ;E;_WTX&*?%0!0BL$^O(!V.8F."X/ M$W%M6]+0"SM]GIJH?^[9\/HFB>*L)_RDH=>O2ANC-Q>:;@?3P):IZKF?1)[ZE*+D6KH#7R;MHET MA1X/5G8BRE(/:1Z"7IO/?9M3D\_GG9LKK[@]!86$1VT\3]T]_2 ?)^SE"7MY MOE@OSY?89Y7+X];<'FNE+$')H(GN@ZY)U4 M/=.M1,4OQ9-J/.B,_D3Y;7V' M+'?=C3*4U;2NA-/.N,8N1PI&%3T]*?R..\]5M.^T]O:BW K8J/.5_&(HYN]- MS*^B6Q0,4_Y"T_WG#>FC0G1MMYAFCQO+;C<8+^?N4L);1FY(V0^?213>YP[1 MY7VA"S2B4,RAF$,QAV)^"V)^U:':E_#OM)H]FO;%-+"W4CIEF#'78&M\[M_E ML=?G';SKJ[V;@BC.7IA'6J6Q_7+U_>T&3\=?I+IXRREH>H*( 8C%]>F+AA].U/WLJWP_T1+E M:RR5)5LM<^?X-=F:AJTX#IE4#S*(H/-8*G7'TN5SA"]1G0]K)&_-(X 5E5!: MKT=:W[JNX,_-V^U'-K\S/]WM;]U,3]]4+;@W6QT:OR>R$1*M'_52-:Q/. MR$T<^^$S>ZM-,R%BW!9B0/L&I15**Y16**TWZ(V]<.SPI3VH19O;0V>MFH MXL7,QUN!!"SPO(X8Y;,%GMFL%[]ZZJ+V?6=V6"RDVD*@S=WLT!WAS=HRS0 F M#T3B=QC%W#$8\V[*.N$UBI>K8S,PC5DG'6&T M@"R9/=\D6@UT,9BJG"? YZ-+WK#Q:S[!C#562\@TOSFTG?J^F^1]=IE3GX7G9]Y;X_C,F' MH&B*7(G]8ADSIK(]0OXQLG1P6LJ*8ZDG;;F)?.1;A>.O4NW?:>R=UTX-7/(S M T^$WX..Z([J6'4CX++%LN/$4W275S V#[^S)'-'DF>YF>CM"X'?RKUX][X$ MK!B&8GV#8OW6Q2QO[0]?:;3V2?OXU;UV^K/#3I@?=W+7:N&'[=CVV7::VT?V MPV?Z#F/.&*^%, )AY )@!%I'*-90K*%80[&^!K&^V2#H3QRU9HUG"6TR1N5D M7!W;&U*QI-C(';4\#OHS3^TFJI5E+P09LT>@5_[E^%'T[XJA6EXE#Y":?A@C M,0C=BN7MP'TKX%M-'+UP.X2+SWN\]!5&M[J<,+UWU96N-Y[NAF(.L]A0S*&8 M0S&'8@[%_#K%O#0O%][>Y9>O$L=')NMNI#TG-[=[6E\:JB]N_CPA\Z.W];)= M*[]3+4==.:#AAU*VR9> EH39MA]$7V^Q>3C(_-SAY2$1VL. %BW;;4VKPFKK M-Z<(KV!<<0$YAL/KQR$803"ZHN#@:X &R8>=6:MS: A(Q\/60Q&S O\$&LQ/ M0>/Z:BFS*:GDD<*;2(*\=-C/#W40(B?B3UBPKT2^8^F5?Z#%?S?K3K]]9=Y+ MFZL+7LB+L%U%].^")^FV<[=0VM_ 4[O@28+2#J7]_4C[FV]2?B]B,@:Q:GE M%]30R[M]W8='EMG&@TR.7E.F#6,>K1>^T"",/][I9&[YUZW-<]N5[1*0RQ65 M#.4FY3K=EL^M66:4#4S!L ^?J;5Z0@%X^,<4?/ M?EE5G>)XM!I7.HD'3LA!H'>G#_GB_?6?UXEXLH&*2+C/EC/DVT&(UA^[)FD[P@&SY"D? ?2->?0WC9#>-%J4YJ/ M_SMG6>5%3\793Q2\/GS\_A&$O#DZ"*,3)T]X(9UD76L-:FM1F%4U1HUQB8ZE M CZH#Y_/@AJW;6PA:OR\E."BI^+"4>/YT^9)X%M;!P5M5%R!U7J@._)@\N?1 MNU]"D)V@[*E1,/1D(#,A@J6HLE\9.8*P&8(0^!W!L1!'((Z\,QPY?USC[P') M#^+_1FR,:N&A%MDBZLQF@Y49:,0+^R _#(FH-.1 _=D0[FBW977Q=0 MDBBC'!6K7XT&]-.^X0O9'Y7=*9N$%T@NKPW='GU+<_PT-Q8:]T5 M!'4UGRZ/<;Y7.7.@@P61YVQ:K9T@;L""/.Z3%844@8ZB'IHC[RCBN7C']95$ M%]."K-0(Z'E[V2!#XR(/!M/(E]X'%I9 7T>?GI>+K=^J_-T04-RL_+V?SD_, MHP(0[BP!6)DXVIWA-%1E:Z!3CND?CP?GSSV;KT>^HHG_@S<72>+"RM<>&?DQ M./68 A((=Y8&3NVGQD#S#:]X2M&)Z@D_B3"FO5Z=F:V$I'5HFRA7)\5QJF3S MQ!:W6.)G#.9"G( X >T4E#\H?U#^H/Q=FI\DKZG.%M.6FMS%^])GH)"P!Z%F1<6= M0Z?+AOR@:$1ZJV'NM[I9Z,)::+SJ94,OL<\JE\7I17 =N;OI);#,7\O8GY!?:@>FOO^X*CE,_UNG_>CGYUSGW6P;N^TKLIB/);V_,@:YA]#"TM MO\[]%&]5TVREHXKE:4Z2SSW<5#\0PG719]7FEL?UR\?WMQD[' M7Z2Z>,LI9GJ"B*(Y\>F+AA].U/WLJWP_T1#E:RAU$SB>KTUYV@9X5>4.[G:O M[ P%)XM0ZAWSQ/7M+U&<#TLD;\TC@ 654%JO1UK?NJS@S\W;[4UOW4Q/WU0OV%0LEAESMB*I-HFM/ V/F\*/B+ZJ_SL_UNOFMZ$5DT?(J:HS$)D"R/[=!G!&L01ZOC5XVKG@Q\_%6 M* $K/*\C2OELA6DX(*N\*5*#MA&(.Q?S:Q?SUUQWJPU7KPU7' M;O_4_W.7$[.Q-[M#N;F-.1*P;@(.A?^7QVA_Z@!>7[WG#T.RZ]!W*X(;./X! M@$HQGY5A$FJF&H'*T%%OHQGC6T5@KU+5WVFX]4$)"J('%<@UX*GXZX*;L8VT M>I3D[<'M2F'&8Z^3*CB=QU^Y.XX\XWU6-^1%OWL7 5:"0FF]'FE]Z]*#M_9> MKS02^D/+]H1GK#5)DU[7^JR,)]N5TQ*E7=#A<\/&?OA\SE/N$"<@3D"K!J45 M2NMM2>M;!22A6%^<6-]LJ/%W'"R^/4P61(^QY(./;,W::K;T;2-WL/+0XQF. MF5],@N(4B2RNW\H/EX<@FR28AH$EGS &^24&62C'$^'&*.ZQBJ(DB0"6([K5 MZE.4/1DI.).'&S&*@86>5S.ZB_<;8*$G%/-W(.97D9R'8@[%'(HY%',HYE#, M+U[,8>GAIK#]=75R5X(,LZ.0*\X?A15\KHZTP]C) :A6[&\';B_0>@F M8ODWU#,1WFE\04.Y>#B%95I06J]'6B\O\P>E%4HKE%8HK5!:K[[[UF_6P&I: MXB9.1JH7NYKO@/L_*\GV/GZVQ% 6-6C*TMCAY=-(_+M?X MT=MZV2Z-WZF6HZX:>O<&<,8M7R@"ZHH9C/S_9G.TS MOF[?GMN215V":F_3Y4JFM\FLNM'5%=\R%)Q3,.S#9YRXHS#ZC!$9B$"7K$D0 M@:"AAFH"U>1&#/4+1TQ_V<;B2= W^.W.MK<#4MUCL<+R"5_86.97;.PU5?C= MOV+US2M2D,M"QJ6C9[^LJD[154^-*Q((XL+_.2$*@=Z=/N3+]==_5K!1RE,Q MT6]4G,A47/>3E0,N0L=?X^PJ'RGB^@4/J\[YH1>N;6J$-A?,UEP>,(:J&W_C ML.KI5&H21_G@LNE_XFRJ,>-U7%BW>O9!VX?Z?IOB!F440_KPF>3N,!J[HXDS M'E&]"86X=Q\N62%*@_^_EXOZ7O*XS][(XO51X/<[7^0WGX$P.G'RA&/0;:ZM M&=!$3E"/#&?-]B-)H$?YD*@/G\_2#/.&K.'[57[ZTL=]XVBUGS>"85C/QBE)Y@@,\_ACD!A/34$B6L% MB5??1TQ&!EVEJC,.%1-[,)BL.@QFO+ N?Z_"K?I^N3_TQ(--FQUNVQ6F/<5( M"Q7.LP,H=8?^_%Z=_\1Y>?89UB0O[[;6A]-7EJ=G0/GI6]7\/@'V]5GL%[HO M"2D\^^H7,V0O/A0MXQV$/QF)]>TP\L^?\LVAI66_G9B@HFH9]F=,'C)-J'A^ MG'&CAMG77L7*'F^$JE,)U#"_I;V2V8U,0-4DVVT"/9>[(A>7FY3*VO)43[,R MXNC!'$4?LT5^R:'_;(D>C^U7LY:ZM?O\5_;CX4F: ]0PAQKSO[H5!8YZ^%1( MXO?K7HA"]F_SE DBJ8]$IM4/Q@1%_YFS^.BYWSP,T8#C_/>YE-?#$\XE,_=3 MB9,/8/P%D8A'\_+HY__^S^/1?$W4(IKO^.&G!W!]-'WW,X,7.&L 9!4"U4;4 M=?;Z3ZJ3JH?H(0O$?,29!^#^] 6@B9PG^B-!_[/R]6,^)Z4U<]4]\FC:[E$= M<< Z_G3ZJX>O"D!^^,Z/BJ#)IQ!D7E'F!'VW8H]6ER:>6MVSN 3$UY7X2ZV8 M80[J_YB(M1\+O)>#M_/?QWG)^Z\R_H],91K8Y[O3=K]OCP0[I/<[4'MXQNR4Q,'DMAKU_F)4*]( MD^S_^L)@(E7$1J76X@=-0:JT!]DOQ%JW)?;JPE@JJIJ8_U:$D=R>+-[02#]7 M7? O^<'B_OM+!<'KLNQO)S>J87/JVC$BL QE%4R2D(A&10H*PK#%!K'=933*91%R0\GT%4? MO.1^L# F R[JR8C1WOF<41O)PY&"*1CQ/>FLV3UFPCS;VJ*/!H=NO8& G:'@ M"O,]Y6;I*WQ"RHF@CL+^D5X1N]%JE%&6']K9KMV>8&BR<%B-*])B2!M-<7M4A3$>I,C":K:H1E>(?+4_K>4.KV(T$82\D)MWL:F3S2B2T=Z9U,B[TF$1M#+YCEE!CZ/:FL3*3FJ-=E97>X.O8%-T,<.$$8W<_:1^Z.:/EX6-I;;3# MFP?4MC;MJ5O#@E44Y>\O#[^_Y^M#++5\6^JPM0$V=1=":"B44GJ_2*=FZQB- M$)DVJF./[&VQ6B/-*$O##WK((&E1LF*+-2T92EY#6(Y&&65I^$;^5)RV&0$Q M98:M;PTF\?B,LCQ\3!C.&\M.M+!GG85,R\MM?](H2$O#=[T^'3$C14-GATV* M=JCQ+$CS]Y>';U+*N#ZK)6O9C3T:$Q;[&=WD%;H\_)GK1RMYY@-[2UM.$^"" ME? CA2[+B;8^"MI<9WS4&@:112^'"C'.*:GO*9V)Y VGI*#*R=CC@V7-C(!N M9)1Y*/Q;TGIWLSIL*&HM)&MW<>R[^*3NYP_%2M._9JV.)5'H7L#1'MYCP%() M%[S"E,&05 M ;6I/!-W+4!VV+K3SBE+G#+=@-A94WQ-M-,2\KO#ST6([G^1))595W/9#D<;>F"M"2HMT::F]Q3IW4%61IUC):K#RP+JJY7;W?.AD1#F]X1M4Y4LYI3))M;O,QMQ^\0"$C?.3;0[M&><$9.6A*: M58=NS^3^L"6(I"]J/,LT#9O/24L#6QPU4-=D-;&;@=9QQ-JA*>P*!MB2&X - MNMR!80$J:1PJUK=^X' %:7D.= WG$]=F$:%9;VM[C'16S4;&+%D>UQ&C#YL% MKQ&HVR$1?*2VNX'*YZ2E<=&UH-7JKH.) .:&WQN.NM%X/LI)2^-*$F?L#CU/ ME44M/<1NIX]9XX*!TK@VR\98M60V$.B5J?$6;6PIJ6"@O%Y1V>3F*R.L?;NX!>DI:?*N+&U5$?JVTF_$[8W M0X3RR30G+5GCE#:Y8XM9=&4Z!0,[]"U[@HURTK(Y)ET?&WK3?E/&A_-A<)P< MJIW4*&A+]E@ZQMB\OY[& AW%XMQA;'HJ%RR4#3*ZR0928_=K8;9#^UB4=MWI M/!O9$Q99NW)ELA<2QJ/9JNC:K:'&2IC3YCO0Z=> PQ.FO*!:@S$QL[+'/V"@=+4 M-A-W/ W&5B;;-%<5)@O:'6T*TO+4SI'NMF]UF#JJLGS+8!G9Y3/W"7O*+6AU M.YT(TX&$-@_5E9 >@YAB3L\M+4/FNV_6*S1QA01L&FNVT]2EQ>FYI5FH+QR/ MH?3-1,8]9$^QWEK4[ODM+=E 8EO]5;O+R5U]I^W=- ++-)O<)QR.)898YLH> MFW836U0/\_XTU1,C)RU-KLFVD#:QHG";'@'<;B+'M!?P.6EY%LC>W-EWL/76 M1C#-G&E1FLR$@H/RR.BN9,S(N8D*XG;&*>Q2.:#U[+E/.!W6 H!Z9Z!549PQ M,VMI-@1<'N6D)6ZQFH2*&ZJKH+7!8I;$'="V1VE.6N:6:4Q'C::A^+8;\)8P M1(@.F!H%;8G;[IS2A)712&UD61,7J-P=)D'&PA..QS[%!)1G9 ^5N$G:'4X" MW^'XG+3$;8 $+M-IM>MR@BY%=LWL]4X_S4G+W!ZT6=)>>(>J[8:[P[3=6-29 M=L%!F=O,Z1V-UF(4HUTZV'1X5^MN\C.73[@I&RI"X]7DH-B WXBS>@,P77.4 MDY:4=]I+4FWM;0)YQC;VM:@9NSTG+SE_$M(3>K*<+R!($]K1?;S6B@H$2 M,J.M-KO@FP1MSYAMYJ?)V&JZ+$C+<]!>CEKBB-"U_\_>E_XHKBSY?G_2^Q]0 MS\S3.1+T]0+&]+US) -FW\%L7RQC)V"\@1>VO_YEVE!%E:GJZFXH#)4CS;G5 MD-B9D1&_6#(R@C?H?"G%M1)*1X&3/6.E=-+R)FL4.@TAQUF%\K2S-#R70T/#2--;;CNM;FTH%-/[SC:E]77.](>&UE7T M\@VS,6860I>02LZ:Y.1RSA]ZQD*@5D:G[*P9+5>8]_/2H#Z \Q>I,_9,E1TR M)6>8<34@YTK.,DVL_49U5!A!>U,39"N>9/$YVIXFS&ICT9ENT- 0+$Y KB<- M)XF=Q@C%C=(M3X2*X@\-PR*]8S;%L2Q!9VE+]:N=E3:>[/T9A*&NUIEWMD.B M2VA><=-WJ8Z25D?!&70;1V0L M=_:P'(P-QVS:=*]>LU6H M0C VM+)-.FG4UI5&DOCE! "*G;QOE8E;N<&CH&4=78O=-;0.]5Z_2S)OE;KW;93?^ MV-!L"Y:8V'AFI2Y0!E6H#%;IFF+X'2E#LW5RL[742&@#WLBGS<1F[;(=O8V& MAF9KM5E&JAGZB&>R;KN1GK*-_6[C][D,T]:NUK*+;:4O&/6ILU24+:-/_,>& M9^OP>74I]-=-WEMHF6(E/];*K1EJA1>.7V7=67] EWI$+BMT$R3?:)?ZLT/7 MO%>*/UO75EZN#,V4%.LI@F&WB/X�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�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end